Targeting the Activator Interaction Domain of Mediator Subunit Med25. by Sturlis, Steven Michael
 1 
Targeting the Activator Interaction Domain of  
Mediator Subunit Med25 
 
by 
 
Steven Michael Sturlis 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Chemistry) 
in the University of Michigan 
2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
Professor Anna K. Mapp, Chair 
Professor Carol A. Fierke 
Associate Professor Jorge A. Iñiguez-Lluhí 
Assistant Professor Brent R. Martin
 0 
© Steven Michael Sturlis 
All Rights Reserved, 2016
 
 
 
 
 
 
 
 
 
 
 
 ii 
 
Acknowledgements 
 Completing my doctorate is perhaps the most challenging thing that I have 
accomplished in my brief twenty-seven years and I will be the first to admit that there were 
plenty of days that I didn’t really think I would see it through to the end. Despite the number 
of times that I swore “today’s the day” while getting ready to leave my apartment, the 
remarkable people around me and the wonderful support system that they represented 
over the last five and a half years were pivotal in getting me to the finish line. Not to 
mention that the majority of them probably would have tried to chain me to my bench if I 
had actually tried to leave. 
 First and foremost, I need to thank my research advisor, Professor Anna K. Mapp, 
without whom I literally could not have completed my PhD. The summer that she let me 
spend in her lab as an REU student was pivotal in my decision to not only attend graduate 
school, but also helped me to identify Michigan as the ideal institution for my graduate 
work. Her guidance over the last five and a half years have taught me how to truly think 
like a scientist, researcher, and at times, educator. Perhaps the single greatest lesson 
she taught me in my time working in her lab was how to persevere even when projects 
and experiments deviate significantly from the plan. I will always value her mentorship 
and the support that she has given me during my tenure at Michigan. I am particularly 
thankful for her guidance with issues that extended beyond the laboratory from career 
development to the two-body opportunity (as she would say). Thank you. 
 I also want to thank the other members of my thesis committee Dean Carol A. 
Fierke, Professor Jorge A. Iñiguez-Lluhí, and Professor Brent R. Martin. Your helpful 
suggestions and constructive criticism throughout the years made me a better scientist 
and pushed me to think critically about my work. 
 My research advisor while I was a student at Illinois Wesleyan University was 
Professor Brian B. Brennan and I also owe him a colossal debt of gratitude for helping to 
 iii 
shape me into the scientist that I am today. I was Brian’s first student and was a biology 
major hell-bent on going to medical school when I started working in his lab as a 
sophomore. Through the course of several illuminating conversations he first convinced 
me to change my major to chemistry with the promise that it would teach me more about 
problem solving than a degree in biology could, before ultimately guiding me down a path 
that led to a summer REU at Michigan working for Anna and ultimately my decision to 
pursue a PhD rather than an MD. His mentorship throughout my academic tenure as both 
an undergraduate and graduate student were invaluable and I am profoundly grateful for 
his friendship. 
 I was incredibly fortunate to be surrounded by an amazing group of colleagues 
throughout my time in the Mapp lab who made coming into the lab a joy every day. I’d 
like to thank Professor Aaron Van Dyke and Dr. Jonas Hojfeldt, who took me under their 
wings and mentored me when I was but a lowly roton. I also need to thank Jonas for being 
such an amazing mentor during the summer I worked in the Mapp lab as an REU student 
as he immediately treated me as a peer and left me clamoring to return to Michigan as a 
graduate student. I will cherish the time I spent and the remarkably diverse conversations 
that I had with Paul and JP who started in the Mapp lab at the same time as I did and with 
my degree completed the last of the “Young Guns” have truly and finally become the the 
“Old Guard”. I’ve known JP for going on a decade now and his continued friendship 
through the years is something I will always value. Paul and I collaborated extensively on 
significant portions of the work published in this thesis, an experience which I thoroughly 
enjoyed. I also need to thank Andy and Matt for their contributions to this project and for 
being excellent cubby-mates and their awesome podcast recommendations. To Rachel, 
Meg, Cassie, Laura, and Omari thank you for your humor and making the Mapp lab such 
a great environment to work in. I also need to collectively thank the past members of the 
Lab for their guidance and support throughout the years. 
 I am truly blessed to have been born into such an amazingly strong and supportive 
family and there is no way that I could have made it this far without them. Mom and Dad, 
you kept me going when things got difficult and I cannot possibly express in words how 
much your love and support over the last twenty-seven years mean to me. I want you 
both to know that you raised me right and I am the man I am today only because of you. 
 iv 
Molly, Nolan, and Becky, you are the best siblings a guy could ask for (even those of you 
who made the misguided decision to attend The Ohio State University). I love you all. 
 Finally, I have to thank my better half. Megan, you have been my rock throughout 
this entire process and I want to first apologize for the amount of crazy that you have had 
to deal with, particularly over the last month and a half while I was writing this dissertation. 
I have loved every minute of our relationship and without your constant love and support 
there is no way I could have made it this far. I am in constant awe of your strength, 
dedication, and compassion. You make me a better man and I cannot wait to see what 
the future holds for us. I love you. A lot. 
To everyone who has helped me get to this point, from teachers in my earlier years 
to family, friends, and colleagues that I have not explicitly mentioned I am eternally 
grateful for your support and guidance. Forever go blue!
 v 
Table of Contents 
 
Acknowledgements ii 
List of Figures ix 
List of Tables xiv 
List of Abbreviations xv 
List of Appendices xvii 
Abstract xviii 
 
CHAPTER 
1 Targeting Transcriptional Protein-Protein Interaction Networks ............................ 1 
1.1 Abstract ............................................................................................................. 1 
1.2 Introduction ...................................................................................................... 2 
1.3 Overview of Transcriptional Activators ......................................................... 2 
DNA-Binding Domains .............................................................................................. 3 
Transcriptional Activation Domains ........................................................................... 4 
1.4 Coregulatory Proteins and the Pre-Initiation Complex ................................ 5 
Masking Proteins ....................................................................................................... 7 
Mediator and Adaptor Coactivators ........................................................................... 7 
Chromatin Modifying Enzyme Complexes .............................................................. 10 
The RNA Polymerase II Pre-Initiation Complex ...................................................... 13 
1.5 Dysregulation of Transcription Contributes to Disease ............................. 14 
Abnormal Expression of Transcription Factors ....................................................... 14 
Chromosomal Translocations ................................................................................. 15 
Mutations in transcription factors ............................................................................ 16 
1.6 Features of Protein-Protein Interaction Networks in Transcription .......... 19 
1.7 Targeting Activator•Coregulator Interactions ............................................. 22 
Exploiting compositional dynamics in transcriptional complexes ............................ 22 
 vi 
Exploiting conformational plasticity of coactivators ................................................. 24 
1.8 Emergent Technologies and Alternative Approaches................................ 27 
1.9 Thesis Summary ............................................................................................ 28 
1.10 References ...................................................................................................... 30 
2  Molecular Underpinnings of Activator•Med25 Interactions ................................. 41 
2.1 Abstract ........................................................................................................... 41 
2.2 Introduction .................................................................................................... 41 
Mediator Subunit 25 (Med25) .................................................................................. 42 
The VP16•AcID Interaction and Structural Insights ................................................. 45 
2.3 Results and Discussion................................................................................. 47 
Determining the Minimal VP16 Interaction Surface ................................................ 47 
VP16•AcID Hotspot Analysis Using Alanine Scanning Mutagenesis ...................... 53 
Electrostatic contacts are critical for the binding of VP16 to AcID .......................... 60 
2.4 Conclusions .................................................................................................... 64 
Assessing the Presence of Distinct Interaction Surfaces on AcID .......................... 66 
2.5 Materials and Methods .................................................................................. 69 
2.6 References ...................................................................................................... 75 
3 Depside and Depsidone Inhibitors of Activator•Med25 Interactions ................... 79 
3.1 Abstract ........................................................................................................... 79 
3.2 Introduction .................................................................................................... 80 
Success in Targeting Transcriptional Coactivators ................................................. 81 
The Activator Interaction Domain of Med25 as a Target for Small Molecule 
Inhibitors .................................................................................................................. 86 
3.3 Results and Discussion................................................................................. 88 
High-Throughput Screen Assay Development ........................................................ 89 
Primary Screen for Inhibitors of VP16(465-490)•AcID ............................................ 92 
Hit Confirmation and Selectivity Studies of Norstictic Acid and Psoromic Acid ...... 94 
Substructure Search of CCG Libraries for Depside and Depsidone-like Molecules98 
Mechanism of Action Elucidation for Norstictic Acid ............................................. 101 
1H,15N-Heteronuclear Single Quantum Coherence (HSQC) NMR Studies of AcID 
Perturbations Induced by Norstictic Acid .............................................................. 107 
 vii 
Mutational Analysis to Identify Sites of Covalent Modification by Norstictic Acid .. 114 
Attempts at Identifying Sites of Covalent Labeling of AcID by Norstictic Acid Using 
Protein Digestion and Mass Spectrometric Analysis ............................................. 129 
Preliminary Cellular Activity of Norstictic Acid and Psoromic Acid ........................ 132 
3.4 Conclusions .................................................................................................. 135 
3.5 Materials and Methods ................................................................................ 138 
3.6 References .................................................................................................... 147 
4 Natural Product Extract Screening to Identify Inhibitors of the PEA3 
Transcriptional Activator Subfamily ......................................................................... 153 
4.1 Abstract ......................................................................................................... 153 
4.2 Introduction .................................................................................................. 154 
The PEA3 Subfamily of ETS Transcriptional Activators Has Been Implicated in the 
Progression of Cancer .......................................................................................... 154 
Previous Success in the Disruption of PEA3 Mediated Transcription by Small 
Molecule Inhibitors ................................................................................................ 155 
PEA3 Transcriptional Activators Interact with AcID .............................................. 157 
Natural Products as Small Molecule Inhibitors ...................................................... 160 
4.3 Results and Discussion............................................................................... 162 
Norstictic Acid and Psoromic Acid Inhibit ERM•AcID Interactions in vitro ............. 162 
ERM•AcID High-Throughput Screening Assay Development ............................... 165 
Primary Screen of NPE Library Against the ERM•AcID Interaction ...................... 169 
Counter-Screens to Eliminate Non-selective ERM•AcID Inhibitors ....................... 174 
Summary of Hit Filtering and Selection of Extracts for Strain Regrowth ............... 179 
Confirmation of Crude Natural Product Extract Activity from Regrown Organisms
 .............................................................................................................................. 182 
4.4 Conclusions .................................................................................................. 186 
4.5 Materials and Methods ................................................................................ 190 
4.6 References .................................................................................................... 197 
5 Conclusions and Future Directions ....................................................................... 202 
5.1 Conclusions .................................................................................................. 202 
5.2 Future Directions ......................................................................................... 208 
 viii 
Using Natural Products as Molecular Probes for PEA3 Dependent Transcriptional 
Processes ............................................................................................................. 208 
5.3 References .................................................................................................... 212 
 ix 
List of Figures 
 
Figure 1.1 Transcriptional Activators are Minimally Composed of a 
Transcriptional Activation Domain and a DNA Binding Domain 
3 
Figure 1.2 Examples of Coregulatory Protein Classes 6 
Figure 1.3 The Mediator Complex Bridges DNA-Bound Activators to the 
RNAPII PIC 
8 
Figure 1.4 Functional Consequences of p53 Activator Mutations 18 
Figure 1.5 The Chemical Space of Protein-Protein Interactions 20 
Figure 1.6 Representative Examples of p53•MDM2 Inhibitor Scaffolds 21 
Figure 1.7 Transcriptional Complexes are Dynamic in Composition 23 
Figure 1.8 Transcriptional Complexes are Dynamic in Conformation 25 
Figure 1.9 The Chemical Cochaperone 1-10 Binds to and Stabilizes KIX 26 
Figure 1.10 Sekikaic Acid and Lobaric Acid are Mixed Orthosteric/Allosteric 
Inhibitors of the KIX Domain 
27 
Figure 2.1 Med25 Organization and AcID Structure 43 
Figure 2.2 Comparison of AcID to other Activator-Targeted Coactivator Folds 44 
Figure 2.3 Med25 AcID Contains Two Binding Sites that Interact with the 
VP16 TAD 
46 
Figure 2.4 Initial Truncation of the VP16 TAD and Determination of Affinity for 
AcID 
48 
Figure 2.5 Direct Binding Assays of VP16(438-454) and VP16(467-488) to 
AcID 
49 
Figure 2.6 Direct Binding of VP16(472-479) to AcID 51 
Figure 2.7 The TAD of PEA3 Family Members Bind to AcID 52 
Figure 2.8 Alanine Scan of VP16(438-454) 55 
Figure 2.9 Alanine Scan of VP16(467-488) 58 
 x 
Figure 2.10 Effect of Salt Concentration on Direct Binding of VP16(465-490) to 
AcID 
61 
Figure 2.11 Effect of R466E Mutation on Binding of VP16(438-454) and (467-
488) 
63 
Figure 2.12 Direct Binding of VP16(438-454) and VP16(467-488) to the 
AcID•VP16 G450C Complex 
66 
Figure 2.13 1H,15N-HSQC NMR Perturbation of VP16 G450C•AcID Complex 67 
Figure 3.1 Transcription Requires the Assembly of Large Multimeric Protein 
Complexes 
81 
Figure 3.2 Examples of TAD Mimetic Transcriptional Inhibitors 83 
Figure 3.3 Examples of Allosteric Transcriptional Inhibitors 85 
Figure 3.4 The Activator Interaction Domain (AcID) of Mediator Subunit 25 87 
Figure 3.5 Fluorescent Tracers Derived from the Truncation of the VP16 TAD 89 
Figure 3.6 Effect of Tracer Concentration on Dynamic Range The binding 
curves of VP16(465-490) 
90 
Figure 3.7 Assay Stability Time Course, DMSO Effects, and NP-40 Effects on 
Tracer Affinity 
91 
Figure 3.8 Primary Screen of Bioactive Compounds 93 
Figure 3.9 Validation of Norstictic and Psoromic Acid with Commercial 
Compounds 
94 
Figure 3.10 Effects of Norstictic and Psoromic Acid on Activator•KIX 
Interactions 
96 
Figure 3.11 Effects of Norstictic and Psoromic Acid on VP16•Med15(1-345) 
Interactions 
97 
Figure 3.12 Substructure Search of CCG Libraries for Depside/Depsidone 
Core 
98 
Figure 3.13 Dose Response Curves of Selected Compounds from 
Substructure Search 
99 
Figure 3.14 Limited Structure Activity Relationship for Potential Lead 
Molecules 
100 
Figure 3.15 Molecular Dynamics Simulations of Norstictic Acid Localization 102 
 xi 
Figure 3.16 Effect of NaCl on Norstictic Acid Inhibition of VP16(465-490)•AcID 102 
Figure 3.17 Covalent Labeling of AcID by Norstictic Acid 104 
Figure 3.18 Benzaldehyde Does Not Inhibit or Covalently Label the AcID Motif 105 
Figure 3.19 Atranorin Does Not Inhibit or Covalently Label the AcID Motif 106 
Figure 3.20 Norstictic Acid Inhibition Time Course of VP16(465-490)•AcID 107 
Figure 3.21 Confirmation of Norstictic Acid Labeling for HSQC Analysis 108 
Figure 3.22 1H,15N-HSQC NMR Spectrum of Norstictic Acid Labeled AcID 
Protein 
110 
Figure 3.23 1H,15N-HSQC NMR Perturbation of AcID Induced by Norstictic 
Acid Binding 
111 
Figure 3.24 Proximity of Lysine Residues to Norstictic Acid Induced Chemical 
Shifts 
113 
Figure 3.25 Direct Binding of VP16(438-454) and VP16(467-488) to H2 Lysine 
Mutants 
115 
Figure 3.26 Effect of H2 Lysine Mutations on Norstictic Acid Inhibition of 
VP16•AcID 
116 
Figure 3.27 Effect of Lysine Mutation on the Covalent Labeling of AcID by 
Norstictic Acid 
119 
Figure 3.28 Direct Binding of VP16(438-454) and VP16(467-488) to H1 Lysine 
Mutants 
120 
Figure 3.29 Effect of H1 Lysine Mutations on Norstictic Acid Inhibition of 
VP16•AcID 
122 
Figure 3.30 Effect of H1 Lysine Mutations on the Covalent Labeling of AcID by 
Norstictic Acid 
123 
Figure 3.31 Effect of H1 and H2 Lysine Mutations on VP16(438-454)•AcID and 
Norstictic Acid Inhibition 
125 
Figure 3.32 Effect of H1 and H2 Mutations on the Covalent Labeling of AcID 
by Norstictic Acid 
126 
Figure 3.33 Norstictic Acid is a Mixed Orthosteric/Allosteric Inhibitor of the 
AcID Motif 
128 
 xii 
Figure 3.34 AcID Labeled with Norstictic Acid Submitted for Proteomics 
Analysis 
129 
Figure 3.35 Possible Modifications of Norstictic Acid During MS/MS Analysis 131 
Figure 3.36 Inhibition of ATF6α Driven Genes by Norstictic and Psoromic Acid 133 
Figure 3.37 Inhibition of a RARα Transcriptional Reporter Assay Using 
Norstictic Acid and Psoromic Acid 
134 
Figure 4.1 Reported Small Molecule Inhibitors of ETV1 156 
Figure 4.2 Structural Features of the N-terminal TAD of the PEA3 Subfamily 158 
Figure 4.3 Truncation and Mutation of the ERM TAD 160 
Figure 4.4 Generalized Iterative Screening Workflow for Allosteric Inhibitors 162 
Figure 4.5 Inhibition of ERM•AcID Interaction by Norstictic Acid and Psoromic 
Acid 
163 
Figure 4.6 Effect of AcID Lysine to Arginine Mutations on Norstictic Acid 
Inhibition of ERM•AcID 
164 
Figure 4.7 Assay Stability Time Course, DMSO Effects, and NP-40 Effects on 
Tracer Affinity 
166 
Figure 4.8 Lichen Rich Natural Product Extracts Tested Against ERM•AcID 168 
Figure 4.9 Campaign View of the ERM•AcID Primary Screen 169 
Figure 4.10 Confirmation of Hits from the ERM•AcID Primary Screen 172 
Figure 4.11 Direct Binding of Fluorescent DNA Oligomer to Gal4(1-100) 175 
Figure 4.12 Gal4(1-100)•DNA Counter Screen of Lead Extracts from 
ERM•AcID Primary Screen 
176 
Figure 4.13 Direct Binding of MLL and pKID to the KIX Domain of CBP/p300 177 
Figure 4.14 MLL•KIX Counter Screen of Lead Extracts from ERM•AcID 
Primary Screen 
178 
Figure 4.15 Schematic Representation of Final Hit Selection 180 
Figure 4.16 Heat Map of Inhibition by Extracts from Regrown Organisms 
Against the ERM•AcID Interaction 
182 
Figure 4.17 Inhibition by Crude Natural Product Extracts from Regrown 
Organisms Against a RARα Luciferase Reporter Assay 
184 
 xiii 
Figure 5.1 Inhibition of MMP-2 and MMP-9 Expression by a Partially Purified 
Extract of Strain 91085R 
210 
 
 xiv 
List of Tables 
 
Table 1.1 Examples of Histone Modifications, Their Effectors, and Functional 
Consequences 
12 
Table 1.2 General Transcription Factors of the RNAPII Pre-Initiation Complex 13 
Table 2.1 Summary of VP16(438-454) Alanine Scan Results 55 
Table 2.2 Summary of VP16(467-488) Alanine Scan Results 59 
Table 3.1 Effect of H2 Binding Site Lysine to Arginine Mutations on VP16 
Affinity 
115 
Table 3.2 Effect of H2 Binding Site Lysine to Arginine Mutations on Norstictic 
Acid Inhibition 
117 
Table 3.3 Effect of H1 Binding Site Lysine to Arginine Mutations on VP16 
Affinity 
121 
Table 3.4 Effect of H1 Binding Site Lysine to Arginine Mutations on Norstictic 
Acid Inhibition 
122 
Table 4.1 Strains Selected for Regrowth with Filtering Statistics 181 
 xv 
List of Abbreviations 
1H,15N-HSQC 1H,15N-Heteronuclear Single Quantum Coherence 
AcID Activator Interaction Domain (Med25) 
ATF6α Activating transcription factor 6 α 
CBP CREB Binding Protein 
CH1 Cystein-histidine rich 1 
co-IP Coimmunoprecipitation 
DBD DNA-Binding Domain 
DMEM Dubelco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic Acid 
E1A Adenovirus-encoded E1A 13S protein 
ESX Epithelial specific transcription factor 
FBS Fetal bovine serum 
FP Fluorescence polarization 
GACKIX Gal11, Arc105, CBP/p300, kinase-inducible domain interacting (KIX) 
GST Glutathione transferase 
GTF General transcription factor 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
HIF1-α Hypoxia inducible factor 1 α 
HPLC High-performance liquid chromatography 
HSV Herpes simplex virus 
HTS High-throughput screen 
IC50 Half-maximal inhibitory concentration 
IPTG Isopropyl-β-D-1-thiogalactopyranoside 
KIX Kinase inducible domain interacting domain of CBP 
 xvi 
MD Molecular dynamics 
MDM2 Murine double minute 2 
Med25 Mediator subunit 25 
MLL Multi-lineage leukemia 
MMP Matrix metalloproteinase 
mRNA Messenger RNA 
MS/MS Tandem mass spectrometry 
Ni-NTA Nickel-Nitrilotriacetic Acid 
NMR Nuclear Magnetic Resonance 
NR Nuclear receptor 
NR Nuclear Receptor 
PC4 Positive Cofactor 4 
PDB Protein DataBank 
pKID Phosphorylated kinase inducible domain (CREB) 
PPI Protein-protein interaction 
PrOF Protein-observed fluorine NMR 
RARα Retinoic acid receptor α 
RNA Ribonucleic acid 
RNAPII RNA Polymerase II 
RPM Revolutions per minute 
RT-qPCR Real time quantitative polymerase chain reaction 
siRNA Small interfering RNA 
TAD Transcriptional Activation Domain 
TAF TBP associated factor 
TBP TATA binding protein 
TFIIA Transcription factor II A 
UV/Vis Ultraviolet/visible spectroscopy 
VP16 Herpes simplex virus protein 16 
VWA Von Willebrand Factor Type A  
 xvii 
List of Appendices 
Appendix A Characterization	of	Synthesized	Peptides 215 
Appendix B List of Confirmed Extracts from NPE Library Screen of 
ERM•AcID Interaction 
257 
 
 
 
 
 
 xviii 
 
Abstract 
 
Transcription, the process by which the expression of every gene encoded in an 
organism’s DNA is regulated, is critical to all cellular processes. As a result of this 
fundamental importance, transcription is tightly regulated at the molecular level by the 
assembly of dynamic protein complexes at gene promoters. That the dysregulation of 
transcription is a cause or consequence of nearly all human diseases underscores the 
importance of this regulation. Given the dire consequences of the loss of transcriptional 
regulation in diseases like cancer, it is apparent that small molecules designed to 
attenuate aberrant transcriptional processes would be particularly useful as mechanistic 
probes or potential therapeutics. 
A mechanism by which this inhibition could be achieved is to target the interactions 
between DNA-bound transcriptional activators and critical coactivator proteins required 
for the assembly of the transcriptional machinery at target genes. These interactions 
typically occur over broad surfaces areas with only moderate affinity, making them 
challenging to target, though recent advances in PPI inhibitor discovery such as exploiting 
conformational plasticity within target proteins has led to some success. In particular, the 
work described in this thesis is focused on disrupting the interactions between a number 
of transcriptional activators and the Activator Interaction Domain (AcID) of Mediator 
subunit Med25. This domain contains a unique protein fold not found in any other known 
transcriptional coactivators, leading to the hypothesis that AcID can be selectively 
targeted. The activators that bind to the AcID motif have been implicated in a number of 
cellular processes including the hijacking of transcriptional machinery by viral activators, 
endoplasmic reticulum stress response, and most interestingly the progression of 
malignant cells to a metastatic phenotype. Thus, selective inhibitors against this domain 
will be useful as mechanistic probes or even potential therapeutics against these 
processes. 
 xix 
 Towards this goal, studies designed to elucidate the underlying molecular features 
that define activator•AcID interactions were performed. These experiments identified a 
minimal interaction surface within the transcriptional activation domains of an activator 
binding partner and that electrostatic contacts are critical for the interaction of activators 
with the domain. Furthermore, hotspot analysis of the VP16 TAD suggests that the 
interaction occurs over broad surfaces within AcID. These molecular features, combined 
with data supporting the hypothesis that the AcID motif is relatively plastic and contains 
distinct activator binding surfaces that may be in allosteric communication provide several 
potential mechanisms by which AcID-dependent interactions might be disrupted. 
 In an effort to identify small molecule inhibitors of the AcID motif, screening 
campaigns against the VP16•AcID and ERM•AcID interactions were completed. In the 
case of the former, screening identified a number of relatively selective inhibitors 
belonging to the depside and depsidone classes of natural products, which have 
previously been identified as inhibitors of activator•coactivator interactions. Biophysical 
and biochemical studies suggest that these inhibitors perturb AcID-dependent 
interactions by binding covalently to lysine residues within the putative activator binding 
sites, thereby potentially disrupting critical electrostatic contacts while simultaneously 
occluding surfaces necessary for activator binding. Additional evidence suggests that 
these inhibitors may allosterically induce structural shifts within AcID that contribute to 
their inhibitory activity. Building on these results, the interaction between ERM, a member 
of the PEA3 subfamily of ETS transcription factors linked to metastasis, and AcID was 
screened against a library of natural product extracts in an effort to identify novel non-
covalent inhibitors of the AcID motif. Through a series of counter screens and stringent 
hit filtering steps, a promising extract with potent activity in vitro against the ERM•AcID 
interaction has been identified and is currently undergoing deconvolution to identify the 
structures of the active natural products within the extracts. The activity and mechanism 
of action for these molecules will be elucidated and they will subsequently be used as 
molecular probes to explore the importance of PEA3 subfamily-regulated transcriptional 
programs in biological processes such as progression to a metastatic phenotype.
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CHAPTER 1 
Targeting Transcriptional Protein-Protein Interaction Networks1 
1.1 Abstract 
Transcription is a critical process required for maintaining homeostasis and ensuring 
proper function within all organisms. Given its central importance, transcription is tightly 
regulated at the level of individual promoters through the formation of dynamic protein 
complexes, and the dysregulation of the assembly process contributes to a host of 
diseases in humans. Thus, modulating aberrant transcription through small molecules 
that target the assembly of these regulatory complexes is an attractive therapeutic goal. 
It is also a difficult one given the large surface areas and modest affinities of the protein-
protein interactions that govern the formation of these complexes. Nonetheless, recent 
advances in targeting protein interaction networks, such as exploiting compositional and 
conformational dynamics, have led to some success in targeting these difficult 
interactions. 
In this chapter, the various proteins required for regulated transcription at individual 
genes are first outlined. The mechanisms by which transcription becomes dysregulated 
and the functional consequences of this loss of transcriptional control are then discussed. 
Finally, we describe different approaches for the development of small molecule inhibitors 
of transcriptional regulators, with a particular focus on inhibitors of activator•coactivator 
interactions. The lessons learned through the successes and pitfalls of these approaches 
are ultimately applied to the overall goal driving the work contained in this thesis, namely 
the development of small molecule inhibitors of a unique transcriptional coactivator 
domain. 
                                            
1 Portions of this chapter were adapted from: Mapp, Anna K.; Pricer, Rachel; Sturlis, 
Steven. Targeting transcription is no longer a quixotic quest. Nat. Chem. Biol. 2015, 11, 
891-894.
 2 
1.2 Introduction 
The existence of endogenous factors that functionally connect DNA-encoded 
information and protein levels was first postulated by Monod and Jacob in 1961.1 In the 
ensuing decades, evidence has mounted that these factors—transcription factors—are 
also critical drivers of human disease. The overexpression, underexpression, and 
formation of fusion proteins of transcription factors underpin a range of human diseases, 
and thus these proteins have high intrinsic value as therapeutic targets. Given the 
fundamental importance of these proteins, the logical questions are why there are no 
drugs that directly target these transcription factors and why there are so few quality probe 
molecules to further dissect the function of these factors. These questions are particularly 
urgent given the avalanche of new data regarding transcription factor localization through 
the transformative technological advances in sequencing and genetic manipulation that 
have occurred in the past decade. 
1.3 Overview of Transcriptional Activators 
Every cellular organism contains all of the requisite instructions to maintain 
homeostasis and proper function encoded in the form of DNA. Proteins known as 
transcriptional activators recognize and bind to specific sequences in the promoters or 
enhancers of cognate genes and recruit a suite of coregulatory proteins that modulate the 
transcriptional output of these genes by modifying chromatin structure and/or assembling 
the RNA Polymerase II (RNAPII) pre-initiation complex.2 
 Transcription is the process by which genetic information encoded within DNA is 
converted to a transferrable signal through which gene products, namely proteins, are 
produced. This critical process is completed using a specific class of proteins termed 
transcriptional activators, which are modular proteins minimally composed of two 
domains: a DNA-binding domain (DBD) and a transcriptional activation domain (TAD).3 
 3 
 
Figure 1.1- Transcriptional Activators are Minimally Composed of a Transcriptional Activation 
Domain and a DNA Binding Domain A schematic representation of the modular nature of 
transcriptional activators is shown on the left. Several structures of representative TADs (red) and 
DBDs (blue) are shown on the right. The TAD structures are derived from solution NMR experiments 
of the indicated activators in complex with binding partners. The DBD structures are derived from x-
ray crystal structures of the transcriptional regulators Kaiso (zinc finger), GCN4 (leucine zipper), and 
Mad/Max in complex with DNA. 
DNA-Binding Domains 
DNA binding domains recognize specific sequences on DNA in target genes 
upstream of the transcription start site. Several folds capable of binding DNA have been 
identified within DBDs such as helix-turn-helix, zinc finger, leucine zipper, and helix-loop-
helix motifs.4 In all of these motifs, the secondary structure of the domain positions the 
side chains of critical amino acids within the major groove of DNA, allowing for 
intermolecular contacts between the DBD and specific bases of DNA and the phosphate 
backbone. Generally, this proper spatial orientation is achieved through the use of alpha-
helical secondary structure, though several examples of beta-turns being used for protein-
 4 
DNA interactions have been reported.5 Furthermore, the majority of the specificity for a 
particular promoter sequence arises from hydrogen bonding with most protein-DNA 
interactions utilizing ten to twelve hydrogen bonds.4 Thus, various transcription factors 
can attain exquisite selectivity for DNA recognition through slight differences in the 
secondary structure of interaction surfaces or the identity of specific amino acids in the 
proper spatial orientation for interaction with the nucleobases or phosphate backbone. 
Representative examples of the structures of zinc finger6, leucine zipper7, and helix-loop-
helix8 DBDs are shown in Figure 1.1 above. 
Transcriptional Activation Domains 
Following localization to the proper genomic sequence through the DBD, the TAD 
recruits coregulatory protein complexes or the transcriptional machinery through a 
network of protein-protein interactions. These domains have been historically classified 
as acidic, glutamine-rich, or proline-rich dependent upon the high prevalence of these 
amino acids within the TAD sequences.9 The acidic activation domains, also called 
amphipathic activation domains, represent the largest and best-studied class and 
includes transcription factors such as the viral activator VP1610,11, the tumor suppressor 
p5312, and the yeast activator Gal413. TADs tend to be intrinsically disordered, often 
existing as random coils in isolation and adopting α-helical secondary structures following 
contact with their binding partners as in the cases of the pKID domain of CREB binding 
to the KIX domain of CBP/p30014, HIF-1α binding to the CH1 domain of CBP/p30015, and 
Gcn4 binding to Med1516. Structures of several representative TADs, including the pKID 
domain of CREB17, VP1610, and Myb18, in complex with coactivator binding partners are 
shown in Figure 1.1 above.  In fact, kinetic and thermodynamic studies of three distinct 
TADs binding to Med15 suggest that activator•coactivator binding is biphasic, with an 
initial diffusion limited binding event followed by conformational changes in the complex.16 
Intrinsic disorder within TADs is hypothesized to be functionally advantageous in that the 
domains can bind to multiple coregulatory partners by adopting unique and 
complementary conformations, allowing for the possibility of transcriptional regulation 
through competition for necessary cofactors. Additionally, disorder allows the TAD to 
interact over a significantly broader surface area than is possible for preordered proteins, 
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providing selectivity for binding partners without the use of prototypical ‘hotspot’ regions.19 
Finally, many transcriptional activators, such as VP1620, the glucocorticoid receptor21, and 
the androgen receptor22, contain more than one activation domain that is capable of 
independently functioning, allowing for recruitment of multiple coregulatory proteins or 
stronger interactions with their binding partners. Furthermore, evidence suggests that 
these distinct TADs may have unique functions in a gene dependent context. For 
example, DNA microarrays and RT-qPCR analysis demonstrated the TADs activation 
function 1 (AF1) and activation function 2 (AF2) of the transcriptional activator 
Glucocorticoid Receptor (GR) were independently required for different subsets of GR 
regulated genes based upon the sequence and structure of the glucocorticoid response 
element within those genes.23 
1.4 Coregulatory Proteins and the Pre-Initiation Complex 
Beyond sequence-specific activators that recognize and bind to DNA, 
transcriptional regulation requires additional proteins that modulate the transcription of 
cognate genes. Coactivators may physically bridge the DNA bound activator to the 
transcriptional machinery or modify chromatin such that transcription is more facile, 
whereas corepressors may block the TAD from contacting necessary cofactors or modify 
chromatin such that transcription is repressed. In the following section we discuss three 
classes of coregulatory proteins: (1) masking proteins, (2) the Mediator complex and other 
adaptor coactivators, and (3) chromatin modifying enzyme complexes, as well as the 
components of the RNAPII pre-initiation complex. 
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Figure 1.2- Examples of Coregulatory Protein Classes (A) Masking proteins bind to the TAD of a 
transcriptional activator, preventing it from binding to other required elements of the transcriptional 
machinery. (B) Adaptor coactivators, including the Mediator Complex, act as scaffolding platforms that 
allow for the assembly of multiprotein complexes required for transcription. (C) Chromatin modifying 
enzyme complexes alter histone protein tails or nucleosome organization to activate or suppress 
transcription. Histone Acetyl Transferase activity is used as a representative example. 
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Masking Proteins 
Perhaps the most intuitive class of coregulatory proteins are the corepressor 
masking proteins that recognize and bind to the TADs of transcriptional activators, 
thereby physically blocking the potential interactions between the TAD and the rest of the 
transcriptional machinery. An excellent example of this type of coregulator is the yeast 
protein Gal80, which interferes with the transcription of yeast GAL genes by masking the 
TAD of the activator Gal4. Upon exposure to galactose, Gal80 undergoes a 
conformational change that unmasks the Gal4 TAD resulting in the upregulation of the 
expression of GAL genes by the unmasked activator.24  In humans, MDM2 forms a 
complex with the TAD of the transcriptional activator p53, which functions as a tumor 
suppressor and regulates cellular responses to cell damage. Similar to Gal4•Gal80, 
MDM2 blocks transcriptional activity of p53 by masking the TAD, but within normal cells 
dissociates following a phosphorylation event on MDM2 in response to DNA damage 
signals.12 Additionally, MDM2 modulates the activity of p53 by altering the lifetime of the 
activator through its E3 ubiquitin ligase activity, targeting p53 for proteasomal 
degradation.25 
Mediator and Adaptor Coactivators 
 Contrary to masking proteins, the primary function of which are to bind and 
sequester the TAD of activators from contacting other elements of the transcriptional 
machinery, a second class of coregulatory proteins function to link components of the 
transcriptional machinery to one another by directing the assembly of large multiprotein 
complexes.26 
 The Mediator complex is a megadalton assembly of twenty-six protein subunits in 
yeast with an additional five subunits found in higher order eukaryotes, the recruitment of 
which is required for the expression of virtually all protein coding genes.27 This complex 
functions by making protein-protein interactions with DNA-bound transcriptional 
activators and components of the general transcriptional machinery, bridging the 
activators to the RNAPII holocomplex and enabling activated transcription. 28,29 Structural 
characterization of the full intact Mediator complex has proven to be quite challenging, 
given the flexibility, low abundance, and heterogeneity of the complex. However, most of 
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the subunits have been localized to approximate locations within the complex and 
comprise three modules termed the head, middle, and tail, as represented below.30  
 
Figure 1.3- The Mediator Complex Bridges DNA-Bound Activators to the RNAPII PIC (A) DNA-
bound activators such as VP16, ATF6α, and the PEA3 subfamily contact the Mediator tail module at 
subunit 25, while the head and middle modules contact components of the RNAPII holoenzyme, aiding 
in the assembly of the PIC at the transcription start site. (B) General organization of the Mediator 
complex as reported by Malik et. al.30 Head module components are shown in blue, middle module 
components in green, and tail module components in red. Med1 and Med26 (yellow) are not uniformly 
found in the complex are believed to lie at the junction of the tail and head modules. Protein binding 
partners for specific subunits are indicated using arrows.  
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The head and middle sections of the Mediator complex are responsible for 
contacting the general transcription factors of the PIC, while the highly modular tail 
contacts various DNA-bound transcriptional activators.31,32 For example, a direct 
interaction has recently been demonstrated between Med26 and the RNAPII pre-initiation 
complex component TFIID.33 Additionally, TFIIH has been reported to interact with 
Med11, further aiding in the assembly of the PIC at target gene promoters.34,35 The 
specific interactions by which elements of the RNAPII holoenzyme interact with the head 
and middle modules of Mediator are still being elucidated, but the role of these modules 
in linking Mediator to RNAPII has been further validated by structural techniques such as 
electron microscopy that examine whole Mediator modules. Additionally, biochemical 
experiments such as activated transcription assays with Mediator subunit or general 
transcription factor depleted nuclear extracts have been used to identify key interactions 
between subunits required for function.36-38 For example, a minimal functional core of the 
Mediator head module comprised of Med17, Med11, and Med22 has been reported to 
bind TBP with a near 1:1 stoichiometry, with transcriptional activity in yeast nuclear 
extracts directly correlated with the amount of TBP present in the extracts.37 Similar 
experiments demonstrated that a recombinantly expressed Mediator head module-bound 
RNAPII subunits Rbp4 and Rbp7, further supporting the role of Mediator in stabilizing the 
assembly of the PIC at target gene promoters. 37,39 Additionally, specific protein-protein 
interactions have been identified between various activators and Mediator subunits such 
as nuclear receptors RARα40,41, ERα42, AR43, and GR44 contacting Med1; Gcn4 
contacting Med2 and Med345; Pdr146, VP1647, and Gal4 interacting with Med15; 
C/EBPβ48, ESX49, E1a50 interacting with Med23; and ATF6α51, VP1652, and ETV553 
contacting Med25 physically linking the aforementioned activators to the rest of the 
Mediator complex and the general transcriptional machinery. Beyond physically linking 
activators to the RNAPII PIC, an additional function of the Mediator complex is that it can 
utilize chromatin looping in order to connect far upstream regulatory elements to the 
transcription start site.32,54 
The master coactivator CBP/p300 is another excellent example of an adaptor 
coactivator. This large protein contains at least six domains (NRID, CH1, KIX, CH2, CH3, 
and IBiD) that have been validated as interaction partners for a variety of activators 
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including numerous nuclear receptors55, c-Jun56, c-Myb18, CREB14, p5357, and HIF-1α15. 
For the KIX domain alone more than fifteen unique binding partners have been identified, 
underscoring the role of CBP/p300 as a ‘master coactivator’ capable of binding a plethora 
of transcriptional activators.18,58-64 Beyond interacting with DNA-bound activators, 
CBP/p300 has been shown to bind other elements of the transcriptional machinery, 
allowing for the assembly of diverse multiprotein complexes. For example, elements of 
the RNAPII pre-initiation complex such as TBP, TFIIB, TFIIE, and TFIIF have been 
reported to bind to CBP/p300, aiding in the assembly of the PIC at gene promoters. 55,65 
Beyond acting as a bridge between DNA-bound activators and the RNAPII PIC, 
CBP/p300 also functions as a scaffold that allows for the recruitment of other necessary 
coactivator proteins for DNA-bound activators, such as the interaction with p160 
coactivators like SRC1 in androgen receptor (AR) dependent transcription.66 
Furthermore, evidence suggests that the N-terminal domain of CBP contacts the Mediator 
complex at subunit Med2541, which may indirectly aid in the recruitment of Mediator to 
gene promoters without a direct contact to a DNA-bound activator. Perhaps the most 
critical function of CBP/p300, beyond its involvement in the assembly of multimeric protein 
complexes, is its enzymatic ability to acetylate chromatin at gene promoters through the 
activity of its histone acetyltransferase domain.67 The importance of this function is 
discussed in greater detail in the following section. 
Chromatin Modifying Enzyme Complexes 
Beyond recruiting coregulators that block or recruit the PIC, many activators also 
recruit proteins or complexes that harbor enzymatic function and modify the local 
structure of chromatin. In the nucleus of eukaryotic organisms, DNA is wrapped around 
an octet of histone proteins, creating a protein-DNA complex referred to as a nucleosome 
that can be visualized as a ‘bead on a string’.68 Transcriptional activity is effectively 
modulated based upon how tightly DNA is wrapped around histones and how tightly 
packaged nucelosomes are in reference to one another. Post-translational modification 
of histone proteins, including lysine acetylation, phosphorylation, ubiquitylation, and 
sumoylation determine how tightly DNA is wrapped around the histone octet.69 For 
example, histone acetyltransferases (HAT) such as CBP or the nuclear receptor 
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coactivator NCOA1 acetylate N-terminal tails of histone H3 and H4, which relieves 
electrostatic interactions between the negatively charged phosphate backbone of DNA 
and the basic lysine residues within the histone tail. 70,71 This results in a looser 
association between DNA and the histones and allows for greater accessibility of cis-
regulatory elements and upregulation of gene expression. In converse, histone 
deacetylases (HDAC) such as HDAC1, HDAC2, and HDAC3 can remove acetyl 
modifications from the histone tails, thereby promoting a tighter interaction between DNA 
and the histones resulting in downregulation of gene expression.72 Thus, enzymatic 
modification of epigenetic marks on histone proteins confers an additional mechanism by 
which transcription is tightly regulated. As an aside, evidence also suggests that HATs 
and HDACs can also act upon non-histone substrates, such as the androgen receptor 
and p53, in order to modify protein-protein interaction networks or protein half-life. 73-75 
Methylation of lysine residues within the histone tail also affects transcriptional 
throughput, though the functional consequence is not as intuitive as differences in 
acetylation state and depends upon the number of methyl modifications and the location 
of these modifications within the histone tail. 76,77 For example, H3K27 mono-methylation 
activates transcription while tri-methylation of the same residue results in repression of 
transcription.78 In addition to recruiting epigenetic modifiers that alter histone marks, many 
activators also recruit nucleosome remodeling complexes that alter the physical 
packaging of nucleosomes into chromatin, such as the SWI/SNF and Mi2/NuRD families 
of protein complexes to positively or negatively affect the transcription of target genes.79 
A table containing examples of several histone modifications, the enzyme responsible, 
and their functional consequences on transcription is presented below. 
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Table 1.1- Examples of Histone Modifications, Their Effectors, and Functional Consequences 
 
 
 
Modification Site Enzyme Functional	Consequence
Acetylation H3K4 Esa1 Transcriptional	Activation
H3K9 Gcn5,	SRC-1 Transcriptional	Activation
H3K14
Gcn5,	Esa1,	
TIP60,	SRC-1,	
p300,	CBP
Transcriptional	Activation,	DNA	
Repair
H3K23
Gcn5,	Sas3,	
p300,	CBP
Transcriptional	Activation,	DNA	
Repair
H3K27 Gcn5 Transcriptional	Activation
H4K5
Esa1,	TIP60,	
p300
Transcriptional	Activation,	DNA	
Repair
H4K8
Gcn5,	PCAF,	
Esa1,	TIP60,	
p300
Transcriptional	Activation,	DNA	
Repair
H4K12
Esa1,	TIP60,	
p300
Transcriptional	Activation,	DNA	
Repair
Methylation H3K4 Set9,	MLL Transcriptional	Activation,	
Transcriptional	Elongation
H3K9 Suv39h,	Clr4 Transcriptional	Repression	(3-Me)
H3K27 Ezh2
Transcriptional	Activation	(1-Me),	
Transcriptional	Repression	(3-Me)
H4K20 Suv4-20h Transcriptional	Repression	(3-Me)
Phosphorylation H2AS1 MSK1 Transcriptional	Repression
H2AS139 DNA-PK DNA	Repair
H2BS14 Mst1 Apoptosis
H2BS33 TAF1 Transcriptional	Activation
H3S10 Snf1 Transcriptional	Activation
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The RNA Polymerase II Pre-Initiation Complex 
 Following the recruitment of the necessary coactivator proteins, the final step in 
transcription is the recruitment of the enzymatic complex responsible for the actual 
reading of the gene and synthesis of the mRNA. This has been termed the pre-initiation 
complex and it is composed of RNAPII, itself a multimeric complex of twelve subunits, 
and a variety of accessory proteins and protein complexes termed the general 
transcription factors (GTF). Specifically, TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH are the 
essential GTFs and carry out a variety of functions including stabilization of RNAPII at the 
transcription start site, ATP-dependent helicase activity responsible for unwinding the 
DNA double helix to form the transcription bubble, enzymes responsible for nucleotide 
excision repair to replace mismatched or mutated nucleotides, and enabling promoter 
clearance by RNAPII.80 The table below defines the function of each the required GTFs.81 
 
Table 1.2- General Transcription Factors of the RNAPII Pre-Initiation Complex 
 
  
Thus, in conclusion, transcriptional activation requires a veritable host of proteins in 
order to ensure the proper regulation of gene expression. These proteins interact directly 
to form large multimeric complexes at the promoters of target genes in order to stabilize 
the RNAPII pre-initiation complex at the transcriptional start site. Notably, these 
Protein	Composition Function
TFIIA p39,	p19,	p12
Stabilizes	TATA-TBP	interaction,	Not	essential	for	PIC	assembly	at	all	
promoters
TFIIB p33 Start	site	selection,	Stabilizes	TATA-TBP	interaction,	Recruits	RNAPII	and	TFIIF
TFIID TBP,	TAFs*	1-14
Core	promoter	(TATA)	binding	factor,	Kinase,	Ubiquitin	activation	and	
conjugation,	Histone	acetyltransferase	activity
TFIIE p56,	p34 Recruits	TFIIH,	Promoter	clearance	by	RNAPII
TFIIF RAP30,	RAP74
Binds	and	recruits	RNAPII	to	promoter,	Recruits	TFIIE	and	TFIIH,	Assists	TFIIB	
and	RNAPII	in	start	site	selection,	Assists	RNAPII	promoter	clearance,	Promotes	
RNAPII-mediated	transcript	elongation
TFIIH
p89,	p80,	p62,	p52,	
p44,	p40/CDK7,	
p38/Cyclin	H,	p34,	
p32/MAT1,	p85/TFB5	
ATPase	activity	for	transcription	initiation	and	promoter	clearance,	Helicase	
activity	to	open	promoter	assisting	PIC	assembly,	Nucleotide	excision	repair	
capability,	Kinase	for	RNAPII	C-terminal	domain	phosphorylation,	E3	ubiquitin	
ligase	activity
*	=	TBP	Associated	Factor
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complexes are highly dynamic, owing to the large surface areas and weak affinities with 
which many of these interactions occur, and modular, with different cellular or promoter 
contexts requiring unique components. 19,82 The dynamics and modular nature of these 
complexes are discussed in more depth in Section 1.6 and Section 1.7. As a result, these 
interactions each represent potential points of intervention for small molecule inhibitors in 
the modulation of transcriptional activity. For example, targeting activator•masking protein 
interactions could be used to reactivate an aberrantly suppressed transcriptional 
activator, as in the case of the p53•MDM2 interaction.83 Conversely, targeting specific 
activator•coactivator interactions for inhibition could be used to suppress the activity of an 
overexpressed transcriptional activator.84 Targeting chromatin modifying complexes is an 
area of very active research at present and has seen promising results as inhibitors 
advance to the clinic and enter the marketplace, such as Vorinostat which has been 
approved for treatment of cutaneous T cell lymphoma. 85-87 In the next section the 
functional consequences and mechanisms of transcriptional dysregulation are outlined. 
1.5 Dysregulation of Transcription Contributes to Disease 
Given the clear importance of transcription in maintaining normal cellular function, it 
is unsurprising that the dysregulation of this process can have dire consequences on 
human health. Perhaps the most prominent example of this phenomenon is the variety of 
pathogenic mechanisms by which dysregulated transcription leads to cancer, including 
abnormal expression of transcription factors, the formation of fusion genes through 
chromosomal translocations, and mutations within transcription factors that alter their 
function. 
Abnormal Expression of Transcription Factors 
 Abnormal changes in the expression profiles of proteins responsible for regulating 
transcription is a common mechanism by which human malignancies occur. For example, 
the c-Myc oncogene is amplified in lung88, breast89, and colon cancers90 resulting in 
overexpression of c-Myc. In turn, an overabundance of c-Myc results in overexpression 
of genes implicated in cell cycle regulation, such as the cyclins and cyclin dependent 
kinases, leading to loss of cell cycle control. Other genomic targets for c-Myc activation 
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include regulators of metabolic processes such as glycolysis, and genes that have been 
linked to immortalization in malignant tissues.91 Importantly, loss of c-Myc function has 
been recently demonstrated to result in tumor regression, underscoring the importance 
of this activator as a therapeutically relevant target. 92,93 As additional examples, c-Myb 
overexpression has been linked to lymphocyte transformation to a leukemic state and 
overexpression of the androgen receptor is required for transformation in prostatic 
malignancies and sensitizes cells to low levels of circulating androgens thereby 
circumventing the most common therapeutic strategy in treatment of PCa. 94,95 
Overexpression of the PEA3 subfamily of Ets transcriptional activators as a result of 
aberrant PI3K/RAS signaling cascades has been linked to tumorigenesis and metastatic 
processes in breast and prostatic carcinomas.96 
 Conversely, underexpression of transcriptional activators responsible for 
regulating tumor suppressor transcriptional programs can also lead to malignancies. For 
example, the retinoblastoma protein (RB), a tumor suppressor whose function is to 
regulate cell cycle progression, is deleted or mutated in 90% of lung cancers, resulting in 
loss of critical cell cycle progression checkpoints ultimately leading to unrestricted cell 
growth. 97,98 Similar loss of normal RB expression has also been demonstrated to result 
in retinoblastoma and osteosarcomas in children.99 Similarly, loss of normal KLF6 
expression in prostatic tissues has been linked to diminished p21 expression and a 
subsequent loss of cell cycle control.100 As a final example, overexpression of the p53 
corepressor MDM2 results in a decrease in cellular p53 concentrations as a consequence 
of proteasomal degradation triggered by MDM2 dependent ubiquitylation, resulting in loss 
of p53 dependent tumor suppressor gene programs.101 
Chromosomal Translocations 
 One mechanism by which transcription becomes dysregulated is through 
chromosomal abnormalities that arise following translocation events in which a coding 
region of a particular gene becomes associated with regulatory elements or coding 
regions of another gene. In the case of the former proteins under tight transcriptional 
regulation may become fused to regulatory elements from a far more actively transcribed 
gene while the latter may result in fusion proteins with aberrant function. For example, all 
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cases of Burkitt’s Lymphoma require a chromosomal translocation of c-Myc to the 
regulatory regions that control expression of the immunoglobulin heavy or light chains in 
lymphocytes. Thus, c-Myc is upregulated far above normal levels resulting in 
transformation of healthy lymphocytes to the lymphoma phenotype as a result of 
excessive activity in c-Myc transcriptional programs.102 A similar example of this 
phenomenon is the TMPRSS2:ERG gene fusion found in a majority of aggressive 
prostate cancer phenotypes, which results in the expression of a truncated form of ERG 
that drives the activation of invasion and metastasis related gene programs.103 In the case 
of alveolar rhabdomyosarcoma, a pediatric cancer of soft tissues that can occur in any 
anatomical location, chromosomal translocations result in the fusion of the PAX3 or PAX7 
DBD to the TAD of FKHR, a member of the forkhead transcription factor family. The 
PAX3/PAX7 TAD is negatively regulated through interactions with the N-terminus of the 
activator, but the chimeric protein containing the FKHR TAD lacks this regulatory 
intramolecular interaction, resulting in abnormally high expression of PAX3/PAX7 gene 
programs ultimately leading to a malignant phenotype.104 
Mutations in transcription factors 
 An additional mechanism by which transcriptional activation may become 
dysregulated is through mutations within transcriptional activators that alter their protein 
interaction networks or function. As a prototypical example, p53 is the most commonly 
mutated gene in human cancers, with more than fifty percent of all malignancies harboring 
mutations in this activator.105 As a result of the clinical implications associated with these 
mutations, p53 is particularly well studied and provides excellent examples of several 
mechanisms by which activator mutations generally lead to loss of transcriptional 
regulation. Mutations within p53 have been linked to four distinct mechanisms by which 
malignant phenotypes are promoted, as shown in Figure 1.4 below. In the first, mutations 
within the p53 DBD impairs DNA recognition of normal p53-target gene regulatory 
elements while simultaneously enabling recognition of non-native promoters. As a result, 
wild type p53 target genes responsible for tumor suppressor activity are downregulated, 
while oncogenic proteins may be upregulated by the intact p53 TAD as a consequence 
of non-native DNA recognition. 106,107 Attempts at identifying specific DNA recognition 
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sequences for p53 mutations in the DNA-binding domain are ongoing, but have yet to 
define a consensus sequence. In fact, these types of mutations initially led to the 
classification of p53 as an oncogene as opposed to a tumor suppressor.  
A second mechanism by which p53 mutation results in malignant transformation is 
the development of new protein-protein interactions between p53 and other 
transcriptional activators, resulting in enhanced transcriptional throughput, as in the case 
of mutant p53•nuclear factor Y (NF-Y) interactions, which may cause loss of cell cycle 
control following DNA damage events.108 More specifically, these interactions recruit the 
potent p53 TAD to NFY regulated genes through p53•NFY•DNA interactions with the 
functional consequence being overexpression of NFY regulated genes as the p53 TAD 
upregulates transcription more efficiently than the NFY TAD.  
A closely related, but functionally distinct mechanism involves p53 mutations that 
allow for non-native protein-protein interactions with other transcription factors that 
mitigate their normal function by interfering with DNA binding or the recruitment of other 
transcriptional coregulators, as in the case of mutant p53 interfering with the normal 
function of p63 and p73.109 
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Figure 1.4- Functional Consequences of p53 Activator Mutations (A) Mutations within the DBD of 
p53 prevent it from activating expression of native tumor suppressor target genes and instead 
activates expression of oncogenes through non-native DBD•DNA interactions. (B) Mutations may 
cause p53 to dimerize with non-native partners such as NF-Y, localinzing the dimer to NF-Y target 
genes. The p53 TAD is more efficient at activating transcription than the TAD of NF-Y, leading to 
upregulated expression of NF-Y target genes. (C) Mutations may cause p53 to dimerize with non-
native partners such as p63, preventing the localization of p63 to target genes. 
In addition to interfering with normal transcriptional activity, mutant p53 can also bind 
to components of other important, non-transcriptionally related, cellular pathways such as 
WT p53 Target Gene Oncogene
Mutant 
DBD
TAD RNAPII
Coactivator
p53
A. DBD Mutations Activate Oncogene Expression
NF-Y Target Gene
DBD
TAD RNAPII
Coactivator
DBD
TAD
p53 NF-Y
B. Non-native Dimerization Enhances Expression
p63 Target Gene
DBD
TAD
RNAPII
Coactivator
DBD
TAD
p53 p63
C. Non-native Dimerization Represses Expression
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interfering with the MRE11-RAD50-NSB1 complex, resulting in diminished DNA-repair 
through homolgous recombination.110 These specific mechanisms are not all-inclusive, 
but instead illustrate the variety of pathways by which mutations in transcriptional 
regulators may result in malignancies. 
Notably, in all three of the above common pathogenic mechanisms (overexpression 
of activators, chromosomal translocations, and activator mutations) small molecules that 
modulate aberrant transcriptional activator function would be useful mechanistic probes 
and promising therapeutic leads. Despite their potential, transcription factor–targeting 
molecules have remained elusive; in more conventional terms, transcription factors have 
largely been classified as undruggable. The origin of this description becomes clear as 
one examines the possible avenues for altering transcription factor activity. Except for 
nuclear receptors, transcription factors do not have native small-molecule ligands; thus, 
the primary options for their alteration involve manipulation of the complex network of 
protein-protein and protein–nucleic acid interactions by which transcription factors 
function. 
1.6 Features of Protein-Protein Interaction Networks in Transcription 
As p53 is an exceptionally well studied transcriptional activator, the PPI network 
required for its regulation has been thoroughly characterized and provides insight to the 
wide range of affinities and surface areas of the complexes required for transcriptional 
regulation in general, as shown in Figure 1.5-A below. The complexes formed between 
p53 and its regulatory partners such as MDM2 are typically high affinity with a relatively 
small surface area, and their interaction energy largely resides in a small number of 
residues. These are structurally well-organized interfaces and are highly amenable to 
structural characterization.12 As with many activators, p53 typically functions as a 
multimer, and the homo-oligomerization interface is another high-affinity, well-organized 
interface, although it takes place over a considerably larger binding surface.111 The final 
group of PPIs that activators such as p53 utilize are those with coactivator proteins, such 
as CBP/p300, typically involved as part of the assembly of the transcriptional machinery 
in the early stages of transcription as discussed above.60 These interactions are the least 
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well characterized, likely because the binding partners are conformationally dynamic, 
inhibiting high-resolution structural studies, and many are of only moderate affinity.112 
 
Figure 1.5- The Chemical Space of Protein-Protein Interactions (A) Protein-protein interactions 
can be classified based upon the surface area over which they occur (x-axis) and the affinity of the 
complex (y-axis). PDB Codes: p53•MDM2- 1YCR, p53 Dimer- 1PET, KIX- 2LQH. (B) The development 
of small molecule PPI inhibitors have been spurred by advances in inhibitor design and screening 
methodologies. Success in targeting high affinity, low surface area interactions has far outpaced 
discovery of inhibitors for broader or weaker interactions. 82,113 
Building on this example, the interaction between p53 and MDM2 serves as a 
useful case study for the successful targeting of transcriptionally relevant PPIs. This is a 
high-affinity complex that masks the p53 activation domain, preventing p53 from 
functioning as a transcriptional activator and regulating its lifetime through its 
ubiquitylation state.101 It is also highly ordered, with a focused interaction surface area of 
<1,800 A2 that has been amenable to structural characterization and has characteristics 
similar to those of receptor-ligand interactions. Specifically, a crystal structure of the N-
terminal TAD of p53 in complex with MDM2 was solved and suggested that the interaction 
is mediated primarily by only three residues (F19, W23, and L26). 12,114 The importance 
of these residues was further supported by functional data wherein transcriptional 
activation by p53 requires that these residues be intact.115 As a result, p53•MDM2 and 
the closely related p53•MDMx complex have been readily targeted with several unique 892 NATURE CHEMICAL BIOLOGY | VOL 11 | DECEMBER 2015 | www.nature.com/naturechemicalbiology
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one to two orders of magnitude weaker than 
p53-MDM2–type interactions7,9. Further, 
the interaction surface is often considerably 
larger, with interaction energies shared over 
a greater number of amino acids, defying 
hotspot analysis.
Despite the challenges, the ability to 
manipulate transcription factor–coactivator 
complexes offers two exciting possibilities. 
The first is context specificity. Many of the 
complexes involved in transcription are 
dynamic in composition and comprise a core 
enzymatic function flanked by scaffolding 
proteins and exchangeable modules. The 
BAF-type chromatin remodeling complexes 
that play a key role in transcription initiation 
are an excellent example. Most share a 
core enzymatic subunit (the ATPase Brg), 
but there are exchangeable subunits that 
vary according to tissue (Fig. 2a)10. In 
the past ten years, evidence has emerged 
that transcription factors target both the 
enzymatic component and exchangeable 
modules in such complexes as part of the 
assembly of the transcriptional machinery. 
In yeast, the application of covalent chemical 
cross-linking to map contacts with the 
BAF-type complex Swi–Snf revealed 
that the transcription factors Gal4 and 
VP16 each contact the core enzymatic 
functionality (Snf1) in addition to auxiliary 
factor Snf5 (ref. 11). Thus, one could 
imagine blocking a PPI that would affect 
the localization of a complex at particular 
gene promoters but would leave the core 
enzyme unaltered, providing functional 
capacity in other contexts. A second group 
of context-dependent transcription factor–
coactivator PPIs are those used by viruses 
to hijack the transcriptional apparatus in 
infected tissues. Arora and Pan recently 
demonstrated that an inhibitor of a complex 
formed between the human papillomavirus 
transcription factor E6 and the coactivator 
p300 restores the ability of p53 to function 
in human papillomavirus–positive head 
and neck cancers and, in doing so, blocks 
tumorigenicity12. A challenge for the coming 
decade is to provide a more comprehensive 
map of the network of transcription factor 
PPIs at gene promoters as there remain 
more questions than answers for most 
transcription factors. Even in the case of the 
well-studied transcription factor p53, it is 
not clear which of its coactivator complexes 
are the most critical to block, either alone or 
in combination; considering its interaction 
with the master coactivator CBP and its 
close relative p300 alone, p53 binds in vitro 
with four of the activator interaction motifs 
within CBP, but the functional relevance 
of each of those interactions is not yet 
defined13. This is an area in which chemical 
biology tools such as covalent chemical 
capture or high-quality small-molecule 
probes will be invaluable.
In addition to compositional dynamics 
within transcription factor complexes, 
many of the individual subunits exhibit 
significant conformational plasticity as a 
means to interact specifically with a variety 
of transcription factors. The low energy 
Figure 1 | The chemical space of protein-protein interactions. (a) Protein-protein interactions can 
be effectively classified by the strength of the complex (y-axis) and the surface area over which the 
interaction occurs (x-axis). Using p53 as an example, transcriptional activator interaction networks 
span a broad range of strength and surface area. PBD ID codes for each structure are as follows: p53-
Mdm2 repressor, PDB 1YCR; p53 dimer, PDB 1PET; GACKIX domain of CBP with proposed bindi g 
residues, PDB 2LQH. (b) Recent advances in protein-protein interaction inhibitor design and screening 
methodologies have led to the discovery of a number of new small-molecule inhibitors, although success 
in targeting high-affinity, small-surface-area interactions has far outpaced broader or weaker interactions. 
SA, surface area. See refs. 7 and 8 for a more detailed discussion.
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one to two orders of magnitude w aker than 
p53-MDM2–type interactions7,9. Further, 
the interaction surface is often co sider bly 
larger, with interaction energies shared over 
a greater umber of amino acids, defying 
h tspot an lysis.
Despite the challenges, the ability to 
manipulate transcription factor–coactivator 
complexes offers two exciting possibilities. 
The first is context specificity. Many of the 
complexes involved in transcription are 
dynamic in composition and comprise a core 
enzymatic function flanked by scaffolding 
proteins and exchangeable modules. The 
BAF-type chromatin remodeling complexes 
that play a key role in transcription initiation 
are an excellent example. Most share a 
core enzymatic subunit (the ATPase Brg), 
but there are exchangeable subunits that 
vary according to tissue (Fig. 2a)10. In 
the past ten years, evidence has emerged 
that transcription factors target both the 
enzymatic component and exchangeable 
modules in such complexes as part of the 
assembly of the transcriptional machinery. 
In yeast, the application of covalent chemical 
cross-linking to map contacts with the 
BAF-type complex Swi–Snf revealed 
that the transcription factors Gal4 and 
VP16 each contact the core enzymatic 
functionality (Snf1) in addition to auxiliary 
factor Snf5 (ref. 11). Thus, one could 
imagine blocking a PPI that would affect 
the localization of a complex at particular 
gene promoters but would leave the core 
enzyme unaltered, providing functional 
capacity in other contexts. A second group 
of context-dependent transcription factor–
coactivator PPIs are those used by viruses 
to hijack the transcriptional apparatus in 
infected tissues. Arora and Pan recently 
demonstrated that an inhibitor of a complex 
formed between the human papillomavirus 
transcription factor E6 and the coactivator 
p300 restores the ability of p53 to function 
in human papillomavirus–positive head 
and neck cancers and, in doing so, blocks 
tumorigenicity12. A challenge for the coming 
decade is to provide a more comprehensive 
map of the network of transcription factor 
PPIs at gene promoters as there remain 
more questions than answers for most 
transcription factors. Even in the case of the 
well-studied transcription factor p53, it is 
not clear which of its coactivator complexes 
are the most critical to block, either alone or 
in combination; considering its interaction 
with the master coactivator CBP and its 
close relative p300 alone, p53 binds in vitro 
with four of the activator interaction motifs 
within CBP, but the functional relevance 
of each of those interactions is not yet 
defined13. This is an area in which chemical 
biology tools such as covalent chemical 
capture or high-quality small-molecule 
probes will be invaluable.
In addition to compositional dynamics 
within transcription factor complexes, 
many of the individual subunits exhibit 
significant conformational plasticity as a 
means to interact specifically with a variety 
of transcription factors. The low energy 
Figure 1 | The chemical space of protein-protein interactions. (a) Protein-protein interactions can 
be effectively classified by the strength of the complex (y-axis) and the surface area over which the 
interaction occurs (x-axis). Using p53 as an example, transcriptional activator interaction networks 
span a broad range of strength and surface area. PBD ID codes for each structure are as follows: p53-
Mdm2 repressor, PDB 1YCR; p53 dimer, PDB 1PET; GACKIX domain of CBP with proposed binding 
residues, PDB 2LQH. (b) Recent advances in protein-protein interaction inhibitor design and screening 
methodologies have led to th  discovery of a number of new small-molecule h bitors, al hough success 
in targeting high-affinity, small-surface-area interactions has far outpaced broader or weaker interactions. 
SA, surface area. See refs. 7 and 8 for a more detailed discussion.
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one to two orders of magnitude weaker than 
p53-MDM2–type interactions7,9. Further, 
the interaction surface is often considerably 
larger, with interaction energies shared over 
a greater number of amino acids, defying 
hotspot analysis.
Despite the challenges, the ability to 
manipulate transcription factor–coactivator 
complexes offers two exciting possibilities. 
The first is context specificity. Many of the 
complexes involved in transcription are 
dynamic in composition and comprise a core 
enzymatic function flanked by scaffolding 
proteins and exchangeable modules. The 
BAF-type chromatin remodeling complexes 
that play a key role in transcription initiation 
are an excellent example. Most share a 
core enzymatic subunit (the ATPase Brg), 
but there are exchangeable subunits that 
vary according to tissue (Fig. 2a)10. In 
the past ten years, evidence has emerged 
that transcription factors target both the 
enzymatic component and exchangeable 
modules in such complexes as part of the 
assembly of the transcriptional machinery. 
In yeast, the application of covalent chemical 
cross-linking to map contacts with the 
BAF-type complex Swi–Snf revealed 
that the transcription factors Gal4 and 
VP16 each contact the core enzymatic 
functionality (Snf1) in addition to auxiliary 
factor Snf5 (ref. 11). Thus, one could 
imagine blocking a PPI that would affect 
the localization of a complex at particular 
gene promoters but would leave the ore 
enzym  unaltered, providing functional 
capacity in other contexts. A second group 
of context-dependent transcription factor–
coactivator PPIs are those used by viruses 
to hijack the transcriptional apparatus in 
infected tissues. Arora a d Pan recently 
demonstrated that an inhibitor of a complex 
formed between the human papillomavirus 
transcription factor E6 and the coactivator 
p300 restores the ability of p53 to function 
in human papillomavirus–positive head 
and neck cancers and, in doing so, blocks 
tumorigenicity12. A challenge for the coming 
decade is to provide a more comprehensive 
map of the network of transcription factor 
PPIs at gene promoters as there remain 
more questions than answers for most 
transcription factors. Even in the case of the 
well-studied transcription factor p53, it is 
not clear which of its coactivator complexes 
are the most critical to block, either alone or 
in combination; considering its interaction 
with the master coactivator CBP and its 
close relative p300 alone, p53 binds in vitro 
with four of the activator interaction motifs 
within CBP, but the functional relevance 
of each of those interactions is not yet 
defined13. This is an area in which chemical 
biology tools such as covalent chemical 
capture or high-quality small-molecule 
probes will be invaluable.
In addition to compositional dynamics 
within transcription factor complexes, 
many of the individual subunits exhibit 
significant conformational plasticity as a 
means to interact specifically with a variety 
of transcription factors. The low energy 
Figure 1 | The chemical space of protein-protein interactions. (a) Protein-protein interactions can 
be effectively classified by the strength of the complex (y-axis) and the surface area over which the 
interaction occurs (x-axis). Using p53 as an example, transcriptional activator interaction networks 
span a broad range of strength and surface area. PBD ID codes for each structure are as follows: p53-
Mdm2 repressor, PDB 1YCR; p53 dimer, PDB 1PET; GACKIX domain of CBP with proposed binding 
residues, PDB 2LQH. (b) Recent advances in protein-protein interaction i hibitor design and screening 
methodologies have led to the discovery of a number of new small-molecule inhibitors, although success 
in targeting high-affinity, small-surface-area interactions has far outpaced broader or weaker interactions. 
SA, surface area. See refs. 7 and 8 for a more detailed discussion.
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small molecules.105 These scaffolds include the benzodiazepinediones116, terphenyls117, 
and chalcones118, and were derived as a result of information gleaned from the 
development of peptidic inhibitors and the first synthetic inhibitor nutlin.83 Perhaps the 
best example of p53-MDM2 inhibitors to date are the spirooxindole derived molecules 
that have single-digit nanomolar affinity for MDM2, maintain bioavailability, and have a 
good pharmacodynamic profile leading to Phase I clinical trials.119  Thus, transcription 
factor PPIs characterized by high affinity and a small interaction surface area are very 
targetable, largely owing to the advances in PPI inhibitor discovery strategies over the 
past decade. This reflects the overall success in targeting high-affinity, small-surface-area 
PPIs in many functional contexts, as these types of interactions most closely mirror 
enzyme-ligand interactions (Figure 1.5-B). 
 
Figure 1.6- Representative Examples of p53•MDM2 Inhibitor Scaffolds Given the low surface area 
and high affinity of the p53•MDM2 interaction a number of effective small molecule scaffolds have 
been developed to inhibit this interaction. Representative examples of each class are shown with their 
affinities for MDM2. 
Perhaps not surprisingly, PPI complexes that utilize broader interaction surfaces and 
occur with weaker affinity have been targeted far less successfully, as shown in Figure 
1.5-B. 82,113 As mentioned above, these broad and weak interactions lead to distinct 
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networks of PPIs being used to assemble the transcriptional machinery. The transient 
and conformationally dynamic complexes are formed with various coactivators and 
coactivator complexes. Traditional probe discovery or design methods are ill equipped to 
target these complexes because one or both binding partners are classified as intrinsically 
disordered proteins, and the complexes often form transiently in the cell, with affinities 
one to two orders of magnitude weaker than p53-MDM2–type interactions.120 Further, the 
interaction surface is often considerably larger, with interaction energies shared over a 
greater number of amino acids, defying hotspot analysis. 
1.7 Targeting Activator•Coregulator Interactions 
Despite the inherent challenges in targeting the interactions between transcriptional 
activators and the coregulatory machinery, doing so offers an opportunity to achieve 
context specificity in perturbing transcriptional processes. 
Exploiting compositional dynamics in transcriptional complexes 
Many of the complexes involved in transcription are dynamic in composition and 
comprise a core enzymatic function flanked by scaffolding proteins and exchangeable 
modules. The BAF-type chromatin remodeling complexes that play a key role in 
transcription initiation are an excellent example. Most share a core enzymatic subunit (the 
ATPase Brg), but there are exchangeable subunits that vary according to tissue.121 As an 
example, subunits within the BAF complex are exchanged as embryonic stem cells 
differentiate into neural progenitors and again as neural progenitors differentiate into 
neurons. Specifically, the neural progenitor BAF (npBAF) complex contains the BAF45a 
and BAF53a subunits and is responsible for maintaining self-renewal potential through 
enhanced NOTCH signaling by binding to the NICD•RBPj complex thereby stabilizing the 
interaction with DNA.122 Notably, loss of BAF45a or BAF53a in neural progenitors resulted 
in a loss of proliferative capacity, while overexpression of BAF45a enhanced proliferative 
capacity. Following differentiation into neurons, BAF45a and BAF53a are exchanged for 
BAF45b and BAF53b, respectively, to form the neuronal BAF (nBAF) complex, which 
assists in neuron-specific functions such as dendritic outgrowth.123  
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Figure 1.7- Transcriptional Complexes are Dynamic in Composition The BAF chromatin 
remodeling complex is a representative example of the dynamic composition of transcriptional 
complexes. The core enzymatic subunit BRG1 is found in all BAF complexes, but exchangeable 
subunits such as BAF45a or BAF45b are found in the complexes in a tissue-dependent manner. 
Evidence has emerged that transcription factors target both the enzymatic 
component and exchangeable modules in such complexes as part of the assembly of the 
transcriptional machinery. In yeast, the application of covalent chemical cross-linking to 
map contacts with the BAF-type complex Swi/Snf revealed that the transcription factors 
Gal4 and VP16 each contact the core enzymatic functionality (Snf1) in addition to auxiliary 
factor Snf5.124 Thus, one could imagine blocking a PPI that would affect the localization 
of a complex at particular gene promoters by targeting tissue or gene specific components 
of the complex, but would leave the core enzyme unaltered. As a result, the core complex 
would remain active at other promoters or within other tissues that utilize a complex with 
a distinct selection of components. 
A second group of context-dependent transcription factor–coactivator PPIs are 
those used by viruses to hijack the transcriptional apparatus in infected tissues. Arora 
and Pan recently demonstrated that an inhibitor of a complex formed between the human 
papillomavirus transcription factor E6 and p300 restores the ability of p53 to function in 
human papillomavirus–positive head and neck cancers and, in doing so, blocks 
tumorigenicity. 125 
Thus, an ongoing challenge is to provide a more comprehensive map of the 
network of transcription factor PPIs at gene promoters as there remain more questions 
than answers for most transcription factors. In doing so, unique complex compositions 
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barriers between individual conformations 
mean that each participant can use the same 
group of amino acids to recognize a variety 
of binding partners, with each complex 
requiring a distinct conformation. As such, 
synthetic regulation of this conformational 
plasticity to direct complex assembly 
represents a second exciting opportunity to 
specifically target transcription pathways. A 
foundational example of this phenomenon 
is the GACKIX (Gal11, Arc105, CBP/
p300, kinase-inducible domain interacting) 
domain of the master coactivators and 
histone acetyltransferases CBP and p300. 
GACKIX is highly plastic, and its two 
transcription factor–binding surfaces 
can accommodate more than 15 distinct 
transcription factor binding partners, in the 
context of binary or ternary complexes, that 
are involved in a variety of physiological 
processes and implicated in diseases from 
cancer to neuropathic pain (Fig. 2b)14. 
The two binding surfaces are allosterically 
connected, allowing for cooperative binding 
of particular transcription factor–GACKIX 
pairs with a wide range of enhancement 
(Fig. 2c). Experimental and computational 
studies indicate that the mechanistic origin 
of the variable cooperativity is differential 
stabilization of the ternary complex15–17. 
Thus by intercepting a particular conformer, 
a small molecule could have either a positive 
or a negative influence on the binary and 
ternary transcription factor–coactivator 
assembly process. Certainly the field can 
be guided by the success seen in targeting 
particular conformational states of kinases 
or of the protein folding machinery for 
enhanced selectivity and context-specific 
effects on downstream processes8,18,19.
Screening techniques that directly 
address the conformational plasticity 
of coactivators have been effective for 
identifying small-molecule modulators 
that capture distinct conformers. The 
site-directed fragment screening strategy 
of tethering first developed at Sunesis is 
one such strategy. When applied to the 
conformationally dynamic GACKIX 
motif, for example, researchers identified 
chemical cochaperones that stabilize a range 
of GACKIX conformations and dictate 
the formation of particular GACKIX–
transcription factor assemblies either 
positively or negatively20. Standard binding 
screens can also be adapted to discover 
modulators that capture unique coactivator 
conformations through the triaging of 
primary screening hits that mimic native 
binding partners. Using this process, the 
natural products sekikaic acid and the 
related lobaric acid capture a conformation 
of the GACKIX motif that showed greatly 
attenuated ternary complex formation21. 
One advantage from this type of strategy is 
that small-molecule modulators are likely to 
exhibit enhanced specificity because they are 
targeting unique coactivator conformations; 
this is true of sekikaic acid and lobaric acid. 
A second advantage is that it presents a 
generalizable mechanism by which allosteric 
modulators of highly challenging binding 
interfaces can be discovered. Again using 
GACKIX as an example, the binding site 
used by the oncogene c-Myb is shallow and 
lacks significant topology. However, the 
second binding site within GACKIX, which 
is targeted by sekikaic acid and lobaric acid, 
is smaller and better defined. By targeting a 
more druggable binding surface, allosteric 
networks within the coactivator can be 
exploited to affect less amenable distal 
binding sites.
Outlook
In the past decade of chemical biology, 
there has been enormous progress in 
targeting protein-protein interactions, 
and this has fueled successes in developing 
small-molecule modulators of a key subset 
of transcriptional activator PPIs. The 
recognition that the dynamic composition 
and structure of transcription factor–
coactivator complexes offers advantages in 
Figure 2 | Transcription complexes are dynamic in composition and conformation. (a) The BAF chromatin 
remodeli g complexes contain he same enzymatic core (BRG1) but have exchangeable subunit  such 
as BAF45a and BAF45b that define tissue specificity. See ref. 10 for a more complete discussion of 
the composition and function of these complexes. (b) The GACKIX (Gal11, Arc105, CBP/p300, kinase-
inducible domain interacting) motif of CBP/p300 uses two binding sites to interact with more than 10 
distinct transcriptional activators. (c) Each ternary complex has a signature conformation with the two 
binding sites in allosteric communication. The structure and function of the GACKIX motif were recently 
reviewed in ref. 14.
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may be identified in a promoter or tissue specific manner, widening the avenues for target 
identification. For example, even in the case of the well-studied transcription factor p53, 
it is not clear which of its coactivator complexes are the most critical to block, either alone 
or in combination; considering its interaction with the master coactivator CBP/p300 alone, 
p53 binds in vitro with four of the activator interaction motifs within CBP/p300, but the 
functional relevance of each of those interactions is not yet defined.126 Identifying critical 
contact points within CPB/p300 for the N-terminal TAD and developing small molecule 
inhibitors of those domains could provide a useful mechanism for blocking the oncogenic 
activity of mutant p53, as discussed above. Thus, this is an area in which chemical biology 
tools such as covalent chemical capture or high-quality small-molecule probes will be 
invaluable. 
Exploiting conformational plasticity of coactivators 
In addition to compositional dynamics within transcription factor complexes, many 
of the individual subunits exhibit significant conformational plasticity as a means to 
interact specifically with a variety of transcriptional activators. The low energy barriers 
between individual conformations mean that each participant can use the same group of 
amino acids to recognize a variety of binding partners, with each complex requiring a 
distinct conformation. As such, synthetic regulation of this conformational plasticity to 
direct complex assembly represents a second exciting opportunity to specifically target 
transcription pathways.  
A foundational example of this phenomenon is the GACKIX (Gal11, Arc105, 
CBP/p300, kinase-inducible domain interacting) domain of the master coactivator and 
histone acetyltransferase CBP/p300. GACKIX is highly plastic, and its two transcription 
factor–binding surfaces can accommodate more than 15 distinct transcription factor 
binding partners, in the context of binary or ternary complexes, that are involved in a 
variety of physiological processes and implicated in diseases from cancer to neuropathic 
pain, as shown in Figure 1.8-A.64 Furthermore, the two binding surfaces are allosterically 
connected, allowing for cooperative binding of particular transcription factor–GACKIX 
pairs with a wide range of enhancement. For example, a pre-formed complex of the KIX 
domain and the lysine methyltransferase MLL, a coactivating histone modifying enzyme, 
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resulted in the enhanced affinity of the transcriptional activators c-Myb and the pKID 
domain of CREB by 2.5-fold and 2-fold, respectively.127 Experimental and computational 
studies indicate that the mechanistic origin of the variable cooperativity is differential 
stabilization of the ternary complex. 128,129 Thus by intercepting a particular conformer, a 
small molecule could have either a positive or a negative influence on the binary and 
ternary transcription factor–coactivator assembly process. Certainly the field can be 
guided by the success seen in targeting particular conformational states of kinases or of 
the protein folding machinery for enhanced selectivity and context-specific effects on 
downstream processes. 130,131 
 
Figure 1.8- Transcriptional Complexes are Dynamic in Conformation (A) The KIX domain of 
CBP/p300 utilizes two binding sites to interact with greater than fifteen distinct transcriptional 
activators. A representative sample of these activators and their biological implications is shown. (B) 
Ternary complexes formed between KIX and two transcription factors requires unique conformational 
signatures as a result of allosteric communication between the two binding sites. 
 Screening techniques that directly address the conformational plasticity of 
coactivators have been effective for identifying small-molecule modulators that capture 
distinct conformers. The site-directed fragment screening strategy of tethering first 
developed at Sunesis is one such strategy. When applied to the conformationally dynamic 
GACKIX motif, for example, researchers identified chemical cochaperones that stabilize 
a range of GACKIX conformations and dictate the formation of particular GACKIX–
transcription factor assemblies either positively or negatively. 129,132 Specifically, the 
disulfide containing fragment 1-10 has been demonstrated to elicit negative cooperativity 
of pKID binding when it is tethered to a mutated cysteine (L664C) within the MLL 
interaction surface. Interestingly, when they same fragment is tethered to a different 
mutated cysteine within the same interface (N627C), pKID affinity is actually enhanced, 
suggesting that 1-10 is stabilizing unique conformations of KIX depending upon it’s 
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barriers between individual conformations 
mean that each participant can use the same 
group of amino acids to recognize a variety 
of binding partners, with each complex 
requiring a distinct conformation. As such, 
synthetic regulation of this conformational 
plasticity to direct complex assembly 
represents a second exciting opportunity to 
specifically target transcription pathways. A 
foundational example of this phenomenon 
is the GACKIX (Gal11, Arc105, CBP/
p300, kinase-inducible domain interacting) 
domain of the master coactivators and 
histone acetyltransferases CBP and p300. 
GACKIX is highly plastic, and its two 
transcription factor–binding surfaces 
can accommodate more than 15 distinct 
transcription factor binding partners, in the 
context of binary or ternary complexes, that 
are involved in a variety of physiological 
processes and implicated in diseases from 
cancer to neuropathic pain (Fig. 2b)14. 
The two binding surfaces are allosterically 
connected, allowing for cooperative binding 
of particular transcription factor–GACKIX 
pairs with a wide range of enhancement 
(Fig. 2c). Experimental and computational 
studies indicate that the mechanistic origin 
of the variable cooperativity is differential 
stabilization of the ternary complex15–17. 
Thus by intercepting a particular conformer, 
a small molecule could have either a positive 
or a negative influence on the binary and 
ternary transcription factor–coactivator 
assembly process. Certainly the field can 
be guided by the success seen in targeting 
particular conformational states of kinases 
or of the protein folding machinery for 
enhanced selectivity and context-specific 
effects on downstream processes8,18,19.
Screening techniques that directly 
address the conformational plasticity 
of coactivators have been effective for 
identifying small-molecule modulators 
that capture distinct conformers. The 
site-directed fragment screening strategy 
of tethering first developed at Sunesis is 
one such strategy. When applied to the 
conformationally dynamic GACKIX 
motif, for example, researchers identified 
chemical cochaperones that stabilize a range 
of GACKIX conformations and dictate 
the formation of particular GACKIX–
transcription factor assemblies either 
positively or negatively20. Standard binding 
screens can also be adapted to discover 
modulators that capture unique coactivator 
conformations through the triaging of 
primary screening hits that mimic native 
binding partners. Using this process, the 
natural products sekikaic acid and the 
related lobaric acid capture a conformation 
of the GACKIX motif that showed greatly 
attenuated ternary complex formation21. 
One dvantage from this type of strategy is 
that small-molecule modulators are likely to 
exhibit enhanced specificity because they are 
targeting unique coactivator conformations; 
this is true of sekikaic acid and lobaric acid. 
A second advantage is that it presents a 
generalizable mechanism by which allosteric 
modulators of highly challenging binding 
interfaces can be discovered. Again using 
GACKIX as an example, the binding site 
used by the oncogene c-Myb is shallow and 
lacks significant topology. However, the 
second binding site within GACKIX, which 
is targeted by sekikaic acid and lobaric acid, 
is smaller and better defined. By targeting a 
more druggable binding surface, allosteric 
networks within the coactivator can be 
exploited to affect less amenable distal 
binding sites.
Outlook
In the past decade of chemical biology, 
there has been enormous progress in 
targeting protein-protein interactions, 
and this has fueled successes in developing 
small-molecule modulators of a key subset 
of transcriptional activator PPIs. The 
recognition that the dynamic composition 
and structure of transcription factor–
coactivator complexes offers advantages in 
Figure 2 | Transcription complexes are dynamic in composition and conformation. (a) The BAF chromatin 
remodeling complexes contain the same enzymatic core (BRG1) but have exchangeable subunits such 
as BAF45a and BAF45b that define tissue specificity. See ref. 10 for a more complete discussion of 
the composition and function of these complexes. (b) The GACKIX (Gal11, Arc105, CBP/p300, kinase-
inducibl  domain interacting) motif of CBP/p300 u es two binding sites to interact with more than 10 
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commentary
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of binding partners, with each complex 
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r prese ts a second exciti g opportunity to 
specifically target transcription pathways. A 
foundational example of this phenomenon 
is the GACKIX (Gal11, Arc105, CBP/
p300, kinase-inducible domain interacting) 
domain of the master coactivators and 
histone acetyltransferases CBP and p300. 
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transcription factor–binding surfaces 
can accommodate more than 15 distinct 
transcription factor binding partners, in the 
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cancer to neuropathic pain (Fig. 2b)14. 
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of particular transcription factor–GACKIX 
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Thus by intercepting a particular conformer, 
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ternary transcription factor–coactivator 
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particular conformational states of kinases 
or of the protein folding machinery for 
enhanced selectivity and context-specific 
effects on downstream processes8,18,19.
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of GACKIX conformations and dictate 
th  formation of particul r GACKIX–
transcrip ion factor assemblies ither 
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modulators that capture unique coactivator 
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binding partners. Using this process, the 
natural product  sek aic acid and the 
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of the GACKIX motif that showed greatly 
attenuated ternary complex formation21. 
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used by th  on ogen  c-Myb is shallow and 
lacks significant topology. However, the 
second binding site within GACKIX, which 
is targeted by sekikaic acid and lobaric acid, 
is smaller and better defined. By targeting a 
more druggable binding surface, allosteric 
networks within the coactivator can be 
exploited to affect less amenable distal 
binding sites.
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location. Furthermore, covalent modification of KIX L664C with the 1-10 disulfide resulted 
in considerably enhanced stability, allowing for crystallization of this highly plastic domain 
and the first ever reported crystal structure, further underscoring the utility of Tethering as 
a strategy for identifying small molecule modulators of activator•coactivator interactions.  
 
Figure 1.9- The Chemical Cochaperone 1-10 Binds to and Stabilizes KIX (A) Structure of the 
disulfide containing 1-10 chemical cochaperone identified through a tethering screen of the KIX 
domain containing engineered cysteine residues. (B) Crystal structure of the 1-10 bound stabilized 
KIX conformation. PDB ID: 4I90 
Standard binding screens can also be adapted to discover modulators that capture 
unique coactivator conformations through the triaging of primary screening hits that mimic 
native binding partners. Using this process, the natural products sekikaic acid and the 
related lobaric acid capture a conformation of the GACKIX motif that showed greatly 
attenuated ternary complex formation.133 More explicitly, these natural products exhibited 
a mixed mode of action in which inhibition was achieved both orthosterically at the MLL 
interaction surface of KIX, against which natural products were screened, as well as 
allosterically at the pKID interaction surface.  
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thought to be integral to the ability of GACKIX to
accommodate diverse native ligands.5,19,21,30
To dissect in more detail how the GACKIX surface remodels
itself to recognize fragment 1-10, we carried out 40 ns
molecular dynamics simulations of the GACKIX crystal
structure with or without ligand 1-10. A gross comparison of
the backbone revealed that a change in the loop conformation
is the most significant, as shown in the rms fluctuations (Figure
S6 in the SI) and in the average structure overlay (Figure S7).
These changes are often difficult to visualize by solution
methods because the loop region contains several proline
residues, but mutagenesis and NMR methods have suggested
that conformational plasticity in this region underlies the ability
of GACKIX to recognize diverse amphipathic sequences.5,20,21
It is this movement of the loop and a rotation of helix α1 that
enable the formation of a narrower binding surface to
accommodate a molecule that is considerably smaller than a
peptidic helix (∼77% smaller volume). The binding surface that
is targeted by 1-10 is also significantly different, both as a result
of loop conformational changes and because of side-chain
motions, as demonstrated by the change in solvent-accessible
surface area of the residues when the fragment is tethered
(Figure 4b). For example, the liganded GACKIX shows a
population shift in the Tyr631 side-chain χ angles relative to the
untethered protein, leading to a hydrophobic binding surface
for deeper interactions (see movie S1 in the SI). Simulations of
2-64 tethered to GACKIX L664C suggested that the binding
mode of this ligand is similar to that of 1-10, further
demonstrating the ability of this protein to adapt to different
binding partners (Figure S8). The helices α3 and α2 must open
to accommodate this larger ligand, and corresponding changes
in the chemical shifts of residues involved in this opening were
observed by NMR spectroscopy (Figures S5 and S7).
In conclusion, we have obtained a 2 Å-resolution snapshot of
the conformationally dynamic coactivator GACKIX domain
complexed with a small molecule. This will significantly
facilitate the use of rational structure-based approaches to
design more potent analogues; for example, current efforts
include extending molecule 1-10 at the C4 position of the
aromatic ring to enable it to engage with the hydrophobic space
within the GACKIX site more effectively. From a broader
perspective, these results in combination with recent studies
Figure 3. (a) Refined crystal structure of GACKIX L664C covalently tethered to fragment 1-10 (refined resolution = 2.0 Å, Rwork/Rfree = 0.2064/
0.2329). (b) Crystal structure of GACKIX L664C tethered to 1-10 (teal) superimposed using Coot on the NMR solution structures of GACKIX in
complex with cognate transcriptional activation domains pKID (yellow, PDB ID 1KDX, rmsd = 1.40 Å), MLL and c-Myb (deep blue, PDB ID
2AGH, rmsd = 1.80 Å), PCET (purple, PDB ID 2KWF, rmsd = 1.81 Å), and FOXO3A (black, PDB ID 2LQH, rmsd = 1.07 Å). (c) Interactions
between 1-10 (yellow) and residue side chains of GACKIX L664C (blue) at the binding surface. (d) 3σ electron density map (Fo − Fc) of 1-10
illustrating the fit of the small molecule.
Figure 4. (a) Results of chemical shift perturbation experiment
(1H,15N-HSQC) with 1-10-tethered GACKIX L664C. Residues that
shifted by more than 1 standard deviation upon 1-10 tethering are
shown in yellow and include Ile611, Leu628, Leu607, Val635, Tyr631,
and Ile660. (b) Difference in the average solvent-accessible surface
area (SASA, in Å2) calculated by residue between simulations of
untethered and 1-10-tethered GACKIX L664C. A residue colored red
is less solvent-exposed in the 1-10-tethered structure, with the color
intensity indicating the extent of the change; blue residues are more
solvent-exposed in the 1-10-tethered structure.
Journal of the American Chemical Society Communication
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Figure 1.10- Sekikaic Acid and Lobaric Acid are Mixed Orthosteric/Allosteric Inhibitors of the 
KIX Domain (A) Structures of the depside sekikaic acid and depsidone lobaric acid. (B) These natural 
product small molecule inhibitors of the KIX domain bind at the MLL site, inhibiting it orthosterically, 
while also inducing conformational changes within the protein that perturb binding events at the distal 
CREB site. PDB ID: 2AGH 
One advantage from this type of strategy is that small-molecule modulators are likely 
to exhibit enhanced specificity because they are targeting unique coactivator 
conformations; this is true of sekikaic acid and lobaric acid. A second advantage is that it 
presents a generalizable mechanism by which allosteric modulators of highly challenging 
binding interfaces can be discovered. Again using GACKIX as an example, the binding 
site used by the oncogene c-Myb is shallow and lacks significant topology. However, the 
second binding site within GACKIX, which is targeted by sekikaic acid and lobaric acid, 
is smaller and better defined. By targeting a more druggable binding surface, we 
hypothesize that allosteric networks within the coactivator can be exploited to affect less 
amenable distal binding sites. 
1.8 Emergent Technologies and Alternative Approaches 
Recent advances in chemical biology, has led to enormous progress in targeting 
protein-protein interactions, and this has fueled successes in developing small-molecule 
modulators of a key, readily targetable subset of transcriptional activator PPIs. The 
recognition that the dynamic composition and structure of transcription factor–coactivator 
complexes offers advantages in terms of specificity and function in recent years now 
opens the door for similar success in targeting significantly more challenging interactions. 
As molecules move toward clinical applications, a question that has yet to be answered 
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is one of potency. At least in vitro, transcription factor–coactivator complexes are an order 
of magnitude or more weaker than complexes such as p53–MDM2. Whether it is possible 
to obtain synthetic modulators that exceed the affinity of the native ligands is still an open 
question. This is an area in which allosteric modulators may offer significant advantages. 
NMR screening techniques that rely on conformational dynamics, such as protein-
observed fluorine (PrOF) NMR spectroscopy, have proven powerful for focusing on 
molecules that capture coactivators in a particular conformational space and will be a key 
discovery tool.134 In addition, screening formats such as small-molecule microarrays that 
facilitate the interrogation of transcription factor binding in the presence of endogenous 
competing factors enable specificity to be assessed much earlier in the discovery 
process. 75,135 
While we have chosen to focus primarily upon protein-protein interactions between 
transcriptional activators and other elements of the transcriptional machinery, there is still 
significant untapped potential in the broader network of transcription factor interactions 
as the field continues to define these critical connections. Approaches such as targeting 
transcription factor dimerization motifs or preventing promoter localization by blocking 
DNA binding of transcription factors are additional strategies being explored that may also 
allow for the successful modulation of transcriptional processes for mechanistic insight or 
therapeutic gain. 
1.9 Thesis Summary 
The overall goal of the research presented in this thesis is to identify small molecule 
inhibitors of a transcriptional coactivator, Med25, by targeting the Activator Interaction 
Domain (AcID) within this protein. AcID is a critical point of contact for a number of 
transcriptional activators with diverse biological functions, but is poorly understood at 
present. Thus, we hypothesize that small molecule inhibitors of the domain will be 
particularly useful as mechanistic probes in the elucidation of the role of Med25 in the 
regulation of transcriptional programs that affect cellular processes such as endoplasmic 
reticulum stress response, viral infection, and the development of metastatic phenotypes 
in a number of cancers. 
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Towards this goal, we first explore in Chapter 2 the molecular underpinnings that 
define interactions between transcriptional activators and the activator interaction domain 
of Med25, with the goal of identifying mechanisms by which we might inhibit 
activator•AcID interactions. In Chapter 3, we apply the insights gained regarding 
interactions between activators and AcID to develop an assay adapted to high-throughput 
screening and describe the discovery of first-generation AcID inhibitors. A hypothetical 
mechanism of action by which these molecules inhibit activator•AcID interactions is also 
discussed. Finally, in Chapter 4 we describe a screen of a library composed of natural 
products extracted from diverse organisms against an interaction between a family of 
activators linked to the progression of cancer to a metastatic phenotype and AcID with 
the goal of identifying second generation AcID inhibitors. 
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CHAPTER 2 
Molecular Underpinnings of Activator•Med25 Interactions2 
2.1 Abstract 
The Activator Interaction Domain (AcID) of Mediator subunit Med25 is a critical 
coactivator binding partner for a variety of transcriptional activators including the herpes 
simplex viral activator VP16, the PEA3 subfamily of Ets transcription factors, and the 
endoplasmic reticulum stress response transcription factor ATF6α. AcID utilizes a unique 
fold found in no other characterized coactivator and as such, very little is understood 
about specific molecular requirements for activator•AcID interactions. In this chapter, 
specific characteristics of these interactions, such as the minimal sequence of the VP16 
TAD capable of interacting with the domain and the role of electrostatics in promoting 
these interactions are explored. Additionally, alanine scanning mutagenesis studies 
demonstrate that these interactions occur over broad surface areas with no defined hot-
spot contacts. Collectively, these data also suggest at least two distinct binding surfaces 
that are allosterically connected. Taken together, the data indicate that this motif will be 
most effectively targeted by allosteric modulators, a strategy that is employed in the work 
of Chapters 3 and 4. 
2.2 Introduction 
Transcription is the critical process by which information encoded within an 
organism’s genome is converted to mRNA before being ultimately translated into protein 
and plays a fundamental role in virtually all cellular processes. This process is tightly 
regulated and requires the assembly of large and dynamic protein complexes at gene 
                                            
2 The research described in this chapter was a collaborative effort. Steven M. Sturlis and 
Paul A. Bruno expressed and purified AcID protein and completed the VP16 truncation 
analysis. Matthew S. Beyersdorf expressed and purified the AcID R466E mutant and 
completed direct binding assays with the mutant protein. 
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promoters through the use of specific protein-protein interactions between complex 
components.1 In particular, interactions between transcriptional activators and 
coactivators are a fundamental requirement for activated transcription at a majority of 
gene promoters and represent a particularly attractive target for inhibitor development 
given the ability to achieve excellent context specificity, as discussed in Chapter 1. 
However, the large surface areas over which these interactions occur and the relatively 
low affinities of activators for coactivator binding partners complicates small molecule 
inhibitor discovery.2 Therefore, in order to identify attractive features for potential 
exploitation in a small molecule inhibition strategy, it is first necessary to determine the 
molecular underpinnings for a particular activator•coactivator interaction. In this case our 
goal is to define the interactions between transcriptional activators and the Activator 
Interaction Domain of Med25, with the ultimate goal of discovering small molecule 
modulators of these complexes (Chapter 3, 4).  
Mediator Subunit 25 (Med25) 
Med25, previously known as ARC92 or DRIP97, is a component of the megadalton 
Mediator complex, a critical coactivator for the expression of virtually protein coding genes 
(described in Chapter 1).3 This subunit is a 92 kDa protein found only in higher eukaryotes 
and is reliant upon three key domains to link transcriptional activators to the rest of the 
Mediator complex, as shown in Figure 2.1 (A).4  At the N-terminus (residues 1-229) is the 
von Willebrand factor type A domain (VWA), which is responsible for the association of 
Med25 with the larger Mediator complex, though the interaction partners within the rest 
of the Mediator complex are currently unknown.5  A LXXLL motif within the nuclear 
receptor box (residues 646-650) is capable of interactions with retinoic acid receptor α 
(RARα) and estrogen receptor α (ERα).6,7 Finally, the Activator Interaction Domain (AcID, 
a.k.a VP16 binding domain, VBD; residues 395-545) is responsible for the association of 
Med25 with transcription factors such as VP168, the PEA3 subfamily of ETS 
transcriptional activators9, the endoplasmic reticulum stress response transcriptional 
activator ATF6α10, and the N-terminal domain of CBP/p3006. Though the specific contact 
points within the Mediator complex have yet to be elucidated, proteomic experiments to 
determine the relative binding locations of the various Mediator subunits have indicated 
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that Med25 is localized within the tail module of the complex, consistent with other 
subunits responsible for linking Mediator to DNA-bound transcriptional activators such as 
Med15 and Med23.11 
 
Figure 2.1- Med25 Organization and AcID Structure. (A) Schematic representation of Med25 
domain organization, with known interaction partners listed below the domains. (B) Cartoon 
representation of AcID. α-helices are shown in yellow, while the β-barrel is shown in blue. 
Recently, solution NMR structures of AcID have been reported by several research 
groups.8,12,13 The studies identify the domain as being composed of a seven-stranded β-
barrel flanked by three α-helices, as shown in Figure 2.1 (B). Interestingly, the architecture 
of ACID represents a novel activator target fold not previously reported. In particular, the 
presence of a β-barrel as the defining structural feature of the domain is unusual, as most 
activator-targeted coactivator domains are highly α-helical in nature, as shown in Figure 
2.2. 14-16 
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Figure 2.2- Comparison of AcID to other Activator-Targeted Coactivator Folds The presence of 
a β-barrel as a defining structural feature of AcID is highly unusual for coactivator proteins. As the four 
examples on the right show, most coactivator folds are highly α-helical, though PC4 demonstrates that 
β-sheets are not necessarily uncommon. 
In fact, a search of known protein structures reveals that there are only two other known 
domains with similar architecture to the ACID, both of which are found in a protein known 
as PTOV1, which is an overexpressed protein of unknown function found in cancerous 
prostate tissue. 8,12,17 Thus, AcID is an attractive potential target for small molecule 
inhibitors given that: (1) the unique nature of the domain’s fold should allow for the 
discovery of highly selective small molecules with few off target effects, and (2)  
development of small molecule inhibitors of activator•AcID interactions would be useful in 
answering mechanistic questions about this poorly understood domain and may serve as 
potential leads in novel therapeutic strategies for diseases linked to AcID dependent 
transcriptional activators. However, the dearth of information surrounding activator•AcID 
interactions requires that their molecular underpinnings be defined in order to identify 
potential molecular features for exploitation and to develop an effective strategy for small 
molecule inhibitor discovery. This is particularly important given the unusual nature of the 
CBP/p300 CH1 Domain 
PDB: 1P4Q
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AcID fold, suggesting that the domain may interact with activator binding partners in 
unique ways not typical of most coactivator proteins. 
The VP16•AcID Interaction and Structural Insights 
Of the four AcID-dependent interactions identified above, the interaction between 
the viral activator VP16 and AcID is perhaps the best studied. VP16 is a critical 
component of the herpes simplex virus (HSV) responsible for the expression of immediate 
early viral genes, which are important for the functional switch from latent to lytic infection 
within host cells.18 This domain is rich in acidic amino acids, making it a prototypical 
member of the acidic class of transcriptional activators, though its function is also 
dependent upon specific hydrophobic residues.19 Furthermore, it has been demonstrated 
that the VP16 TAD contains two subdomains termed H1 (residues 410-452) and H2 
(residues 453-490) that are capable of independently initiating transcription using distinct 
molecular mechanisms.20,21 Interestingly, there is significant evidence that free VP16 TAD 
is flexible and relatively disordered, but adopts an α-helical conformation upon binding to 
target proteins.15 This observation has been made for interactions between VP16 and 
coactivator proteins with α-helical secondary structure, thus the importance of the putative 
VP16 α-helices for interactions with the β-barrel of AcID will be an important point of 
inquiry in this chapter. 
The discovery that VP16 interacts with Med25 was initially made based on the 
observation that an affinity column composed of an immobilized VP16-GST fusion was 
capable of purifying the Mediator complex from HeLa cell nuclear extracts22, which was 
shown to by mediated by Med25 following a more stringent analysis.23 More recently, 
1H,15N-HSQC NMR chemical shift perturbation studies of 15N-labeled AcID in complex 
with unlabeled VP16 TAD have been reported, revealing two putative binding sites for the 
VP16 H1 andH2 subdomains, as shown below in Figure 2.3. 8,12,13 
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Figure 2.3- Med25 AcID Contains Two Binding Sites that Interact with the VP16 TAD The VP16 
TAD contacts two distinct surfaces of the AcID domain located on opposite faces of the protein. The 
darker shaded sites in each surface represent the residues most strongly perturbed in HSQC 
experiments in which the VP16 TAD was titrated. 
More specifically, an examination of the chemical shift perturbations in the NMR 
spectrum of AcID following the titration of full length VP16 TAD suggested that the binding 
interface occurs over a broad surface of the protein. Subsequent titration of isolated VP16 
H1 or H2 subdomains demonstrated that the subdomains perturbed individual subsets of 
the chemical shifts induced by the binding of the full length TAD. Together, these data 
indicated that the H1 and H2 subdomains of the VP16 TAD contact distinct binding sites 
on opposite faces of AcID, as shown in Figure 2.3. Residues that were most significantly 
perturbed in the HSQC experiments are highlighted in bright blue or yellow8,12, while the 
lighter shades represent the full estimated interaction surfaces. Measurements using 
PyMol indicate that both surfaces cover approximately 1800 Å2, suggesting that 
activator•AcID interactions occur over very broad surface areas. Though there is 
information available with regards to the effects of VP16 binding on the structure of AcID, 
very little is known with regards to the molecular determinants within the TAD that are 
required for binding to AcID.  
The relative importance of these binding surfaces for interaction with VP16 is a 
matter of debate. In one report, mutation of the H1 subdomain had a minimal impact on 
transcriptional activity of a Gal4-VP16 fusion in yeast nuclear extracts, while mutation of 
the H2 subdomain resulted in a significant decrease in activity. Similarly, the H1 
VP16 H1 Binding Site VP16 H2 Binding Site
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subdomain alone was insufficient for transcriptional activation while the H2 subdomain 
was capable of moderate activation, suggesting that the H2 binding surface may be a 
more functionally significant binding surface.12 Alternative evidence suggests that the H1 
subdomain binds with significantly higher affinity than the H2 subdomain and also 
undergoes more significant structural shifts following binding to AcID based on HSQC 
studies using 15N-labeled VP16. 8,23 
In this Chapter we aim to elucidate underlying molecular features of activator 
interactions with the Activator Interaction Domain (AcID) of Med25 in order to identify 
potential mechanisms by which small molecule inhibitors could inhibit these interactions. 
For example, we will identify the minimal sequences of the VP16 TAD that interact with 
the AcID motif. We will also determine whether activator•AcID interactions occur primarily 
through the use of focused hotspot residues or over broad surfaces. Finally, we will 
explore the importance of electrostatic interactions in activator•AcID complexes, given the 
highly basic character of AcID and acidic character of known activator binding partners. 
2.3 Results and Discussion 
Determining the Minimal VP16 Interaction Surface 
 Following expression of the AcID protein, we next sought to determine the critical 
VP16 sequences that are capable of interacting with AcID in order to determine important 
molecular features for recognition and affinity. Previous studies have demonstrated that 
two regions within the VP16 TAD can adopt an α-helical structure.15,24 1H,15N-HSQC 
perturbation experiments of VP16(413-451), the H1 subdomain, demonstrated 
particularly strong structural changes in residues 435-442. This region encompasses one 
of the purported α-helices and the lack of perturbation in the N-terminal region of the TAD 
suggests that it may be dispensable for binding. Furthermore, the observation that the 
chemical shifts in residues 435-442 were only observable following titration of AcID 
supports previous observations that the VP16 TAD is intrinsically disordered and only 
adopts secondary structure following interaction with a coactivator binding partner.8 
Analogous studies completed with VP16(452-490), the H2 subdomain, failed to identify 
specific structural changes within the TAD due to significant line broadening that 
precluded prediction of VP16 H2 secondary structure following binding to AcID. However, 
 48 
the approximately 1:1 stoichiometry required to saturate AcID, indicated that the VP16 
H2•AcID interaction is relatively high affinity.12 
For our purposes, the VP16 TAD was truncated into three peptides spanning the 
full length of the TAD, VP16(413-437), VP16(438-464), and VP16(465-490). Fluorescein 
was appended to the N-terminus of the peptides following a β-alanine linker and the 
affinity of the peptides was assessed for AcID using fluorescence polarization. 
 
Figure 2.4- Initial Truncation of the VP16 TAD and Determination of Affinity for AcID (A) 
Sequence of the VP16 TAD with the indicated truncations represented by the colored bars beneath 
the sequence. Purported α-helical regions within the TAD are indicated by underlining within the TAD. 
(B) Direct binding curves for the initial VP16 truncation color coded to match the sequences in (A). 
Curves represent the mean values of three independent experiments with error bars indicating the 
standard deviation of the fraction bound at each concentration of the purified AcID protein. (With Paul 
A. Bruno) 
 The N-terminus of the VP16 TAD contributes very little to the interaction between 
the VP16 TAD and AcID, as evidenced by the low affinity of VP16(413-437) for the purified 
domain. In fact, an accurate Kd for VP16(413-437) could not be determined due to 
limitations in concentrating the expressed AcID protein. VP16(438-464) and VP16(465-
490) bound to AcID with Kd values of 3.4 µM and 0.58 µM, indicating that these are 
relatively high affinity interactions compared to several other activator•coactivator 
interactions.25-27 Interestingly, these two peptides contain sequences that have been 
previously reported to be functionally independent and capable of adopting α-helical 
secondary structure upon binding to target coactivators.15,24 Thus, a potential hypothesis 
is that VP16•AcID interactions may also be dependent upon α-helical secondary structure 
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within the TAD contacting the β-barrel of AcID. Such a binding mode would be similar to 
other activator•coactivator interactions in that the TAD becomes α-helical following 
contact with its binding partner, but unique in that the TAD contacts a β-barrel as opposed 
to helices within the coactivator. 
In order to begin to test this hypothesis, the VP16 TAD was further truncated to 
produce peptides that contained only the purported α-helices and three residues on either 
side in order to allow for maximal potential helicity within the peptides. While these 
experiments do not directly examine the required secondary structure of AcID binding 
partners, they are useful in further minimizing the VP16 surfaces that interact efficiently 
with AcID. These shorter peptides, VP16(438-454) and VP16(467-488) were conjugated 
to fluorescein and their affinities for AcID were again measured by fluorescence 
polarization. 
 
Figure 2.5- Direct Binding Assays of VP16(438-454) and VP16(467-488) to AcID The affinity of 
VP16(438-454) and VP16(467-488) were determined using fluorescence polarization. Curves 
represent the mean values of three independent experiments with error bars indicating the standard 
deviation of the fraction bound at each concentration of the purified AcID protein. (With Paul A. Bruno) 
 As shown in Figure 2.5, the truncated tracers maintained comparable binding 
affinity to their larger counterparts. Specifically, VP16(438-454) is within error of 
VP16(438-464), and VP16(467-488) has an only slightly lower affinity than VP16(465-
490) with Kd values of 0.90 µM compared to 0.58 µM. A possible explanation for the slight 
difference between VP16(467-488) and VP16(465-490) is that the theoretical binding site 
on AcID for the H2 derived peptides is comprised almost entirely of the β-barrel and thus 
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lacks significant topology, unlike the binding site for H1 derived peptides which bind to a 
surface that contains a significant cleft formed by the β-barrel and helix α3. Thus, the 
VP16 H2 derived peptides may be more dependent upon weak hydrophobic interactions, 
though the difference between the two affinities is insignificant enough that the data 
support the hypothesis that the purported α-helical region of the TAD is a key contributor 
to the VP16(465-490)•AcID interaction. 
The affinities of these shorter peptides for AcID appears to further support the 
hypothesis that the domain contains two independent binding sites. Other VP16 
coactivator binding partners, such as PC4, require the simultaneous binding of both of 
the α-helical sequences to maintain a functionally relevant affinity. More specifically, the 
full length VP16 TAD binds to PC4 with an affinity of 0.7 ± 0.2 µM, while the H1 subdomain 
does not bind with a detectable affinity and the H2 subdomain binds with an affinity of 15 
± 6 µM, more than twenty-fold weaker than the full length TAD.15 Thus, the relatively high 
affinity of VP16(438-454) and VP16(467-488) for AcID supports that both of these 
sequences are capable of making necessary intermolecular contacts. 
As a final experiment to determine the minimal interaction surface of VP16 for 
AcID, an eight amino acid peptide was synthesized based upon the purported α-helical 
sequence in the H2 subdomain. VP16(472-479) has been examined before in the 
literature and was found to be capable of stimulating transcription, indicating that this 
sequence represents a minimal functional unit of the VP16 TAD.24 
 51 
 
Figure 2.6- Direct Binding of VP16(472-479) to AcID The affinity of VP16(472-479) was determined 
using fluorescence polarization. Curves represent the mean values of three independent experiments 
with error bars indicating the standard deviation of the fraction bound at each concentration of the 
purified AcID protein. 
 Even this significantly truncated peptide is capable of interacting with AcID with 
modest affinity, with a Kd value of 8.2 µM representing only a ten-fold loss in affinity from 
VP16(467-488). Thus, the collective truncation data demonstrates that the VP16•AcID 
interaction does not require the full length TAD or even the intact H1 or H2 subdomains 
and can be minimized to relatively short sequences containing previously identified 
functional units within the TAD that may adopt an α-helical conformation. 
The transcriptional activation domains of activators frequently adopt an α-helical 
conformation in order to efficiently bind to coactivator binding partners. For example, a 
phosphorylation event at serine 133 within the CREB kinase inducible domain (KID) 
stabilizes α-helical structure allowing the TAD to contact the coactivator CBP/p300.28 
Thus, given the prominent role that this secondary structure appears to play in 
activator•coactivator interactions in general, the finding that the minimal VP16 interaction 
surfaces for the AcID motif may also adopt α-helical secondary structure is unsurprising 
and suggests that activator binding partners of AcID may be α-helical despite the 
interaction occurring at a surface primarily composed of a β-barrel. Though most 
coactivator domains are highly α-helical in terms of secondary structure, as shown in 
Figure 2.2, reported molecular docking experiments combined with HSQC chemical shift 
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perturbation experiments suggest that the VP16 TAD adopts an α-helix and binds to a 
positive ‘channel’ formed by a series of highly basic β-sheets within a homodimer of the 
coactivator PC4, further supporting this hypothesis.15 Additional analysis including 
mutations to disrupt helical propensity or NMR solution structures of 15N labeled peptides 
in complex with the domain will be completed to further explore this hypothesis. 
Furthermore, this trend appears to apply to activators that bind to AcID beyond 
VP16, with ERM/ETV5 as an excellent example. 
 
Figure 2.7- The TAD of PEA3 Family Members Bind to AcID. (A) The three transcriptional activators 
that comprise the PEA3 subfamily contain TADs that are highly conserved. (B) Secondary structure 
predictions demonstrate with a high degree of confidence that the ERM TAD adopts an α-helical 
conformation at its N-terminus. (C) The ERM TAD, residues 38-68, bind to AcID with relatively high 
affinity. 
As shown in Figure 2.7 (A), the TADs of the three members that comprise the PEA3 
subfamily are highly conserved and highly acidic, similar to the VP16 TAD. In (B) 
secondary structure prediction suggests with high confidence that the N-terminal 
sequence of the ERM TAD, ERM(38-68), adopts an α-helical secondary structure, and in 
(C) the binding curve of the fluorescein labeled peptide shows that the ERM TAD binds 
to AcID with an affinity of approximately 520 nM, consistent with literature reports.9 
Recently published NMR studies of the ERM TAD in complex with AcID further supports 
that the TAD is disordered in solution, but adopts an α-helical conformation following 
contact and sampling of AcID binding surfaces.29 Though additional analysis is 
necessary, such as mutations to disrupt helical propensity or truncations similar to those 
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described above for VP16, the emerging model is that ERM binds to AcID using 
predominantly α-helical secondary structure. 
VP16•AcID Hotspot Analysis Using Alanine Scanning Mutagenesis 
 Based on the observation that the majority of the interaction could be recapitulated 
with sequences containing the putative α-helical portions of the VP16 TADs, we next 
sought to determine if specific residues within those sequences are particularly critical for 
the majority of the binding energy in order to identify potential hotspot residues within the 
interaction. In order to accomplish this, an alanine scan of VP16(438-454) and VP16(467-
488) was completed. Specifically, this hotspot analysis was completed by synthesizing 
fluorescein labeled peptides in which each residue within the VP16(438-454) and 
VP16(467-488) sequence was sequentially mutated to an alanine, determining the affinity 
of the mutant for AcID by FP, and comparing the mutant affinity to the wild type affinity in 
order to determine the individual contribution for each residue to the binding energy. 
Alanine scanning hotspot analysis is a common method to determine the energetic 
contributions of individual amino acids in protein-protein interactions.30,31 
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Figure 2.8- Alanine Scan of VP16(438-454). (A) The sequence of VP16(438-454) is shown. Each 
residue was sequentially mutated to an alanine, with the exception of 438, which would generate the 
parent sequence. (B) Direct binding curves of each mutant compared to the wild type peptide. 
Table 2.1- Summary of VP16(438-454) Alanine Scan Results 
 
 In order to be considered a hotspot, mutation of the residue in question to alanine 
should result in a loss of binding energy such that the ∆∆G between the wild type and 
alanine mutant should be greater than 1.5 kcal/mol.30,32  None of the mutated residues 
within the VP16(438-454) sequence exhibits a ∆∆G greater than 0.9 kcal/mol. Thus, the 
VP16(438-454) interaction does not contain any specific hotspot residues, per accepted 
definitions, but instead relies upon a broad interaction network where many residues 
contribute to binding. In fact, the affinity of all of the mutated peptides were lower for AcID 
with the exception of G448A and S452A, with the remaining mutants demonstrating 
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Residue Kd (µM) Kd / Kd(WT) ΔΔG (kcal/mol) ∆∆G/ΔG(WT)*
A 1.92 ± 0.20 1.00 0.000 0.000
L 3.29 ± 0.28 1.71 0.319 0.041
D 5.30 ± 0.42 2.76 0.602 0.077
D 4.16 ± 0.35 2.17 0.458 0.059
F 6.92 ± 0.63 3.60 0.760 0.097
D 6.98 ± 0.63 3.64 0.765 0.098
L 7.95 ± 1.42 4.14 0.842 0.108
D 3.90 ± 0.34 2.03 0.420 0.054
M 2.28 ± 0.19 1.19 0.102 0.013
L 3.66 ± 0.24 1.91 0.382 0.049
G 1.81 ± 0.15 0.94 -0.035 -0.004
D 2.86 ± 0.28 1.49 0.236 0.030
G 2.30 ± 0.37 1.20 0.107 0.014
D 2.92 ± 0.39 1.52 0.248 0.032
S 1.93 ± 0.19 1.01 0.003 0.000
P 2.76 ± 0.26 1.44 0.215 0.028
G 2.23 ± 0.20 1.16 0.089 0.011
*	∆G(WT)	=	7.8	kcal/mol
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anywhere from a 1.2-fold to 4.1-fold decrease in affinity for AcID. This finding is consistent 
with most activator•coactivator interactions in that it occurs with weak to moderate affinity 
over a broad surface area.2 Though there may not be hot spots, mutation of F442, D443, 
and L444 to alanine result in the most significant decrease in affinity for AcID. In fact, 
comparing the ∆∆G values for these mutations to the ∆G for the binding of the wild-type 
peptide to AcID, suggests that these three residues account for greater than 30% of the 
total interaction energy. Thus, these residues appear to disproportionately contribute to 
the binding of the peptide to AcID and may constitute a critical surface within the 
interaction. Experiments in which all three residues are mutated to alanine may 
demonstrate the collective importance of these residues. Furthermore, though many of 
the acidic residues within the sequence appear to contribute to the affinity for AcID, D443 
has nearly twice the binding energy of any of the other acidic residues, suggesting that 
D443 is involved in a particularly important electrostatic or hydrogen-bonding interaction. 
 Previous mutational analysis of the VP16 H1 subdomain indicate that L439, F442, 
and L444 are critical for the transcriptional activity of the VP16 TAD in yeast nuclear 
extracts, with F442 being the most critical of the three.19,33 Alanine is a well tolerated 
mutation in terms of helical propensity, indicating that observed effects on transcriptional 
activity or binding affinity do not result from loss of α-helical secondary structure, but are 
instead likely a result of a loss of critical contacts with the bulky hydrophobic side chains 
of these residues. While L439 does not appear to contribute significantly to affinity for 
AcID, the observation that F442 and L444 are among the most important contributors to 
the interaction with AcID is consistent with these previous findings and suggests that 
VP16(438-454) may generally bind to coactivator partners with a conserved structure.  
 In addition to VP16(438-454), an alanine scan was also completed for the 
sequence VP16(467-488) to determine if perhaps the H2 binding site had more specific 
molecular requirements than the H1 binding site, the results of which are reported in 
Figure 2.9 and Table 2.2. 
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Figure 2.9- Alanine Scan of VP16(467-488). (A) The sequence of VP16(467-488) is shown. Each 
residue was sequentially mutated to an alanine, with the exception of 467, 471, and 482 which would 
generate the parent sequence. (B) Direct binding curves of each mutant compared to the wild type 
peptide. 
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Table 2.2- Summary of VP16(467-488) Alanine Scan Results 
 
 Similar to VP16(438-454), none of the residues in VP16(467-488) met the 
accepted criteria to be considered a hot-spot as the largest ∆∆G for any of the mutants 
was 0.7 kcal/mol. Thus, much like VP16(438-454), many of the residues within VP16(467-
488) contribute weakly to binding, indicating that the interaction of this sequence also 
occurs over a broad surface area. Generally, the individual amino acids within this peptide 
appear to contribute less to the interaction energy than the residues within the VP16(438-
454) peptide. This is not entirely unexpected, as the H2 interaction surface is comprised 
predominantly of the β-barrel, whereas the H1 interaction surface contains a more 
topographically defined cleft created by the interface between the β-barrel and helix three. 
Thus, the shallower and less defined topography of the β-barrel likely requires that most 
residues contribute approximately equally to binding. Similar to the VP16(438-454)•AcID 
interaction, a small cluster of three amino acids appear to contribute disproportionately to 
the interaction. Specifically, L468, D469, and M470 account for 20% of the total 
interaction energy after comparing the ∆∆G values for these residues to the ∆G for the 
binding of the wild type peptide to the domain. Of these three, the most important residue 
for the interaction appears to be D469, which exhibits a 3.5-fold decrease in affinity for 
Residue Kd (nM) Kd / Kd(WT) ΔΔG (kcal/mol) ∆∆G/∆G(WT)*
A 540 ± 60 1.00 0.000 0.000
L 1220 ± 170 2.26 0.483 0.056
D 1900 ± 180 3.52 0.745 0.087
M 1100 ± 110 2.04 0.422 0.049
A ----- ----- ----- -----
D 490 ± 80 0.91 -0.058 -0.007
F 660 ± 100 1.22 0.119 0.014
E 540 ± 60 1.00 0.000 0.000
F 910 ± 220 1.69 0.309 0.036
E 620 ± 130 1.15 0.082 0.010
Q 200 ± 50 0.37 -0.588 -0.069
M 660 ± 60 1.22 0.119 0.014
F 1200 ± 180 2.22 0.473 0.055
T 380 ± 50 0.70 -0.208 -0.024
D 630 ± 100 1.17 0.091 0.011
A ----- ----- ----- -----
L 720 ± 170 1.33 0.170 0.020
G 560 ± 140 1.04 0.022 0.003
I 620 ± 160 1.15 0.082 0.010
D 600 ± 140 1.11 0.062 0.007
E 590 ± 140 1.09 0.052 0.006
Y 480 ± 120 0.89 -0.070 -0.008
*	∆G(WT)	=	8.55	kcal/mol
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AcID following mutation to alanine. It is therefore possible that this residue in particular 
makes a critical electrostatic or hydrogen-bonding contact with AcID, as the other six 
acidic residues within the peptide do not demonstrate anywhere near as strong of an 
importance to the binding energy of the AcID interaction.  
 Previous mutational analysis of the VP16 TAD revealed that F473, F475, F479, 
and E476 were amongst the most important residues for transcriptional activation in 
reporter assays that utilized the VP16 TAD.34 Of these functionally important residues, 
only F479 exhibits a greater than two fold decrease in affinity for AcID following mutation 
to alanine. Thus, these data would appear to suggest that VP16(467-488) may interact 
with the H2 binding site of AcID in a unique manner not previously observed for other 
VP16•coactivator interactions. Taken together, the hot-spot analyses of VP16(438-454) 
and VP16(467-488) suggest that the VP16•AcID interactions occur over broad surface 
areas with many residues contributing weakly to the interaction with small clusters of 
sequential amino acids representing ‘hot-patches’ that disproportionately contribute to the 
binding energy. 
Electrostatic contacts are critical for the binding of VP16 to AcID 
 Based upon the highly basic character of AcID, due to the eleven lysine residues 
and six arginine residues within the protein, and the fact that many of the activator binding 
partners are highly acidic in nature, the importance of electrostatic interactions in the 
binding of activators to AcID was next examined. Furthermore, electrostatics have 
previously been demonstrated as an important factor in VP16•coactivator interactions, 
including interactions with PC4 and TFIIB.15 In order to assess the importance of 
electrostatic interactions in VP16•AcID interactions, the affinity of VP16(465-490) was 
measured in the presence of various concentrations of NaCl, NaSCN, and MgCl2, as 
shown in Figure 2.10. In electrostatically driven interactions, increasing salt 
concentrations leads to the shielding of charged amino acids, resulting in decreased 
affinity.35,36 
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Figure 2.10- Effect of Salt Concentration on Direct Binding of VP16(465-490) to AcID. (A) Affinity 
of VP16(465-490) was measured in the presence of various concentrations of sodium chloride. (B) 
Plot of apparent Kd value vs. sodium chloride concentration. (C) Affinity of VP16(465-490) was 
measured in the presence of various concentrations of sodium thiocyanate. (D) Affinity of VP16(465-
490) was measured in the presence of various concentrations of magnesium chloride. 
 Increasing the concentration of NaCl in the assay buffer in which the fluorescence 
polarization assays were run shows a clear effect on the affinity of VP16(465-490) for 
AcID, with the interaction becoming weaker in the presence of higher salt concentrations. 
A ten-fold increase in the concentration of salt from 100 mM NaCl to 1 M salt results in a 
more than thirty-fold decrease in affinity of the peptide for AcID. Thus, the strong 
dependence of the interaction on salt concentration indicates that the VP16(465-
490)•AcID interaction is strongly dependent on electrostatic interactions. 
 Additionally, the effects of NaSCN and MgCl2 concentration on the affinity of 
VP16(465-490) were determined. These salts were selected because they differentially 
shield cationic amino acid side chains and anionic side chains, respectively. The 
interaction strength between salt ions and proteins is directly related to the size and 
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polarizability of the ions. Specifically, the positively-charged side chains of arginine and 
lysine residues are shielded more effectively by large, polarizable anions such as 
thiocyanate (-SCN). Conversely, the negatively-charged side chains of acidic residues 
like aspartate and glutamate are shielded more effectively by small, less polarizable 
cations such as magnesium (Mg+2).37  Therefore, testing the effect of NaSCN and MgCl2 
on the affinity of VP16(465-490) for AcID may provide insight as to whether the anionic 
side chains of the TAD or the cationic side chains of AcID contribute more strongly to the 
interaction. In contrast to sodium chloride, both of these salts had significantly 
pronounced effects with 200 mM NaSCN and MgCl2 resulting in a ten-fold to twenty-five-
fold decrease in affinity compared to the affinity in 100 mM NaCl, further supporting the 
hypothesis that VP16•AcID interactions rely strongly upon electrostatic contacts. The 
apparent stronger effect of magnesium chloride relative to sodium thiocyanate suggests 
that anionic side chains may contribute more significantly to binding, though the exact 
molecular mechanism by which this occurs is unclear. 
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Figure 2.11- Effect of R466E Mutation on Binding of VP16(438-454) and (467-488) Completed by 
Matthew S. Beyersdorf. (A) Direct binding of VP16(438-454) and VP16(467-488) to the AcID mutant 
R466E compared to the wild type protein. Curves represent the mean values of three independent 
experiments with error bars indicating the standard deviation of the fraction bound at each 
concentration of the purified AcID protein. (B) Structure of AcID with the position of R466 shown in 
red. The blue residues are those that are heavily perturbed following binding of VP16 H1 and the 
yellow residues are those that are heavily perturbed following the binding of VP16 H2. 
 The mutation R466E was initially reported following structural work completed by 
Cramer and colleagues.12 This mutation was reported to abrogate the ability of the VP16 
TAD to bind to AcID in gel supershift assays and was also incapable of squelching 
transcription in yeast nuclear extracts by a Gal4(DBD)-VP16(TAD) fusion protein, in 
contrast to the wild type protein. However, a more specific analysis of the effect on VP16 
TAD affinity for this mutant was not reported. In Figure 2.11, the direct binding of 
VP16(438-454) and VP16(467-488) to the R466E mutant is compared to the affinity for 
the wild type AcID. This mutation results in an approximately 7.2-fold decrease in affinity 
for VP16(438-454) (8.6 µM vs. 1.2 µM) and an approximately 13.8-fold decrease in affinity 
for VP16(467-488) (12.0 µM vs. 0.87 µM), further underscoring the importance of 
electrostatic contacts between the VP16 TAD and AcID. The more pronounced effect on 
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the binding of VP16(467-488) is unsurprising given the proximity of R466 to the VP16 H2 
interaction surface as shown in panel (B) of Figure 2.11. The charge inversion introduced 
by this mutation likely results in a repulsive effect that diminishes the ability of VP16(467-
488) to bind to the H2 interaction surface.  
The molecular cause for the impact on the binding of VP16(438-454) is less 
immediately apparent, but one possibility is that the charge inversion affects the tertiary 
structure of the domain. Though R466 is located nearer to the H2 binding site, it is near 
the interface between the two binding surfaces. Thus, minor changes in the orientation of 
helix one and helix three may affect the affinity of both VP16(438-454) and (467-488). For 
example, D529 is located at the bottom of helix three in close proximity to R466. Though 
the distance between these residues it too large to allow for formation of a salt bridge 
based on measurements of the various NMR structures, the charge inversion present in 
the mutant may distort the position of helix three, which is a significant component of the 
VP16 H1 interaction surface based upon HSQC NMR perturbation studies of VP16 H1 
binding to AcID.8  Further, the mutation R469E, which was selected based on its close 
spatial orientation to R466, had no significant effect on the affinity of VP16(438-454) or 
(467-488). The absence of any perturbation of the affinity for either of the VP16 derived 
peptides thus further supports the notion that the R466E mutation results in a perturbation 
of the tertiary structure of the domain. Solution of the NMR structure of this mutant or a 
comparative analysis of HSQC perturbations elicited following incubation with VP16 TAD 
would be useful in further corroborating this hypothesis. 
2.4 Conclusions 
 The Activator Interaction Domain of Med25 contains an uncommon fold that has 
recently emerged as an important coactivator binding partner for a number of 
transcriptional activators. Previous reports suggest that the domain contains two distinct 
binding sites for VP16 located on opposite faces of the motif and that the TAD binds over 
a very large surface area estimated to be approximately 3600 Å2. Serial truncation of the 
VP16 TAD, as reported in this chapter, revealed that short segments of the TAD could 
recapitulate the majority of the binding affinity, suggesting that the the critical contacts 
within the interaction surface occur over a significantly more concise surface than is 
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required for binding of the full TAD. Thus, the fact that activator•AcID interactions can be 
localized to relatively concise surfaces suggested that it would be possible to identify 
small molecule inhibitors of these interactions. 
 Consistent with other activator•coactivator interactions, alanine scanning 
mutagenesis analyses of the minimal VP16 interaction sequences revealed that these 
binding partners do not contain specific hotspot residues, suggesting that the interactions 
are dependent upon weak contacts from each of the amino acids within these peptides. 
This was particularly apparent for the H2 derived minimal peptide as only one of the 
alanine mutations resulted in a greater than two-fold decrease in affinity. Though no single 
residue was of critical importance for the interaction, small clusters of sequential amino 
acids in each of the H1 and H2 derived peptides contribute disproportionately to the 
affinity of the peptide for the domain, suggesting that they constitute surfaces of particular 
importance to the interactions. The further minimization of the binding surfaces further 
underscores the potential for identification of small molecule inhibitors of these 
interactions. 
The highly acidic nature of most activator binding partners for the AcID motif and 
the highly basic character of the domain itself, along with previous observations of 
VP16•coactivator interactions, suggested that electrostatic interactions may play an 
important role in activator•AcID interactions. Increasing the concentration of salt within 
the binding assays resulted in a significant decrease in the affinity of the activator-derived 
peptides for the domain, with 1M NaCl resulting in a greater than thirty-fold decrease in 
the affinity of VP16(465-490) for the AcID motif. Thus, this suggests that electrostatic 
interactions play a particularly important role in the binding of activators to AcID and that 
small molecule inhibitors that interfere with these electrostatic contacts may be effective. 
Furthermore, the AcID charge inversion point mutation R466E results in a significant 
decrease in affinity for the VP16 TAD, suggesting that this residue may be involved in a 
particularly important electrostatic interaction with the VP16 TAD. The observation that 
this mutation affects affinity of peptide ligands for both of the AcID binding sites suggests 
that this residue may also be important to the secondary or tertiary structure of the domain 
and that the two binding sites may be allosterically connected. 
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Taken together, these data provide insight into the mechanisms by which we might 
be able to use small molecules to disrupt activator•AcID interactions. For example, 
molecules that disrupt critical electrostatic contacts between activators and the domain 
by targeting positive surfaces on AcID may be particularly effective. Additionally, given 
that activators do not appear to bind through the use of critical hotspot residues but 
instead require broad interaction surfaces, molecules that can induce allosteric structural 
shifts within the domain may offer an attractive mechanism for inhibiting these 
interactions. 
Assessing the Presence of Distinct Interaction Surfaces on AcID 
 An alternative area of research within our laboratory is focused on further validating 
the hypothesis that AcID contains two distinct interaction surfaces that can independently 
bind activators. This study is being completed using a peptide, VP16(438-454) G450C, 
that covalently binds to AcID at the H1 interaction site through the formation of a disulfide 
between an engineered cysteine within the TAD and a native cysteine residue within the 
binding site, as has been previously reported for studies involving 3-phosphoinositide-
dependent kinase 1.38 This work and the findings relevant to the molecular underpinnings 
of the VP16•AcID interaction are summarized in this section.  
 The affinity of VP16(438-454) and VP16(467-488) was determined for unlabeled 
AcID and AcID labeled with the G450C mutant peptide using fluorescence polarization, 
as shown in Figure 2.12. 
 
Figure 2.12- Direct Binding of VP16(438-454) and VP16(467-488) to the AcID•VP16 G450C 
Complex. AcID was covalently labeled using disulfide exchange with VP16 mutant G450C and the 
affinity of VP16(438-454) and VP16(467-488) was assessed for the covalent complex and compared 
to unlabeled AcID. Curves represent the mean values of three independent experiments with error 
bars indicating the standard deviation of the polarization at each concentration of the purified AcID 
protein. (Completed by Andrew R. Henderson) 
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 The VP16 H2 derived peptide, VP16(467-488), binds to the G450C•AcID complex 
with essentially no loss in affinity relative to unlabeled AcID, supporting the hypothesis 
that the domain contains two functionally distinct binding sites. Interestingly, VP16(438-
454) binds to the G450C•AcID complex with a mere 1.4-fold decrease in affinity. One 
possible explanation for the lack of perturbation in the affinity of VP16(438-454) for the 
covalently labeled complex is that it may be capable of binding to the VP16 H2 binding 
site in the event that the H1 binding site is already occupied, given the similarity between 
the two sequences. 
 1H,15N-HSQC NMR perturbation studies of the G450C•AcID complex were also 
completed to identify regions perturbed by the covalent binding of the peptide, as shown 
in Figure 2.13. 
 
Figure 2.13- 1H,15N-HSQC NMR Perturbation of VP16 G450C•AcID Complex. Structure of AcID 
with perturbations induced by labeling with the VP16(438-454) G450C peptide. Heavily perturbed (>2 
standard deviations) residues are shown in red, while significantly perturbed (>1 standard deviation) 
residues are shown in orange. The H1 binding interface is shown on the left and the H2 binding 
interface on the right. (Completed by Andrew R. Henderson and Felicia Gray) 
 A number of the perturbed residues in the G450C•AcID complex are consistent 
with the perturbations previously reported for binding of VP16 H1 to AcID and thus 
represent a subset of the observed shifts for binding of the full H1 subdomain. 
Interestingly, a number of perturbed residues, such as I453 (red sticks in Figure 2.13) and 
F494 (orange sticks in Figure 2.13) are located at the interface of the H1 and H2 binding 
sites. Furthermore, perturbations in residues within the H2 binding site indicate that the 
binding of VP16(438-454) to the H1 interaction surface is capable of inducing chemical 
shifts in the H2 binding site. Thus, these data suggest that not only does AcID contain 
question that arose was whether the two binding sites within Med25 AcID are allosterically connected, similar 
to other coactivator domains such as GACKIX within the master coactivator CBP/p300.  
 
We carried out a comprehensive series of biophysical 
experiments aimed at answering the two questions, including 
protein NMR experiments and fluorescence-based 
experiments of Med25 AcID and AcID mutants complexed 
with ETV/PEA3 TADs, VP16, and VP16 mutants and 
truncations. A key set of data emerged from experiments 
carried out with a cysteine mutant of VP16 that we covalently 
Tethered to the H1 interaction surface of Med25 AcID, using a 
method previously described.(65) Chemical shift perturbation 
experiments with this complex showed not only significant 
shifts in the H1 binding site, as expected, but also shifts in a 
series of residues connecting the two binding surfaces, 
namely at I453 and F494, in addition to perturbations on the 
H2 binding surface, consistent with allosteric connectivity. 
Supporting this observation, in fluorescence-based binding 
studies, we observe at least 3-fold cooperativity between th  two binding ites using VP16-derived AcID 
ligands. Binding studies of ETV/PEA3 TAD with Tethered Med25 AcID in which th  H1 binding surface has 
been blocked also suggests that the H1 binding surface is the preferred site of interaction for the ETV/PEA3 
activators, as the KD for the H2 site is significantly larger. Recently, Verg r et al published a thorough chemical 
shift analysis of the ERM•AcID complex demonstrating perturbations that are consistent with a complex 
formed with the H1 site.(17) Although outside of the scope of this proposal, we have established a 
collaboration with the Verger lab for structural dissection of ETV/PEA3•Med25 AcID complexes and the data 
that emerge from this will be highly informative for the work in this proposal. Importantly,$ the$data$overall$
suggests$ that,$ like$ our$ success$ with$ targeting$ the$ GACKIX$ motif,$ our$ screening$ strategy$ should$ identify$
allosteric$ modulators$ of$ ETV•Med25$ complex$ formation,$ and,$ further,$ that$ allosteric$ enhancers$ of$ binding$
should$be$accessible.  
$
Preliminary( data:( pilot( screen( produces( 3( initial( inhibitors(To$ define$ the$ feasibility$ of$ an$ ETV•Med255targeting$
screen,$we$carried$out$a$pilot$screen.$The$pilot$was$carried$out$using$conditions$analogous$to$those$previously$
described$ [3845well$plate$ format,$ final$Med25$concentration$850$nM,$ tracer$ (fluorescein5labeled$ETV5$(38572)$
concentration$ of$ 20$ nM,$ and$ small$ molecule$ concentration$ 20$ µM](12).$ The$ pilot$ screen$ of$ 2400$ known$
bioactives$(approved$drugs,$natural$products,$probe$molecules)$had$a$campaign$Z’$score$of$0.87$and$a$hit$rate$
of$ 1.6%,$with$a$hit$defined$as$active$within$ three$ standard$deviations$of$ the$positive$ control.! $ Following$hit$
filtering$to$remove$compounds$with$known$chemical$reactivity,$toxicity,$broad$activity,$aggregation$properties$
and$native$fluorescence$we$identified$3$compounds$belonging$to$the$depside$and$depsidone$classes$of$small$
molecules$ (Figure$ 6a);$ we$ have$ previously$ found$ depsides$ and$ depsidones$ to$ be$ effective$ modulators$ of$
activator5coactivator$ interactions.(13)$Dose5response$ experiments$with$ re5purchased$CCG538381$CCG538361,$
and$CCG540171$confirmed$that$the$molecules$were$effective$inhibitors$of$ETV5/ERM$binding,$with$CCG538381$
being$the$most$potent$of$the$three$(Figure$6b).$The$molecules$are$also$specific$for$the$AcID$motif,$exhibiting$no$
Figure! 5$Ch mical$ shift$ perturbations$ of$VP16$ TAD$
tethered$to$AcID$via$disulfide$formation$at$C506.$
Figure! 6.! A)$ Structures$ of$ three$ initial$ inhibitors$ from$ the$ pilot$ screen$ along$ with$ EC50$ values$ from$ full$ dose5response$
experiments.$ Functional$ groups$ colored$ in$ blue$and$green$ are$ likely$ to$be$key$ for$binding$ and$ inhibition,$when$ compared$ to$
related$ depside$ and$ depsidones.$ B)$ Representative$ curve$ of$ CCG538381$ inhibition$ against$ the$ Med25•ERM$ (38572)$ complex$
(average$of$3$ independent$experiments).$C)$Representative$experiment$with$CCG538381$showing$no$ inhibition$against$another$
coactivator$motif,$CBP$KIX,$and$two$of$its$binding$partners,$MLL$and$the$phosphorylated$KID$domain$of$CREB$(pKID).$!
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two functionally distinct binding surfaces, but that these surfaces may also be within 
allosteric communication.  
Taken together, the data presented in this section are consistent with the 
hypothesis that AcID contains two distinct binding sites capable of interacting with 
transcriptional activators. Furthermore, these data suggest that AcID may be a relatively 
plastic protein fold with the two binding sites potentially allosterically connected. Thus, the 
plasticity present within AcID following the binding of the covalent peptide to the H1 
binding site suggests that it may be possible to identify small molecule inhibitors that can 
induce allosteric changes within the domain, providing a potential approach to disrupting 
the broad interaction surfaces required for activator binding.  
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2.5 Materials and Methods 
Plasmids 
Plasmid pET21b-Med25(394-543)-His6, henceforth referred to as pAcID-His6, was a 
generous gift from Patrick Cramer.12 pAcID(R466E) was generated by Matthew S. 
Beyersdorf using site directed mutagenesis as previously described.39 
 
Protein Expression and Purification 
AcID (Med25394-543) protein was expressed and purified together with Paul A. Bruno. 
Plasmid pAcID-His6 was transformed into heat-shock competent Rosetta pLysS cells 
(Novagen), streaked onto LB Agar plates containing ampicillin and chloramphenicol, and 
incubated at 37 °C overnight. The next evening, a 25 mL Terrific Broth (TB) starter culture 
with 0.1 mg/mL ampicillin and 0.034 mg/mL chloramphenicol was then inoculated with a 
colony selected from the LB Agar plate and incubated at 37 °C overnight. The next 
morning, 5 mL from the starter culture was added to 1L TB containing ampicillin and 
bacteria were grown at 37 °C to an OD600 of 0.8. Temperature was reduced to 18 °C and 
protein expression was induced upon addition of IPTG to a final concentration of 0.5 mM.  
Cells were incubated overnight at 18 °C. The 1 L cultures were then collected and 
centrifuged at 6000xg for 20 mins at 4 °C. Cell pellets were stored at -80 °C prior to 
purification. The harvested pellet was thawed on ice and resuspended in 20 mL of lysis 
buffer (50 mM phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 6.8). Cells were 
then lysed by sonication on ice and cellular lysates were cleared by centrifugation at 9500 
rpm for 20 min at 4 °C. The supernatant lysate was then added to Ni-NTA beads (Qiagen) 
and incubated for 1 hour at 4 °C. The resin was pelleted by centrifugation at 2500 rpm for 
2 min at 4 °C and washed with wash buffer (50 mM phosphate, 300 mM sodium chloride, 
30 mM imidazole, pH 6.8) a total of five times. Protein was then eluted with 2 mL of elution 
buffer (50 mM phosphate, 300 mM sodium chloride, 400 mM imidazole, pH 6.8) a total of 
three times. Eluent was then pooled and purified by cation exchange FPLC (Source 15S, 
GE Healthcare) using a gradient of Buffer B (50 mM phosphate, 100 mM NaCl, 1 mM 
DTT, pH 6.8) in Buffer A (50 mM phosphate, 1 mM DTT). The FPLC purified protein was 
then dialyzed into storage buffer (10 mM phosphate, 50 mM NaCl, 10% v/v glycerol, 
0.001% v/v NP-40, pH 6.8) overnight, concentrated, aliquoted, and stored at -20 °C.  Final 
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protein was greater than 90% pure as determined by coomassie stained polyacrylamide 
gel. Protein concentration was determined by UV-Vis spectroscopy using an extinction 
coefficient, ε = 22,460 M-1cm-1.  
 
AcID(R466E) was expressed and purified as described above by Matthew S. Beyersdorf. 
 
Peptide Synthesis 
Peptides were synthesized on CLEAR amide resin (Peptides International) using 
standard HBTU/HOBT/DIEA coupling conditions as previously described.40 TFA cleaved 
peptides were purified using reverse-phase HPLC (Agilent 1260) on a C18 Poroshell 
column (Agilent) using 20 mM ammonium acetate and acetonitrile as the eluent with the 
gradient indicated for each peptide. Following HPLC purification, fractions were pooled, 
lyophilized, and reconstituted in DMSO. The concentration of fluorescein labeled peptides 
was then determined by UV-Vis spectroscopy following 1:1000 dilution of the DMSO stock 
into 10 mM PBS, pH 7.4 using ε = 72,000 M-1cm-1, per the manufacturer (Pierce). Peptide 
identity was confirmed by electrospray mass spectrometry. Analytical HPLC spectra of all 
synthesized peptides can be found in Appendix A. 
 	
Flo-VP16(413-437) was synthesized and purified by Paul A. Bruno. Fluorescein 
isothiocyanate and β-alanine were coupled to a sequence containing VP16 residues 413-
437 to produce FITC-βA-APPTDVSLGDELHLDGEDVAMAHAD. A gradient of 10-40% 
acetonitrile over 30 min was used for HPLC purification.  
  
Flo-VP16(438-464) was synthesized and purified by Paul A. Bruno. Fluorescein 
isothiocyanate and β-alanine were coupled to a sequence containing VP16 residues 438-
464 to produce FITC-βA-ALDDFDLDMLGDGDSPGPGFTPHDSAP. A gradient of 10-
40% acetonitrile over 30 min was used for HPLC purification. 
  
Flo-VP16(465-490) was synthesized and purified by Paul A. Bruno. Fluorescein 
isothiocyanate and β-alanine were coupled to a sequence containing VP16 residues 465-
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490 to produce FITC-βA-YGALDMADFEFEQMFTDALGIDEYGG. A gradient of 10-40% 
acetonitrile over 30 min was used for HPLC purification.  
	
Flo-VP16(438-454) was synthesized and purified as described above. Fluorescein 
isothiocyanate and β-alanine were coupled to a sequence containing VP16 residues 438-
454 to produce FITC-βA-ALDDFDLDMLGDGDSPG. A gradient of 10-40% acetonitrile 
over 30 min was used for HPLC purification.   
	
Flo-VP16(467-488) was synthesized and purified as described above. Fluorescein 
isothiocyanate and β-alanine were coupled to a sequence containing VP16 residues 467-
488 to produce FITC-βA-ALDMADFEFEQMFTDALGIDEY. A gradient of 10-40% 
acetonitrile over 30 min was used for HPLC purification. 
 
Flo-VP16(472-479) was synthesized and purified as described above. Fluorescein 
isothiocyanate and β-alanine were coupled to a sequence containing VP16 residues 472-
479 to produce FITC-βA-DFEFEQMF. A gradient of 10-30% acetonitrile over 20 min was 
used for HPLC purification. 
  
Flo-ERM(38-68) was synthesized and purified as described above. Fluorescein 
isothiocyanate and β-alanine were coupled to a sequence containing ERM residues 38-
68 to produce FITC-βA-ALDMADFEFEQMFTDALG. A gradient of 10-40% acetonitrile 
over 30 min was used for HPLC purification.  
 
Flo-VP16(438-454) alanine scanning mutants were synthesized and purified as described 
for Flo-VP16(438-454). Fluorescein isothiocyanate and β-alanine were coupled to the 
sequences indicated in the table below. A gradient of 10-30% acetonitrile over thirty 
minutes was used for HPLC purification. 
VP16(438-454) L439A: AADDFDLDMLGDGDSPG 
VP16(438-454) D440A: ALADFDLDMLGDGDSPG 
VP16(438-454) D441A: ALDAFDLDMLGDGDSPG 
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VP16(438-454) F442A: ALDDADLDMLGDGDSPG 
VP16(438-454) D443A: ALDDFALDMLGDGDSPG 
VP16(438-454) L444A: ALDDFDADMLGDGDSPG 
VP16(438-454) D445A: ALDDFDLAMLGDGDSPG 
VP16(438-454) M446A: ALDDFDLDALGDGDSPG 
VP16(438-454) L447A: ALDDFDLDMAGDGDSPG 
VP16(438-454) G448A: ALDDFDLDMLADGDSPG 
VP16(438-454) D449A: ALDDFDLDMLGAGDSPG 
VP16(438-454) G450A: ALDDFDLDMLGDADSPG 
VP16(438-454) D451A: ALDDFDLDMLGDGASPG 
VP16(438-454) S452A: ALDDFDLDMLGDGDAPG 
VP16(438-454) P453A: ALDDFDLDMLGDGDSAG 
VP16(438-454) G454A: ALDDFDLDMLGDGDSPA 
 
Flo-VP16(467-488) alanine scanning mutants were synthesized and purified as described 
for Flo-VP16(467-488). Fluorescein isothiocyanate and β-alanine were coupled to the 
sequences indicated in the table below. A gradient of 10-40% acetonitrile over thirty 
minutes was used for HPLC purification. 
VP16(467-488) L468A: AADMADFEFEQMFTDALGIDEY 
VP16(467-488) D469A: ALAMADFEFEQMFTDALGIDEY 
VP16(467-488) M470A: ALDAADFEFEQMFTDALGIDEY 
VP16(467-488) D472A: ALDMAAFEFEQMFTDALGIDEY 
VP16(467-488) F473A: ALDMADAEFEQMFTDALGIDEY 
VP16(467-488) E474A: ALDMADFAFEQMFTDALGIDEY 
VP16(467-488) F475A: ALDMADFEAEQMFTDALGIDEY 
VP16(467-488) E476A: ALDMADFEFAQMFTDALGIDEY 
VP16(467-488) Q477A: ALDMADFEFEAMFTDALGIDEY 
VP16(467-488) M478A: ALDMADFEFEQAFTDALGIDEY 
VP16(467-488) F479A: ALDMADFEFEQMATDALGIDEY 
VP16(467-488) T480A: ALDMADFEFEQMFADALGIDEY 
VP16(467-488) D481A: ALDMADFEFEQMFTAALGIDEY 
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VP16(467-488) L483A: ALDMADFEFEQMFTDAAGIDEY 
VP16(467-488) G484A: ALDMADFEFEQMFTDALAIDEY 
VP16(467-488) I485A: ALDMADFEFEQMFTDALGADEY 
VP16(467-488) D486A: ALDMADFEFEQMFTDALGIAEY 
VP16(467-488) E487A: ALDMADFEFEQMFTDALGIDAY 
VP16(467-488) Y488A: ALDMADFEFEQMFTDALGIDEY 
 
Fluorescence polarization direct binding assays 
Direct binding assays were performed in triplicate with a final sample volume of 20 μL in 
a low volume, non-binding, 384-well black plate (Corning). FITC-labeled peptides were 
diluted in assay buffer (10 mM PBS, 100 mM NaCl, 10 % glycerol, 0.001% NP-40 pH 6.8) 
to a centration of 40 nM. 10 µL of AcID protein was serially diluted two-fold on the 384-
well plate for the number of data points indicated for each experiment using assay buffer. 
10 µL of the diluted fluorescent peptide stock was then added to each well of diluted 
protein for a final tracer concentration of 20 nM. An additional well containing 10 µL buffer 
and 10 µL fluorescent peptide was prepared for use as a ‘tracer only control’ to determine 
optimal gain settings on the plate reader. Samples were then incubated for 30 minutes at 
room temperature before fluorescence polarization was measured on a Pherastar plate 
reader with polarized excitation at 485 nm and emission intensity measured through a 
parallel and perpendicularly polarized 535 nm. A binding isotherm that accounts for ligand 
depletion (assuming a 1:1 binding model of peptide to ACID) was fit to the observed 
polarization values as a function of ACID to obtain the apparent equilibrium dissociation, 
Kd:  
 𝑦 = 	𝑐 + 𝑏 − 𝑐 	×	 𝐾* + 	𝑎 + 𝑥 − (𝐾* + 𝑎 + 𝑥)/ − 4𝑎𝑥2𝑎  
 
Where “a” and “x” are the total concentrations of fluorescent peptide and AcID, 
respectively, “y” is the observed anisotropy at a given AcID concentration, “b” is the 
maximum observed anisotropy value, and “c” is the minimum observed anisotropy value. 
Each data point is an average of three independent experiments with the indicated error 
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representing the standard deviation of the three replicates. All curves and calculations 
were generated using GraphPad Prism 5. 
 
Hotspot Analysis 
Direct binding experiments for each of the alanine mutants of VP16(438-454) and 
VP16(467-488) were completed as described above. The calculated Kd value for each 
mutant was then compared to the calculated Kd value for the wild-type peptide in order to 
calculate the ∆∆G of each residue using the following equation: 
 ∆∆𝐺 = 	𝑅𝑇 ln𝐾*89:𝐾*;<  
 
Where, “R” is the ideal gas constant in units of kcalK-1mol-1, “T” is the temperature in 
kelvin, “KdWT” is the calculated Kd value of the WT peptide binding to AcID, and “Kdmut” is 
the calculated Kd value of the indicated alanine mutant. 
 
Salt Titration Direct Binding Experiments  
The direct binding experiments were performed as noted above with several 
modifications. The salt concentration of assay buffer was adjusted to the indicated 
concentrations by adding an appropriate volume of assay buffer containing 5 M of the 
indicated salt prior to adding components to the 384-well plate. For NaSCN and MgCl2 
titrations, AcID protein was dialyzed into storage buffer containing 100 mM of the 
appropriate salt in place of NaCl. All curves and calculations were generated using 
GraphPad Prism 5.  
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CHAPTER 3 
Depside and Depsidone Inhibitors of Activator•Med25 Interactions3 
3.1 Abstract 
The central hypothesis guiding the work described in this chapter is that the AcID 
motif of Med25 is amenable to the development of selective small molecule inhibitors that 
perturb the binding of activators to the domain. The results discussed previously in 
Chapter 2 suggest that small molecules that allosterically alter the conformation of the 
protein or disrupt critical electrostatic contacts between activators and the AcID motif will 
be particularly effective. In order to identify these inhibitors, a screen of biologically active 
small molecules was screened using a fluorescence polarization based binding assay 
and hits were subsequently filtered to eliminate non-selective inhibitors of AcID, ultimately 
providing lead molecules that belong to the depside and depsidone classes of natural 
products. The most potent lead molecule, norstictic acid, is a covalent inhibitor of AcID 
and reacts with reactive lysine side chains near surfaces important for the binding of 
transcriptional activators. Interestingly, the binding of the inhibitor to one activator binding 
site is capable of simultaneously perturbing binding at the second activator binding site, 
consistent with a model in which norstictic acid functions as a mixed orthosteric/allosteric 
inhibitor. Finally, preliminary evidence supports a mechanistic model in which norstictic 
                                            
3 The research described in this chapter was a collaborative effort. Steven M. Sturlis and 
Paul A. Bruno synthesized and purified fluorescent tracers, expressed and purified 
protein, optimized the FP HTS assay, performed the primary screen, and analyzed 
covalent adducts by mass spectrometry. Paul A. Bruno completed the cellular assays, 
prepared samples for HSQC analysis, and expressed Med15 protein. Jessica Gagnon 
(Brooks Lab, University of Michigan) completed MD simulations of norstictic acid in 
complex with AcID. Felicia Gray (Cierpicki Lab, University of Michigan) performed HSQC 
analysis of AcID•norstictic acid adducts. Giselle Tamayo-Castillo (INBio) provided 
additional samples of norstictic acid. A manuscript is in preparation based on portions of 
this chapter: Sturlis, Steven M.*; Bruno, Paul A.*; Gray, Felicia; Gagnon, Jessica K.; 
Tamayo-Castillo, Giselle; Sherman, David H.; and Mapp, Anna K. Identifying Depside and 
Depsidone Inhibitors of Med25 AcID-mediated Transcription. Manuscript in preparation. 
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acid and the closely related molecule psoromic acid are capable of perturbing AcID-
dependent transcriptional processes in a cellular context. 
3.2 Introduction 
Given the fundamental role that transcription plays in all cellular processes and the 
fact that transcriptional dysregulation has been linked to virtually all human diseases as 
either a cause or consequence, small molecule inhibitors of transcriptional processes 
would be remarkably useful as mechanistic probes or novel therapeutic agents.1-4 
Transcription is an inherently difficult process to target; this is largely due to the fact that, 
with the notable exception of nuclear receptors, transcriptional activators do not require 
the binding of small molecules for their function. The primary avenue by which they can 
be targeted involves disrupting the dynamic network of protein-protein interactions that 
govern the assembly of the large multimeric protein complexes required for the 
expression of target genes.5 Targeting transcription is further complicated by the 
characteristics of the majority of the protein-protein interactions involved in transcriptional 
regulation. Typically they occur over broad surface areas with weak to moderate affinity 
and defy hotspot analysis, leading to their frequent characterization as ‘undruggable’.6 
Despite these inherent challenges, transcriptional inhibitors are attractive as mechanistic 
probes and/or as therapeutic agents as the disruption of transcriptionally relevant protein-
protein interactions offers an unparalleled opportunity to achieve context specificity, as 
discussed in Chapter 1. Furthermore, recent advances in discovery strategies for protein-
protein interaction inhibitors have made the task of developing transcriptional modulators 
more readily achievable.7 In particular, protein-protein interactions between activators 
and coactivators are attractive targets as their disruption will allow for the inhibition of 
specific activator-driven gene expression programs. 
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Figure 3.1- Transcription Requires the Assembly of Large Multimeric Protein Complexes 
Activators bind to DNA through sequence-specific interactions between their DNA binding domains 
(DBD) and elements within the promoter regions of target genes. The transcriptional activation 
domains (TAD) of these activators in turn make critical contacts with other elements of the 
transcriptional machinery including, but not limited to: chromatin modifying enzymes or complexes that 
alter the local chromatin structure, enabling or suppressing transcription of the target gene8,9; the 
Mediator complex, which bridges the DNA-bound activator to RNA Polymerase II and the general 
transcription factors10,11; or alternative coactivator proteins that may function as ‘bridging’ proteins that 
facilitate interactions between the activator and other elements of the transcriptional machinery.12 
Success in Targeting Transcriptional Coactivators 
 Despite the significant challenges, a number of small molecule transcriptional 
modulators have been identified in the past decade based upon design strategies that 
mimic the structure of transcriptional activation domains.7,13-16 These small molecules 
inhibit activator•coactivator interactions by binding to target coactivators at surfaces 
required for interaction with native activator binding partners. The first reported example 
of this strategy was a series of compounds built upon an isoxazolidine core to which 
various functional groups such as hydroxyl, phenyl, or isobutyl could be appended. These 
molecules mimic critical residues of transcriptional activation domains and have been 
shown to be capable of activating transcription to comparable levels as a minimal 
sequence of the potent VP16 TAD following their localization to DNA.17 Subsequent 
experiments, including pull-down experiments from cellular lysates with biotinylated 
molecule and fluorescence polarization assays with purified domains, revealed that one 
of these isoxazolidines, iTAD 1, was capable of binding to the KIX domain of the master 
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coactivator CBP. Furthermore, 1H,15N-HSQC chemical shift perturbation studies revealed 
that the binding of iTAD 1 to the KIX domain induced similar shifts as the binding of native 
activator binding partners, suggesting that the molecules bind to similar surfaces within 
the domain.18 
 The ability of isoxazolidine TAD mimetics to inhibit activator•coactivator 
interactions by competing for necessary coactivator binding surfaces has also been 
investigated. ErbB2 is a surface receptor tyrosine kinase, the overexpression of which 
leads to an enhanced metastatic phenotype and resistance to chemotherapies in breast 
cancer. 19-21 The transcriptional activator ESX has been demonstrated as a central 
regulator in the expression of ErbB2 and is dependent upon interactions with Mediator 
subunit Med23 for its transcriptional activity. 22,23 Furthermore, inhibition of the 
ESX•Med23 complex has been shown to reduce the proliferative capacity of ErbB2 
overexpressing breast cancer cell lines, underscoring the role of ESX and ErbB2 in breast 
cancer.22,24 Consistent with these prior reports, a biphenyl containing isoxazolidine similar 
in structure to iTAD 1 was capable of inhibiting the formation of the ESX•Med23 and led 
to a decrease in the expression of ErbB2 and a decrease in the cellular proliferation of 
ErbB2 dependent breast cancer cell lines such as SKBR3.14 Interestingly, the unmodified 
iTAD 1 molecule exhibited no effect against ErbB2 expression or the proliferation of 
SKBR3 cells, presumably as a result of its ten fold lower affinity for Med23 relative to the 
affinity of the biphenyl containing molecule, demonstrating that this class of transcriptional 
inhibitor is tunable and dependent upon specific functional groups for their activity. 
Recently, the biphenyl isoxazolidine ESX inhibitor was shown to act synergistically with 
afatinib, an irreversible EGFR/ErbB2 tyrosine kinase inhibitor, in an in vivo mouse model 
of head and neck squamous cell carcinoma, underscoring the potential utility of these 
transcriptional inhibitors.25 
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Figure 3.2- Examples of TAD Mimetic Transcriptional Inhibitors (A) Examples of molecules 
belonging to the isoxazolidine class of transcriptional inhibitors. iTAD 1 functions as a synthetic 
activation domain upon localization to DNA by binding to the KIX domain of CBP/p300. HSQC data 
indicates that the molecule binds to the surface of KIX (yellow) utilized by the transcription factor MLL 
(red) (PDB ID: 2AGH).  Biphenyl is an inhibitor of the ESX•Med23 interaction and has been 
demonstrated to downregulate the expression of ESX target genes, such as ErbB2. (B) Example of 
an oligooxopiperazine helix mimetic that has been shown to inhibit the interaction between HIF1α (red) 
and the CH1 domain of CBP (yellow), thereby downregulating the expression of HIF1α dependent 
genes (PDB ID: 1P4Q). 
 Another synthetic scaffold that has been effectively exploited in the development 
of activator TAD mimetics is derived from the functionalization and oligomerization of 
oxopiperazines. These molecules, termed oxopiperazine helix mimetics (OHM), offer 
significant advantages over similar molecules that utilize aromatic scaffolds as the 
oxopiperazine backbone is chiral, positioning side chains more effectively in three 
dimensional space allowing for more efficient inhibition of three dimensional binding 
surfaces with greater specificity. Furthermore, an oxopiperazine dimer approximately 
spans the length of an eight-mer helix, positioning side-chain-like functionalities in a 
similar spatial orientation as the i, i+4, and i+7 positions within α-helices. Biophysical 
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methods including circular dichroism, COSY NMR spectroscopy, and NOESY NMR 
spectroscopy confirm that the OHMs adopt α-helical like geometries.13 
 Recently, the oxopiperazine helix mimetic OHM 1 has been shown to inhibit 
hypoxia inducible factor 1 (HIF1α) regulated gene expression and has been show to 
reduce tumor growth rates in mouse MDA-MB-231 xenograft models.26 Under hypoxic 
conditions that frequently accompany the growth of solid tumors the expression of HIF1α 
is induced, resulting in the upregulation of transcriptional programs that drive 
angiogenesis and contribute to invasion and altered energy metabolism in cancer.27 
Transcriptional activation by HIF1α requires an interaction with the cysteine-histidine rich 
1 (CH1) domain of the master coactivator CBP/p300. 28,29 OHM 1 effectively inhibits the 
HIF1α•CH1 interaction by mimicking critical hot-spot residues located within an eight-mer 
α-helix of the C-terminal TAD of HIF1α required for interaction with CH1.26 Thus, 
isoxazolidine and oxopiperazine derived TAD mimetics demonstrate that synthetic small 
molecules are capable of inhibiting activator•coactivator interactions and that these small 
molecules are useful as mechanistic probes, even in in vivo contexts. 
 More recently developed strategies have sought to inhibit interactions between 
activators and coactivators through small molecules that do not merely mimic structural 
features of transcriptional activation domains, but instead induce structural shifts that 
interfere with protein-protein interactions in target coactivators through allosteric 
mechanisms. An example is the disulfide-containing small molecule fragment 1-10, which 
was originally identified in a Tethering screen of the KIX domain of CBP/p300.30 The KIX 
domain contains two distinct binding sites for transcriptional activators that are within 
allosteric communication. More specifically, the binding of an activator, such as MLL, to 
the domain induces allosteric shifts within the protein that enhance the binding of a 
second ligand at an alternative site, such as the pKID domain of the activator CREB. 31,32 
The binding of 1-10 to an engineered cysteine mutation within the MLL binding site has 
been shown to significantly inhibit the binding of MLL to KIX through orthosteric inhibition, 
while also inhibiting the binding of pKID to the secondary site by inducing allosteric 
changes within the domain. 30,33 Though this inhibition was a modest two-fold decrease 
in affinity for the pKID domain, 1-10 serves as a useful example of a small molecule that 
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can induce allosteric changes within a coactivator that modulates its ability to bind a native 
activator partner. 
 
Figure 3.3- Examples of Allosteric Transcriptional Inhibitors (A) 1-10 is a small molecule fragment 
that binds to an engineered cysteine mutant of the KIX domain through disulfide exchange. (B) 
Sekikaic acid and lobaric acid are small molecules belonging to the depside and depsidone class of 
lichen-derived natural products. (C) The KIX domain of CBP/p300 with the MLL binding site indicated 
in red and the binding site for the pKID domain of the activator CREB indicated in blue. (D) Molecular 
dynamics simulations suggest that depsides such as sekikaic acid can adopt α-helical like 
conformations. Sekikaic acid is shown overlaid with an amphipathic helix of the p53 TAD. 
 The lichen-derived natural products sekikaic acid and lobaric acid  were recently 
discovered as inhibitors of the CBP/p300 KIX domain.34 These molecules were identified 
by a fluorescence polarization-based high-throughput screen of the MLL•KIX interaction, 
which occurs at a flexible interface of the domain (Figure 3.3 C). Screening of a 50,000 
compound small molecule library failed to identify any potential lead molecules, but 
subsequent screening of a 15,000-sample natural product extract library identified sixty-
four extracts with inhibitory activity. This observation underscores the potential of natural 
products as inhibitors of protein-protein interactions as they tend to be more complex and 
three-dimensional than ‘drug-like’ molecules typical of commercially available screening 
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libraries. An iterative screening strategy in which these extracts were then tested against 
two other protein-protein interactions and one protein-DNA interaction identified two 
extracts with specificity for the KIX domain. Compound isolation and characterization 
identified sekikaic acid as the most abundant component of these extracts with lobaric 
acid subsequently identified as a result of its structural similarities. These compounds 
were then tested against the pKID•KIX interaction, which occurs at a second broader and 
shallower binding site on the KIX domain, and were found to inhibit this interaction in 
addition to the MLL•KIX interaction. Subsequent biophysical characterization 
demonstrated that the inhibition of the pKID•KIX interaction was achieved through 
allosteric shifts within the protein following the binding of the molecule to the MLL 
interaction site. Molecular dynamics simulations of sekikaic acid suggests that the 
structure adopts a three-dimensional orientation similar to an α-helix with the aryl 
substituent arrangement resulting in amphipathic character, as shown in Figure 3.3 D. 
Taken together, these observations demonstrate for the first time that small molecules 
can inhibit activator•KIX interactions at both activator binding sites through a mixed 
orthosteric/allosteric mode of action. 
The above examples of small molecule transcriptional inhibitors demonstrate that 
the inhibition of activator•coactivator interactions can be achieved by developing small 
molecules that: (1) compete with native activator binding partners for critical binding 
surfaces within coactivators or (2) by inducing allosteric changes within the activator 
binding domains of coactivators that alter critical activator binding surfaces. 
The Activator Interaction Domain of Med25 as a Target for Small Molecule Inhibitors 
 The Activator Interaction Domain (AcID) of the Mediator subunit, Med25, contains 
a unique protein fold consisting of a seven-stranded β-barrel flanked by three α-helices, 
as shown in Figure 3.4 A. 35-37 This particular fold has not been previously observed in 
any other known coactivator protein and has been identified in only one other protein of 
unknown function that is overexpressed in cancerous prostate tissue. 35,36,38 Known 
activator binding partners of AcID include the PEA3 subfamily of ETS transcription factors 
that have been implicated in tumor progression and metastatic phenotypes in breast and 
prostate cancer39-41, the endoplasmic reticulum stress response transcription factor 
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ATF6α42, and the potent viral activator VP16 that is responsible for the functional switch 
from latent to lytic infection in herpes simplex virus infections. 35,36,43,44 
 
Figure 3.4- The Activator Interaction Domain (AcID) of Mediator Subunit 25 (A) A cartoon 
schematic of the AcID motif reveals that the unique fold consists of a seven-stranded β-barrel flanked 
by three α-helices. (B) 1H,15N-HSQC NMR chemical shift perturbation studies of the binding of the 
VP16 TAD to AcID reveals two distinct binding sites for the H1 and H2 subdomains of the TAD. 
 Recent NMR studies demonstrated that the VP16 TAD binds to AcID over a broad 
surface with individual titration of the H1 or H2 subdomains binding to distinct interaction 
surfaces on opposite faces of the protein, as shown in panel B of Figure 3.4. 35,36 Results 
discussed in Chapter 2 suggest that the VP16•AcID interaction is predominantly 
dependent upon reported α-helices within the VP16 TAD and that the individual VP16 H1 
and H2 binding sites within AcID may be capable of allosteric communication. Thus, the 
AcID motif of Med25 is an attractive target for the development of small molecule 
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inhibitors given that: (1) the unique nature of the domain’s fold should allow for the 
discovery of highly selective small molecules with few off target effects, (2) previous 
success in targeting α-helix mediated activator•coactivator interactions has been 
achieved, and (3)  development of small molecule inhibitors of activator•AcID interactions 
would be useful in answering mechanistic questions about this poorly understood domain, 
could be used to validate future discoveries of activator binding partners for AcID, and 
could serve as potential leads in novel therapeutic strategies for diseases linked to AcID 
dependent transcriptional activators.  
Given the broad surface area over which activators interact with the AcID motif and 
the conformational plasticity within the domain, particularly the allosteric communication 
between the two putative binding sites, inhibitors that function through an allosteric 
mechanism of action will likely be particularly effective at disrupting activator•AcID 
interactions. In order to select lead compounds with this activity, hits identified in the 
primary screen are tested for inhibition against functionally related activator•coactivator 
interactions. This filter eliminates compounds that merely mimic TADs or amphipathic 
helices, resulting in lead compounds with excellent selectivity profiles for the target of 
interest and likely function through allosteric mechanisms. This screening strategy is 
discussed in the context of a larger screening campaign in Chapter 4. 
3.3 Results and Discussion 
VP16 is perhaps the best studied example of the amphipathic acidic class of 
activators and given its demonstrated interaction with the Activator Interaction Domain 
(AcID) of Med25, serves as a useful binding partner for the identification of inhibitors of 
activator•AcID interactions.35-37,44-46 One of the primary concerns with small molecule 
inhibitors is that non-specific inhibition of alternative targets may result in significant off-
target effects that preclude their use as mechanistic probes or potential lead compounds 
in novel therapeutic strategies. In order to combat this potential issue in the context of 
activator•coactivator interaction inhibitors, a fluorescence polarization based assay 
adapted to a high-throughput format and a series of counter-screens that will test the 
ability of identified hits to inhibit unrelated and related activator•coactivator interactions 
will be employed. In this manner, hits will be filtered to remove those compounds that 
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merely mimic the VP16 transcriptional activation domain or those that non-specifically 
block transcriptionally relevant protein-protein interactions. Our lab has previously utilized 
this strategy to identify inhibitors of other activator•coactivator interactions.34 
High-Throughput Screen Assay Development 
 As was previously discussed at length in Chapter 2, a truncation study of the VP16 
TAD was completed to identify specific elements of the domain that contribute strongly to 
interaction with the AcID motif of Med25. This data is presented again in Figure 3.5 for 
the sake of clarity. 
 
Figure 3.5- Fluorescent Tracers Derived from the Truncation of the VP16 TAD The VP16 TAD 
was truncated into three peptides of approximately equally length and an additional two peptides were 
synthesized based on purported α-helices within the TAD (underlined sequences within the TAD). The 
peptides were conjugated to fluorescein and the Kd of each peptide was determined for AcID using 
fluorescence polarization. Curves represent the means of three independent experiments with error 
bars representing the standard deviation of the fraction bound at the indicated concentration of AcID 
protein. Curves were fit using GraphPad Prism 5. (With Paul A. Bruno) 
 VP16(465-490) was selected for high-throughput screening because it is the 
sequence that binds to the domain with the highest affinity, suggesting that this particular 
TAD sequence is critical for interaction with the domain, and the dynamic range for 
binding of the tracer to AcID spans approximately 250 mA units. 
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Figure 3.6- Effect of Tracer Concentration on Dynamic Range The binding curves of VP16(465-
490) at tracer concentrations of 50 nM and nM are compared. Curves represent the means of three 
independent experiments with error bars representing the standard deviation of the anisotropy at the 
indicated concentration of AcID protein. Curves were fit using GraphPad Prism 5. 
 Following the selection of VP16(465-490) as the fluorescent tracer for use in the 
screen, we next sought to determine if the concentration of tracer present in the assay 
had a significant effect on the dynamic range of the binding curve. Minimizing the 
concentration of tracer in the FP assay would reduce the amount of material required for 
the screen, saving time and resources. In Figure 3.6 the binding curves of VP16(465-490) 
to AcID with 20 nM tracer and 50 nM tracer present are compared. Excess tracer did not 
further enhance the dynamic range relative to that observed with 20 nM tracer, and the 
lower concentration was thus used in the screen. 
 Subsequently, the assay was further optimized for HTS by testing the effects of 
NP-40 and DMSO on the interaction of VP16(465-490) and AcID and the stability of the 
assay over time. Very low concentrations (0.001% v/v) of the detergent NP-40 is included 
in the assay buffer in order to minimize aggregation of the protein or small molecules and 
to minimize non-specific interactions between the protein and equipment used to 
dispense assay components.47 Since small molecules are added from concentrated 
DMSO stocks, demonstrating that DMSO does not have deleterious effects on the assay 
provides further confidence in identified hit molecules. Finally, assay plates may sit at 
room temperature for a period of several hours while waiting to be read by plate reader, 
so it is necessary that the assay be stable over a significant period of time. The effects of 
DMSO, NP-40, and the stability of the assay over time is shown below in Figure 3.7. 
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Figure!3.8!Comparison!of!tracer!concentration!Compared!the!effects!of!either!20!nM!or!50! nM! of! Fl :VP16(465:490)! o ! dynamic! range! of! FP! assay.! L s ! than! 5%! change! in!dyna ic!range!observed!with!50!nM!trace!compared!to!20! M!tracer.!We! also! tested! the! effects! of! DMSO! and! NP:40! on! our! FP! assay.! When! testing! against!compounds!in!a!high:throughput!screen,!samples!are!added!as!a!solution!of!DMSO!and!it!is!sometimes! necessary! to! use! high! concentrations! of! DMSO! in! order! to! obtain! the!appropriate! effective! concentration! to! test! compound! stocks! at! lower! starting!oncentrations! or! to! obtain! full! dose! curves! wh n! validating! initial! hits.! The efore,! it! is!critical!to!determine!the!effects!of!DMSO!on!the!high:throughput!assay.!Additionally,!NP:40!is!often!used!in!high:throughput!assays!in!order!to!inhibit!non:specific!binding!and!also!to!help! solubilize! less! soluble! compounds! to! prevent! them! from! crashing! out! in! the! assay!buffer.!It!is!often!sufficient!to!add!NP:40!to!a!final!co centration!of!0.001%!v/v.!The!results!of! the! assay! looking! at! the! effects! of! DMSO! and! NP:40! on! the! Flo:VP16(465:490):ACID!interaction!are!depicted!in!Figure!3.9.!Based!on!the!results!demonstrated!in!Figure!3.9,!we!conclude!that!NP:40!(0.001%!v/v)!has!no!effects!on!the!high:throughput!assay!and!DMSO!up!to!5%!v/v!is!well!tolerated!as!evidenced!by!the!Kd!being!perturbed!only!2:fold!from!the!original!Kd!determined!(Figure!3.9).!
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Figure 3.7- Assay Stability Time Course, DMSO Effects, and NP-40 Effects on Tracer Affinity. 
The effects of 0.001% NP-40 and 5% DMSO are shown in isolation (blue and green curves, 
respectively) or in combination (red curve). Additionally, the stability of the assay is shown after 1, 2, 
4, 6, 8, and 20 hours. Curves represent the means of three independent experiments with error bars 
representing the standard deviation of the anisotropy at the indicated concentration of AcID protein. 
Curves were fit using GraphPad Prism 5. (With Paul A. Bruno) 
 The 0.001% NP-40 had a negligible impact on the affinity of VP16(465-490) for 
AcID as the Kd value was 0.72 µM in the presence of the detergent, compared to 0.58 µM 
without NP-40 present. DMSO at 5% v/v had a slightly stronger, though still negligible, 
effect as the Kd value shifted to 1.5 µM at this concentration of DMSO. The standard 
protocol for compound addition to the assay results in a 1% final DMSO concentration, 
but demonstrating the minimal perturbation caused by a 5% final concentration would 
allow for testing compounds at a higher concentration in the event that the standard 
protocol failed to identify any lead molecules. Furthermore, the simultaneous presence of 
NP-40 and DMSO did not result in effects on the assay different than either component 
in isolation. Finally, the assay is highly stable over time as the Kd value shifted less than 
thirty percent even after being incubated at room temperature for twenty hours. ! 86!
!
Figure! 3.9! Effect! of! DMSO! and! NP240! on! the! Kd! of! Flo2VP16(4652490)2ACID!
interaction! A! directing! binding! assay! was! set! up! using! 20! nM! of! tracer! titrated! with!increasing!concentration!of!ACID!protein.!Effects!of!DMSO,!NP:40,!or!the!a!combination!of!the!two!were!investigated!by!adding!DMSO!(5%!v/v),!NP:40!(0.001%!v/v),!or!DMSO!(5%!v/v)!and!NP:40!(0.001%!v/v).!These!three!conditions!were!monitored!over!6!time!points:!1,!2,!4,!6,!8,!and!20!hours.!The!last!parameter!that!we!investigate!for!the!high:throughput!screen!was!determining!the!Z’!score!of!our!assay.!The!Z’!statistic! is!used!to!determine!the!quality!of! the!assay.!The!Z’!score!was!determined!at!three!protein!concentrations:!500!nM,!850!nM,!and!2.5!μM!using!the!following!equation:!!!! !! = !1− 3 !! + !!!!! − !!! ! (Equation!!3.1)!σ!=!standard!deviation!of!positive/negative!population!μ!=!mean!value!of!positive!and!negative!population!
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Additionally, NP-40, DMSO, and extended incubations had no effect on the dynamic 
range of the experiment, indicating that the assay is well adapted to HTS. 
 The final parameter to optimize prior to screening was the concentration of AcID 
protein to use in the assay. In order to accomplish this, the calculated Z’ scores for 500 
nM, 850 nM, and 2.5 µM AcID in the presence of 20 nM VP16(465-490) fluorescent tracer 
were compared. The Z’ score is a metric, measured from zero to one with one 
representing a theoretically perfect assay, that defines the quality of an assay based upon 
the dynamic range and the reproducibility of the positive and negative controls as defined 
by their standard deviations. Increasing protein concentrations results in larger dynamic 
ranges, and thus larger Z’ scores. Standard convention for high-throughput screening 
dictates that Z’ scores greater than 0.6 indicate an excellent assay.48 These scores are 
calculated using Equation 3.1: 𝑍> = 	1 −	3(𝜎B + 𝜎C)𝜇B − 𝜇C  𝜎 = 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑	𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛	𝑜𝑓	𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒	𝑜𝑟	𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒	𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝜇 = 𝑚𝑒𝑎𝑛	𝑣𝑎𝑙𝑢𝑒	𝑜𝑓	𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒	𝑜𝑟	𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒	𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
 Within the context of the fluorescence polarization assay, the positive control was 
defined as the polarization of the tracer alone and the negative control was defined as the 
polarization of the tracer bound to AcID protein in the presence of one percent DMSO. 
AcID concentrations of 500 nM, 850 nM, and 2.5 µM produced Z’ scores of 0.76, 0.81, 
and 0.88, respectively. Furthermore, the dynamic range of the assay with 500 nM, 850 
nM, and 2.5 µM spanned 70, 95, and 136 mP, respectively. Thus, the screen was run 
with an AcID concentration of 850 nM as these conditions produced an excellent Z’ score 
and demonstrated a broad dynamic range without requiring large amounts of purified 
protein. Taken together, the above data is consistent with a robust and high-fidelity assay 
that is well suited for high-throughput screening. 
Primary Screen for Inhibitors of VP16(465-490)•AcID 
 Following the successful optimization of an FP assay well suited for HTS 
applications, a primary screen at the University of Michigan Center for Chemical 
Genomics (CCG) was completed. In this screen, 4,046 compounds were tested at a 
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concentration of 20 µM from the MS Spectrum 2000, Focused Collections, and BioFocus 
NCC libraries, which include known bioactive molecules, secondary metabolites, natural 
products, and FDA approved drugs. The primary screening campaign had an average Z’ 
score of 0.87, indicating an excellent assay, and a 1.6% hit rate. For the purposes of this 
screen, a hit was defined as any compound that resulted in inhibition greater than three 
standard deviations above the negative control, which corresponded to approximately ten 
percent inhibition. Following the primary screen, hits were filtered and compounds with 
known chemically reactive properties as well as those compounds that demonstrated 
native fluorescence greater than ten percent of the fluorescence produced by the tracer 
were removed. Following the filtering step, we identified the compounds CCG-38381 
(norstictic acid), CCG-38361 (psoromic acid),CCG-40171 (baeomycesic acid), and CCG-
40095, as shown in Figure 3.8. 
 
Figure 3.8- Primary Screen of Bioactive Compounds. (A) Campaign view of the primary screen 
against VP16(465-490)•AcID. Red points represent positive controls, blue points represent negative 
controls, green points are the inhibition induced by test compounds, and the red line represents the 
threshold for hits. (B) Structures of the most promising hits following filtering. The percent inhibition of 
the VP16(465-490)•AcID interaction is denoted below the CCG identifier. (With Paul A. Bruno) 
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!
Figure!3.10!Pilot!screen!against! the!Flo2VP162ACID!interaction!Performed!with!Steve!Sturlis.! A.! Campaign! view!of! the! pilot! screen! run! against! 4,046! compounds.! The! red! and!blue!dots!represent!the!negative!and!positive!contr ls,!respectively.!Green!dots!represent!the!tested!compounds!with!all!compounds!above!the!red!line!(>3SD)!representing!hits.!B.!The!identified!hits!from!the!pilot!screen!with!the!initial!inhibitions!noted!as!a!%.!
Substructure!search!of!compounds!containing!the!depside!or!depsidone!scaffold!These!results!were!exciting!based!on!the!fact!that!we!saw!a!reoccurrence!of!the!privileged!scaffold! that! was! first! identified! in! a! natural! product! extract! screen! of! the! MLL:KIX!interaction.! Based! on! the! observation! that! our! confirmed!hits! shared! a! common! scaffold!previously! identified! against! another! activator:coactivator! PPI,! we! performed! a!substructure!search!of!the!CCG!database!for!other!compounds!that!contained!the!depside!and! depsidone! core,! yielding! 15! additional!molecules! to! be! tested! against! the! Flo:VP16:ACID!interaction!(Figure!3.11).!
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 All four of these lead compounds belong to a class of molecules known as 
depsides and depsidones, which are natural products derived from lichens and were well 
studied by Emil Fischer.49 This result was particularly exciting given that previously 
identified molecules belonging to this class have been reported as effective inhibitors of 
α-helix dependent activator•coactivator interactions by our group.34 Molecular dynamics 
simulations of the depside sekikaic acid revealed that the central ester can rotate, 
displaying the aromatic side chains in an orientation similar to an α-helix. Thus, an 
intriguing possibility is that this class of molecules represent a privileged scaffold for the 
inhibition of α-helix dependent protein-protein interactions, though additional 
experimentation will be necessary to more definitively demonstrate this. 
Hit Confirmation and Selectivity Studies of Norstictic Acid and Psoromic Acid 
 In order to confirm that norstictic acid and psoromic acid are inhibitors of the 
VP16•AcID interaction, samples of both molecules were acquired from commercial 
sources and their activity against the VP16(465-490)•AcID FP assay was retested. 
Unfortunately, we were unable to secure a commercial source for baeomycesic acid and 
so we were unable to further confirm it as an AcID inhibitor. Freshly purchased norstictic 
acid and psoromic acid were tested for inhibition of VP16(465-490)•AcID as well as 
VP16(438-464)•AcID in order to determine if the molecules are site selective inhibitors of 
the AcID motif, as shown in Figure 3.9. 
	
 
Figure 3.9- Validation of Norstictic and Psoromic Acid with Commercial Compounds. The ability 
of Norstictic and psoromic acid to inhibit VP16(438-464)•AcID and VP16(465-490)•AcID was tested 
with freshly prepared compound obtained from commercial sources. Curves represent the mean 
values of three independent experiments and vertical error bars represent the standard deviations of 
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the fraction bound at the indicated concentrations of small molecule. Curves were fit with GraphPad 
Prism 5. 
 The freshly prepared stocks of norstictic acid and psoromic acid were significantly 
more potent than the compounds held within the CCG libraries. Norstictic acid inhibits 
VP16(438-464)•AcID with an IC50 (30 Min) value of 1.2 µM and VP16(465-490)•AcID with 
an IC50 (30 Min) value of 1.8 µM compared to 13 µM for the library stocks (Figure 3.13). 
Thus, the fresh compound is more potent by approximately ten-fold. Psoromic acid 
inhibits VP16(438-464)•AcID with an IC50 (30 Min) value of 2.3 µM and VP16(465-490)•AcID 
with an IC50 (30 Min) value of 3.9 µM compared to 107 µM for the library stock (Figure 3.13), 
representing a greater than twenty-five fold enhancement in potency. The largely 
enhanced potency observed with freshly purchased compounds is consistent with 
norstictic acid and psoromic acid as inhibitors of VP16•AcID interactions.  
 In order to determine whether these molecules are selective for inhibition of AcID-
dependent interactions, the ability of the molecules to inhibit alternative 
activator•coactivator interactions was determined. Two CBP/p300 KIX domain-dependent 
interactions were tested to demonstrate that the molecules do not function as generic 
TAD or amphipathic helix mimetics and the VP16•Med15 interaction was tested to 
demonstrate that the molecules do not specifically mimic the VP16 TAD structure. These 
experiments support the hypothesis that norstictic acid and psoromic acid are selective 
inhibitors of the AcID motif, suggesting that they may function by allosterically inhibiting 
activator interactions with the domain which is further explored in subsequent sections of 
this Chapter. 
Specifically, the ability of norstictic acid and psoromic acid to inhibit the 
activator•coactivator interactions between MLL and the KIX domain of CBP/p300, as well 
as the interaction between the phosphorylated activation domain of CREB (pKID) and the 
KIX domain was determined. Our lab and others have extensively studied these 
interactions and demonstrated that they rely upon α-helical secondary structure within the 
TADs of the activator binding partner.50,51 Thus, given that these interactions occur with 
similar structural features to the VP16•AcID interaction and the demonstrated utility of 
these binding assays, the MLL•KIX and pKID•KIX interactions are useful in determining 
the specificity of norstictic acid and psoromic acid for the AcID motif of Med25. As shown 
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in panels B and C of Figure 3.10, neither norstictic acid nor psoromic acid demonstrated 
any significant perturbation of the interaction between MLL and KIX or the pKID domain 
of CREB and KIX. Thus, these data are consistent with the hypothesis that norstictic acid 
and psoromic acid are selective inhibitors of AcID and do not function as generic TAD 
mimics. 
 
Figure 3.10- Effects of Norstictic and Psoromic Acid on Activator•KIX Interactions. (A) Binding 
of MLL and the pKID domain of CREB occurs at distinct surfaces on the KIX domain and requires that 
the TADs adopt an α-helical secondary structure. (B) Inhibition of norstictic acid against the MLL•KIX 
interaction (Red curve) and the pKID•KIX interaction (Blue curve) (C) Inhibition of psoromic acid 
against the MLL•KIX interaction (Red curve) and the pKID•KIX interaction (Blue curve). Curves 
represent the mean values of three independent experiments and were plotted using GraphPad Prism 
5. 
 In order to further confirm that norstictic acid and psoromic acid are selective for 
AcID, their ability to inhibit the interaction between VP16 and Mediator Subunit 15 was 
also determined. Testing this particular interaction will allow us to determine if the 
identified lead molecules are merely acting as VP16 mimetics, as comparable inhibition 
of VP16•Med15 interactions would indicate. In order to test the inhibition of VP16•Med15 
interactions, Med15(1-345), which contains a GACKIX domain and the A and B boxes 
which serve as VP16 interaction sites, was expressed.52 The expressed protein was then 
confirmed to be binding-competent by testing the direct binding of the VP16 derived 
A
B
C
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peptide VP2 (DFDLDMLGDFDLDMLG), which is a single repeat of VP16(441-448), as 
well as VP16(438-454) and VP16(467-488). 
 
Figure 3.11- Effects of Norstictic and Psoromic Acid on VP16•Med15(1-345) Interactions. (A) 
Direct binding of VP2, VP16(438-454) (αH1), and VP16 (467-488) (αH2) to Med15(1-345). (B) 
Inhibition of VP16•Med15 interactions by norstictic acid and psoromic acid. Curves represent the mean 
values of three independent experiments, and error bars represent the standard deviation of the 
fraction of tracer bound at the indicated concentration of protein or small molecule. Curves were fit 
with GraphPad Prism 5. (With Paul A. Bruno) 
 As shown in panel A of Figure 3.11, VP2 bound to Med15 with a Kd value of 16.0 
µM, consistent with reported literature values.52 VP16(438-454) and VP16(467-488), 
denoted as αH1 and αH2 on the curves, bound to Med15 with Kd values of 27.7 and 7.4 
µM, respectively, indicating that the protein was properly folded and capable of binding 
VP16 derived peptides. Inhibition curves of the three VP16•Med15 interactions 
demonstrate that norstictic acid and psoromic acid are relatively weak inhibitors of 
VP16•Med15 interactions with IC50 values greater than 60 µM and 105 µM respectively; 
values that are significantly larger than those observed for the inhibition of VP16•AcID 
interactions. Thus, it is possible that the small molecules weakly mimic some aspects of 
the VP16 TAD, though the significantly greater potency against VP16•AcID interactions 
suggests that they are more selective for AcID than one of its native activator binding 
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partners. Taken together, the above data demonstrate that norstictic acid and psoromic 
acid are effective and selective inhibitors of VP16•AcID interactions and do not merely 
mimic the structure of an amphipathic helix generally or the VP16 TAD specifically. The 
possibility that this selectivity is achieved through the induction of allosteric changes 
within the domain will be explored in subsequent sections of this Chapter.  
Substructure Search of CCG Libraries for Depside and Depsidone-like Molecules 
 Based upon these observations, a substructure search of the small molecule 
libraries held by the CCG was completed using the depside and depsidone core scaffold 
defined in panel A of Figure 3.12 in order to identify closely related compounds. 
 
Figure 3.12- Substructure Search of CCG Libraries for Depside/Depsidone Core. (A) The core 
depside and depsidone scaffolds that were utilized in the substructure search. (B) Compounds 
identified within the CCG libraries that contain the core depside and depsidone scaffold. (With Paul A. 
Bruno) 
 This substructure search revealed sixteen additional molecules that contain the 
depside or depsidone core with unique patterns of aryl substituents. These compounds, 
in addition to the four identified in the primary screen, were then subjected to a dose-
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response analysis. Additionally, the order of addition of assay components was reversed 
for the dose-response assays, with the addition of compound to buffer to first check for 
native fluorescence of the compounds, followed by the addition of the tracer to check for 
fluorescence quenching caused by the molecules. None of the compounds demonstrated 
native fluorescence outside of acceptable limits nor significant fluorescence quenching of 
the tracer. Inhibition curves of active compounds were subsequently fit to determine 
approximate IC50 values, as shown in Figure 3.13. 
 
 
Figure 3.13- Dose Response Curves of Selected Compounds from Substructure Search. 
Inhibition assays were completed in duplicate at eight concentrations of inhibitor ranging from 150 µM 
0.0 0.5 1.0 1.5 2.0 2.5
50
100
150
CCG-38361
log [Compound] (µM)
m
P
IC50 = 106.6 ± 15.6 µM
0.0 0.5 1.0 1.5 2.0 2.5
50
100
150
Norstictic Acid
IC50 = 13.02 ± 0.96 µM
Ki = 4.40 ± 0.32 µM
log [Norstictic Acid] (µM)
m
P
0.0 0.5 1.0 1.5 2.0 2.5
50
100
150
CCG-38584
log [Compound] (µM)
m
P
0.0 0.5 1.0 1.5 2.0 2.5
50
100
150
CCG-38587
log [Compound] (µM)
m
P
0.0 0.5 1.0 1.5 2.0 2.5
50
100
150
CCG-40171
log [Compound] (µM)
m
P
IC50 = 80.9 ± 6.1 µM
0.0 0.5 1.0 1.5 2.0 2.5
50
100
150
CCG-76904
log [Compound] (µM)
m
P
IC50 = 243.8 ± 27.5 µM
CH3
HO
O
O
O
O
CH3
OH
OHO
O
O
O
O
OH
HO
O
H3C
O
CH3
O
CH3
O
O
OH
O
O
CH3
OH
CH3
OH
O
O
O H3C
O
O
O
O
CCG-38381
CH3
HO
O
O
O
O
CH3
O
HO
O
CH3
O
O
O
O
O
CH3
OH
OHO O
 100 
to 4.1 µM. Curves were fit using GraphPad Prism 5 to determine approximate IC50 values. CCG-38587, 
lobaric acid, is a previously identified activator•coactivator interaction inhibitor, the compounds in the 
left column are closely related depsidones, and CCG-40171, baeomycesic acid, is the lone active 
depside. (With Paul A. Bruno) 
 The majority of the twenty compounds tested did not demonstrate significant 
inhibition of VP16(465-490)•AcID, with the exception of the compounds identified in the 
primary screen. A number of the compounds lacked particularly complex or complete 
substitution of the aryl rings that comprised the core scaffold, suggesting that this 
substitution is critical for function. Furthermore, compound CCG-38587 (lobaric acid), 
which was previously identified as an inhibitor of activator•coactivator interactions, failed 
to demonstrate any inhibition of the VP16•AcID interaction over the tested concentration 
range. This suggests that the identity of the substituents on the aryl rings are capable of 
conferring specificity. Ultimately, the substructure search failed to produce additional 
compounds from those identified in the primary screen, but did provide some preliminary 
structure-activity-relationship data, as shown in in Figure 3.14. 
 
 
Figure 3.14- Limited Structure Activity Relationship for Potential Lead Molecules. Comparisons 
of the activity of closely related molecules in the dose response screen provides some insight into 
important structural elements of the potential lead molecules. Potential hydrophobic contacts are 
shown in green and important polar functionalities are shown in blue and purple. 
 Norstictic acid, psoromic acid, and baeomycesic acid are similarly substituted, 
suggesting that these functionalities may be important for the specific inhibition of AcID 
dependent interactions. All of the hits contain an ortho-phenol substituted aldehyde. 
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Notably, stictic acid, an analogue of norstictic acid is methylated at the ortho-phenol and 
lacks all inhibitory activity, suggesting that a free phenol at this position is indispensable 
for activity. The three lead compounds also contain hydrophobic methyl functionalities 
(green functional groups on the structures in Figure 3.14) on the same face of the 
molecules, while the opposite face of the molecules contain an acidic functionality in 
addition to the polar phenol group (blue functional groups on the structures in Figure 
3.14). Thus, the presence of a hydrophobic face and a distinct hydrophilic face suggests 
that these molecules may be amphipathic in nature, similar to the VP16 TAD, perhaps 
explaining their relatively potent activity. The acidic functionality on norstictic acid exists 
as a lactonol that results from an intramolecular reaction with a second aldehyde. Finally, 
the three lead molecules also contain a polar functional group, either a phenol or 
methylated phenol, adjacent to one of the methyl groups (purple functional groups on the 
structures in Figure 3.14). The fact that this functional group may be a free phenol or a 
methylated phenol suggests that it may function as a hydrogen bond acceptor and does 
not necessarily need to act as a hydrogen bond donor. 
Mechanism of Action Elucidation for Norstictic Acid 
 After confirming that norstictic acid and psoromic acid are inhibitors of the 
VP16•AcID interaction in vitro and that the inhibition was selective, we next sought to 
determine the mode of action by which inhibition is achieved. The majority of these 
experiments were completed with norstictic acid, given its greater potency in inhibiting 
VP16•AcID interactions. Molecular dynamics (MD) simulations were completed in 
collaboration with the Brooks lab at the University of Michigan to attempt to identify 
potential binding surfaces for norstictic acid. The MD simulations revealed that the highest 
density of molecule clusters around surfaces rich in lysine residues, which is unsurprising 
given the acidic, negatively charged, functionalities present on norstictic acid and the 
positively charged side chains of the lysine residues. The clustering of norstictic acid near 
regions rich in lysine residues and the lowest energy conformations of the molecule at 
those surfaces on AcID are shown below in Figure 3.15. 
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Figure 3.15- Molecular Dynamics Simulations of Norstictic Acid Localization. (A) Molecular 
dynamics simulation that reveals the predicted locations with the highest norstictic acid density (Red) 
on the AcID surface. Blue surfaces indicate lysine residues (B) Molecular dynamics simulation that 
shows the lowest energy conformations (Green) of norstictic acid within the regions of highest density 
on the AcID surface. Blue surfaces indicate lysine residues. (Completed by Jessica K. Gagnon)	
  
In order to support the hypothesis that electrostatic interactions between the small 
molecule and protein play a critical role in the inhibition of VP16•AcID interactions by 
norstictic acid, a sodium chloride titration experiment was completed for the inhibition of 
VP16(465-490)•AcID by norstictic acid. The ability of norstictic acid to inhibit VP16(465-
490)•AcID in the presence of sodium chloride concentrations ranging from 100 mM to 
1000 mM is reported below in Figure 3.16. 
  
Figure 3.16- Effect of NaCl on Norstictic Acid Inhibition of VP16(465-490)•AcID. Inhibition of 
VP16(465-490)•AcID at various concentrations of sodium chloride ranging from 100 mM to 1000 mM. 
Curves represent the mean values of three independent experiments with error bars representing the 
standard deviation of the fraction of tracer bound at the indicated concentration of small molecule. 
Curves were fit with GraphPad Prism 5. 
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determined.!Additionally,!areas!on!the!protein!that!binds!the!highest!density!of!ligand!can!be!highlighted,!providing!additional! information!about!the! inhibitors!possible!mechanism!of! action.! An! MD! simulation! performed! with! ACID! and! norstictic! acid! revealed! that!norstictic!acid!clustered!at!the!lysines!on!ACID.!This!is!somewhat!unsurprising!considering!that!there!are!several!lysines!on!the!ACID!protein!and!norstictic!acid!contains!a!carboxylic!acid! that! is! part! of! the! lactone! on! ring! B,! suggesting! that! electrostatics! likely! plays! an!important!role!in!the!interaction!between!the!depsidones!and!ACID.!The!highest!density!of!norstictic!acid!on!ACID!and!the! lowest!energy!members!of!norstictic!acid!on!ACID!can!be!seen!in!Figure!3.17!A!and!B.!
!
Figure! 3.17! M lecular! dynamics! (MD)! simulation! with! norstictic! ! a d! ACID!Performed! by! Jessica! Gagnon.! A.!MD! simulation! i entifying!where! the! highest! density! of!norstictic!acid! is! found!on!ACID.!B.!MD!simulation!demonstrating!what!the! lowest!energy!members!of!norstictic!acid!and!ACID!are!based!on!where!the!highest!density!of!norstictic!acid!is!found.!
The!effects!of!salt!on!ACID!binding!to!VP16!and!inhibition!with!norstictic!acid!There!have!been!separate!studies!that!have!identified!the!importance!of!electrostatics!for!both! ACID! and! the! VP16! TAD.! In! the! case! of! ACID,! it! was! recently! reported! that! the!arabadopsis!Med25:ACID! and! human!Med25:ACID! relied! on! electrostatics! for! binding! to!dehydration! responsive! element! binding! protein! 2A! (Dreb2A).! This! was! determined! by!looking! at! the! ΔH! and! TΔS! values! using! isothermal! titration! calorimetry! (ITC),! which!identified! large! contributions! from! enthalphy! compared! to! entropic! contributions! of! the!interaction.52! Based! on! the! observation! that! ACID! relies! on! electrostatics! for! interaction!with! other! activators,! it! is! likely! that! electrostatics! contribute! to! binding! with! other!
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 There is a clear salt dependence on the inhibition of VP16(465-490)•AcID by 
norstictic acid as the IC50 (30 Min) values increase significantly with increasing 
concentrations of sodium chloride. The IC50 (30 Min) value has shifted to larger than 110 µM 
in the presence of 600 mM sodium chloride and cannot be accurately determined in the 
presence of greater than 800 mM salt due to solubility constraints of the small molecule 
in the assay buffer. Thus, these data support the hypothesis that the interaction of 
norstictic acid with the AcID motif is dependent upon electrostatic interactions between 
the small molecule and protein. 
 One of the defining molecular features of the three compounds identified as lead 
molecules in the primary screen is the presence of an aldehyde functionality on one of 
the aryl rings, though in the case of norstictic acid there are two aldehyde functionalities, 
one of which is involved in an intramolecular reaction to generate the lactonol ring. 
Aldehydes are highly electrophilic and their presence in other inhibitors has been 
previously demonstrated to result in the covalent binding of the inhibitor to the target 
protein through the formation of a Schiff base, a fully substituted imine, through the 
dehydration reaction of the aldehyde with the nucleophilic amine of lysine residues. 53,54 
Thus, we next sought to determine if norstictic acid was capable of covalently binding to 
AcID. Notably, such a modification would not only immobilize the inhibitor on the surface 
of the protein, but would also result in the loss of a positive charge on the surface of the 
domain. 
Given the demonstrated importance of electrostatic contacts in the interaction 
between the VP16 TAD and AcID, the loss of critical electrostatic contacts through 
covalent binding of norstictic acid with nucleophilic lysine residues may be a significant 
contributor to the inhibitory activity of the molecule. 
 
 104 
 
Figure 3.17- Covalent Labeling of AcID by Norstictic Acid. (A) Mass spectrometry results that 
demonstrate norstictic acid covalently binds to the AcID motif. Protein was incubated with four 
equivalents of molecule and reduced with sodium borohydride. (B) Reduction of the Schiff base formed 
following the reaction between the protein and norstictic acid results in reduction of the second 
aldehyde in addition to the imine. (With Paul A. Bruno) 
 The results shown in Figure 3.17, confirm that norstictic acid is capable of 
covalently labeling AcID. Purified AcID protein was incubated with four equivalents of 
norstictic acid and treated with sodium borohydride to reduce the resultant imine. The 
labeled complex was then subjected to mass spectrometric analysis, revealing that the 
domain (18,126 Da) could be labeled with multiple equivalents of small molecule as 
demonstrated by the presence of peaks in the spectrogram at molecular weights of 
18,484 Da and 18,843 Da, corresponding to the addition of one and two norstictic acid 
molecules, respectively. The protein was labeled with four equivalents of molecule as this 
was the stoichiometry of molecule present relative to protein at the IC50 value of norstictic 
acid. Of note, the reduction following reaction of norstictic acid with the domain also 
reduces the second aldehyde within the lactonol ring, explaining why reduction results in 
a mass increase of four Daltons, as opposed to the expected two Dalton increase. The 
observation that the resultant covalent adduct can be reduced is consistent with the 
hypothesis that the covalent interaction occurs through the formation of an imine. 
Additionally, the covalent adduct formed between norstictic acid and the AcID motif is 
particularly stable as it can be observed by mass spectrometric analysis even in the 
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absence of sodium borohydride reduction, as is shown later in this chapter in Figure 3.21 
and Figure 3.27. 
 In order to demonstrate that the observed inhibition of AcID-dependent interactions 
by norstictic acid is not a result of the nonspecific labeling of lysine residues within the 
domain, the ability of alternative aldehyde containing small molecules to inhibit 
VP16•AcID interactions was next determined. Benzaldehyde, which has been previously 
demonstrated to modify lysine residues, was tested as in order to determine the general 
ability of aromatic aldehydes to modify the AcID motif, as shown below in Figure 3.18.54 
 
Figure 3.18- Benzaldehyde Does Not Inhibit or Covalently Label the AcID Motif (A) Mass 
spectrometric analysis of AcID in the presence of four equivalents of benzaldehyde. The expected 
mass of the adduct was 18,232 Da. (B) Inhibition experiments of benzaldehyde against the VP16(438-
454) and VP16 (467-488) interactions with AcID. 
 Mass spectrometric analysis of AcID protein treated with four equivalents of 
benzaldehyde revealed that the small molecule is incapable of covalently modifying the 
domain, consistent with the hypothesis that norstictic acid specifically modifies the AcID 
motif. Furthermore, benzaldehyde fails to inhibit the interaction of both VP16(438-454) 
and VP16(467-488) with AcID, providing further evidence that the activity of norstictic acid 
against the domain is not solely dependent upon the reactivity of its aldehydes. 
 In addition to benzaldehyde, which is significantly less structurally complex than 
norstictic acid, the ability of atranorin, a closely related depside to norstictic acid, to 
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Figure! 3.23! Mass! spectrometry! analysis! of! Med25! ACID! in! the! presence! of!
benzaldehyde!Performed!by!Paul!Bruno.!A.!Spectra!of!ACID!protein! in!the!presence!of!4!equivalents! of! benzaldehyde.! To! obtain!mass! spectra,! 10!μM!ACID!was! incubated!with!4!equivalents!of!benzaldehyde!(40!μM)!and!complex!was!left!to!incubate!for!2!hours.!Sample!of!mixture!was!analyzed!using!mass!spectrometry!to!obtain!spectra.!B.!Competition!assay!with!benzaldehyde!against!the!VP16(438:454):ACID!and!VP16(467:488):ACID!interaction.!As!demonstrated! in!Figure!3.23,! benzaldehyde!was!unable! to! covalently! label!ACID.!This!result!demonstrates!that!the!reactivity!of!the!aldehyde!is!not!sufficient!for!covalent!labeling!of! ACID! (Figure! 3.23A),! further! validating! the! importance! of! the! ortho! phenol! to! the!aldehyde!on!the!A!ring.!Additionally,!benzaldehyde!is!also!incapable!of!inhibiting!either!the!VP16(438:454):ACID!and!VP16(467:488):ACID!interaction!in!a!competition!assay!(Figure!3.23B).!This!result!is!important!because!it!suggests!that!norstictic!acid!and!psoromic!acid!need!to! first! interact!with!ACID,!which!will!place!the!molecule! in!proximity!to!a! lysine!to!form!an!imine,!highlighting!the!importance!of!norstictic!acid!and!psoromic!acid!interacting!with!ACID.!One!possible!explanation!for!benzaldehyde!not!being!able!to!label!ACID!could!be!that!the!phenyl!group!does!not!have!affinity!for!ACID,!causing!the!molecule!to!never!be!in!proximity!to!a!lysine!for!imine!formation.!!
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Figure! 3.23! M s! spectrometry! analysis! of! Med25! ACID! in! the! pr sence! of!
benzaldehyde!Perform d!by!Paul!Bruno.!A.!Spectra!of!ACID!protein! in!the!presence!of!4!equivalents! of! benzaldehyde.! To! obtain!mass! spectra,! 10!μM!ACID!was! incubated!with!4!equivalents!of!benzaldehyde!(40!μM)!and!complex!was!left!to!incubate!for!2!hours.!Sample!of!mixture!was!analyzed!using!mass!spectrometry!to!obtain!spectra.!B.!Competition!assay!with!benzaldehy e!against!the!VP16(438:454):ACID!and!VP16(467:488):ACID!interaction.!As!demonstrated! in!Figure!3.23,! benzaldehyde!was!unable! to! covalently! label!ACID.!This!result!demonstrates!that!the!reactivity!of!the!aldehyde!is!not!sufficient!for!covalent!labeling!of! ACID! (Figure! 3.23A),! further! validating! the! importance! of! the! ortho! phenol! to! the!aldehyde!on!the!A!ring.!Additionally,!benzaldehyde!is!also!incapable!of!inhibiting!either!the!VP16(438:454):ACID!and!VP16(467:488):ACID!interaction!in!a!competition!assay!(Figure!3.23B).!This!result!is!important!because!it!suggests!that!norstictic!acid!and!psoromic!acid!need!to! first! interact!with!ACID,!which!will!place!the!molecule! in!proximity!to!a! lysine!to!form!an!imine,!highlighting!the!importance!of!norstictic!acid!and!psoromic!acid!interacting!with!ACID.!One!possible!explanation!for!benzaldehyde!not!being!able!to!label!ACID!could!be!that!the!phenyl!group!does!not!have!affinity!for!ACID,!causing!the!molecule!to!never!be!in!proximity!to!a!lysine!for!imine!formation.!!
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covalently modify the AcID motif and inhibit the VP16•AcID interaction was next 
determined, as shown below in Figure 3.19. 
 
Figure 3.19- Atranorin Does Not Inhibit or Covalently Label the AcID Motif (A) Mass spectrometric 
analysis of AcID in the presence of four equivalents of Atranorin. The expected mass of the covalent 
adduct was 18,500 Da. (B) Inhibition of the VP16(438-464)•AcID interaction by atranorin. 
 Atranorin contains an ortho-phenolic aldehyde, similar to norstictic acid, but is 
incapable of covalently modifying the AcID motif, further supporting the hypothesis that 
norstictic acid specifically modifies AcID. Furthermore, atranorin is not an effective 
inhibitor of the VP16•AcID interaction as the IC50 of the small molecule was determined 
to be in excess of 250 µM. Atranorin contains a methyl ester as opposed to a free 
carboxylic acid and thus may lack a critical electrostatic interaction with the domain that 
is important for inhibitory activity, as has been previously demonstrated for norstictic acid. 
Taken together, the inability of other aldehyde containing small molecules to inhibit the 
VP16•AcID interaction or covalently modify the AcID motif is consistent with the 
hypothesis that norstictic acid is a selective inhibitor of the domain. 
 Following the observation that norstictic acid is a covalent inhibitor of AcID, we 
next sought to determine how quickly maximal inhibition was achieved. Optimizing 
incubation time to allow for complete formation of the imine between the molecule and 
protein would allow for a more accurate determination of the full inhibitory potential of the 
molecule. In order to accomplish this, the IC50 of norstictic acid against VP16(465-
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490)•AcID was measured at various time points to determine at which point maximal 
inhibition was achieved. The results of this time course study are shown below in Figure 
3.20. 
 
Figure 3.20- Norstictic Acid Inhibition Time Course of VP16(465-490)•AcID. The IC50 of norstictic 
acid was determined for inhibition of the VP16(465-490)•AcID interaction at various time points to 
determine how quickly inhibition was achieved. Curves represent the mean values of three 
independent experiments, with vertical error bars representing the standard deviation of the mean 
polarization at the indicated concentration of norstictic acid. Curves were fit using GraphPad Prism 5. 
 The time course reveals that norstictic acid inhibits VP16(465-490)•AcID over a 
fairly rapid time frame, with maximal inhibition achieved after approximately ten minutes 
as the IC50 values determined after this point are within error. At the later time points the 
dynamic range of the binding curve decreases slightly, most likely as a result of 
photobleaching of the fluorescein tag on the peptide due to repeated measurements of 
the same samples, which may provide an explanation for the slight decrease in IC50 
values at late time points. Thus, these data suggest that the aldehyde is particularly 
reactive as maximal inhibition is achieved rapidly. Importantly, previously completed 
experiments testing the inhibition of norstictic acid against the VP16•AcID interaction were 
all incubated for thirty minutes prior to analysis which was well beyond the time required 
to achieve maximal inhibition. 
1H,15N-Heteronuclear Single Quantum Coherence (HSQC) NMR Studies of AcID 
Perturbations Induced by Norstictic Acid 
 Norstictic acid has been identified as a potent and selective inhibitor of VP16•AcID 
interactions. Molecular dynamics simulations have demonstrated that norstictic acid 
clusters near positively charged surfaces on the AcID protein likely through critical 
electrostatic contacts, a hypothesis that has been further supported by demonstrating that 
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increasing salt concentration perturbs the activity of norstictic acid. Furthermore, it has 
been demonstrated that norstictic acid is a covalent inhibitor that labels AcID likely 
through a reaction with the nucleophilic amine of lysine residues on the domain, further 
underscoring the importance of the localization of the small molecule to lysine containing 
regions of the protein. In order to provide further evidence that norstictic acid clusters 
near lysine rich regions of the domain and to determine if norstictic acid induces allosteric 
changes to the structure of the AcID motif, 1H,15N-HSQC NMR perturbation experiments 
of the AcID protein in complex with norstictic acid were completed. In order to accomplish 
this, 15N labeled AcID protein was expressed and purified and incubated with norstictic 
acid prior to NMR analysis. Mass spectrometric characterization of the complexes is 
shown in Figure 3.21. 
 
Figure 3.21- Confirmation of Norstictic Acid Labeling for HSQC Analysis. 15N labeled AcID 
protein was treated with three or five equivalents of norstictic acid or DMSO as a control and incubated 
at room temperature for two hours. The samples were then analyzed by mass spectrometry prior to 
confirm sufficient labeling prior to analysis by NMR. (Completed by Paul A. Bruno) 
 15N-labeled AcID was incubated with DMSO as a vehicle only control, three 
equivalents of norstictic acid, or five equivalents of norstictic acid for two hours at room 
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Figure!3.25!Mass!spectrometry!analysis!of!15N2labeled!ACID!in!the!presence!of!DMSO!
and! norstictic! acid!Performed!by!Paul!Bruno.!The!ACID!protein! (30!μM)!was! incubated!with! DMSO,! 3! equivalents! norstictic! acid,! and! 5! equivalents! norstictic! acid.! Complex!mixtures! were! incubated! for! 2! hours! at! room! temperature.! Samples! of! the! complex!mixtures!were!analyzed!using!mass!spectrometry!to!confirm!covalent!adduct!formation.!In!order!to!inv stigate!ACID!chemical!shift!perturbations!in!the!presence!of!nors ictic!acid,!samples!of!15N:labeled!ACID!we e!incubated!wi h!DMSO!(negative!c ntrol),!3!equivalents!norstictic!acid,!or!5!equivalents!norstictic!acid.!These!samples!were! left! to! incubate! for!2!hours!at!room!temperature.!After!the!2!hour!incubation,!samples!of!the!complex!mixtures!were! analyzed! using! mass! spectrometry! to! confirm! covalent! adduct! formation! (Figure!3.25).!Once! the! covalent! adduct! formation!was! confirmed,! the! sample!was! submitted! for!1H:15N!HSQC!protein!NMR.!This!was!done!to!minimize!precipitation!of!the!protein!during!the!experiment.!The!NMR!buffer!and!15N:labeled!protein!stocks!do!not!contain!glycerol!or!NP:40,!which!significantly!help!solubilize!the!protein!therefore,!all!samples!were!prepared!and! analyzed! immediately! before! submission! for! 1H:15N!HSQC!protein!NMR.!The!protein!was! assigned! using! the! assignments! previously! described! for! Med25! ACID.4! Initial!observations! of! the! protein! NMR! experiment! confirmed! that! norstictic! acid! does! not!destabilize! the! protein! as! indicated! by! the! resolved! amide! backbone! signals!maintained!
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Figure!3.25!Mass!spectro etry!analysis!of!15N2labeled!ACID!in!the!presence!of!DMSO!
and! norstictic! acid!Performed!by!Paul!Bruno.!The!ACID!protein! (30!μM)!was! incubated!with! DMSO,! 3! equivalents! norstictic! acid,! and! 5! equivalents! norstictic! acid.! Co plex!ixtures! were! incubated! for! 2! hours! at! room! temperature.! Samples! of! the! complex!mixtures!were!analyzed!using!mass!spectrometry!to!confirm!covalent!adduct!formation.!In!order!to!investigate!ACID!chemical!shift!perturbations!in!the!presence!of!norstictic!acid,!samples!of!15N:labeled!ACID!were! incubated!with!DMSO!(negative!control),!3!equivalents!norstictic!acid,!or!5!equivalents!norstictic!acid.!These!samples!were! left! to! incubate! for!2!hours!at!room!temperature.!After!the!2!hour!incubation,!samples!of!the!complex!mixtures!were! analyzed! using! mass! spectrometry! to! confirm! covalent! adduct! formation! (Figure!3.25).!Once! the! covalent! adduct! formation!was! confirmed,! the! sample!was! submitted! for!1H:15N!HSQC!protein!NMR.!This!was!done!to!minimize!precipitation!of!the!protein!during!the!experiment.!The!NMR!buffer!and!15N:labeled!protein!stocks!do!not!contain!glycerol!or!NP:40,!which!significantly!help!solubilize!the!protein!therefore,!all!samples!were!prepared!and! analyzed! immediately! before! submission! for! 1H:15N!HSQC!protein!NMR.!The!protein!was! assigned! using! the! assignments! previously! described! for! Med25! ACID.4! Initial!observations! of! the! protein! NMR! experiment! confirmed! that! norstictic! acid! does! not!destabilize! the! protein! as! indicated! by! the! resolved! amide! backbone! signals!maintained!
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Figure!3.25!Mass!spectrometry!analysis!of!15N2labeled!ACID!in!the!presence!of!DMSO!
and! norstictic! acid!Performed!by!Paul!Bruno.!The!ACID!protein! (30!μM)!was! incubated!with! DMSO,! 3! equivalents! norstictic! acid,! and! 5! equivalents! nor tictic! acid.! Complex!mixtures! were! incubated! for! 2! hours! at! room! temperature.! Samples! of! the! complex!mixtures!were!analyzed!using!mass!spectrometry!to!confirm!covalent!adduct!formation.!In!order!to!investigate!ACID!chemical!shift!perturbations!in!the!presence!of!norstictic!acid,!samples!of!15N:labeled!ACID!were! incubated!with!DMSO!(negative!control),!3!equivalents!norstictic!acid,!or!5!equivalents!norstictic!acid.!These!samples!were! left! to! incubate! for!2!hours!at!room!temperature.!After!the!2!hour!incubation,!samples!of!the!co plex!mixtures!were! analyzed! using! mass! spectro etry! to! confirm! covalent! adduct! formation! (Figure!3.25).!Once! the! covalent! adduct! formation!was! confirmed,! the! sample!was! submitted! for!1H:15N!HSQC!protein!NMR.!This!was!done!to!minimize!precipitation!of!the!protein!during!the!experiment.!The!NMR!buffer!and!15N:labeled!protein!stocks!do!not!contain!glycerol!or!NP:40,!which!significantly!help!solubilize!the!protein!therefore,!all!samples!were!prepared!and! analyzed! immediately! before! submission! for! 1H:15N!HSQC!protein!NMR.!The!protein!was! assigned! using! the! assignments! previously! described! for! Med25! ACID.4! Initial!observations! of! the! protein! NMR! experiment! confir ed! that! norstictic! acid! does! not!destabilize! the! protein! as! indicated! by! the! resolved! amide! backbone! signals!maintained!
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temperature in order to analyze the range of chemical shifts induced by the formation of 
a covalent complex of AcID and norstictic acid. These three samples were then subjected 
to mass spectrometric analysis to confirm that a covalent complex had been formed. The 
DMSO control sample showed only unlabeled 15N-AcID (18,353 Da), while samples 
treated with norstictic acid contained singly labeled complexes (18,707 Da) or doubly 
labeled complexes (19,062 Da). As expected, incubation with five equivalents resulted in 
a higher degree of labeling for both the singly bound and doubly bound complexes. The 
three samples were then immediately subject to NMR analysis following the confirmation 
of complex formation as the buffer these samples were prepared in lacked glycerol and 
NP-40, which are critical for maintaining solubility of the AcID protein over time. Thus, by 
minimizing the time from sample preparation to NMR analysis, the potential loss of signal 
that results from the precipitation of the protein•norstictic acid complex over time was also 
minimized. 1H,15N-HSQC peaks were then assigned using previously published chemical 
shifts for the AcID motif and the spectra were overlaid for the sake of comparison, as 
shown in Figure 3.22.35 
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Figure 3.22- 1H,15N-HSQC NMR Spectrum of Norstictic Acid Labeled AcID Protein The full 1H,15N-
HSQC spectra of 15N-labeled AcID treated with DMSO (red spectrum), three equivalents of norstictic 
acid (purple spectrum), or five equivalents of norstictic acid (blue spectrum) is shown in the upper right 
hand corner. Additionally, representative chemical shifts (G462, C497, and L464/K520/N535) are 
shown as inserts. (Completed by Felicia Gray) 
 The most immediate observation is that the addition of norstictic acid to the AcID 
protein produces spectra with relatively small changes in the backbone amide signals and 
that these signals remain well resolved. This observation suggests that covalently labeled 
AcID protein is not destabilized, as such an event would result in the time-dependent 
clustering of residues in the 1H,15N-HSQC spectrum. Additionally, the observation that 
induced chemical shifts were minor in terms of intensity suggests that the binding of 
Norstictic AcID induces subtle structural changes, as opposed to large scale shifts in the 
global protein structure which would have resulted in significantly larger chemical shifts. 
Examples of the intensity of observed chemical shifts are shown as inserts in Figure 3.22. 
A significant majority of the amide backbone resonances were assigned using previously 
published results, but not every peak was effectively assigned as several of them were 
significantly broadened by the addition of norstictic acid. Particularly notable shifts were 
! 114!
!
Figure!3. 6!1H215N!HSQC!experiment!performed!w th!M d25!ACID!and!norstictic!acid!Perform d!with!Felicia!Grey.!15N:labeled!ACID!protein!(30!μM)!was!incubated!with!DMSO!(negative! control),! 3! equivalents! norstictic! acid,! or! 5! equivalents! of! norstictic! acid.! The!spectra! from! the! experiment! are! overlaid:! DMSO! (red! signals),! 3! equivalents! (purple!signals),!and!5!equivalents!norstictic!acid!(blue!signals).!Snapshots!of!3!different!regions!of!the!overlaid!experi ent! r !presented.!From!the!results!of!this!experiment,!it!is!apparent!that!norstictic!acid!induces!chemical!shift!perturbations! on! 15N:labeled!ACID.! As! illustrated! in! Figure! 3.26,!we! observed! both! peak!broadening! and! small! chemical! shifts! upon! labeling! ACID! with! norstictic! acid.! These!observed! chemical! shift! perturbations! further! support! the!notion! that!norstictic! acid! can!interact!with!ACID.!Interestingly,!the!observed!chemical!shifts!are!localized!to!two!specific!regions!on! the!protein,! specifically! the!H1!and!H2!binding!sites.!Overlaying! the!observed!chemical!shifts!with!norstictic!acid!and!the!previously!reported!chemical!shifts!from!VP16!H1!and!VP16!H2!binding! to!ACID,!we!see! that! there! is!considerable!overlap!between! the!sets!of!shifts!(Figure!3.27B).!This!result!suggests!that!norstictic!acid!binds!to!sites!on!ACID!similar!to!the!native!ligands!VP16!H1!and!VP16!H2.!!
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observed for AcID residues W408, Q409, G462, L483, G485, L486, G491, G493, C496, 
C497, V498, L513, S516, K520, and N535. These residues were mapped onto the AcID 
structure and compared to observed chemical shifts induced by the binding of the VP16 
TAD to the H1 and H2 interaction surfaces of AcID in Figure 3.23. 
 
 
Figure 3.23- 1H,15N-HSQC NMR Perturbation of AcID Induced by Norstictic Acid Binding. 
Significantly perturbed residues are shown in red on the reported structure of the AcID motif. 
Additionally, the induced chemical shifts following the binding of the VP16 TAD to the H1 and H2 
binding sites are shown in blue and yellow, respectively. Shifts in helix α-2 (perpendicular to the β-
barrel), are unique to norstictic acid binding events. 
 Interestingly, the majority of the strongest chemical shifts induced by binding of 
norstictic acid to AcID occurred at surfaces within the H1 and H2 binding sites, suggesting 
that the inhibitor is binding to the protein in locations required for interaction with VP16. 
Furthermore, norstictic acid does not appear to be inducing structural changes at 
positions far from the VP16 TAD binding sites, further supporting the notion that the 
preferred binding locations of the small molecule on AcID is similar to the binding sites of 
the native ligands. The observation of induced chemical shifts at both the VP16 H1 and 
H2 binding sites is consistent with previous observations that norstictic acid is capable of 
perturbing binding events at both surfaces. Whether these perturbations are a result of 
orthosteric inhibition at both sites following the binding of norstictic acid to lysine residues 
H2 Binding SiteH1 Binding Site
question that arose was whether the two binding sites within Med25 AcID are allosterically connected, similar 
to other coactivator domains such as GACKIX within the master coactivator CBP/p300.  
 
We carried out a comprehensive series of biophysical 
experiments aimed at answering the two questions, including 
protein NMR experiments and fluorescence-based 
experiments of Med25 AcID and AcID mutants complexed 
with ETV/PEA3 TADs, VP16, and VP16 mutants and 
truncations. A key set of data emerged from experiments 
carried out with a cysteine mutant of VP16 that we covalently 
Tethered to the H1 interaction surface of Med25 AcID, using a 
method previously described.(65) Chemical shift perturbation 
experiments with this complex showed not only significant 
shifts in the H1 binding site, as expected, but also shifts in a 
series of residues connecting the two binding surfaces, 
namely at I453 and F494, in addition to perturbations on the 
H2 binding surface, consistent with allosteric connectivity. 
Supporting this observation, in fluorescence-based binding 
studies, we observe at least 3-fold cooperativity between the two binding sites us ng VP16-d r ved AcID 
ligands. Binding studies of ETV/PEA3 TAD with Tethered Med25 AcID in which the H1 binding surface has 
been blocked also suggests that the H1 binding surface is the preferred site of int raction for he ETV/PEA3 
activators, as the KD for the H2 site is significantly larger. Recently, Verger et al published a thorough chemical 
shift analysis of the ERM•AcID complex demonstrating perturbations that are consistent with a complex 
formed with the H1 site.(17) Although outside of the scope of this proposal, we have established a 
collaboration with the Verger lab for structural dissection of ETV/PEA3•Med25 AcID complexes and the data 
that emerge from this will be highly informative for the work in this proposal. Importantly,$ the$data$overall$
suggests$ that,$ like$ our$ success$ with$ targeting$ the$ GACKIX$ motif,$ our$ screening$ strategy$ should$ identify$
allosteric$ modulators$ of$ ETV•Med25$ complex$ formation,$ and,$ further,$ that$ allosteric$ enhancers$ of$ binding$
should$be$accessible.  
$
Preliminary( data:( pilot( screen( produces( 3( initial( inhibitors(To$ define$ the$ feasibility$ of$ an$ ETV•Med255targeting$
screen,$we$carried$out$a$pilot$screen.$The$pilot$was$carried$out$using$conditions$analogous$to$those$previously$
described$ [3845well$plate$ format,$ final$Med25$concentration$850$nM,$ tracer$ (fluorescein5labeled$ETV5$(38572)$
concentration$ of$ 20$ nM,$ and$ small$ molecule$ concentration$ 20$ µM](12).$ The$ pilot$ screen$ of$ 2400$ known$
bioactives$(approved$drugs,$natural$products,$probe$molecules)$had$a$campaign$Z’$score$of$0.87$and$a$hit$rate$
of$ 1.6%,$with$a$hit$defined$as$active$within$ three$ standard$deviations$of$ the$positive$ control.! $ Following$hit$
filtering$to$remove$compounds$with$known$chemical$reactivity,$toxicity,$broad$activity,$aggregation$properties$
and$native$fluorescence$we$identified$3$compounds$belonging$to$the$depside$and$depsidone$classes$of$small$
molecules$ (Figure$ 6a);$ we$ have$ previously$ found$ depsides$ and$ depsidones$ to$ be$ effective$ modulators$ of$
activator5coactivator$ interactions.(13)$Dose5response$ experiments$with$ re5purchased$CCG538381$CCG538361,$
and$CCG540171$confirmed$that$the$molecules$were$effective$inhibitors$of$ETV5/ERM$binding,$with$CCG538381$
being$the$most$potent$of$the$three$(Figure$6b).$The$molecules$are$also$specific$for$the$AcID$motif,$exhibiting$no$
Figure! 5$Chemical$ shift$ perturbations$ of$VP16$ TAD$
tethered$to$ cID$vi $disulfide$formation$at$C506.$
Figure! 6.! A)$ Structures$ of$ three$ initial$ inhibitors$ from$ the$ pilot$ screen$ along$ with$ EC50$ values$ from$ full$ dose5response$
experiments.$ Functional$ groups$ colored$ in$ blue$and$green$ are$ likely$ to$be$key$ for$binding$ and$ inhibition,$when$ compared$ to$
related$ depside$ and$ depsidones.$ B)$ Representative$ curve$ of$ CCG538381$ inhibition$ against$ the$ Med25•ERM$ (38572)$ complex$
(average$of$3$ independent$experiments).$C)$Representative$experiment$with$CCG538381$showing$no$ inhibition$against$another$
coactivator$motif,$CBP$KIX,$and$two$of$its$binding$partners,$MLL$and$the$phosphorylated$KID$domain$of$CREB$(pKID).$!
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within both surfaces or as a result of allosteric changes that result from the binding of the 
inhibitor to alternative surfaces cannot be determined based on the HSQC results alone. 
 Interestingly, the binding of norstictic acid to the AcID motif induces a number of 
chemical shifts within helix α2, which is located at the top of the β-barrel at the interface 
of the H1 and H2 binding sites. These chemical shifts are not observed following the 
binding of either VP16 H1 or H2, suggesting that the binding of norstictic acid may result 
in unique structural changes not caused by the binding of native ligands. Thus, this data 
provides evidence that norstictic acid may be exerting its effects through allosteric shifts 
in the protein in addition to the direct competition for critical binding surfaces required by 
native ligands, such as VP16. Such a mechanism of action may provide some explanation 
for the observed selectivity of the molecules against the domain. Two flexible loop regions 
are located near the top of the H1 and H2 binding sites in close proximity to helix α2, the 
orientations of which may be affected by shifts within α2. Significant additional 
experimentation will be required to confirm the role of helix α2 in a potential allosteric 
mechanism of inhibition, including mutational analyses and further structural elucidation 
using alternative NMR techniques. 
 Given that norstictic acid covalently binds to AcID by forming an imine with reactive 
lysine residues, the chemical shifts induced by the binding of the inhibitor were compared 
to the locations of the eleven lysine residues within the domain, as shown in Figure 3.24, 
in order to attempt to determine which lysine residues might be involved in imine formation 
with norstictic acid. 
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Figure 3.24- Proximity of Lysine Residues to Norstictic Acid Induced Chemical Shifts (A) The 
eleven lysine residues within the AcID motif are shown as green sticks, while residues perturbed by 
the binding of norstictic acid are shown in red, and perturbations induced by binding of the VP16 TAD 
to the H1 and H2 binding sites are shown in blue and yellow, respectively. (B) K411 and K413 (green 
sticks) are located on a flexible loop within the H1 binding site of AcID. K518 (green sticks), K519 
(green sticks), and K520 (red sticks) are located on a small flexible loop within the H2 binding site of 
the domain. 
 Highlighting the location of the lysine residues within the AcID motif in conjunction 
with mapping the chemical shifts induced by the binding of norstictic acid reveals a 
number of lysine residues in close proximity to the inhibitor induced perturbations. In 
particular, K411 and K413 are located on a large, highly flexible loop within the H1 binding 
site that may account for the observed chemical shifts induced by norstictic acid following 
imine formation. Furthermore, K518, K519, and K520 are located on a short flexible loop 
within the H2 binding site that may similarly account for chemical shifts following imine 
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question that arose was whether the two binding sites within Med25 AcID are allosterically connected, similar 
to other coactivator domains such as GACKIX within the master coactivator CBP/p300.  
 
We carried out a comprehensive series of biophysical 
experiments aimed at answering the two questions, including 
protein NMR experiments and fluorescence-based 
experiments of Med25 AcID and AcID mutants complexed 
with ETV/PEA3 TADs, VP16, and VP16 mutants and 
truncations. A key set of data emerged from experiments 
carried out with a cysteine mutant of VP16 that we covalently 
Tethered to the H1 interaction surface of Med25 AcID, using a 
method previously described.(65) Chemical shift perturbation 
experiments with this complex showed not only significant 
shifts in the H1 binding site, as expected, but also shifts in a 
series of residues connecting the two binding surfaces, 
namely at I453 and F494, in addition to perturbations on the 
H2 binding surface, consistent with allosteric connectivity. 
Supporting this observation, in fluorescence-based binding 
studies, we observe at least 3-fold cooperativity between the two binding sites using VP16-derived AcID 
ligands. Binding studies of ETV/PEA3 TAD with Tethered Med25 AcID in which the H1 binding surface has 
been blocked also suggests that the H1 binding surface is the preferred site of interaction for the ETV/PEA3 
activators, as the KD for the H2 site is significantly larger. Recently, Verger et al published a thorough chemical 
shift analysis of the ERM•AcID complex demonstrating perturbations that are consistent with a complex 
formed with the H1 site.(17) Although outside of the scope of this prop sal, we have esta lished a 
collaboration with the Verger lab for structural dissection of ETV/PEA3•Med25 AcID complexes and the data 
that emerge from this will be highly informative for the work in this proposal. Importantly,$ the$data$overall$
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screen,$we$carried$out$a$pilot$screen.$The$pilot$was$carried$out$using$conditions$analogous$to$those$previously$
described$ [3845well$plate$ format,$ final$Med25$concentration$850$nM,$ tracer$ (fluorescein5labeled$ETV5$(38572)$
concentration$ of$ 20$ nM,$ and$ small$ molecule$ concentration$ 20$ µM](12).$ The$ pilot$ screen$ of$ 2400$ known$
bioactives$(approved$drugs,$natural$products,$probe$molecules)$had$a$campaign$Z’$score$of$0.87$and$a$hit$rate$
of$ 1.6%,$with$a$hit$defined$as$active$within$ three$ standard$deviations$of$ the$positive$ control.! $ Following$hit$
filtering$to$remove$compounds$with$known$chemical$reactivity,$toxicity,$broad$activity,$aggregation$properties$
and$native$fluorescence$we$identified$3$compounds$belonging$to$the$depside$and$depsidone$classes$of$small$
molecules$ (Figure$ 6a);$ we$ have$ previously$ found$ depsides$ and$ depsidones$ to$ be$ effective$ modulators$ of$
activator5coactivator$ interactions.(13)$Dose5response$ experiments$with$ re5purchased$CCG538381$CCG538361,$
and$CCG540171$confirmed$that$the$molecules$were$effective$inhibitors$of$ETV5/ERM$binding,$with$CCG538381$
being$the$most$potent$of$the$three$(Figure$6b).$The$molecules$are$also$specific$for$the$AcID$motif,$exhibiting$no$
Figure! 5$Chemical$ shift$ perturbations$ of$VP16$ TAD$
tethered$to$AcID$via$disulfide$formation$at$C506.$
Figure! 6.! A)$ Structures$ of$ three$ initial$ inhibitors$ from$ the$ pilot$ screen$ along$ with$ EC50$ values$ from$ full$ dose5response$
experiments.$ Functional$ groups$ colored$ in$ blue$and$green$ are$ likely$ to$be$key$ for$binding$ and$ inhibition,$when$ compared$ to$
related$ depside$ and$ depsidones.$ B)$ Representative$ curve$ of$ CCG538381$ inhibition$ against$ the$ Med25•ERM$ (38572)$ complex$
(average$of$3$ independent$experiments).$C)$Representative$experiment$with$CCG538381$showing$no$ inhibition$against$another$
coactivator$motif,$CBP$KIX,$and$two$of$its$binding$partners,$MLL$and$the$phosphorylated$KID$domain$of$CREB$(pKID).$!
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formation. The close spatial arrangement of these residues, K411/K413 and 
K518/K519/K520, also result in significant regions of dense positive charge on the AcID 
surface, which may assist in the localization of norstictic acid to preferred binding 
locations through critical electrostatic contacts. Additionally, K484 is a potential residue 
of interest, as it is located on helix α2 and lies at the interface of the H1 and H2 binding 
sites on the AcID protein. Thus, based on the combined evidence provided by MD 
simulations, NMR perturbations, and mass spectrometric analysis of the covalent 
norstictic acid•AcID complex, it was hypothesized that K411, K413, K18, K519, and K520 
may be potential sites for imine formation with norstictic acid. 
Mutational Analysis to Identify Sites of Covalent Modification by Norstictic Acid 
 In order to attempt to support the hypothesis that these lysine residues may 
function as inhibitor binding sites, a mutational analysis was next completed in which the 
nucleophilic lysine residues were mutated to non-nucleophilic arginine residues. This 
mutation conserves the presence of a positive charge at the aforementioned locations on 
the AcID motif, and thus should have a minimal impact on the binding of the VP16 TAD 
as electrostatic contacts should be maintained, but removes the ability of norstictic acid 
to covalently bind through the formation of an imine as arginine lacks a nucleophilic 
amine. The ability of norstictic acid to inhibit the binding of VP16(438-454) and VP16(467-
488) to the mutant proteins was then assessed. A decrease in the potency of the molecule 
against the mutant proteins would suggest that the inhibitor has lost a site of covalent 
binding. In order to accomplish this, site-directed mutagenesis was performed on the 
plasmid encoding the wild type domain in order to generate a series of single and multiple 
mutants, which were then expressed and purified following standard procedures.  
 Initially, lysine residues K518, K519, and K520 within the H2 binding site were 
mutated as the presence of three sequential lysine residues results in a region of densely 
packed positive charge, representing a highly attractive site for norstictic acid. Three 
single point mutants, K518R, K519R, and K520R; a double point mutant K518R/K519R; 
and a triple point mutant K18R/K519R/K520R were generated. As a note on the naming 
conventions we have elected to use in referring to the lysine to arginine mutants, 
KK518RR refers to the double mutant K518R/K519R and KKK518RRR refers to the triple 
 115 
mutant K518R/K519R/K520R. After expressing and purifying the mutants, their ability to 
bind VP16(438-454) and VP17(467-488) was tested in order to confirm that the mutations 
did not significantly alter the structure or binding competence of the domain, as shown 
below in Figure 3.25 and summarized in Table 3.1. 
 
Figure 3.25- Direct Binding of VP16(438-454) and VP16(467-488) to H2 Lysine Mutants (A) 
Structure of the AcID motif with perturbations induced by the binding of norstictic acid shown in red, 
perturbations induced by the binding of VP16 H1 and H2 shown in blue and yellow, respectively, and 
K518/K519/K520 shown as sticks within the H2 binding site. (B) Direct binding curves of VP16(438-
454) and VP16(467-488) to various AcID constructs. Curves represent the mean values of three 
independent experiments with vertical error bars representing the standard deviation of the fraction of 
tracer bound at the indicated AcID concentration. Curves were fit with GraphPad Prism 5. 
Table 3.1- Effect of H2 Binding Site Lysine to Arginine Mutations on VP16 Affinity 
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413-APPTDVSLGDELHLDGEDVAMAHADALDDFDLDMLGDGDSPGPGFTPHDSAPYGALDMADFEFEQMFTDALGIDEYGG-490 
VP16 Transcriptional Activation Domain 
438$454& 467$488&
A
B
Kd Fold	Change Kd Fold	Change
WT 3.7	±	0.2 --- 0.90	±	0.08 ---
K518R 2.2	±	0.1 -1.68 0.84	±	0.08 -1.07
K519R 0.88	±	0.11 -4.20 0.39	±	0.05 -2.31
K520R 2.4	±	0.3 -1.54 0.65	±	0.08 -1.38
KK518RR 2.7	±	0.3 -1.37 0.69	±	0.08 -1.30
KKK518RRR 1.4	±	0.1 -2.64 0.43	±	0.05 -2.09
VP16(438-454) VP16(467-488)
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As expected, the conservative lysine to arginine mutations did not have a 
deleterious effect on the affinity of VP16(438-454) or VP16(467-488) for AcID. In fact, the 
affinity of the VP16 derived peptides for the domain was slightly enhanced following 
mutation of the indicated lysine residues to arginine, though this enhancement is not 
significant and the mechanism by which this occurs is unclear. 
 The effect that these mutations had on the activity of norstictic acid against the 
interaction was then assessed by determining the IC50 (30 Min) values for the inhibition of 
the interaction between VP16(438-454) or VP16(467-488) and AcID. In all cases the 
molecule was tested against a VP16•AcID complex in which the tracer was 50% bound 
and all samples were incubated for thirty minutes to account for potential time-dependent 
inhibition. The results of these experiments are shown below in Figure 3.26 and 
summarized in Table 3.2. 
 
	
 
Figure 3.26- Effect of H2 Lysine Mutations on Norstictic Acid Inhibition of VP16•AcID. 
Competition experiments of norstictic acid for the VP16(438-454)•AcID and VP16(467-488)•AcID 
413-APPTDVSLGDELHLDGEDVAMAHADALDDFDLDMLGDGDSPGPGFTPHDSAPYGALDMADFEFEQMFTDALGIDEYGG-490 
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interactions with the various AcID constructs. Curves represent the mean values of three independent 
experiments with vertical error bars representing the standard deviation of the relative fraction of tracer 
bound in the presence of the indicated concentration of norstictic acid. Curves were fit using GraphPad 
Prism 5.  
Table 3.2- Effect of H2 Binding Site Lysine to Arginine Mutations on Norstictic Acid Inhibition 
  
 
These data demonstrate that the sequential mutation of lysine residues within the 
K518/K519/K520 loop region results in the significant loss of inhibition by norstictic acid. 
The triple mutant KKK518RRR results in an approximately five-fold decrease in the 
potency of the small molecule for AcID interactions with both VP16(438-454) and 
VP16(467-488). The individual point mutations of K518, K519, and K520 fail to 
recapitulate this loss in activity, suggesting that the residues may be interchangeable as 
sites for imine formation with norstictic acid, which is reasonable given their immediate 
proximity. Of the three single point mutants, only K519R demonstrated significant 
perturbation in the activity of norstictic acid, suggesting that this residue may be of 
particular importance. The side chain of K519 points into the H2 binding surface and thus 
in prime position for disruption of H2 binding site dependent interactions following imine 
formation with norstictic acid, whereas K518 and K520 point out of the binding site and 
are in close proximity to helix α2. The double mutant KK518RR failed to fully recapitulate 
the loss of activity observed with the KKK518RRR mutant, but had significantly stronger 
effects than any of the single mutants, further supporting the hypothesis that the three 
lysine residues within this loop may be interchangeable as sites for the covalent 
attachment of norstictic acid. 
The observation that mutations within the H2 binding site also affect the ability of 
norstictic acid to perturb the binding of VP16(438-454) to the H1 binding site of AcID was 
perhaps unexpected, but is consistent with an allosteric mechanism of action for inhibition 
IC50	(30	Min) Fold	Change IC50	(30	Min) Fold	Change
WT 7.3	±	1.0 --- 5.0	±	0.6 ---
K518R 7.1	±	1.2 -1.03 6.1	±	1.2 1.22
K519R 18.3	±	5.0 2.51 14.3	±	2.5 2.86
K520R 12.7	±	1.7 1.74 7.6	±	1.1 1.52
KK518RR 25.7	±	5.4 3.52 25.3	±	8.3 5.06
KKK518RRR 35.0	±	10.1 4.79 26.8	±	4.8 5.36
VP16(438-454) VP16(467-488)
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by norstictic acid. As was discussed previously, the binding of norstictic acid induces a 
number of significant chemical shifts within helix α2, which is located at the interface 
between the H1 and H2 binding sites, that may result in structural changes within both 
binding sites. Thus, the loss of norstictic acid binding at K518, K519, or K520 may mitigate 
the induced α2 structural changes, thereby disrupting structural changes within the H1 
binding site resulting in a concomitant decrease in potency against interactions that occur 
at the H1 site. 
Following the observation that mutation of lysine residues to arginine within the H2 
binding site led to a decrease in the potency of norstictic acid, it was next sought to 
confirm that this effect was a result of the decreased covalent binding of norstictic acid to 
the mutants, relative to the wild type domain. In order to accomplish this, each of the 
mutants was incubated with four equivalents of norstictic acid at room temperature for 
two hours and resulting complexes were analyzed by mass spectrometry in order to 
determine the degree of labeling of the AcID protein by norstictic acid. The results of these 
experiments are shown below in Figure 3.27. 
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Figure 3.27- Effect of Lysine Mutation on the Covalent Labeling of AcID by Norstictic Acid. The 
indicated AcID construct was incubated with four equivalents of norstictic acid at room temperature 
for two hours prior to being subjected to analysis by mass spectrometry. Peaks of interest are labeled 
in the spectra with ‘AcID’ referring to the mass of the unlabeled construct and ‘+X NA’ referring to the 
number of norstictic acid molecules bound to the protein. Percentages refer to the approximate 
composition of the indicated species in the sample as determined by individual peak intensity over the 
total intensity of peaks of interest. 
 Consistent with the observations from the competition experiments with the various 
AcID mutants, mutation of lysine residues within the H2 binding site resulted in a decrease 
in the degree of covalent labeling of AcID by norstictic acid. The single point mutant 
K518R did not significantly alter the labeling of the domain, consistent with the hypothesis 
that the three lysine residues may be interchangeable sites for imine formation. The 
double mutant KK518RR and triple mutant KKK518RRR resulted in significantly reduced 
labeling of the domain by norstictic acid, consistent with the observations that these 
mutations also reduced the potency of the molecule in inhibiting VP16•AcID interactions. 
Taken together, these data suggest that the three lysine residues K518, K519, and K520 
are likely sites for the covalent binding of norstictic acid to the AcID motif. However, the 
triple mutant KKK518RRR is still labeled to a moderate degree by norstictic acid, 
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+1 NA (23.0%)
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+3 NA (ND)
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suggesting that these residues are not the only binding site for norstictic acid on the 
domain. 
 The 1H,15N-HSQC perturbation experiments also indicated that K411 or K413 may 
also be sites for the covalent binding of norstictic acid, given their proximity to a number 
of observed chemical shifts induced by the binding of the inhibitor. In order to confirm the 
role of these residues in the activity of norstictic acid, the same battery of experiments 
was completed for K411 and K413 as had been completed for K518, K519, and K520. 
After expressing and purifying the AcID mutant K411R/K413R the ability of VP16(438-
454) and VP16(467-488) to bind to the mutant domain was assessed. The results of those 
experiments are shown below in Figure 3.28 and summarized in Table 3.3. 
 
 
Figure 3.28- Direct Binding of VP16(438-454) and VP16(467-488) to H1 Lysine Mutants. (A) 
Structure of the AcID motif with perturbations induced by the binding of norstictic acid shown in red, 
perturbations induced by the binding of VP16 H1 and H2 shown in blue and yellow, respectively, and 
K411/K413 shown as sticks within the H1 binding site. (B) Direct binding curves of VP16(438-454) and 
VP16(467-488) to wild type and K411R/K413R AcID. Curves represent the mean values of three 
independent experiments with vertical error bars representing the standard deviation of the fraction of 
tracer bound at the indicated AcID concentration. Curves were fit with GraphPad Prism 5. 
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Table 3.3- Effect of H1 Binding Site Lysine to Arginine Mutations on VP16 Affinity 
 
 
The binding of VP16(438-454) is unperturbed by the mutations K411R and K413R 
as the Kd value of the peptide for the mutant protein is within error of the Kd value for the 
wild type protein. This was the expected result as the mutation to arginine maintains the 
positive charge, and thus any critical electrostatic contacts with the VP16 TAD. The 
binding of VP16(467-488) is moderately perturbed by the mutations, which is unexpected 
given that the peptide likely binds to the H2 binding site and not near the mutated 
residues. This finding suggests that the mutation of K411 and K413 may have induced 
minor structural changes within the H2 binding site, which is plausible given that K411 
and K413 are located on a large and highly flexible loop near the interface of the H1 and 
H2 binding sites. Additional mechanistic and structural studies will be necessary to 
determine the source of this perturbation, though it appears to support the hypothesis that 
AcID is relatively plastic and the distinct binding surfaces may be in allosteric 
communication. 
 The ability of norstictic acid to perturb interactions between the K411R/K413R 
double mutant and VP16(438-454) and VP16(467-488) was then compared to the activity 
against the interactions with the wild type protein, as shown below in Figure 3.29 and 
summarized in Table 3.4. In all cases the molecule was tested against a VP16•AcID 
complex in which the tracer was 50% bound and all samples were incubated for thirty 
minutes to account for potential time-dependent inhibition. 
 
Kd Fold	Change Kd Fold	Change
WT 3.7	±	0.2 --- 0.90	±	0.08 ---
K411R/K413R 4.0	±	0.2 1.08 4.8	±	0.9 5.33
VP16(438-454) VP16(467-488)
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Figure 3.29- Effect of H1 Lysine Mutations on Norstictic Acid Inhibition of VP16•AcID. 
Competition experiments of norstictic acid for the VP16(438-454)•AcID and VP16(467-488)•AcID 
interactions with the H1 double mutant and wild type AcID. Curves represent the mean values of three 
independent experiments with vertical error bars representing the standard deviation of the relative 
fraction of tracer bound in the presence of the indicated concentration of norstictic acid. Curves were 
fit using GraphPad Prism 5. 
Table 3.4- Effect of H1 Binding Site Lysine to Arginine Mutations on Norstictic Acid Inhibition 
  
 
Consistent with the hypothesis that K411 and K413 are sites of covalent 
modification by norstictic acid, mutation of these residues to arginine significantly 
perturbed the ability of norstictic acid to inhibit VP16(438-454) and VP16(467-488) 
interactions with AcID. The degree of perturbation was similar to the results observed for 
the H2 site mutations, with the potency of the molecule decreasing four to six fold 
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IC50	(30	Min) Fold	Change IC50	(30	Min) Fold	Change
WT 7.3	±	1.0 --- 5.0	±	0.6 ---
K411R/K413R 27.9	±	5.3 3.82 29.5	±	16.4 5.90
VP16(438-454) VP16(467-488)
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following mutation of the lysine residues to arginine. Interestingly, the K411 and K413 
mutations affected the ability of the molecule to disrupt interactions at both the H1 and 
H2 binding sites, similar to the effects observed following the mutation of lysine residues 
within the H2 site. This finding further supports the hypothesis that the H1 and H2 binding 
sites are in allosteric communication and suggests that lysine residues within both binding 
sites may play a critical role in these structural changes, possibly through interaction with 
helix α2. 
 In order to further support K411 and K413R as sites of covalent modification by 
norstictic acid, the ability of the molecule to label the mutant protein was assessed by 
mass spectrometry, as shown in Figure 3.30. 
 
Figure 3.30- Effect of H1 Lysine Mutations on the Covalent Labeling of AcID by Norstictic Acid. 
The H1 double mutant AcID protein was incubated with four equivalents of norstictic acid for two hours 
at room temperature and then subjected to analysis by mass spectrometry. Peaks of interest are 
labeled in the spectra with ‘AcID’ referring to the mass of the unlabeled protein and “+X NA” referring 
to the masses of protein labeled with the indicated number of norstictic acid molecules. Percentages 
refer to the approximate composition of the indicated species in the sample as determined by individual 
peak intensity over the total intensity of peaks of interest. 
 The H1 site double mutant K411R/K413R was incubated with four equivalents of 
norstictic acid for two hours at room temperature and the resulting complex was then 
analyzed by mass spectrometry and compared to the labeling observed for treatment of 
the wild type domain with norstictic acid. The mutations result in a significant decrease in 
the labeling of the domain by norstictic acid, consistent with observations that the 
molecule is significantly less potent in inhibiting VP16•AcID interactions with the mutated 
K411R/K413R AcID
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Wild Type AcID
AcID
(16.7%)
+1 NA (48.9%)
+2 NA (27.3%)
+3 NA (7.1%)
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construct. Additionally, this finding is consistent with previous observations of the effects 
of lysine mutations within the H2 binding site. Residual labeling of the mutated 
K411R/K413R AcID may result from the binding of the molecule to a residue within the 
H2 binding site, or to an alternative lysine residue. Taken together, these data are 
consistent with the hypothesis that K411 and K413 are potential sites for the covalent 
modification of the AcID motif.  
 As an additional method to support the hypothesis that K411, K413R, K518, K519, 
and K520 are potential sites for the covalent binding of norstictic acid to the AcID motif, a 
mutant AcID construct in which all five residues were mutated to arginine was expressed 
and purified, which we refer to as the ‘Quint. Mutant’ in the data below. Following the 
expression and purification of the quintuple mutant K411R/K413R/K518R/K519R/K520R, 
the ability of the mutant to bind VP16(438-454) and the ability of norstictic acid to inhibit 
the interaction of VP16(438-454) with the mutant AcID construct was determined, as 
shown below in Figure 3.31. 
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Figure 3.31- Effect of H1 and H2 Lysine Mutations on VP16(438-454)•AcID and Norstictic Acid 
Inhibition. Direct binding of VP16(438-454) to the quintuple lysine to arginine AcID mutant is shown 
in the top figure. An inhibition experiment of norstictic acid on the interaction between VP16(438-454) 
is shown in the bottom figure. Curves represent the mean values of three independent experiments 
with vertical error bars representing the standard deviation of the fraction of tracer bound at the 
indicated concentration of AcID or norstictic acid. Curves were fit using GraphPad Prism 5. 
 The direct binding experiments indicate that the mutation of the five lysine residues 
to arginine does not significantly perturb the ability of the construct to bind VP16(438-
454), consistent with expectations and previous observations of the effects of mutation 
on the lysine residues within the H1 and H2 binding site individually. Furthermore, the 
potency of norstictic acid is decreased approximately seven fold by the mutation of the 
five lysine residues, which is a greater perturbation than was observed for the mutation 
of lysine residues within the H1 or H2 binding site individually, further supporting the 
hypothesis that both sites may simultaneously be labeled by norstictic acid. The residual 
effects of norstictic acid for inhibition of VP16(438-454)•AcID may be a result of the 
competition of the molecule for TAD binding sites in the absence of covalent linkage to 
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the domain, or may be the result of the molecule binding covalently to alternative lysine 
residues that have yet to be identified. 
 As further support of these five lysine residues as potential sites for covalent 
binding of norstictic acid, the ability of the molecule to covalently label the mutant AcID 
construct was determined by mass spectrometry and compared to the labeling observed 
with wild type AcID protein, as shown below in Figure 3.32. 
 
Figure 3.32- Effect of H1 and H2 Mutations on the Covalent Labeling of AcID by Norstictic Acid. 
The quintuple mutant AcID protein was incubated with four equivalents of norstictic acid for two hours 
at room temperature and then subjected to analysis by mass spectrometry. Peaks of interest are 
labeled in the spectra with ‘AcID’ referring to the mass of the unlabeled protein and “+X NA” referring 
to the masses of protein labeled with the indicated number of norstictic acid molecules. Percentages 
refer to the approximate composition of the indicated species in the sample as determined by individual 
peak intensity over the total intensity of peaks of interest. 
 Mass spectrometric results of the AcID quintuple mutant demonstrate that the 
mutation of lysine residues in both the H1 and H2 binding sites severely attenuates the 
ability of norstictic acid to covalently label AcID, with only a very small fraction, 
approximately 8%, of the protein bearing a single norstictic acid modification. These data 
suggest that K411, K413, K518, K519, and K520 represent the most significant binding 
sites on the domain for norstictic acid, as their mutation to arginine significant reduces the 
potency of the small molecule in the inhibition of VP16•AcID interactions. The trace 
amounts of protein that are still labeled in this sample are likely the result of nonspecific 
reactions between norstictic acid and the AcID motif. Thus, the observed IC50 of 44 µM 
for norstictic acid against the interaction between VP16 and the quintuple mutant is likely 
K411R/K413R/K518R/K519R/K520R AcID
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+3 NA (7.1%)
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the activity of the molecule in the absence of the formation of a covalent adduct. 
Therefore, because the molecule was in equilibrium under these conditions, the Ki of the 
inhibitor for the AcID motif was calculated and determined to be 22.1 µM. 
Overall, the above mutational analysis experiments confirm that norstictic acid 
covalently binds to the AcID motif through the formation of an imine between the reactive 
amine of lysine residues within the domain and an aldehyde present on norstictic acid. 
Lysine residues within the H1 (K411 and K413) and H2 (K518, K519, and K520) binding 
sites on the domain appear to be critical sites of covalent modification as demonstrated 
by a series of inhibition assays and mass spectrometric analysis. 1H,15N-HSQC chemical 
shift perturbation experiments indicate that these lysine residues are within close 
proximity to perturbations induced by the binding of norstictic acid and are located within 
the VP16 H1 and H2 binding sites on the domain. Functionally, the formation of these 
imines may interfere with critical electrostatic contacts between the VP16 TAD and AcID 
by relieving the positive charge of the targeted lysine residues. Additionally, the binding 
of norstictic acid at these sites may add considerable steric bulk to surfaces important for 
the binding of the VP16 TAD, thereby further inhibiting the ability of the TAD to bind to 
the domain. In order to validate this hypothesis, additional AcID mutants in which the 
lysine residues in question are mutated to alanine or glutamate will be prepared. The 
mutation of the lysine residues to alanine will remove positively charged contacts from 
the surface of the protein without significantly altering local secondary structure55, thereby 
supporting the role of these residues as critical points of electrostatic interaction. As a 
result, the expectation would be for the binding of the VP16 TAD to be compromised and 
norstictic acid to be far less potent as it may no longer be electrostatically attracted to a 
critical surface of AcID. Additional mutation of these residues to glutamate results in a 
charge inversion, which one would expect to abrogate the binding of VP16 and the activity 
of norstictic acid to an even more significant extent than observed for the mutation of 
these sites to alanine as a result of significant repulsion between the negatively charged 
TAD or small molecule and the negative surface of the AcID protein.  
In addition, the mutational analyses and 1H,15N-HSQC data suggest that the 
molecules can induce allosteric changes within the domain. Thus, the binding of a single 
norstictic acid molecule to AcID may inhibit the binding of activators at both interaction 
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surfaces by orthosterically inhibiting interactions at the binding site to which the molecule 
is bound and allosterically inhibiting interactions at the secondary site through 
conformational modulation of the domain, consistent with the conformational plasticity 
following activator binding discussed in Chapter 2. The mutational analysis data suggests 
that norstictic acid does not have a particular preference for either the H1 or H2 binding 
site, suggesting that the allosteric modulation of the domain is bidirectional, with binding 
at either site inducing allosteric shifts in the alternative site. This hypothesis is 
demonstrated below in Figure 3.33. 
 
Figure 3.33- Norstictic Acid is a Mixed Orthosteric/Allosteric Inhibitor of the AcID Motif The 
binding of norstictic acid at either the H1 or H2 binding site orthosterically inhibits interactions at that 
binding surface and induces conformational changes within the alternative binding site that inhibits 
activator interactions. 
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Attempts at Identifying Sites of Covalent Labeling of AcID by Norstictic Acid Using 
Protein Digestion and Mass Spectrometric Analysis 
 In order to attempt to further support that K411, K413, K518, K519, and K520 are 
sites for the covalent binding of norstictic acid to the AcID motif, we next sought to use a 
combination of protein digestion and mass spectrometric analysis to determine which 
specific lysine residues were covalently modified by the small molecule. Towards this 
end, a sample of wild type AcID protein was incubated with four equivalents of norstictic 
acid for two hours at room temperature and subsequently reduced with sodium 
borohydride for an hour. The samples were then checked by mass spectrometry to 
confirm that the protein had been covalently labeled by the inhibitor as shown in Figure 
3.34. 
 
Figure 3.34- AcID Labeled with Norstictic Acid Submitted for Proteomics Analysis Wild type acid 
protein was incubated with four equivalents of norstictic acid for two hours and then reduced with 
sodium borohydride for one hour prior to analysis by mass spectrometry. 
 After confirming that the AcID protein had been labeled by norstictic acid, it was 
subsequently purified by SDS-PAGE and the protein bands of interest were stained with 
Coomassie blue and excised. The excised gel slices were then submitted to the 
Proteomics and Peptide Synthesis Core at the University of Michigan for digestion and 
proteomic analysis. The labeled AcID protein was then digested in gel overnight using 
chymotrypsin and the resulting peptide fragments were extracted and analyzed by mass 
spectrometry for covalent modification of lysine residues within the resulting peptides. 
The mass spectrometric analysis of the fragments generated following chymotrypsin 
digestion resulted in the observation of fragments that covered greater than 95% of the 
AcID protein including all eleven of the lysine residues. Unfortunately, the analysis failed 
to reveal the norstictic acid modification (+358.06 Da) on of any of the lysine residues 
+4 Equivalents Norstictic Acid with Sodium Borohydride Reduction
AcID
+1 NA
+2 NA
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within the resulting peptide fragments, despite clear evidence that the intact protein was 
labeled with the small molecule. 
 One possibility for the lack of observed norstictic acid modifications is that the 
MS/MS conditions under which the peptidic fragments are analyzed are a significantly 
harsher environment that results in the fragmentation or degradation of the covalently 
bound norstictic acid molecule. This phenomenon has been previously reported in the 
literature during an MS/MS characterization of lichen-derived natural products, including 
norstictic acid.56 The norstictic acid fragmentation products observed under MS/MS 
conditions reported in the literature are shown in panel A of Figure 3.35. Notably, the 
modifications shown in Figure 3.35 include the reduction of the molecule that occurs 
during sample preparation prior to proteomic analysis and thus are slightly different than 
the fragmentations reported in the literature. Additionally, storing the norstictic acid 
labeled protein or the peptidic fragments following digestion with chymotrypsin in aqueous 
buffer for extended periods of time could theoretically result in the hydrolysis of the central 
7-membered lactone or the formation of a new 5-membered lactone from the reduced 
aldehyde and carboxylic acid if the buffer were slightly acidic. These possible 
modifications to the covalently bound norstictic acid molecule are shown in panel B of 
Figure 3.35. 
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Figure 3.35- Possible Modifications of Norstictic Acid During MS/MS Analysis. (A) Possible 
fragmentations of norstictic acid under harsh MS/MS conditions, as reported in the literature.56 These 
potential modifications include the reduction of the second aldehyde, which occurs following treatment 
of the sample with sodium borohydride during preparation. (B) Possible modifications of the bound 
norstictic acid molecule that may occur under storage in aqueous environments. 
 The original data collected following chymotrypsin digestion and mass 
spectrometric analysis was analyzed a second time to search for the modifications shown 
in Figure 3.35. Unfortunately, this subsequent analysis again failed to identify any 
modification of the lysine residues on the peptidic fragments following chymotrypsin 
digestion. One possible explanation for this phenomenon is that the treatment of the 
molecule by sodium borohydride may cause the resulting reduced compound to fragment 
through unique mechanisms not observed for the parent molecule during MS/MS 
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analysis. As such, it is possible that the correct mass for the norstictic acid modifications 
on the lysine containing fragments has still not been identified. An additional possibility is 
that modification of the fragments by norstictic acid may alter the solubility of the resultant 
peptides or otherwise interfere with the ability to extract these fragments from the SDS-
PAGE slices following digestion. In this case, the sample may simply not contain enough 
of the labeled fragments to be effectively observed by MS/MS analysis. Given the 
importance of this data in validating the binding site of norstictic acid on the AcID motif, 
this experiment will be repeated using a sample in which the norstictic acid•AcID complex 
is not treated with sodium borohydride in addition to a fresh sample that has been 
reduced. In the event that these samples still fail to generate conclusive evidence of the 
norstictic acid binding sites on AcID, a more thorough analysis of the effects of MS/MS 
conditions on covalently bound norstictic acid will be undertaken in order to determine the 
most abundant fragmentation products before repeating the analysis of the digested 
material.    
Preliminary Cellular Activity of Norstictic Acid and Psoromic Acid 
 We next sought to determine if norstictic acid and the closely related lead molecule 
psoromic acid could perturb AcID-dependent transcriptional processes within a cellular 
context. The first assay by which this hypothesis was tested involved examining the 
expression of endogenous HSPA5 by Real Time quantitative Polymerase Chain Reaction 
(RT-qPCR) of reverse transcribed mRNA transcripts. HSPA5 is a canonical target gene 
of the endoplasmic reticulum stress response transcription factor activating transcription 
factor 6 (ATF6α), which is dependent upon interaction with the AcID motif of Med25 for 
full transcriptional activation.42 This interaction occurs through an eight amino acid 
sequence within the TAD of ATF6α, DFDLDLMP, which bares striking similarity to the 
VP16 sequence, DFDLDMLG, which is termed VN8.57 Free VN8 peptide is capable of 
competing with the interaction between ATF6α and Med25, indicating that the ATF6α 
TAD binds to a similar surface within the domain as VP16. Furthermore, siRNA mediated 
knockdown of Med25 expression has been shown to significantly abrogate the expression 
of HSPA5 following the induction of oxidative stress.42 Schematically, DNA-bound ATF6α 
interacts with the AcID motif of Med25, thereby recruiting the Mediator complex to the 
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promoters of ATF6α dependent genes. Mediator then in turn recruits other required 
coactivator proteins and the RNAPII holocomplex, thereby upregulating expression of the 
target gene. Thus, blocking the critical interaction between the ATF6α TAD and Med25 
through the use of small molecule inhibitors of AcID should result in a decrease in the 
expression of ATF6α target genes such as HSPA5, similar to observations following 
knockdown of Med25 expression. The results of this experiment are shown below in 
Figure 3.36. 
 
Figure 3.36- Inhibition of ATF6α Driven Genes by Norstictic and Psoromic Acid On the left is a 
schematic representation of Med25-dependent activation of ATF6α target genes. On the right is a 
graph showing the effects of Norstictic and psoromic acid on the expression of HSPA5 following 
induction of ER stress. Cells were incubated with DMSO (negative control) or 25 μM of norstictic acid 
or psoromic acid for 12 hours. Cells were then treated with thapsigargin at a final concentration of 500 
nM to induce ER stress and incubated an additional three hours. Cells were then lysed and isolated 
mRNA was quantified for HSPA5 activation. All cells treated with control (DMSO) or compounds 
contained 0.5% v/v DMSO. All signals are the mean and standard deviation of 3 technical replicates. 
**, P < 0.01, n = 3. (Completed by Paul A. Bruno) 
 Treatment of cells with norstictic acid or psoromic acid for twelve hours prior to the 
induction of ER stress through treatment with thapsigargin resulted in inhibition of the 
expression of HSPA5, relative to untreated cells, as shown in Figure 3.36. This 
observation is consistent with the hypothesis that norstictic acid and psoromic acid may 
be capable of perturbing activator•AcID interactions within a cellular context.  
 Another transcriptional activator that interacts with Med25 in order to recruit the 
Mediator complex is retinoic acid receptor α (RARα), as demonstrated by Lee and 
colleagues.58 RARα does not interact with Med25 at the AcID motif, but instead contacts 
the subunit at the nuclear receptor (NR) box located near its C-terminus, as demonstrated 
by a series of yeast two-hybrid assays and co-immunoprecipitation experiments. siRNA 
mediated knockdown of Med25 demonstrates a more significant loss of RARα 
transcriptional activity in reporter assays than knockdown of Med1, another well 
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studies! demonstrating! VP16! binds! to! the!Mediator! complex! through!Med2527! and!more!specifically,!the!ACID!domain!of!Med25,!3,4!suggests!that!ATF6α!could!also!interact!with!the!Med25,!and!possibly!through!interaction!with!the!ACID!domain.!Follow:up!studies!by!Sela!and!coworkers!demonstrated!that!the!ATF6α!TAD!did!in!fact,!interact!with!the!Med25!ACID!domain! and! that! the! VN8! peptide! was! able! to! compete! with! the! ATF6α! TAD:ACID!interaction,! suggesting! that! the! ATF6α! TAD! and! VP16! TAD! use! overlapping! interaction!surfaces!on!ACID.!Given!the!ability!of!our!depsidones!to!inhibit!the!VP16:ACID!interaction,!we!reasoned!that!our!depsidones!should!also!be!able!to!inhibit!the!ATF6α!Med25:mediated!transcriptional! processes! t rough! inhibition! of! the! ACID! domain.! One! such! ATF6α:media ed! transcriptional!process! that! that!was!demonstrated! to!be!dependent!on!Med25!interaction!is!the!ER!stress:induc d!HSPA5!gene.5!We!hypothesized!that!pre: reating!cells!with! norstictic! acid! or! psoromic! acid! before! inducing!HSPA5! expression!would! result! in!inhibition!of!HSPA5!expression!compared!to!untreated!cells!(Figure!3.34).!
!
Figure! 3.34! Inhibition! of! ATF6α! Med252mediated! HSPA5! expression! Performed! by!Paul!Bruno.!Diagram!illustrating!the!ATF6α!Med25:mediated!transcriptional!activ tion!of!the! HSPA5! gene.! On! the! right,! is! a! graph! demonstrating! inhibition! of! HSPA5! activati n!using!norstictic!acid!and!psoromic!acid.!Cells!were!incubated!with!DMSO!(negative!control)!or!25!μM!of!norstictic!acid!or!psoromic!acid!for!12!hours!at!which!point,!thapsigargin!was!added!to!cells!at!a!final!concentration!of!500!nM!and!left!to!incubated!with!treated!cells!for!3!hours!to!stimulate!HSPA5!expression.!After!the!3!hour!incubation!with!thapsigargin,!cells!lysed!and!isolated!mRNA!was!quantified!for!HSPA5!activation.!All!cells!treated!with!control!(DMSO)!or!compounds!contained!0.5%!v/v!DMSO.!All! signals!are! the!mean!and!sta dard!deviation!of!3!technical!replicates.!**,!P!<!0.01,!n!=!3.!
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characterized nuclear receptor binding subunit within the Mediator complex.59 In turn, the 
master coactivator and histone acetyltransferase (HAT) CBP is recruited to the DNA-
bound RARα•Mediator complex through an interaction between a sequence within the N-
terminal domain of CBP and the AcID motif of Med25. The recruitment of CBP and its 
requisite HAT activity is a requirement for full transcriptional activity of RARα.60-62 Thus, 
Med25 acts as an important coactivator target that allows for the simultaneous 
recruitment of the HAT CBP and the Mediator complex, which in turn recruits the 
transcriptional machinery, by the nuclear receptor RARα. The simultaneous 
overexpression of Med25 and CBP results in the significantly enhanced transcriptional 
activation of RARα, relative to the individual overexpression of CBP or Med25, suggesting 
that both coactivators are important for RARα function. Therefore, it was hypothesized 
that norstictic acid or psoromic acid may be capable of inhibiting the recruitment of CBP 
to the promoter of a RARα reporter plasmid by blocking its interaction with the AcID motif 
of Med25, resulting in a decrease in RARα transcriptional activity within the reporter 
assay. The results of this experiment are shown below in Figure 3.37. 
 
 
 
Figure 3.37- Inhibition of a RARα Transcriptional Reporter Assay Using Norstictic Acid and 
Psoromic Acid On the left is a schematic representation of the RARα reporter assay. RARα binds to 
a response element on the reporter plasmid following treatment with retinoic acid and recruits the 
Mediator complex through an interaction with the NR box of Med25. CBP is then recruited to the 
promoter through an interaction with the AcID motif and its HAT activity acetylates adjacent histones, 
resulting in upregulation of the reporter gene. On the right is a graph showing the effects of various 
concentrations of norstictic acid and psoromic acid on the expression of the luciferase reporter gene. 
Cells transfected with pRARE-luciferase reporter and pCMV-β-Gal were dosed with retinoic acid and 
either DMSO or compound as noted above. All DMSO levels were kept below 1% v/v for cellular 
dosing. All signals were normalized to β-Gal activity and represent the mean and standard deviation 
of 4 biological replicates. (Completed by Paul A. Bruno) 
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coworkers!performed!two:hybrid!assays!with!the!RAR!ligand:binding!domain,! identifying!the! Med25! as! an! interaction! partner.24! The! interaction! was! localized! to! the! NR! box! of!Med25! and! the! RAR! ligand:binding! domain;! however,! assays! that! overexpressed!Med25!did!not!result!in!greatly!enhanced!activity!of!RAR,!suggesting!that!recruitment!of!Med25!is!not!solely!sufficient!for!transcriptional!upregulation.!It!has!been!previously!demonstrated!that!CBP,! 63:65! a!histone! acetyl! transferase! (HAT),! is! recruited! to! induce!RAR! target! gene!upregulation,!resulting!in!a!hypothesis!that!both!CBP!and!Med25!need!to!both!be!recruited!to! induce! RAR! transcriptional! activity.! Pull:downs!with! the!Med25! domains! VWR,! ACID,!and!NR!box!demonstrated!that!the!ACID!domain!interacts!with!CBP,!specifically!to!the!N:terminus!of!CBP.!This!result!provides!a!possible!mechanism!for!how!RAR!can!recruit!both!Med25!and!CBP!to!its!promoter.!More!specifically,!an!interaction!between!RAR!and!the!NR!box!of!Med25!recruits!Med25!to!the!RAR!promoter!then,!Med25!can!recruit!CBP!through!the!Med25!ACID!do ain!and! the!N:terminus!of!CBP,! resulting! in!CBP! recruitment! to! the!RAR! promoter24! (Figure! 3.34).! Ov rexpression! of! both! Med25! and! CBP! re ult d! in!substantial! increases! in! transcriptional! activity! at! the!RA !promoter,!when! compared! to!ov rexpression! of! Med25! or! CBP! individually.! This! result! suggests! that! interruption! of!Med25!ACID!and!CBP!N:terminus!interaction!would!result! in!reduced!recruitment!of!CBP!to! the! RAR! promoter! and! reduced! transcriptional! activity! at! the! RAR! promoter.! We!hypothesize! that! using! psoromic! acid! and! norstictic! acid! to! inhibit! the! Med25! ACID!interaction!with!the!CBP!N:terminus!will!result!in!reduced!activity!at!the!RAR!promoter.!In!order! to! test! this! hypothesis,! we! co:dosed! cells! transfected! with! a! luciferase! reported!containing! a! retinoic! acid! receptor! promoter! (pRARE:luc)! along! with! a! constitutively!expressed!β:Gal!reporter!(pCMV:β:Gal)! to!monitor!off:target!effects.!All! luciferase!signals!were!normalized!to!β:Gal!signal.!The!results!of!the!assay!are!as!illustrated!in!Figure!3.37.!
!
Figure! 3.37! Inhibiting! RARα! transcriptional! activity! with! psoromic! acid! and!
norstictic! acid! Performed! by! Paul! Bruno.! On! the! left,! is! a! diagram! of! RARα! coactivator!
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 Both norstictic acid and psoromic acid demonstrate a dose dependent inhibition of 
the expression of a luciferase reporter gene by RARα, consistent with the hypothesis that 
the molecules may interfere with the recruitment of CBP through its interaction with AcID. 
These data demonstrating that norstictic acid and psoromic acid may be capable of 
inhibiting ATF6α and RARα transcriptional programs is encouraging and suggests that 
these small molecules warrant further investigation as potential mechanistic probes for 
Med25-dependent transcriptional processes. 
3.4 Conclusions 
At the outset of the work discussed in this chapter we sought to determine if we 
could identify small molecule inhibitors of the interaction between the VP16 transcriptional 
activation domain and one of its coactivator binding partners, Med25. Towards this end, 
a fluorescence polarization based assay using the VP16(465-490)•AcID interaction was 
developed and optimized for high-throughput screening. This assay was then used to 
screen a library containing 4,000 biologically active molecules and led to the identification 
of a number of lead molecules belonging to the depside and depsidone classes, 
supporting the hypothesis that activator•AcID interactions could be effectively targeted by 
small molecule inhibitors. Interestingly, our lab has previously identified the depside 
sekikaic acid and depsidone lobaric acid as inhibitors of another activator•coactivator 
interaction, suggesting that the depside and depsidone core scaffold may be privileged 
for the inhibition of activator•coactivator interactions. 
Importantly, norstictic acid and the closely related depsidone psoromic acid appear 
to be selective for the AcID motif as both molecules failed to inhibit alternative 
activator•coactivator interactions. Specifically, these inhibitors failed to perturb the 
unrelated activator•coactivator interactions between MLL or CREB and the KIX domain 
of CBP/p300, suggesting that these molecules do not merely mimic transcriptional 
activation domains or generic amphipathic helices. More impressively, both molecules 
also failed to comparably inhibit the VP16•Med15 interaction, demonstrating that these 
inhibitors are not VP16 mimetics as they fail to inhibit other VP16•coactivator interactions. 
Thus, both norstictic acid and psoromic acid are actually more selective for the AcID motif 
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than one of its native binding partners, indicating that they may be particularly useful 
probes for studying AcID-dependent transcriptional processes. 
The salt-concentration dependent activity of norstictic acid against the VP16•AcID 
interaction is consistent with the hypothesis that the molecules form electrostatic contacts 
with the domain, similar to activator binding partners as described in Chapter 2. 
Additionally, a reactive ortho-phenolic aldehyde functionality on these molecules is 
capable of forming covalent adducts with the domain following reaction with the ε-amine 
of reactive lysine residues within the protein. The formation of this covalent adduct 
relieves a positive charge on the surface of the domain, which may contribute to the 
inhibition of the VP16•AcID interaction as electrostatic contacts have been previously 
shown to be of particular importance for the interactions. Furthermore, chemical shift 
perturbation analysis of AcID in complex with norstictic acid reveals that the molecule 
induces shifts within the H1 and H2 binding sites, suggesting that the molecules are 
competing for surfaces critical for the VP16 interaction and further supporting the 
hypothesis that the molecules interfere with electrostatic contacts within these interaction 
surfaces in addition to sterically blocking activator binding.  
Interestingly, the binding of the molecule also induces significant chemical shifts in 
regions of the domain that are not perturbed following activator binding, specifically at 
helix α2, which is located at the interface of the H1 and H2 binding sites. These data are 
consistent with a model in which norstictic acid is capable of inducting conformational 
shifts of the domain that interferes with the binding of activators to the motif. Mutational 
analysis in which specific lysine residues were mutated to arginine in order to abrogate 
the formation of the covalent adduct while maintaining critical electrostatic contacts 
identified specific lysine residues within the H1 and H2 binding surfaces as the sites for 
adduct formation. Mutation of lysine residues within the H2 binding site affected the ability 
of norstictic acid to inhibit interactions at the H2 interface, as expected, but also affected 
the ability of the molecule to inhibit interactions at the H1 binding site, further supporting 
the hypothesis that norstictic acid can function as an allosteric modulator in addition to 
orthosterically blocking activator binding surfaces. The converse was also demonstrated 
as well, where mutation of critical lysine residues within the H1 binding site perturbed the 
activity of the molecule at the H2 interface as well as the H1 surface. Mass spectrometric 
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analysis of AcID in complex with norstictic acid demonstrates that the major population of 
the sample contains a single norstictic acid modification.  Taken together, these results 
are consistent with a mechanism of action in which norstictic acid functions as a mixed 
orthosteric/allosteric inhibitor of VP16•AcID interactions, capable of simultaneously 
perturbing binding events at both binding sites regardless of which site the molecule is 
bound to. Thus, this finding further supports the advantage of identifying inhibitors that 
function through allosteric modulation and target unique coactivator conformations. 
Finally, norstictic acid and psoromic acid were tested for their ability to perturb 
AcID-dependent transcriptional processes within a cellular context. RT-qPCR analysis of 
the expression of HSPA5, a canonical target gene of the ER stress response transcription 
factor ATF6α, reveals that expression of the gene is inhibited by treatment with norstictic 
acid and psoromic acid prior to induction of ER stress. Similarly, norstictic acid and 
psoromic acid are capable of inhibiting the transcriptional activity of RARα in a reporter 
assay, likely by inhibiting the recruitment of the histone acetyl transferase CBP through 
its interaction with the AcID motif. These results are consistent with the hypothesis that 
norstictic acid and psoromic acid are cell permeable small molecules that can perturb 
AcID-dependent transcriptional processes. Thus, this preliminary evidence suggests that 
norstictic acid and psoromic acid warrant further analysis and validation as molecular 
probes that target the AcID motif in order to further elucidate the role of activator•AcID 
interactions in a variety of important cellular processes.  
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3.5 Materials and Methods 
Plasmids 
Plasmid pET21b-Med25(394-543)-His6, henceforth referred to as pAcID-His6, was a 
generous gift from Patrick Cramer.36 AcID mutants were generated by site directed 
mutagenesis of the as previously described using the primers indicated below.63 pAcID-
(KK518RR)-His6 was generated by site directed mutagenesis of pAcID-(K518R)-His6. 
pAcID-(KKK518RRR)-His6 was generated by site directed mutagenesis of pAcID-
(KK518RR)-His6. pAcID-(K411R/K413R/K518R/K519R/K520R)-His6 was generated by 
site directed mutagenesis of pAcID-(KKK518RRR)-His6 using the pAcID-
(K411R/K413R)-His6 primer set. pAcID-(K411R/K413R)-His6 was prepared by Paul A. 
Bruno. pGL3-RARE-luc was purchased from Addgene and as previously described.64 
pCMV-β-Gal and pBSSK (non-coding plasmid) were kind gifts from Jorge Iñiguez-Lluhí. 
 
 
 
Protein expression and purification 
AcID (Med25394-543) protein was expressed and purified together with Paul A. Bruno. 
Plasmid pAcID-His6 was transformed into heat-shock competent Rosetta pLysS cells 
(Novagen), streaked onto LB Agar plates containing ampicillin and chloramphenicol, and 
incubated at 37 °C overnight. The next evening, a 25 mL Terrific Broth (TB) starter culture 
with 0.1 mg/mL ampicillin and 0.034 mg/mL chloramphenicol was then inoculated with a 
colony selected from the LB Agar plate and incubated at 37 °C overnight. The next 
morning, 5 mL from the starter culture was added to 1L TB containing ampicillin and 
Column1 Column2Column3
pAcID-(K518R)-His6 F	Pr. TCATGCTCCTGTACTCGTCCAGGAAGAAGATCTTCATGGGCCTCATCCC
R	Pr. GGGATGAGGCCCATGAAGATCTTCTTCCTGGACGAGTACAGGAGCATGA
pAcID-(K519R)-His6 F	Pr. TCATGCTCCTGTACTCGTCCAAGAGGAAGATCTTCATGGGCCTCATCCC
R	Pr. GGGATGAGGCCCATGAAGATCTTCCTCTTGGACGAGTACAGGAGCATGA
pAcID-(K520R)-His6 F	Pr. TCATGCTCCTGTACTCGTCCAAGAAGAGGATCTTCATGGGCCTCATCCC
R	Pr. GGGATGAGGCCCATGAAGATCCTCTTCTTGGACGAGTACAGGAGCATGA
pAcID-(KK518RR)-His6 F	Pr. TCATGCTCCTGTACTCGTCCAGGAGGAAGATCTTCATGGGCCTCATCCC
R	Pr. GGGATGAGGCCCATGAAGATCTTCCTCCTGGACGAGTACAGGAGCATGA
pAcID-(KKK518RRR)-His6 F	Pr. TCATGCTCCTGTACTCGTCCAGGAGGAGGATCTTCATGGGCCTCATCCC
R	Pr. GGGATGAGGCCCATGAAGATCCTCCTCCTGGACGAGTACAGGAGCATGA
pAcID-(K411R/K413R)-His6 F	Pr. GGGGTCCTGGAGTGGCAAGAGAGACCCAGACCTGCCTCAGTGGATGCCAAC
R	Pr. GTTGGCATCCACTGAGGCAGGTCTGGGTCTCTCTTGCCACTCCAGGACCCC
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bacteria were grown at 37 °C to an OD600 of 0.8. Temperature was reduced to 18 °C and 
protein expression was induced upon addition of IPTG to a final concentration of 0.5 mM.  
Cells were incubated overnight at 18 °C. The 1 L cultures were then collected and 
centrifuged at 6000xg for 20 mins at 4 °C. Cell pellets were stored at -80 °C prior to 
purification. The harvested pellet was thawed on ice and resuspended in 20 mL of lysis 
buffer (50 mM phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 6.8). Cells were 
then lysed by sonication on ice and cellular lysates were cleared by centrifugation at 9500 
rpm for 20 min at 4 °C. The supernatant lysate was then added to Ni-NTA beads (Qiagen) 
and incubated for 1 hour at 4 °C. The resin was pelleted by centrifugation at 2500 rpm for 
2 min at 4 °C and washed with wash buffer (50 mM phosphate, 300 mM sodium chloride, 
30 mM imidazole, pH 6.8) a total of five times. Protein was then eluted with 2 mL of elution 
buffer (50 mM phosphate, 300 mM sodium chloride, 400 mM imidazole, pH 6.8) a total of 
three times. Eluent was then pooled and purified by cation exchange FPLC (Source 15S, 
GE Healthcare) using a gradient of Buffer B (50 mM phosphate, 100 mM NaCl, 1 mM 
DTT, pH 6.8) in Buffer A (50 mM phosphate, 1 mM DTT). The FPLC purified protein was 
then dialyzed into storage buffer (10 mM phosphate, 50 mM NaCl, 10% v/v glycerol, 
0.001% v/v NP-40, pH 6.8) overnight, concentrated, aliquoted, and stored at -20 °C.  Final 
protein was greater than 90% pure as determined by coomassie stained polyacrylamide 
gel. Protein concentration was determined by UV-Vis spectroscopy using an extinction 
coefficient, ε = 22,460 M-1cm-1. 
 
15N-labeled AcID protein was expressed and purified together with Paul A. Bruno. Rosetta 
pLys cells transformed with pAcID-His6 were used to inoculate a 25 mL LB starter culture 
with 0.1 mg/mL ampicillin and 0.034 mg/mL chloramphenicol. The starter culture was 
pelleted by centrifugation at 2500 RPM and washed twice with 20 mL of M9 minimal 
media. Following the second wash, cells were resuspended in 20 mL of M9 minimal media 
and two 500 mL cultures of M9 minimal mediated supplemented with ampicillin and 3 mL 
10x BioXpress media (Cambridge Isotope Laboratories) were inoculated with 5 mL of the 
resuspended starter culture. Bacteria were grown at 37 °C to an OD600 of 0.8, at which 
point the temperature was reduced to 18 °C and expression was induced by addition of 
IPTG to a final concentration of 0.5 mM. Cells were incubated at 18 °C overnight and 
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pelleted at 6000 xg the following morning. Protein purification was as described for the 
unlabeled AcID protein. 
 
Med25 AcID (K518R) was expressed and purified as described for the WT Med25 AcID 
protein. The presence of the desired mutation was confirmed by mass spectrometric 
analysis of the purified protein on an Agilent Q-ToF LC/MS. 
 
Med25 AcID (K519R) was expressed and purified as described for the WT Med25 AcID 
protein. The presence of the desired mutation was confirmed by mass spectrometric 
analysis of the purified protein on an Agilent Q-ToF LC/MS. 
 
Med25 AcID (K520R) was expressed and purified as described for the WT Med25 AcID 
protein. The presence of the desired mutation was confirmed by mass spectrometric 
analysis of the purified protein on an Agilent Q-ToF LC/MS. 
 
Med25 AcID (KK518RR) was expressed and purified as described for the WT Med25 
AcID protein. The presence of the desired mutation was confirmed by mass spectrometric 
analysis of the purified protein on an Agilent Q-ToF LC/MS. 
 
Med25 AcID (KKK518RRR) was expressed and purified as described for the WT Med25 
AcID protein. The presence of the desired mutation was confirmed by mass spectrometric 
analysis of the purified protein on an Agilent Q-ToF LC/MS. 
 
Med25 AcID (K411R/K413R) was expressed and purified as described for the WT Med25 
AcID protein. The presence of the desired mutation was confirmed by mass spectrometric 
analysis of the purified protein on an Agilent Q-ToF LC/MS. 
 
Med25 AcID (K518R/K519R/K520R/K411R/K413R) was expressed and purified as 
described for the WT Med25 AcID protein. The presence of the desired mutation was 
confirmed by mass spectrometric analysis of the purified protein on an Agilent Q-ToF 
LC/MS. 
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Med15 (1-345) was expressed and purified by Paul A. Bruno as previously described.65 
 
CBP/p300 KIX protein was expressed and purified together with Paul A. Bruno as 
previously described.30 
 
Gal4 (1-100) was expressed and purified by Paul A. Bruno as previously described.51 
 
Peptides 
All peptides used in the studies described in this chapter have been previously reported 
in Chapter 2. 
 
Fluorescence polarization direct binding assays 
Direct binding assays were performed in triplicate with a final sample volume of 20 μL in 
a low volume, non-binding, 384-well black plate (Corning). FITC-labeled peptides were 
diluted in assay buffer (10 mM PBS, 100 mM NaCl, 10 % glycerol, 0.001% NP-40 pH 6.8) 
to a centration of 40 nM. 10 µL of AcID protein was serially diluted two-fold on the 384-
well plate for the number of data points indicated for each experiment using assay buffer. 
10 µL of the diluted fluorescent peptide stock was then added to each well of diluted 
protein for a final tracer concentration of 20 nM. An additional well containing 10 µL buffer 
and 10 µL fluorescent peptide was prepared for use as a ‘tracer only control’ to determine 
optimal gain settings on the plate reader. Samples were then incubated for 30 minutes at 
room temperature before fluorescence polarization was measured on a Pherastar plate 
reader with polarized excitation at 485 nm and emission intensity measured through a 
parallel and perpendicularly polarized 535 nm. A binding isotherm that accounts for ligand 
depletion (assuming a 1:1 binding model of peptide to ACID) was fit to the observed 
polarization values as a function of ACID to obtain the apparent equilibrium dissociation, 
Kd:  
 𝑦 = 	𝑐 + 𝑏 − 𝑐 	×	 𝐾* + 	𝑎 + 𝑥 − (𝐾* + 𝑎 + 𝑥)/ − 4𝑎𝑥2𝑎  
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Where “a” and “x” are the total concentrations of fluorescent peptide and AcID, 
respectively, “y” is the observed anisotropy at a given AcID concentration, “b” is the 
maximum observed anisotropy value, and “c” is the minimum observed anisotropy value. 
Each data point is an average of three independent experiments with the indicated error 
representing the standard deviation of the three replicates. All curves and calculations 
were generated using GraphPad Prism 5. 
 
Primary screen of bioactive compounds 
The primary screen was completed together with Paul A. Bruno at the Center for Chemical 
Genomics (University of Michigan) in collaboration with Martha Larsen and Steve Vander 
Roest. Assays were performed in a final volume of 20 µL in a low volume, non-binding, 
black 384- well plate (Corning) and read by plate reader (Pherastar) with polarized 
excitation at 485 nm and emission intensity measured through parallel and 
perpendicularly polarized 535 nm filters. Final concentration of AcID protein was 850 nM, 
final concentration of Flo-VP16(465-490) was 20 nM, and compounds were assayed at a 
concentration of 20 µM with a final DMSO concentration of 1% v/v.  10 µL of AcID protein 
at a concentration of 1.7 µM was added to columns 1-22 of the assay plate by Multidrop 
dispenser (Thermo Fisher Scientific). Next, compounds were added to columns 3-22 of 
the assay plate and DMSO was added to columns 1-2 (negative control, AcID•VP16 
complex) and 23-24 (positive control, VP16 tracer only) by pin tool. Finally, Flo-VP16(465-
490) was added to all wells at a concentration of 40 nM. Plates were incubated for thirty 
minutes at room temperature and read by plate reader as described above with gain 
settings determined based on a well from columns 23-24 (tracer only). Data was 
published to and analyzed using MScreen (http://mscreen.lsi.umich.edu). 
 
Substructure search of CCG libraries for compounds containing Depside/Depsidone core 
All CCG compound libraries were searched for the depside and depsidone core scaffold 
described in panel A of Figure 3.12 above using cross-reference tools included in the 
MScreen software package. The substructure search was completed together with Paul 
A. Bruno. 
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Fluorescence polarization dose-response inhibition assays 
Inhibition assays were performed in triplicate with a final sample volume of 20 μL in a low 
volume, non-binding, 384-well black plate (Corning). A complex of the indicated 
fluorescent tracer and protein was prepared at a 2x concentration such that 50% of the 
tracer was bound following dilution onto the assay plate. Small molecule inhibitors were 
diluted in assay buffer (10 mM PBS, 100 mM NaCl, 10 % glycerol, 0.001% NP-40 pH 6.8) 
to the desired concentration and serially diluted two-fold on the assay plate to a final 
volume of 10 µL. 10 µL of the pre-formed fluorescent tracer-protein complex was then 
added to each well for a final volume of 20 µL. An additional well containing tracer only 
was prepared and used to determine optimal gain settings on the plate reader. Samples 
were incubated for thirty minutes at room temperature before fluorescence polarization 
was measured on a Pherastar plate reader with polarized excitation at 485 nm and 
emission intensity measured through a parallel and perpendicularly polarized 535 nm. 
Polarization values were converted to relative fraction bound and plotted opposite the log 
of inhibitor concentration using GraphPad Prism 5 and curves were fit with a non-linear 
regression using the built-in equation “log(inhibitor) vs response – variable slope” from 
which the IC50 value was calculated. 
 
Salt titration effects on Norstictic Acid inhibition 
The fluorescence polarization inhibition experiments were performed as noted above with 
one modification. The NaCl concentration of assay buffer was adjusted to the indicated 
concentrations by adding an appropriate volume of assay buffer containing 5 M NaCl prior 
to preparing assay components. 
 
Mass spectrometric analysis of covalent adducts reduced with NaBH4 
AcID protein was diluted to a concentration of 20 µM using storage buffer (10 mM 
phosphate, 50 mM NaCl, 10% v/v glycerol, 0.001% v/v NP-40, pH 6.8). Norstictic acid 
was added to the diluted protein to a final concentration of 80 µM (4 equivalents). Samples 
were incubated for two hours at room temperature with gentle mixing on an orbital shaker. 
Samples were subsequently reduced by addition of a 100 mM freshly prepared stock of 
NaBH4 in storage buffer to a final concentration of 1 mM NaBH4. Samples were incubated 
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with the reducing agent at room temperature for one hour with gentle mixing on an orbital 
shaker. Samples were subsequently diluted five-fold and buffer exchanged into fresh 
storage buffer. Samples were the analyzed by mass spectrometry using an Agilent Q-
ToF LC/MS equipped with a Poroshell 300SB C8 reverse-phased column using a gradient 
of 5-100% acetonitrile with 0.1% formic acid in water with 0.1% formic acid over five 
minutes. Analysis of data was completed using the Agilent Qualitative Analysis Program 
with background subtraction and deconvolution settings for an intact protein of 10,000-
30,000 Da. 
 
Mass spectrometric analysis of non-reduced covalent adducts 
Mass spectrometric analysis of AcID•norstictic acid covalent adducts without sodium 
borohydride reduction were completed as described above without the reduction step. 
 
Norstictic Acid inhibition time course 
The norstictic acid inhibition time course was completed as described above with several 
modifications. Small molecule inhibitor was serially diluted onto the assay plate and the 
preformed AcID•Flo-VP16(465-490) was added rapidly to the wells using a multi-dropping 
multi-channel pipette. Samples were incubated five-minutes before being read by plate 
reader as described. Additional measurements were made of the same plate at the 
indicated time points. 
 
1H,15N-HSQC NMR chemical shift perturbation experiments of covalent adducts 
Sample preparation was completed by Paul A. Bruno. 15N-labeled AcID protein was 
expressed and purified as described above. Protein was diluted to a concentration of 30 
µM and separate samples containing DMSO (negative control), 90 µM norstictic acid, or 
150 µM norstictic acid were prepared. Samples were incubated for two hours at room 
temperature and analyzed by mass spectrometry as described above. Following 
confirmation, samples were immediately submitted for 1H,15N-HSQC analysis by Felicia 
Gray (Cierpicki Lab, University of Michigan). Peak assignment and chemical shift 
perturbation assessment was completed by Felicia Gray. 
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Covalent adduct digestion and proteomic analysis 
A 500 µL sample of AcID protein in complex with 4 equivalents of norstictic acid was 
reduced with sodium borohydride as described above. Labeling was verified by mass 
spectrometric analysis. Samples were then purified by SDS-polyacrylamide gel 
electrophoresis using a 4-12% bis-tris gel (Roche). Gels were stained with coomassie 
blue and bands of interest were excised and submitted to the Peptide Synthesis and 
Proteomics Core (University of Michigan) for in-gel chymotrypsin digestion and 
subsequent mass spectrometric analysis. 
 
RT-qPCR analysis of HSPA5 gene expression 
RT-qPCR analysis of endogenous HSPA5 gene expression levels was completed by Paul 
A. Bruno. For endogenous gene expression analysis, 1x105 HeLa cells were seeded into 
a 24:well plate and allowed to adhere overnight. Media was removed and replaced with 
OptiMem media containing vehicle or compound delivered in DMSO (0.5% v/v) at the 
indicated concentrations. After incubating for 12 h, cells were treated with thapsigargin at 
a final concentration of 500 nM. After 3 h, the media was removed and total RNA was 
isolated using RNeasy Plus RNA isolation kits (Qiagen) according to manufacturer’s 
instructions. Each RNA sample was used to synthesize cDNA using iScript cDNA 
synthesis kits (Bio-Rad). RT-qPCR reactions were carried out in triplicate in an Applied 
Biosystems StepPlusOne instrument using SYBR green master mix and primers for: 
human RPL19 F pr. 5’:ATGTATCACAGCCTGTACCTG:3’; R Pr., 5’:TTCTT 
GGTCTCTCTTCCTCCTTG:3’) and HSPA5 (F Pr., 5’:CTGGGTACATTTGATCTGACTG 
G:3’; R Pr., 5’: CTTACCGACCTTTCGGTGGTCCTACG:3’). RT:qPCR analysis was 
carried out using the comparative CT Method (ΔΔCT Method) to estimate HSPA5 mRNA 
levels relative to the reference RPL19 mRNA levels.  
 
RARα luciferase reporter assay 
The RARα luciferase reporter assay experiments were completed by Paul A. Bruno. The 
RARα luciferase reporter containing 3 tandem RARα sites (RARα-luc) was obtained from 
Addgene. CMV-β-Gal, and pBSSK were generously provided by Dr. Jorge Iñigues-Lluhí. 
All cells were maintained in 5% CO2 at 37°C. HeLa cells were grown in Dulbecco’s 
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modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% FBS. For 
luciferase assays, 4x105 cells were seeded in a 6:well dish and allowed to adhere 
overnight. The media was removed and cells were transfected in OptiMem (Invitrogen) 
with 1 μg RARα:luc, 200 ng CMV:β:Gal, and 800 ng pBSSK using Lipofectamine 2000 
(Life Technologies) according to manufacturer’s instructions. After 4.5 h, transfection 
solution was removed and replaced with DMEM containing 10% FBS. At 24 h after 
transfection, cells were trypsinized and resuspended in DMEM supplemented with 10% 
FBS and seeded into a 96:well plate at a density of 8x103 cells per well. After an additional 
16 h, media was removed and replaced with OptiMem containing vehicle or small 
molecule at the indicated concentration as a solution in DMSO co-dosed with retinoic acid 
(1 μM). Cells were incubated with either vehicle or compound and retinoic acid for 16 h, 
media was removed and cells were lysed with 60 μL of passive lysis buffer. Luciferase 
and β:Galactosidase activities were determined as previously described. RARα luciferase 
activity was plotted using GraphPad Prism 5.  
  
 147 
3.6 References 
1. Gann, M. P. A. A. Genes and Signals. 1–209 (2005). 
 
2. Giordano, A. & Avantaggiati, M. L. p300 and CBP: partners for life and death. J. 
Cell. Physiol. 181, 218–230 (1999). 
 
3. Davidson, B. et al. PEA3 is the second Ets family transcription factor involved in 
tumor progression in ovarian carcinoma. Clin. Cancer Res. 9, 1412–1419 (2003). 
 
4. Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 
25, 276–308 (2004). 
 
5. Mapp, A. K., Pricer, R. & Sturlis, S. Targeting transcription is no longer a quixotic 
quest. Nat. Chem. Biol. 11, 891–894 (2015). 
 
6. Thompson, A. D., Dugan, A., Gestwicki, J. E. & Mapp, A. K. Fine-tuning 
multiprotein complexes using small molecules. ACS Chemical Biology 7, 1311–
1320 (2012). 
 
7. Cesa, L. C., Mapp, A. K. & Gestwicki, J. E. Direct and Propagated Effects of 
Small Molecules on Protein-Protein Interaction Networks. Front Bioeng Biotechnol 
3, 119 (2015). 
 
8. Ng, H. H. & Bird, A. Histone deacetylases: silencers for hire. Trends Biochem. 
Sci. 25, 121–126 (2000). 
 
9. Peterson, C. L. & Laniel, M.-A. Histones and histone modifications. Curr. Biol. 14, 
R546–51 (2004). 
 
10. Kornberg, R. D. Mediator and the mechanism of transcriptional activation. Trends 
Biochem. Sci. 30, 235–239 (2005). 
 
11. Conaway, R. C. & Conaway, J. W. Function and regulation of the Mediator 
complex. Curr. Opin. Genet. Dev. 21, 225–230 (2011). 
 
12. Goodman, R. H. & Smolik, S. CBP/p300 in cell growth, transformation, and 
development. Genes Dev. 14, 1553–1577 (2000). 
 
13. Tosovská, P. & Arora, P. S. Oligooxopiperazines as nonpeptidic alpha-helix 
mimetics. Org. Lett. 12, 1588–1591 (2010). 
 
14. Lee, L. W. et al. Inhibition of ErbB2(Her2) expression with small molecule 
transcription factor mimics. Bioorganic & Medicinal Chemistry Letters 19, 6233–
6236 (2009). 
 
 
 148 
15. Yin, H. et al. Terphenyl-based helical mimetics that disrupt the p53/HDM2 
interaction. Angew. Chem. Int. Ed. Engl. 44, 2704–2707 (2005). 
 
16. Kushal, S. et al. Protein domain mimetics as in vivo modulators of hypoxia-
inducible factor signaling. Proceedings of the National Academy of Sciences 110, 
15602–15607 (2013). 
 
17. Minter, A. R., Brennan, B. B. & Mapp, A. K. A small molecule transcriptional 
activation domain. J. Am. Chem. Soc. 126, 10504–10505 (2004). 
 
18. Buhrlage, S. J. et al. Amphipathic small molecules mimic the binding mode and 
function of endogenous transcription factors. ACS Chemical Biology 4, 335–344 
(2009). 
 
19. Kristensen, V. N. et al. Gene expression profiling of breast cancer in relation to 
estrogen receptor status and estrogen-metabolizing enzymes: clinical 
implications. Clin. Cancer Res. 11, 878s–83s (2005). 
 
20. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–
752 (2000). 
 
21. Pupa, S. M., Tagliabue, E., Ménard, S. & Anichini, A. HER-2: a biomarker at the 
crossroads of breast cancer immunotherapy and molecular medicine. J. Cell. 
Physiol. 205, 10–18 (2005). 
 
22. Asada, S. et al. External control of Her2 expression and cancer cell growth by 
targeting a Ras-linked coactivator. Proc Natl Acad Sci USA 99, 12747–12752 
(2002). 
 
23. Benz, C. C. et al. HER2/Neu and the Ets transcription activator PEA3 are 
coordinately upregulated in human breast cancer. Oncogene 15, 1513–1525 
(1997). 
 
24. Shimogawa, H. et al. A wrench-shaped synthetic molecule that modulates a 
transcription factor-coactivator interaction. J. Am. Chem. Soc. 126, 3461–3471 
(2004). 
 
25. Zhang, M. et al. Genetic and chemical targeting of epithelial-restricted with serine 
box reduces EGF receptor and potentiates the efficacy of afatinib. Mol. Cancer 
Ther. 12, 1515–1525 (2013). 
 
26. Lao, B. B. et al. In vivo modulation of hypoxia-inducible signaling by topographical 
helix mimetics. Proceedings of the National Academy of Sciences 111, 7531–
7536 (2014). 
 
 
 149 
27. Hirota, K. & Semenza, G. L. Regulation of angiogenesis by hypoxia-inducible 
factor 1. Crit. Rev. Oncol. Hematol. 59, 15–26 (2006). 
 
28. Freedman, S. J. et al. Structural basis for recruitment of CBP/p300 by hypoxia-
inducible factor-1 alpha. Proc Natl Acad Sci USA 99, 5367–5372 (2002). 
 
29. Dames, S. A., Martinez-Yamout, M., De Guzman, R. N., Dyson, H. J. & Wright, P. 
E. Structural basis for Hif-1 alpha /CBP recognition in the cellular hypoxic 
response. Proc Natl Acad Sci USA 99, 5271–5276 (2002). 
 
30. Wang, N. et al. Ordering a dynamic protein via a small-molecule stabilizer. J. Am. 
Chem. Soc. 135, 3363–3366 (2013). 
 
31. Goto, N. K., Zor, T., Martinez-Yamout, M., Dyson, H. J. & Wright, P. E. 
Cooperativity in transcription factor binding to the coactivator CREB-binding 
protein (CBP). The mixed lineage leukemia protein (MLL) activation domain binds 
to an allosteric site on the KIX domain. Journal of Biological Chemistry 277, 
43168–43174 (2002). 
 
32. De Guzman, R. N., Goto, N. K., Dyson, H. J. & Wright, P. E. Structural basis for 
cooperative transcription factor binding to the CBP coactivator. J. Mol. Biol. 355, 
1005–1013 (2006). 
 
33. Wang, N., Lodge, J. M., Fierke, C. A. & Mapp, A. K. Dissecting allosteric effects of 
activator-coactivator complexes using a covalent small molecule ligand. 
Proceedings of the National Academy of Sciences 111, 12061–12066 (2014). 
 
34. Majmudar, C. Y. et al. Sekikaic acid and lobaric acid target a dynamic interface of 
the coactivator CBP/p300. Angew. Chem. Int. Ed. 51, 11258–11262 (2012). 
 
35. Milbradt, A. G. et al. Structure of the VP16 transactivator target in the Mediator. 
Nat. Struct. Mol. Biol. 18, 410–415 (2011). 
 
36. Vojnic, E. et al. Structure and VP16 binding of the Mediator Med25 activator 
interaction domain. Nat. Struct. Mol. Biol. 18, 404–409 (2011). 
 
37. Bontems, F. et al. NMR structure of the human Mediator MED25 ACID domain. 
Journal of Structural Biology 174, 245–251 (2011). 
 
38. Benedit, P. et al. PTOV1, a novel protein overexpressed in prostate cancer 
containing a new class of protein homology blocks. Oncogene 20, 1455–1464 
(2001). 
 
39. Verger, A. et al. The Mediator complex subunit MED25 is targeted by the N-
terminal transactivation domain of the PEA3 group members. Nucleic Acids Res. 
41, 4847–4859 (2013). 
 150 
40. Kinoshita, J. et al. Clinical significance of PEA3 in human breast cancer. Surgery 
131, S222–5 (2002). 
 
41. Aytes, A. et al. ETV4 promotes metastasis in response to activation of PI3-kinase 
and Ras signaling in a mouse model of advanced prostate cancer. Proceedings of 
the National Academy of Sciences 110, E3506–15 (2013). 
 
42. Sela, D. et al. Role for human mediator subunit MED25 in recruitment of mediator 
to promoters by endoplasmic reticulum stress-responsive transcription factor 
ATF6α. J. Biol. Chem. 288, 26179–26187 (2013). 
 
43. Wysocka, J. & Herr, W. The herpes simplex virus VP16-induced complex: the 
makings of a regulatory switch. Trends Biochem. Sci. 28, 294–304 (2003). 
 
44. Yang, F., DeBeaumont, R., Zhou, S. & Näär, A. M. The activator-recruited 
cofactor/Mediator coactivator subunit ARC92 is a functionally important target of 
the VP16 transcriptional activator. Proc Natl Acad Sci USA 101, 2339–2344 
(2004). 
 
45. Johnson, P. F., Sterneck, E. & Williams, S. C. Activation domains of 
transcriptional regulatory proteins. The Journal of Nutritional Biochemistry 4, 386–
398 (1993). 
 
46. Jonker, H. R. A., Wechselberger, R. W., Boelens, R., Folkers, G. E. & Kaptein, R. 
Structural properties of the promiscuous VP16 activation domain. Biochemistry 
44, 827–839 (2005). 
 
47. McGovern, S. L., Helfand, B. T., Feng, B. & Shoichet, B. K. A specific mechanism 
of nonspecific inhibition. J. Med. Chem 46, 4265–4272 (2003). 
 
48. Zhang, J., Chung, T. & Oldenburg, K. A Simple Statistical Parameter for Use in 
Evaluation and Validation of High Throughput Screening Assays. Journal of 
Biomolecular Screening 4, 67–73 (1999). 
 
49. Fischer, E. SYNTHESIS OF DEPSIDES, LICHEN-SUBSTANCES AND 
TANNINS. J. Am. Chem. Soc. 36, 1170–1201 (1914). 
 
50. Parker, D. et al. Analysis of an activator:coactivator complex reveals an essential 
role for secondary structure in transcriptional activation. Molecular cell 2, 353–359 
(1998). 
 
51. Wands, A. M. et al. Transient-state kinetic analysis of transcriptional 
activator·DNA complexes interacting with a key coactivator. Journal of Biological 
Chemistry 286, 16238–16245 (2011). 
 
 
 151 
52. Majmudar, C. Y., Wang, B., Lum, J. K., Håkansson, K. & Mapp, A. K. A high-
resolution interaction map of three transcriptional activation domains with a key 
coactivator from photo-cross-linking and multiplexed mass spectrometry. Angew. 
Chem. Int. Ed. 48, 7021–7024 (2009). 
 
53. McMillen, D. A. et al. Identifying regions of membrane proteins in contact with 
phospholipid head groups: covalent attachment of a new class of aldehyde lipid 
labels to cytochrome c oxidase. Biochemistry 25, 182–193 (1986). 
 
54. Sakaguchi, K., Miyakawa, T. & Takeuchi, S. Interaction of benzaldehyde to the 
membrane protein of Escherichia coli. Agricultural and … (1979). 
doi:10.1080/00021369.1979.10863704 
 
55. Triezenberg, S. J., Kingsbury, R. C. & McKnight, S. L. Functional dissection of 
VP16, the trans-activator of herpes simplex virus immediate early gene 
expression. Genes Dev. 2, 718–729 (1988). 
 
56. Parrot, D., Jan, S., Baert, N., Guyot, S. & Tomasi, S. Comparative metabolite 
profiling and chemical study of Ramalina siliquosa complex using LC-ESI-MS/MS 
approach. Phytochemistry 89, 114–124 (2013). 
 
57. Thuerauf, D. J., Morrison, L. E., Hoover, H. & Glembotski, C. C. Coordination of 
ATF6-mediated transcription and ATF6 degradation by a domain that is shared 
with the viral transcription factor, VP16. Journal of Biological Chemistry 277, 
20734–20739 (2002). 
 
58. Lee, H.-K. H., Park, U.-H. U., Kim, E.-J. E. & Um, S.-J. S. MED25 is distinct from 
TRAP220/MED1 in cooperating with CBP for retinoid receptor activation. EMBO 
J. 26, 3545–3557 (2007). 
 
59. Poss, Z. C., Ebmeier, C. C. & Taatjes, D. J. The Mediator complex and 
transcription regulation. Crit. Rev. Biochem. Mol. Biol. 48, 575–608 (2013). 
 
60. Kamei, Y. et al. A CBP integrator complex mediates transcriptional activation and 
AP-1 inhibition by nuclear receptors. Cell 85, 403–414 (1996). 
 
61. Torchia, J. et al. The transcriptional co-activator p/CIP binds CBP and mediates 
nuclear-receptor function. Nature 387, 677–684 (1997). 
 
62. Kawasaki, H. et al. Distinct roles of the co-activators p300 and CBP in retinoic-
acid-induced F9-cell differentiation. Nature 393, 284–289 (1998). 
 
63. Pomerantz, W. C. et al. Profiling the dynamic interfaces of fluorinated transcription 
complexes for ligand discovery and characterization. ACS Chemical Biology 7, 
1345–1350 (2012). 
 
 152 
64. Hoffman, L. M. et al. BMP action in skeletogenesis involves attenuation of retinoid 
signaling. J. Cell Biol. 174, 101–113 (2006). 
 
65. Majmudar, C. Y. et al. Sekikaic acid and lobaric acid target a dynamic interface of 
the coactivator CBP/p300. 51, 11258–11262 (2012). 
 
 
 153 
CHAPTER 4 
Natural Product Extract Screening to Identify Inhibitors of the PEA3 
Transcriptional Activator Subfamily4 
4.1 Abstract  
The PEA3 subfamily of ETS transcriptional activators, comprised of three distinct 
proteins with highly similar transcriptional activation domains, have been reported as 
activator binding partners of the Activator Interaction Domain of Mediator subunit 25. 
Furthermore, this activator•coactivator interaction has been shown to be necessary for 
the full transcriptional activity of the subfamily. Transcriptional programs mediated by 
these activators have been linked to a variety of malignant cellular processes, including 
tumorigenesis and metastasis and as a result represent attractive targets for the 
development of small molecule inhibitors. Given the previously demonstrated success in 
targeting protein-protein interactions between transcriptional activators and the AcID 
motif of Med25 using small molecule natural products in Chapter 3, it was next sought to 
identify novel natural products capable of disrupting the interaction between PEA3 
subfamily members and AcID. Inhibitors that are not reliant on the formation of covalent 
adducts with the domain for their activity, unlike norstictic acid and psoromic acid, are 
particularly attractive as it is hypothesized that non-covalent inhibitors may have 
enhanced selectivity for AcID in a complex cellular context and may offer an alternative 
mechanism of action for the inhibition of AcID-dependent transcriptional processes. 
                                            
4 The work completed in this chapter was a collaborative effort. The primary screen, 
Gal4•DBD counter screen, and MLL•KIX counter screen were completed by Steven M. 
Sturlis and Paul A. Bruno. Extract triage and final hit selection was completed in 
collaboration with Martha Larsen and Steve Vander Roest of the Center for Chemical 
Genomics at the University of Michigan. The selection of strains for regrowth was 
completed by Prof. David H. Sherman,  Pamela Schultz, and Matthew S. Beyersdorf. 
Strains were regrown, fresh extracts prepared, confirmation of activity against the 
ERM•AcID assay, and initial fractionation were completed by Matthew S. Beyersdorf. The 
RARα reporter assay was performed by Paul A. Bruno. 
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Towards this goal, a primary screen of the full Natural Product Extract Library held 
by the Center for Chemical Genomics at the University of Michigan using an optimized 
ERM•AcID fluorescence polarization assay was completed to identify extracts with 
inhibitory activity against this interaction. Ultimately, 332 extracts with potent activity 
against the ERM•AcID interaction were identified, with thirty-one selected for further 
analysis. Fractionation and structural elucidation of the most active extract is currently 
ongoing and will yield potent inhibitors of the ERM•AcID interaction. 
4.2 Introduction 
The PEA3 Subfamily of ETS Transcriptional Activators Has Been Implicated in the 
Progression of Cancer 
 The ETS superfamily of transcriptional activators contains over twenty-five unique 
proteins that are central drivers of a multitude of cellular processes including cell cycle 
regulation and proliferation, tissue remodeling during development, and cellular 
differentiation. 1,2 Given their central importance in cellular processes, the dysregulation 
of members of this superfamily have been implicated in a variety of cancers.3,4 One 
subfamily of ETS transcription factors of particular interest is the PEA3 subfamily, 
composed of three transcriptional activators ETV1/ER81, ETV4/PEA3, and ETV5/ERM, 
which have been reported as important in the progression of a variety of cancers to a 
metastatic phenotype. 5-9 As metastasis is the ultimate cause of mortality in more than 
90% of cancers, the disruption of this process would be an attractive therapeutic strategy 
as it could keep cancers from spreading beyond the primary tumor, allowing for more 
effective eradication of the disease by surgical, chemotherapeutic, or radiological 
means.10 
 For example, in breast cancer the overexpression of one or multiple members of 
the PEA3 subfamily results in an invasive phenotype and subsequent knockdown of the 
overexpressed PEA3 activators can abrogate this phenotype. 9,11 The activators within 
the PEA3 subfamily govern the expression of genes that are important for cellular 
invasion and migration, such as the matrix metalloproteinases (MMP). 12,13 Studies have 
demonstrated that in triple negative breast cancer shRNA mediated knockdown of these 
activators results in reduced expression of genes such as the MMPs, resulting in a less 
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invasive phenotype. Importantly, the most effective inhibition of cellular invasion required 
that all three activators be knocked down, suggesting that there may be significant 
functional overlap between the members of this subfamily in driving metastatic 
processes.14 
 Based on this observation, small molecule inhibitors that are capable of disrupting 
the transcriptional activity of all three activators simultaneously will be more effective than 
designing inhibitors that target the activators individually. One manner by which this could 
be achieved would be by targeting a common activator•coactivator interaction required 
by the three members of the subfamily for transcriptional activity. The N-terminal 
transactivation domains of all three proteins are highly conserved, as shown in Figure 
4.2, suggesting that the coactivators that are recruited during the course of transcriptional 
activation are also conserved.12,13 Consistent with this model, recent studies reveal that 
the three PEA3 activators require the recruitment of the Mediator complex through an 
interaction with the Activator Interaction Domain of Mediator subunit Med25 for full 
transcriptional activity.13,15 The common requirement of this interaction for all three 
activators suggests that this is an attractive point of intervention for the development of 
small molecule inhibitors. Such molecules would be useful as mechanistic probes in the 
further elucidation of the role of the subfamily in the progression of cancer to a metastatic 
phenotype, as well as other cancer progression pathways such as tumorigenesis, and 
may also serve as potential lead compounds in the development of novel therapeutic 
strategies. 
Previous Success in the Disruption of PEA3 Mediated Transcription by Small Molecule 
Inhibitors 
 Despite the demonstrated role of the PEA3 subfamily in the disease progression 
of cancers including breast cancer, prostate cancer, and pancreatic cancer there have 
been few successful attempts at inhibiting the activity of these activators using small 
molecule inhibitors. 5,16-19 Specifically, there are no published reports of inhibitors of ETV4 
nor ETV5 mediated transcriptional processes and only two reports of small molecules that 
directly inhibit the activity of ETV1, via the targeting of the DNA binding moiety.  
 The first of these inhibitors, known as YK-4-279, was reported in 2009 as an 
inhibitor of the fusion protein EWS-FLI1 in Ewing’s Sarcoma.20 FLI1, ETV1, and ERG are 
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all ETS transcription factors that share 60% identity and 80% homology in their primary 
structures, suggesting that YK-4-279 may also function as an inhibitor of ETV1 and 
ERG.21 The compound was tested within the prostate cancer derived cell lines LNCaP 
and VCaP, which are FLI1 negative but ERG and ETV1 positive, and shown to be capable 
of inhibiting the expression of ETV1 and ERG dependent genes to levels comparable to 
siRNA knockdowns of these activators.22 The mechanism by which this inhibition is 
achieved has not yet been elucidated, but surface plasmon resonance (SPR) studies 
demonstrate that YK-4-279 interacts with ETV1 and ERG directly, though it is unclear 
where on the protein this interaction occurs. As a consequence of the inhibition of ETV1 
and ERG dependent transcription, treated LNCaP and VCaP cells demonstrated reduced 
invasive potential and cellular motility, underscoring the role of ETV1 and ERG in cellular 
processes that result in a metastatic phenotype. More recent reports have demonstrated 
that this inhibitor is also capable of inhibiting metastatic phenotypes in vivo in mouse 
xenograft models of prostate cancer.23 The differential effects of YK-4-279 against ETV1 
and ERG are currently unclear, which, coupled with the currently uncharacterized 
mechanism of action, suggests that this inhibitor may not be particularly useful as a 
mechanistic probe for PEA3 dependent transcriptional processes. 
 
 
Figure 4.1- Reported Small Molecule Inhibitors of ETV1 YK-4-279 and BRD32048 are the only 
reported inhibitors of one of the PEA3 subfamily members. 
 The second reported ETV1 inhibitor is BRD32048, which was first reported in 2014 
by Pop and colleagues.24 This inhibitor was identified using a small molecule microarray 
to screen 45,000 small molecules against ETV1 from cellular lysates. Subsequent SPR 
and pull-down experiments using modified BRD32048 demonstrated that the inhibitor 
interacts with ETV1 directly. Genome wide microarray profiling of ETV1 regulated genes 
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demonstrated that BRD32048 was capable of modulating a subset of ETV1 dependent 
genes compared to shRNA mediated knockdown of ETV1 gene expression. As a 
functional consequence of this transcriptional modulation, BRD32048 was shown to 
inhibit cellular invasion in ETV1-dependent prostate cancer model cell lines. Initial studies 
to determine the mechanism by which inhibition of ETV1 is achieved suggest that the 
small molecule blocks acetylation of critical lysine residues responsible for maintaining 
the stability of the protein. As a result of the inhibition of this acetylation event, the protein 
is destabilized and subsequently degraded. Thus, the molecule achieves its inhibitory 
activity by decreasing the half-life of ETV1 within the cell. 
 While these molecules are relatively potent inhibitors of ETV1 capable of 
downregulating the expression of ETV1 dependent genes and inhibiting cellular invasion 
in a number of prostate cancer cell lines, they are specifically targeted to ETV1 and thus 
do not inhibit the other member of the PEA3 subfamily. Given the potential for functional 
overlap between the three members of the subfamily and their differential expression in 
a variety of cancers, the inhibition of a common activator•coactivator interaction required 
by all three should result in more pronounced inhibition of cellular invasion across a 
number of cancer phenotypes. 
PEA3 Transcriptional Activators Interact with AcID 
 A recent report in the literature from the laboratory of Alexis Verger demonstrated 
that the PEA3 subfamily interacts with the AcID motif of Med25 through its N-terminal 
TAD (residues 1-72).13 Notably, the N-terminal TADs of the three PEA3 subfamily 
members are highly conserved, as shown in Figure 4.2, suggesting that they may bind to 
the same coactivator targets. Furthermore, this highly conserved TAD sequence is 
homologous to the VP16 TAD, particularly the C-terminal elements of the VP16 H1 
subdomain. Secondary structure prediction suggested that the N-terminal TAD of 
ETV5/ERM is capable of adopting an α-helical secondary structure, specifically between 
residues 42 and 57 of the TAD, which was later supported by NMR solution structures of 
the TAD in complex with AcID.15 Thus, the PEA3 subfamily was hypothesized to bind to 
the AcID motif in a similar fashion as VP16 given the common structural features between 
the two TADs. 
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Figure 4.2- Structural Features of the N-terminal TAD of the PEA3 Subfamily (A) The three 
activators that comprise the subfamily have N-terminal TADs that are highly conserved. (B) The N-
terminal TAD of the PEA3 subfamily is homologous to the TAD of VP16, specifically the C-terminal 
portion of the VP16 H1 subdomain as shown in this sequence alignment. Identical residues are 
highlighted in gray and conserved residues are indicated by a black box. (C) Secondary structure 
prediction of the conserved PEA3 TAD suggests it is capable of adopting an α-helical secondary 
structure. 
 In order to demonstrate that this interaction actually occurs within the cell, Verger 
and colleagues first performed a GST pull-down assay and demonstrated that the N-
terminal TAD of ERM was capable of precipitating Med25 from cellular lysates and the 
GST-tagged AcID was capable of precipitating ERM from cellular lysates. Subsequent 
ITC experiments using ERM(38-68) and purified AcID protein demonstrated that the two 
interact with an apparent Kd value of approximately 540 nM. Additional precipitation 
experiments using Halo-tagged ERM(1-72) demonstrated that this interaction did not 
disrupt the interaction between Med25 and the rest of the Mediator complex, indicating 
that this interaction would result in the recruitment of the full Mediator complex to ERM 
target genes. In support of this conclusion, reporter assays using a Gal4(DBD)-ERM(1-
72) fusion protein demonstrated that the interaction between the ERM TAD and Med25 
was required for full transcriptional activity. The repressive effect of overexpression of 
AcID on the activity in the reporter assay demonstrates that the TAD interacts with AcID, 
while the repressive effect of overexpression of the VWA domain of Med25 demonstrates 
that the recruitment of the Mediator complex through the AcID interaction is required for 
full activity. This hypothesis was further supported by the observation that the siRNA 
mediated knockdown of Med25 and overexpression of a ∆AcID Med25 mutant did not 
recover transcriptional activity. Finally, this interaction was shown to relevant in the 
context of endogenous gene expression as the siRNA mediated knockdown of Med25 
resulted in decreased expression of the ETV4 target gene MMP-1 that could not be 
recovered by overexpression of ETV4 as determined by RT-qPCR. The same level of 
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decreased expression required that all three PEA3 subfamily members be knocked down, 
suggesting that there may be significant functional overlap between the subfamily 
members. 
 Mutational experiments of critical residues within the VP16 H1 and H2 binding sites 
suggest that the PEA3 TADs bind to a surface within the H1 binding site, which was 
corroborated later by 1H,15N-HSQC chemical shift perturbation studies of the domain in 
complex with the TAD.15 The degree of overlap between the binding site for VP16 H1 and 
the PEA3 TAD is still unclear and it is possible that the two TADs bind to similar but 
distinct surfaces of the domain. 
 Building from the results first published by Verger and colleagues, we developed 
a fluorescently labeled peptide of ERM(38-68) for use in fluorescence polarization assays 
and found that it bound to AcID with comparable affinity to the values reported by Verger, 
as shown in Figure 4.3.13 Truncation of this peptide to include only the purported α-helical 
sequence resulted in an approximately five-fold decrease in affinity, suggesting that the 
α-helix likely contributes significantly to the interaction with the AcID motif, consistent with 
previous observations of the interaction between the VP16 TAD and AcID. Furthermore, 
the N-terminal TADs of PEA3 family members contain a tryptophan residue (W53) that 
was suspected to function as a hot-spot within the interaction as tryptophan residues 
account for 21% of all characterized hot-spots.25 Mutation of this tryptophan to bulky 
hydrophobic amino acids such as phenylalanine or leucine, relatively conservative 
mutations, resulted in an approximately six fold decrease in affinity. Mutation of the 
tryptophan to alanine, a less conservative mutation, resulted in greater than fifteen-fold 
decrease in affinity, underscoring the importance of this residue in the interaction with 
AcID. With a ∆∆G of 1.6 kCal/mol, the W53A mutation does not qualify this tryptophan 
residue as a hotspot, but nevertheless suggests that the ERM•AcID interaction may utilize 
more focused contacts than the previously discussed VP16•AcID interaction. 
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Figure 4.3- Truncation and Mutation of the ERM TAD The VP16 TAD was truncated to produce a 
peptide containing the putative α-helix alone, which bound with only moderately attenuated affinity. An 
important tryptophan residue was mutated to generate three distinct peptides and their affinity for the 
domain was assessed. (Completed by Nicholas Foster) 
Thus, given the demonstrated functional importance of the PEA3•AcID interactions 
for the full transcriptional activity of this subfamily of activators and the similarity in 
molecular features of the interactions to those of VP16•AcID, we hypothesized that this 
interface represents an attractive point of intervention for small molecule inhibitors. We 
further hypothesize that the inhibition of this interaction will result in a decrease in the 
transcriptional activation of PEA3 target genes, as demonstrated for siRNA mediated 
knockdown of Med25, and a concomitant decrease in metastatic potential in a variety of 
cancer-derived cell lines. Furthermore, the inhibition of this interaction using small 
molecule inhibitors will also allow for greater perspective of the role of these activators in 
other cancer-related cellular processes including tumorigenesis. 
Natural Products as Small Molecule Inhibitors 
 In order to identify inhibitors of the PEA3•AcID interaction, we performed a high-
throughput screen of the Natural Product Extract Library held by the Center for Chemical 
Genomics at the University of Michigan against a fluorescence polarization based assay 
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of the interaction between the TAD of the PEA3 subfamily member ERM and the AcID 
motif. This library contains natural product extracts (NPE) from remarkably diverse 
organisms including terrestrial and marine microorganisms, plants, and lichens amongst 
other organisms of interest and has been successfully screened to identify natural product 
inhibitors against a variety of targets. 26-29 The genetic diversity of the organisms from 
which these NPEs have been collected indicates that the library likely contains small 
molecules with structural diversity that is unmatched by more traditional small molecule 
screening libraries which generally contain flat, aromatic, and relatively simple chemical 
scaffolds. Thus, the structural diversity contained within the NPE library dramatically 
increases the opportunity to find potent inhibitors of activator•coactivator interactions as 
the more complex and three-dimensional structures typical of natural products are more 
likely to match the complex topography common to most protein-protein interaction 
interfaces. 30,31 The identification of the depsidones norstictic acid and psoromic acid as 
inhibitors of AcID-dependent activator•coactivator interactions in Chapter 3 supports this 
hypothesis and the decision to screen the NPE library. 
 The NPE library was screened using an iterative screening strategy that our group 
has previously utilized to identify selective allosteric inhibitors of KIX-dependent 
activator•coactivator interactions.28 A generalized version of this protocol is shown below 
in Figure 4.4. Following primary screening of the NPE library, false positives and extracts 
with reactive or overly fluorescent components are removed from follow up study using 
standard screening techniques. Subsequently, active extracts are tested for inhibition 
against a series of functionally related protein-protein interactions, such as the interaction 
between activators and the KIX or CH3 domains of CBP/p300 or activator interactions 
with TBP. These selectivity filters remove extracts that are not selective for the coactivator 
target of interest and eliminates inhibitors that merely function as TAD or general 
amphipathic α-helix mimetics. By selecting only extracts that are selective for the 
coactivator of interest, the preliminary hits are enriched for extracts that likely contain 
allosteric inhibitors of the target. 
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Figure 4.4- Generalized Iterative Screening Workflow for Allosteric Inhibitors of Activator-
Coactivator Interactions Following primary screening and the removal of false positives or 
fluorescent/reactive extracts, initial hits are tested against a series of functionally related protein-
protein interactions to identify inhibitors that are selective for the target of interest. Preliminary hits are 
subsequently fractionated and the structures of the active components elucidated. 
 In screening the ERM•AcID interaction, counter screens that test initial hits against 
Gal4•DNA and MLL•KIX interactions were utilized in order to identify selective inhibitors 
of ERM•AcID. We hypothesize that these inhibitors will likely be allosteric modulators of 
the AcID domain, allowing for the disruption of the broad ERM•AcID interaction surface. 
4.3 Results and Discussion 
Norstictic Acid and Psoromic Acid Inhibit ERM•AcID Interactions in vitro 
 Given the functional importance of the PEA3 subfamily of ETS transcription factors 
in a variety of cancers and the apparent importance of the interaction between the TADs 
of these activators and the AcID motif of Med25 for their activity, we sought to identify 
small molecule inhibitors that are capable of disrupting this interaction. These inhibitors 
will be useful mechanistic probes in exploring the role of the PEA3 subfamily in the 
establishment of metastatic phenotypes, the role of these activators in tumorigenesis, and 
could ultimately lead to the development of novel therapeutic strategies. In order to 
demonstrate that this interaction is targetable, the ability of norstictic acid and psoromic 
acid to inhibit the interaction between the ERM TAD and AcID was tested in vitro. The 
results of these experiments are shown below in Figure 4.5. It was hypothesized that 
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these molecules would be effective in disrupting ERM•AcID interactions as well as 
VP16•AcID interactions because of the similarity in the sequences of the two activators 
and the fact that both TADs contain α-helices that are responsible for the majority of their 
affinity, suggesting that they likely bind to similar surfaces of AcID using similar features 
for molecular recognition. Furthermore, this hypothesis is consistent with published NMR 
solution structures of the domain in complex with ERM and VP16. 15,32-34 
 
Figure 4.5- Inhibition of ERM•AcID Interaction by Norstictic Acid and Psoromic Acid Competitive 
inhibition experiments of the ERM(38-68)•AcID interaction by psoromic acid and norstictic acid. Curves 
represent the mean values of three independent experiments with vertical error bars representing the 
standard deviation of the relative fraction of tracer bound at the indicated concentration of small 
molecule. Curves were fit using GraphPad Prism 5. 
 Consistent with this hypothesis, the ERM•AcID interaction is effectively inhibited 
by both psoromic acid and norstictic acid with IC50 values of 32.5 µM and 6.4 µm, 
respectively. Interestingly, psoromic acid, which inhibits the VP16(438-464)•AcID and 
VP16(465-490)•AcID interactions with IC50 values of 1.8 µM and 3.9 µM, is significantly 
less potent against the ERM•AcID interaction than VP16•AcID interactions. Norstictic 
acid, conversely, inhibits the ERM•AcID interaction with approximately the same potency 
as the VP16•AcID interactions. This observation suggests that the two molecules may 
bind to distinct surfaces of the AcID motif, given their differential activity against ERM and 
VP16 interactions. Alternatively, these data may suggest that norstictic acid induces more 
significant structural changes within the activator binding surfaces of AcID, resulting in 
the enhanced potency of this inhibitor against a number of activators. More importantly, 
these results suggest that, like the VP16•AcID interaction, the ERM•AcID interaction can 
be effectively targeted by small molecule inhibitors. 
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 Subsequent to these observations, we next sought to demonstrate that norstictic 
acid has a similar mode of action against the ERM•AcID interaction as the VP16•AcID 
interaction by exploring the effects of lysine to arginine mutations on the activity of the 
inhibitor. These mutations, first described in Chapter 3, remove the ability of the inhibitor 
to bind covalently to specific surfaces on the AcID motif within the purported VP16 H1 
and H2 binding sites and resulted in four to six fold decreases in potency when multiple 
residues were mutated within the same binding surface.  
 
Figure 4.6- Effect of AcID Lysine to Arginine Mutations on Norstictic Acid Inhibition of 
ERM•AcID (A) Direct binding of the fluorescent ERM(38-68) tracer to a variety of AcID constructs. (B) 
norstictic acid inhibition of the fluorescent ERM(38-68) interaction with a variety of AcID constructs. 
K518, K519, and K520 are located within the H2 binding site, while K411 and K413 are located within 
the H1 binding site. KK518RR refers to the double mutant K518R/K519R and KKK518RRR refers to 
the triple mutant K518R/K519R/K520R. Curves represent the mean values of three independent 
experiments with vertical error bars indicating the standard deviation of the fraction of tracer bound at 
the indicated protein or small molecule concentration. Curves were fit with GraphPad Prism 5. 
 The lysine to arginine mutations generally had little impact on the ability of 
ERM(38-68) to bind to AcID, with the exception of K411R/K413R, which resulted in an 
approximately four-fold decrease in affinity of the tracer for the domain. This mutation did 
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not perturb the binding of VP16(438-454), which is hypothesized to bind to a similar 
surface as ERM on AcID within the H1 binding site, but perturbed the binding of 
VP16(467-488) more strongly than ERM. Thus, these data may suggest that ERM binds 
to an AcID surface that is unique from either of the surfaces used by VP16(438-454) or 
VP16(467-488). The mutations K519R and K520R moderately enhanced the affinity of 
the ERM tracer for the domain, and this indicate allosteric communication between the 
binding sites within the domain that has been discussed previously in Section 3.3. 
 The lysine to arginine mutations moderately attenuated the inhibitory activity of 
norstictic acid against the ERM•AcID interaction, consistent with previous observations 
for the effects of the mutations on the inhibition of VP16•AcID interactions. This 
attenuation ranges from approximately two to three fold decreases in potency and 
requires that multiple lysine residues be mutated within the same interaction surface 
similar to the results obtained against the VP16•AcID interactions. The effects on potency 
against the ERM•AcID interaction were not as pronounced as the effects on potency 
against VP16•AcID interactions, indicating that the mechanism of action against the ERM 
interaction may be distinct from that of VP16. For example, the ERM•AcID interaction may 
be less dependent upon electrostatic contacts or the ERM binding site may be far enough 
removed from the mutated lysine residues that the loss of covalent labeling at those sites 
does not as adversely effect the inhibition of ERM. 
ERM•AcID High-Throughput Screening Assay Development 
 Following the encouraging observation that small molecule inhibitors of the 
VP16•AcID interaction also demonstrated activity against the ERM•AcID interaction in 
vitro, we decided to complete a full high-throughput screen against the ERM•AcID 
interaction. In order to accomplish this, a fluorescence polarization based assay adapted 
for a high-throughput screening format using the ERM(38-68) fluorescent tracer and 
purified AcID protein was developed and optimized. The data shown in Figure 4.2 C 
demonstrates that this tracer binds to AcID over a broad dynamic range spanning 
approximately 160 mP. This span is slightly less than the approximately 210 mP observed 
for the VP16(465-490) tracer used in the screen discussed in Chapter 3, but more than 
sufficient. Building from this result, the dependence of the dynamic range of the binding 
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assay on the fluorescent tracer concentration was assessed by comparing direct binding 
assays completed with 20 nM fluorescent ERM(38-68) tracer and 50 nM tracer. Both 
assays gave identical dynamic ranges and Kd values, indicating that the assay is not 
dependent upon tracer concentration and that 20 nM tracer is sufficient for the screen. 
 Subsequently, the effects of DMSO and low concentrations of NP-40 were tested 
on the behavior of the assay, as was previously completed in the development of the 
VP16(465-490)•AcID HTS assay reported in Chapter 3. Compounds are added to the 
assay plates from concentrated DMSO stocks and NP-40 at concentrations of 0.001% 
v/v are added to assay buffer in order to minimize protein loss from non-specific 
interactions with the liquid-handling equipment used to prepare the assay plates and also 
minimizes protein or small molecule aggregation in solution. Furthermore, the behavior 
of the ERM(38-68)•AcID assay was tested over time in order to demonstrate that it is 
stable over the time period that a typical HTS assay requires. These results are shown 
below in Figure 4.7. 
 
Figure 4.7- Assay Stability Time Course, DMSO Effects, and NP-40 Effects on Tracer Affinity 
The effects of NP-40 and DMSO on the ERM(38-68)•AcID interaction was assessed over time. Curves 
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represent the mean values of three independent experiments with vertical error bars representing the 
standard deviation of the polarization at the indicated protein concentration. Curves were fit and 
analyzed using GraphPad Prism 5. (With Paul A. Bruno) 
 NP-40 at a concentration of 0.001% v/v has a minimal effect on the binding of 
ERM(38-68) to the AcID motif as the Kd value determined in the presence of NP-40 is 
within error of the value in the absence of the detergent. DMSO at a concentration of 5% 
v/v has a slightly stronger effect as the Kd value in the presence of DMSO at this 
concentration approximately doubles the value in the absence of the solvent. However, 
this effect is not so strong as to preclude the use of this assay in a HTS format and actual 
concentrations of DMSO used in the primary screen will be 1% v/v, unless higher 
concentrations of extracts are required to identify lead molecules. Finally, the assay is 
highly stable at room temperature over extended periods of time as the Kd values were 
within error of one another at one hour and twenty hours. Thus, these results indicate that 
an FP assay based upon the interaction between a fluorescent tracer of the ERM TAD 
and AcID is well suited to a high-throughput screening format. 
 The final experimental parameter to optimize prior to beginning the screen was the 
concentration of AcID protein to use in the assay. It was hypothesized that a concentration 
of 850 nM AcID protein would be appropriate given that this is the concentration of protein 
used in the VP16•AcID screen and the similarity in the affinities of VP16(465-490) and 
ERM(38-68) for AcID. In order to demonstrate that this concentration of protein was 
optimal for use in an HTS assay the Z’ score was calculated using Equation 3.1 for a 384-
well plate containing 182 wells each of the positive and negative controls. In this assay 
format, the positive control is the polarization of a sample containing the fluorescent ERM 
tracer only and the negative control is the polarization of a sample containing the 
fluorescent ERM tracer in complex with AcID. This experiment resulted in a calculated Z’ 
score of 0.69 for 850 nM AcID, above the 0.6 threshold for an assay to be defined as high 
quality.35 Thus, these experiments suggest that the ERM•AcID assay is well adapted to 
HTS and suitably optimized. 
Given the demonstrated efficacy of natural products, specifically depsides and 
depsidones, against the VP16•AcID interaction and prior observations of molecules of 
this class inhibiting CBP/p300 KIX domain-dependent activator•coactivator interactions, 
we decided to screen the Natural Product Extract (NPE) library held by the Center for 
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Chemical Genomics (CCG) at the University of Michigan rather than more traditional 
small molecule libraries.28 It was hypothesized that the greater structural diversity 
afforded by natural products may produce a greater number of lead molecules than the 
more ‘flat’ and drug-like structures typical of small-molecule compound libraries. As a 
proof of principle to support this hypothesis, a plate (Plate #2041) from the NPE library 
rich in extracts collected from lichens was tested for inhibition against the ERM•AcID FP 
assay. This plate was selected as lichens contain a significant number of depsides and 
depsidones and thus, based on the evidence presented in Chapter 3 that compounds of 
these classes may be privileged for the inhibition of activator•coactivator interactions, 
would presumably yield a relatively high hit rate. 36-40 
 
Figure 4.8- Lichen Rich Natural Product Extracts Tested Against ERM•AcID (A) Campaign view 
of NPE Library Plate 2041 showing percent inhibition against the ERM•AcID interaction on the y-axis. 
(B) Heat map of NPE Library Plate 2041 showing inhibition against the ERM•AcID interaction. (With 
Paul A. Bruno) 
 The ERM•AcID FP assay performed well in testing against a representative 
segment of the NPE library with a Z’ score of 0.88. Using the least stringent definition of 
a hit, a percent inhibition that is three standard deviations above the negative control 
(approximately 8% inhibition in this case), the lichen rich extracts produced 151 hits, for 
a hit rate of 47.2%. This rate is significantly higher than would be desired given the 
necessary work to validate extracts as hits and to elucidate active components from the 
extracts. Therefore, if such a rate were to manifest itself in the full NPE Library screen, 
alternative criteria to select lead compounds would be necessary. However, it was 
hypothesized at the time that this hit rate was most likely inflated and not necessarily 
indicative of expected performance in a full primary screen of the NPE library on the basis 
A B
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that this plate is rich in lichen extracts and thus likely contains numerous extracts 
abundant in depsides and depsidones. Additionally, these results serve as further 
evidence consistent with the hypothesis that depsides and depsidones are privileged for 
the inhibition of activator•coactivator interactions. 
 Taken together, the above data demonstrate that we have developed a 
fluorescence polarization based assay of the interaction between the TAD of the 
transcriptional activator ERM and the AcID motif of Med25. Furthermore, this assay was 
tested against a small portion of the NPE library held by the CCG and found to perform 
well in a high-throughput format, though it was hypothesized at the time that alternative 
criteria for selecting hits might ultimately be necessary. 
Primary Screen of NPE Library Against the ERM•AcID Interaction 
 Following the successful development of an assay of the ERM•AcID interaction 
that is well adapted to high-throughput screening and the encouraging results of a limited 
pilot screen of one NPE library plate against the target, a primary screen of the full NPE 
library against the ERM•AcID interaction was completed. In total, 33,400 unique extracts 
were tested against the assay, providing a significant number of potential lead extracts 
for further validation and analysis. The results of the primary screen, which had an 
average Z’ score of 0.78, are presented as a campaign view in Figure 4.9 below. 
	
 
Figure 4.9- Campaign View of the ERM•AcID Primary Screen A full campaign view of the primary 
screen of the NPE library against the ERM•AcID interaction. Positive control well measurements 
(tracer and protein, treated with DMSO) are shown as red points, negative control well measurements 
Lichen	Derived	Extracts
NPE	Library	Part	1 NPE	Library	Part	2
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(tracer only, treated with DMSO) are shown as blue points, and wells treated with 200 nL of extract 
are shown as green points. The x-axis represents the sample number, and the y-axis indicates the 
percent inhibition relative to positive and negative controls. The library has been broken into two parts 
given the dramatic shit in hit rates midway through the library. NPE library plates 2041 and 2042 are 
believed to be rich in extracts derived from lichens and are marked as such beneath the campaign 
view. (With Paul A. Bruno) 
 A striking feature of the primary screen campaign view is the dramatic shift in hit 
rates and extract efficacy midway through the screen. This is not a result of experimental 
error in preparing the assay or a failure of the assay design, but is instead a result of 
different methods for extract preparation. As the NPE library collection grew at a rapid 
pace, protocols for preparing extracts were changed from performing crude extraction 
with three solvents to using only two solvents. Furthermore, growth and media conditions 
were modified for extracts sourced from some bacterial strains, which may have had an 
effect on the production of certain natural products within these organisms. As a result, 
the extracts from the second part of the library now contain a greater number of 
component molecules at higher concentrations, which results in significantly inflated hit 
rates, as has been observed in other screens of the NPE library according to CCG 
personnel. Thus, when the initial hit filtering to select extracts for follow up study required 
the establishment of two distinct sets of criteria for the two subsets of the NPE library.  
Beyond the dramatic difference in hit rates for the two methods of extract 
preparation within the library, there was also a significant increase in the hit rate near the 
end of the first part of the library. This segment of the library contains library plates 2041 
and 2042, which are rich in extracts prepared from lichens and thus are likely abundant 
in depsides and depsidones. Thus, given the demonstrated efficacy of molecules 
belonging to these classes at inhibiting activator•coactivator interactions and the 
previously observed hit rate of plate 2041 against the ERM•AcID interaction, this high hit 
rate is not unexpected. 
Overall, the least stringent definition of a hit as being an extract that demonstrated 
a percent inhibition greater than three standard deviations above the negative control, 
would result in 14,575 hits against the ERM•AcID interaction with 3,636 of them coming 
from the first portion of the library and 10,939 coming from the second portion. This would 
result in an overall hit rate of 43.6%, with individual hit rates of 20.8% and 68.4% for the 
first and second portions of the library, respectively. Obviously, such a vast number of 
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hits could not be sufficiently analyzed in follow up studies, requiring that alternative criteria 
be developed to select leads for further analysis. 
For the first portion of the library, a hit was defined having greater than or equal to 
30% inhibition of the ERM•AcID interaction relative to controls, identifying 557 extracts, 
or inhibition that was greater than or equal to three standard deviations above all wells on 
the plate, identifying an additional 166 extracts. Including extracts that are above three 
standard deviations of all wells on the plate ensured that a mix of extracts from a variety 
of organisms was selected by advancing the best extracts from each plate, even if the 
activity was below the 30% threshold. Of the 723 total extracts identified from the first 
portion of the library, eleven were eliminated on the basis of excess fluorescence within 
the well and 43 were eliminated on the basis of promiscuity, with a promiscuous 
compound defined as being active in more than 30% of screens it is tested against. Thus, 
the first portion of the NPE library ultimately provided 669 compounds for further analysis 
and a significantly more manageable hit rate of 3.4%. 
For the second portion of the library, an extract was defined as a hit if it had greater 
than 60% inhibition or extracts that displayed inhibition greater than three standard 
deviations above all wells on the plate, again to provide extracts from a mix of plates and 
not just those compounds with the greatest apparent efficacy. These criteria identified 
1240 extracts, 265 of which were eliminated on the basis of excess fluorescence within 
the well and 42 of which were eliminated on the basis of promiscuity. Thus, the second 
portion of the library identified 933 extracts for further analysis and a hit rate of 5.8%. 
Combined, the two portions of the NPE library provided 1,602 extracts, with an overall hit 
rate of 4.8%, for follow up study that spanned a range of efficacies and were derived from 
a number of genetically diverse organisms. Overall, the identification of 1,602 hits using 
stringent selection criteria suggests that the AcID motif may be significantly more 
targetable than typical coactivator proteins. For example, a high-throughput screen of the 
NPE library against the interaction of the transcription factor MLL with the KIX domain of 
CBP/p300 identified 280 hits for follow up studies, where a hit was defined as greater 
than 20% inhibition of the interaction.28 
The next step in the screening strategy was to further filter the 1,602 extracts 
identified in the primary screen by eliminating those samples that demonstrated 
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significant native fluorescence or quenched the fluorescent ERM tracer, as these 
phenomena could interfere with the read-out of the FP assay. Additionally, the primary 
extracts were retested against the ERM•AcID interaction and eliminated if they did not 
inhibit the assay greater than 50% in two out of the three wells, which served as a method 
to eliminate false positives and also functioned as an additional potency filter. The results 
of these three confirmation experiments are presented below in Figure 4.10. 
 
Figure 4.10- Confirmation of Hits from the ERM•AcID Primary Screen   (A) The top 1,602 extracts 
identified in the primary screen against the ERM•AcID interaction were retested in triplicate to remove 
false positives from final hit selection. (B) Intrinsic fluorescence of lead extracts identified in the primary 
screen against the ERM•AcID interaction. (C) Fluorescence quenching of the ERM tracer by lead 
extracts identified in the primary screen against the ERM•AcID interaction. (With Paul A. Bruno) 
 In order to complete these confirmation experiments, the order of addition of assay 
components was reversed. Specifically, extracts were first added to buffer and intrinsic 
fluorescence was measured, the fluorescent ERM tracer was added second and the plate 
was measured for fluorescence quenching, and AcID protein was added last at which 
point samples were incubated for thirty minutes and the polarization of the samples were 
B C
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measured. Following these assays, the 1,602 lead extracts were filtered to reduce the 
number of hits carried on to final analysis.  
The first criterion used in this filtering step was potency, wherein only extracts that 
achieved a greater than 50% inhibition in all three of the retest samples were selected as 
hits, based on the results shown in Figure 4.10 A. The potency filter eliminated 888 of the 
initial lead extracts, leaving 714 extracts for further consideration.  
The second criterion used for initial hit filtering was significant intrinsic fluorescence 
of compounds within the extracts. Extracts that resulted in a fluorescence signal of greater 
than 40,000 mAU in the parallel channel in two of the three retest samples were 
eliminated from further consideration, a value which represents a 40% increase over the 
fluorescence of the tracer alone or a 15% increase over the fluorescence of the tracer in 
complex with the AcID protein. Though, fluorescent compounds may still be capable of 
inhibition, the potential for false positives as a result of interference in the FP results 
requires that these extracts be removed from follow up study.41 Using this criterion for 
significant intrinsic fluorescence, 406 extracts were flagged as fluorescent from the full 
sample of 1,602 extracts; of the 714 extracts that passed the potency filter, an additional 
254 were removed following the intrinsic fluorescence filter, resulting in 460 extracts 
selected for further analysis. 
The final criterion used to further filter the additional hits identified in the primary 
screen was the ability of the extracts to quench the fluorescence of the tracer, could result 
in the identification of false positives as hits.41 Specifically, extracts were added to sample 
wells that contained tracer only and were eliminated from further consideration if their 
ability to quench the fluorescein tag of the tracer resulted in greater than 30% inhibition 
in two of the three retest samples, corresponding to three standard deviations above the 
negative control. On the basis of this criterion, twenty-seven of the 1,602 extracts 
identified in the primary screen were found to significantly quench the fluorescent tracer, 
though these twenty-seven extracts had been eliminated from further consideration by 
the previous potency and intrinsic fluorescence filtering steps. Ultimately, the initial hit 
filtering completed on the 1,602 extracts identified for follow up study from the primary 
screen resulted in 460 extracts that were validated as inhibitors of the ERM•AcID FP 
assay.  
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Counter-Screens to Eliminate Non-selective ERM•AcID Inhibitors 
 In order to increase the likelihood that extracts with natural products that selectively 
target the ERM•AcID interaction were identified and to further refine the number of 
extracts identified as hits against this target, a series of counter screens to eliminate 
inhibitors that do not specifically inhibit AcID-dependent interactions were completed. The 
first counter screen utilized to further filter the selected extracts was an FP assay based 
upon the interaction between the DNA binding domain of the yeast transcriptional 
activator Gal4, spanning residues 1-100, and a fluorescently tagged DNA oligomer. This 
assay, developed by our laboratory, uses a fluorescein-tagged twenty base pair DNA 
oligomer containing a consensus Gal4 DBD binding sequence that has been annealed to 
an unlabeled complementary oligonucleotide to simulate the binding of the DBD to 
double-stranded DNA.42 Furthermore, our lab has previously employed this assay in a 
high-throughput format as a counter-screen in the discovery of natural product inhibitors 
of the interaction between transcriptional activators and the KIX domain of CBP/p300.28 
In particular, it was hypothesized that this was an attractive assay to use as a counter 
screen in order to eliminate natural products that may interfere with the ability of 
transcriptional activators to bind to their requisite DNA sequences. Furthermore, DNA-
protein interactions are partially driven by electrostatic interactions, similar to the 
interaction between activators and AcID.43 Thus, a counter screen against an 
electrostatically driven interaction would also be useful in eliminating NPEs that 
indiscriminately interfere with electrostatic contacts. Prior to completing the counter 
screen, we first ran a direct binding experiment of the fluorescent DNA oligomer to Gal4(1-
100) in order to ensure that the assay performed as expected in our hands, as shown in 
Figure 4.11. 
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Figure 4.11- Direct Binding of Fluorescent DNA Oligomer to Gal4(1-100) The Gal4(1-100)•DNA 
FP assay was tested prior to use as a counter screen by performing a direct binding experiment of the 
oligomer to the Gal4 DBD. The curve represents the mean values of three independent experiments 
with vertical error bars representing the standard deviation of the polarization in the presence of the 
indicated concentration of protein. Curves were fit using GraphPad Prism 5. (Completed by Paul A. 
Bruno) 
 The assay performed as expected with a calculated Kd value of 25 ± 15 nM, which 
was within error of previously reported values for the affinity of this interaction.42 
Subsequently, this FP assay was utilized in a high-throughput format as a counter screen 
against the 1,602 extracts identified as hits from the primary screen of the NPE library 
against the ERM•AcID interaction, as shown in the campaign view of Figure 4.12. The 
screen was completed using 50 nM Gal4(1-100) and 10 nM fluorescent DNA tracer with 
extracts tested in triplicate, per conditions previously utilized in counter screening 
applications.28 
Direct Binding of DNA to Gal4(1-100)
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Figure 4.12- Gal4(1-100)•DNA Counter Screen of Lead Extracts from ERM•AcID Primary Screen 
Campaign view of Gal4(1-100)•DNA counter screen against the 1,602 extracts selected from the 
primary screen of the ERM•AcID interaction. Red points represent positive controls (fluorescent tracer 
only), blue points represent negative controls (tracer in complex with Gal4(1-100)), and green points 
represent samples treated with NPEs. The percent inhibition of the assay is shown on the y-axis. 
(Completed with Paul A. Bruno) 
 Given the relatively large standard deviation within the negative controls of 13% 
inhibition, a threshold of 50% inhibition in at least two of the three samples was set for the 
elimination of an extract from further consideration. Using this criterion, 291 extracts were 
identified as inhibitors of the Gal4(1-100)•DNA interaction. Of those extracts, only ten had 
not been previously eliminated from further consideration by the initial hit filtering steps, 
leaving 450 extracts for further analysis.  
One striking result observed in the campaign view of this counter screen is the 
number of extracts that demonstrated a significant negative percent inhibition. One 
potential explanation for this phenomenon is that the dynamic range of this assay spans 
approximately 35 mP, which is significantly smaller than the dynamic range of the primary 
assay. Furthermore, the standard deviation for the polarization values of the positive and 
negative controls were 4.23 mP and 4.82 mP, respectively, further obfuscating the 
analysis by decreasing the effective dynamic range. A final potentially confounding factor 
is that the concentration of fluorescent tracer in this assay was only 10 nM, as opposed 
to the 20 nM concentration used in the primary screen. Thus, even though the fluorophore 
was identical between the two assays, the higher gain setting of the plate reader for the 
Gal4(1-100)•DNA interaction likely increased the noise within the measurements as the 
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intrinsic fluorescence of compounds within the extracts would be elevated relative to the 
fluorescence of the tracer at higher gain settings. 
Subsequently, a counter screen of the 1,602 extracts identified in the primary 
screen against the interaction between the transcription factor MLL and the KIX domain 
of CBP/p300 was completed. This assay was previously used as a method for 
demonstrating the selectivity of norstictic acid and psoromic acid against activator•AcID 
interactions in Chapter 3 and has also been previously utilized in a high-throughput 
screening application by our laboratory.28 This assay is an attractive counter screen as 
our lab and others have extensively studied the interaction and demonstrated that it relies 
upon α-helical secondary structure within the TAD of MLL and that the binding of the TAD 
occurs through a two-step mechanism wherein the unstructured TAD makes preliminary 
contact to KIX before properly folding into an α-helix, similar to several of the features 
common to activator•AcID interactions.42,44 Thus, this counter screen was useful for the 
elimination of generic TAD mimetics and enriched the preliminary hits for inhibitors 
selective for the AcID motif. Prior to completing the counter screen, a direct binding 
experiment of the fluorescent MLL tracer to the KIX domain, as well as a direct binding 
experiment of a fluorescent tracer derived from the TAD of the transcriptional activator 
CREB (pKID), were completed in order to ensure that the assay performed well in our 
hands, as shown in Figure 4.13.  
 
Figure 4.13- Direct Binding of MLL and pKID to the KIX Domain of CBP/p300 (A) Structure of the 
KIX domain in complex with the TADs of MLL and CREB indicating their preferred binding sites on the 
domain. (B) Direct Binding of the MLL and pKID fluorescent tracers to the KIX protein. Curves 
represent the mean values of three independent experiments with vertical error bars representing the 
standard deviation of the polarization value at the indicated concentration of protein. Curves were fit 
with GraphPad Prism 5. 
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 The direct binding assays performed as expected with the calculated Kd values of 
both tracers within error of previously reported values, indicating that the assay performs 
well in our hands with the prepared fluorescent tracer and purified protein. 42,45,46 The 
MLL•KIX FP assay was then used as a counter screen against the 1,602 extracts 
identified in the primary screen of the ERM•AcID interaction, as shown in Figure 4.14. 
The counter screen was completed with 10 µM KIX protein and 25 nM fluorescent MLL 
tracer with extracts tested in triplicate, consistent with conditions utilized in a previous 
screening application.28 
 
Figure 4.14- MLL•KIX Counter Screen of Lead Extracts from ERM•AcID Primary Screen 
Campaign view of the MLL•KIX counter screen against the 1,602 extracts selected from the primary 
screen of the ERM•AcID interaction. Red points represent positive controls (fluorescent tracer only), 
blue points represent negative controls (tracer in complex with KIX), and green points represent 
samples treated with NPEs. The percent inhibition of the assay is shown on the y-axis. (Completed 
with Paul A. Bruno) 
 The MLL•KIX counter screen assay performed as expected with a Z’ score of 0.72, 
indicating a high quality assay. A threshold of 35% inhibition in at least two of the three 
replicates was set in order to eliminate an extract from further consideration. This value 
was selected in order to eliminate extracts with relatively potent inhibition of KIX-
dependent activator•coactivator interactions. On the basis of this criterion, 85 extracts 
were identified as inhibitors of the MLL•KIX interaction, with 33 of these extracts not 
having been eliminated by previous filtering steps, leaving 417 extracts for further analysis 
with demonstrated selectivity for AcID-dependent interactions. The relatively low hit rate 
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of the extracts identified from the primary screen is consistent with previous observations 
that targeting the KIX domain of CBP/p300 is challenging.28 
 As a last filter prior to determining the final list of confirmed hits, extracts that had 
been active in greater than ten screens of the NPE library were eliminated in order to 
remove overly promiscuous natural products. Using this criterion, an additional eighty-five 
extracts that had not been removed by previous filtering steps were eliminated for a final 
total of 332 unique natural product extracts that harbor activity against the ERM•AcID 
interaction. 
Summary of Hit Filtering and Selection of Extracts for Strain Regrowth 
 Following the filtering of lead extracts identified in the primary screen and the 
completion of counter screens to identify selective inhibitors of the ERM•AcID interaction, 
we identified 332 unique extracts as containing potential inhibitors of the interaction 
between the ERM TAD and the AcID motif of Med25. The full process that identified the 
final extracts for fractionation and active component elucidation in summarized below in 
Figure 4.15. A full listing, with relevant screening statistics, of the 332 extracts identified 
as inhibitors of the ERM•AcID interaction is presented in Appendix B. 
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Figure 4.15- Schematic Representation of Final Hit Selection The full battery of screens and 
counter screens utilized to identify natural product extracts containing small molecule inhibitors of the 
ERM•AcID interaction is represented schematically. 
 Subsequent to the final hit selection, a subset of extracts was selected to 
characterize further. This process requires extracting new samples from the original 
organisms, either by growing new cultures of microorganisms or obtaining intact samples 
of macroscopic organisms depending on the extract, retesting the crude extracts for 
activity to confirm that the active component in the NPE library is not a result of 
degradation of the sample, fractionating the extract to isolate and purify the active 
components, and finally elucidating the structure of the active molecule. Subsequent to 
this characterization, the genome of the organism that provided the natural product is 
submitted for sequencing in order to definitively identify the organism and to potentially 
identify the biosynthetic pathways responsible for the production of the molecule.47 In 
collaboration with the laboratory of Prof. David Sherman at the University of Michigan, 
who are responsible for preparation of the extracts for the NPE library and have significant 
experience with the isolation and structural characterization of natural products, thirty-one 
NPE Library Primary Screen of ERM•AcID
33,400 Extracts Tested
Hit (NPE Library Part 1): ≥ 30% Inhibition
Hit (NPE Library Part 2): ≥ 60% Inhibition
OR
Hit (Full Library): ≥ 3 St. Dev. by Plate
EXCEPT
Full Library: Parallel Fluorescence ≥ 40,000 mAU
Hit Validation and Counter Screening
1,602 Extracts Tested
Intrinsic Fluorescence Filtering
Hit: ≤ 40,000 mAU in Parallel Channel
460 Validated Extracts
254 Extracts Eliminated
Fluorescence Quenching Filtering
Hit: ≤ 30% Inhibition by Quenching
460 Validated Extracts
0 Extracts Eliminated
Potency and Reproducibility Filtering
Hit: ≥ 50% Inhibition in Triplicate
714 Validated Extracts
888 Extracts Eliminated
Inhibition of MLL•KIX Interaction
Hit: ≥ 35% Inhibition in Duplicate
417 Validated Extracts
33 Extracts Eliminated
Inhibition of Gal4(DBD)•DNA Interaction
Hit: ≥ 50% Inhibition in Duplicate
450 Validated Extracts
10 Extracts Eliminated
Validated Extracts for Follow Up Study
332 Extracts
Selected for regrowth on basis of genetic diversity, 
range of inhibitory activity against ERM•AcID, and 
strain accessibility 
Strains Regrown and Compounds Extracted
31 Strains Regrown and Extracted
Promiscuity Filter
Hit: Active in ≤ 10 other screens
332 Validated Extracts
85 Extracts Eliminated
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extracts were selected for further characterization. These extracts were selected on the 
basis of: (1) genetic diversity by selecting extracts from across the NPE library collected 
from a variety of locales across the globe, (2) a range of inhibitory activity against the 
ERM•AcID interaction to identify a variety of molecules with distinct modes of action that 
occupy distinct chemical space, and (3) accessibility of the organism that yielded the initial 
extract held within the NPE library. These thirty-one extracts were all derived from 
microorganisms, with the majority believed to belong to the Actinomyces genus of the 
actinobacteria class, though the specific species of the organisms has not yet been 
determined. This observation is encouraging given that marine actinomycetes have been 
demonstrated as a remarkable source of diverse biologically active natural products with 
unique anti-microbial and anti-cancer activities.48 The Sherman lab was in possession of 
spore stocks of all thirty-one organisms and was able to reconstitute pure cultures 
following standard protocols. 28,29,49,50 The thirty-one strains regrown for further analysis, 
along with their activities in the various screens and counter screens, are shown below in 
Table 4.1. 
Table 4.1- Strains Selected for Regrowth with Filtering Statistics 
 
Strain CCG	Identifier
%	ERM•AcID	
Inhibition
Parallel	
Fluorescence
%	Fluorescence	
Quenching
%	Gal4(DBD)•DNA	
Inhibition
%	MLL•KIX	
Inhibition Promiscuity	Filter
A 06131R SID-142998 56.3 35430 -6.1 -47.7 -7.9 2
B 12587-2Z SID-143065 83.2 37498 3 -32.8 9.1 5
C 32294-H1Z SID-142868 82.1 35766 3.1 -103.6 13 5
D 34908-2Z SID-142867 83.2 35799 -3.7 -108.6 8.2 2
E 54916-1C SID-141597 75 38438 -26.3 -101.4 7.9 4
F 78874R SID-143056 65.5 36958 -6.5 -10.1 9.9 3
G 91085R SID-142997 85.2 35887 -8.6 30.6 7.1 4
H PAN101-7I SID-32305 74.1 38049 -20.4 -88.2 9.1 5
I 41445-N3I SID-31523 80.4 39056 -13.9 -28.7 13.3 8
J 44293-N1N SID-33128 77.8 38368 -21.9 -90.4 -0.9 8
K 71961N SID-69043 70 38711 -14.3 -53.4 3.4 5
L 41429-N1I SID-68148 82.3 39516 -28.6 -85.4 4.1 4
M 39040-1I SID-27645 64.4 39972 -15.1 -68.2 1.7 6
N 68157N SID-32195 55.1 36047 -3.1 -20.7 -1 3
O 36180-2N SID-31830 57.4 37403 -10 -16.4 3.9 4
P 49546-N4I SID-68085 52 39949 -14.7 -52.7 -4.3 8
Q 52245-N2N SID-33188 101.7 35559 -18.2 11.9 20 5
R 58236N SID-140604 79.9 33193 -0.3 -7.9 9.3 5
S 65440-N1N SID-68121 70 36498 -10.3 -34.5 6.5 3
T 71747Z SID-142274 81.2 38212 -16.8 -74 10.8 4
U 86815-N2Z SID-143008 102.5 38773 -8.9 -19.8 40.1 4
V 5538-A2N SID-33057 86.2 38027 -19 -54.9 7.1 7
W 18163-N13Z SID-142848 96.6 33242 3.9 -66.3 27.3 4
X 24815-H2Z SID-142871 90.4 33750 32.7 -33 24.1 4
Y 55270-N4N SID-68851 73.7 39860 -18.4 -60.5 2.8 4
Z 74604-N1I SID-140915 74 38202 -18.3 -45.9 6.1 3
AA 82349-N4I SID-140914 73.6 37721 -13.3 -39.7 7.2 2
BB 20731-H2I SID-18195 77 34656 -5.9 -4.5 2.2 10
CC 73401N SID-140641 57 36386 -10.6 -46.6 5.1 2
DD 67360-N9N SID-68685 70.1 35517 -3.6 -18 11.4 4
EE 84215-1I SID-141865 100.5 35290 -4.5 -33.1 16.7 3
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For the purpose of ease in identifying these strains and their extracts in subsequent 
experiments and discussions, they have each been assigned a letter ranging from A to 
EE, as indicated in Table 4.1. 
Confirmation of Crude Natural Product Extract Activity from Regrown Organisms 
 Following the growth of pure samples of the organisms selected for further 
analysis, the cultures were homogenized and crude natural product extracts were 
prepared using a variety of solvents including acetone (solvent 1), methanol (solvent 2), 
dichloromethane (solvent 3), and a one to one mixture of acetone and methanol (solvent 
4). The extracts from each organism were thus named by the letter corresponding to the 
strain from which the extract was derived and the number of the solvent used to prepare 
the extract. In total, sixty-nine crude extracts were prepared, and the ability of these 
extracts to inhibit the ERM•AcID interaction was determined by testing their ability to 
inhibit the ERM•AcID FP assay used in the primary screen in duplicate. The results of this 
experiment are presented as a heat map in Figure 4.16. 
 
Figure 4.16- Heat Map of Inhibition by Extracts from Regrown Organisms Against the ERM•AcID 
Interaction The letter in the extract identifier at the top of each well refers to the 31 strains from Table 
4.1, while the number after the dash in the identifier refers to the solvent used to extract compounds 
from the homogenized organism. Specifically, 1 refers to extraction with acetone, 2 refers to extraction 
with methanol, 3 refers to extraction with dichloromethane, and 4 refers to extraction with a one to one 
mixture of acetone and methanol. The percent inhibition of the ERM•AcID FP assay by the crude 
extracts are given below the extract identifier. All measurements were made in duplicate and percent 
inhibitions were calculated using positive (ERM tracer only) and negative (ERM•AcID treated with 
DMSO) controls. (Completed by Matthew S. Beyersdorf) 
A-1 A-2 A-3 B-1 B-2 B-3 C-1 C-2 C-3 D-1 D-2 D-3
43.3 67.1 69.4 66.6 85.3 85.2 64.1 87.2 89.4 55.2 60.3 80.8
E-1 E-2 E-3 F-1 F-2 F-3 G-1 G-2 G-3 H-4 H-3 I-4
54.0 94.8 94.5 46.4 86.3 89.3 95.4 97.4 101.0 47.5 59.7 72.8
I-3 J-4 J-3 K-4 K-3 K-2 L-3 M-4 M-3 N-4 N-3 O-4
73.7 57.7 45.0 56.1 53.8 49.5 59.7 79.6 61.3 68.3 40.0 33.0
O-3 P-4 P-3 Q-4 Q-3 R-4 R-3 S-4 S-3 T-4 T-3 U-4
45.2 80.7 83.9 4.5 7.7 68.3 42.8 64.7 38.3 70.0 45.3 57.8
U-3 V-4 V-3 W-4 W-3 X-4 X-3 Y-4 Y-3 Z-4 Z-3 AA-4
37.5 56.9 80.5 36.9 32.4 32.4 66.6 64.1 51.5 43.2 96.8 63.5
AA-3 BB-4 BB-3 CC-4 CC-3 DD-4 DD-3 EE-4 EE-3
65.5 59.3 35.5 71.9 31.5 92.4 44.9 38.0 -2.1
%	Inhibition: 0	- 20% 20.1	- 40	% 40.1	- 60	% 60.1	- 80	% >	80	%
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 With the exception of strains O, Q, W, and EE, all strains produced at least one 
extract with greater than fifty percent inhibition of the ERM•AcID interaction, the previously 
used threshold in selecting the final hits from the screen. In particular, strain Q appears 
to have been a false positive given that the two extracts prepared from this organism 
inhibited the interaction by 4.5% and 7.7%. A possible explanation for this false positive 
result could be that the compounds within the extract degraded into more active 
molecules over time. Generally, the freshly prepared crude extracts were able to 
reconstitute the activities against the ERM•AcID interaction that were observed during the 
original screen of the interaction. Of particular note, strain G appears to be especially 
promising as all three extracts prepared from this organism resulted in greater than 95% 
inhibition when tested against the ERM•AcID FP assay. Overall, these data demonstrate 
that a majority of the strains selected for further analysis likely contain active natural 
products capable of inhibiting the interaction between the ERM TAD and AcID and that 
additional filtering will be necessary prior to selecting an extract for fractionation and 
structural elucidation of the active components. 
 In addition to testing the extracts from the regrown strains against the ERM•AcID 
FP assay, they were also tested against the retinoic acid receptor α (RARα) reporter 
assay first described in Chapter 3. This assay was performed in order to determine which 
extracts contained component molecules that were cell permeable and capable of 
disrupting AcID-dependent interactions in a complex cellular context. Med25 acts as an 
important coactivator contact for RARα that allows for the simultaneous recruitment of the 
Mediator complex as well as the HAT CBP.51,52 The recruitment of CBP and its requisite 
HAT activity is a requirement for full transcriptional activity of RARα.53-55 Therefore, it was 
hypothesized that, similar to results obtained with norstictic acid and psoromic acid in 
Chapter 3, that the freshly prepared extracts would be capable of decreasing RARα 
activity in a luciferase reporter assay if they contained component small molecules that 
were cell permeable and capable of inhibiting the interaction between the N-terminus of 
CBP and the AcID motif of Med25. The results of testing the extracts prepared from 
regrown strains against the RARα reporter assay are shown below in Figure 4.17. 
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Figure 4.17- Inhibition by Crude Natural Product Extracts from Regrown Organisms Against a 
RARα Luciferase Reporter Assay (A) Schematic of the reporter assay and the assembly of the PPI 
network at the Retinoic Acid Response Element. NPEs are hypothesized to inhibit the interaction 
between CBP and the AcID motif of Med25. (B) Inhibition of luciferase expression by the indicated 
crude NPE. The dashed lines represent the negative control, which is activity following induction by 
retinoic acid in the absence of inhibitor. All values represent biological duplicates. (Completed by Paul 
A. Bruno) 
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 A number of the extracts tested against the RARα reporter assay demonstrated 
significant inhibition of RARα activation. In particular, the dichloromethane extracts of 
strains G and P demonstrated significant inhibition in the assay, suggesting that the active 
molecules within these extracts are cell permeable and capable of inhibiting AcID-
dependent interactions in a cellular context. This activity is consistent with the results of 
these extracts against the ERM•AcID FP assay. Beyond these samples, a number of 
other extracts also demonstrated inhibition of the reporter assay, though not as effectively 
as extracts from strains G and P. Additionally, a number of other extracts showed no 
inhibition of the reporter assay, such as extracts from strains A, B, E, F, I, J, K, L, M, O, 
Q, R, T, U, and Y suggesting that the active molecules within these extracts may not be 
cell permeable. Another possibility for the lack of activity in these extracts is that little is 
known about the binding surfaces required for the interaction between the N-terminus of 
CBP and AcID and it is possible that this interaction occurs at a site on AcID unique from 
the binding site for ERM. Thus, these extracts may be selective for inhibition of the 
ERM•AcID interaction. Additional experiments will be completed to further explore the 
activity of these extracts in disrupting ERM•AcID interactions in a cellular context. Despite 
these caveats, this experiment is useful in selecting an initial extract for fractionation and 
structural characterization. Specifically, the dichloromethane extract of strain G, sample 
G-3, was selected for fractionation in order to identify and structurally characterize the 
active small molecule inhibitor, which is currently ongoing. 
Fractionation of the extract by sequential preparative HPLC purification has 
identified three fractions that harbor significant activity against the ERM•AcID interaction 
(>75% inhibition). Additional HPLC purification of these fractions is being completed to 
ensure that they have been purified to homogeneity, at which point the material will be 
analyzed and structurally characterized using a combination of mass spectrometry, NMR, 
and x-ray crystallography if the chemical properties of the purified natural products permit. 
Furthermore, genomic DNA has been isolated from cultures of strain 91085R and 
submitted for sequencing in the hopes of identifying the specific species of the strain and 
to potentially identify the biosynthetic pathway by which the natural product of interest is 
produced. Following the final purification and structural elucidation, a full battery of in vitro 
experiments will be completed to more thoroughly characterize the activity of these 
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molecules against the ERM•AcID interaction and to identify the mechanism of action for 
the observed inhibition. Subsequent experiments will explore the use of the natural 
products as chemical probes in a cellular context in order to explore the role of Med25 in 
PEA3 transcriptional programs and the effect of this interaction on specific functional and 
phenotypic responses within a variety of cancer-derived cell lines. These experiments are 
described in greater detail in the Future Directions section of Chapter 5. 
4.4 Conclusions 
The driving hypothesis for the work completed within this chapter was that novel 
natural products capable of inhibiting the interaction between the transcriptional activation 
domains of the PEA3 subfamily of ETS transcription factors and the AcID motif of Med25 
could be identified by screening a library containing approximately 33,000 natural product 
extracts against this interaction. The discovery of such molecules is an attractive goal as 
these inhibitors will be useful molecular probes for the elucidation of the role of the PEA3 
subfamily in cellular processes related to cancer progression, specifically metastasis and 
possibly tumorigenesis, and could potentially serve as lead molecules in the development 
of novel therapeutic strategies. Though the depsidones norstictic acid and psoromic acid 
have been previously identified as covalent inhibitors of AcID-dependent 
activator•coactivator interactions, it is hypothesized that alternative non-covalent 
inhibitors of AcID-dependent interactions may allow for greater selectivity in a complex 
cellular environment and may be capable of inhibiting activator interactions with the 
domain through an alternative mechanism of action. In order to identify these inhibitors, 
an iterative screening strategy was utilized that eliminates generic TAD mimetics and 
identifies molecules that selectively target AcID-dependent interactions, thereby 
increasing the likelihood of identifying conformationally selective inhibitors of the domain. 
Towards this goal, the ability of norstictic acid and psoromic acid to inhibit the 
interaction between the TAD of the PEA3 subfamily member ERM and AcID was tested 
using an FP assay to demonstrate that the interaction could be effectively targeted and 
inhibited by small molecules. Both molecules were capable of inhibiting the ERM•AcID 
interaction, albeit with reduced potency in the case of psoromic acid relative to the 
inhibition of the VP16•AcID interaction as shown in Chapter 3. These data suggest that 
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the ERM•AcID interaction can be inhibited by small molecule natural products and that 
the TADs of PEA3 subfamily members may interact with AcID at a surface unique from 
the VP16 interaction surface. Thus, in addition to inhibiting activator•AcID interactions 
through unique mechanisms of action, novel natural product derived inhibitors identified 
in a screen may also be significantly more potent for inhibition of ERM•AcID interactions 
by more directly interfering with the AcID surfaces required for interaction with the PEA3 
subfamily. By targeting the AcID motif instead of the activators themselves inhibitors will 
perturb the activity of all three PEA3 subfamily members, mitigating functional 
redundancy within the subfamily in the regulation of transcriptional programs related to 
the progression of several cancers. 
Following the observation that the ERM•AcID interaction could be effectivity 
inhibited by small molecules, a fluorescence polarization based assay of this interaction 
was developed and optimized for high-throughput screening. Subsequently, a primary 
screen of the NPE library against the optimized ERM(38-68)•AcID assay resulted in 1,602 
hits that were selected for further filtering steps. These extracts were selected using 
criteria significantly more stringent than is typically used in screens at the CCG in order 
to reduce the number of lead extracts to a manageable quantity. The fact that such 
measures were necessary suggests that the ERM•AcID interaction is likely far more 
amenable to small molecule inhibitors than is typical for protein-protein interactions in 
general and activator•coactivator interactions in particular. For comparison, a screen of 
the interaction between the transcription factor MLL and the KIX domain of CBP/p300 
identified only 280 lead extracts using far laxer criteria. Had the same criteria been used 
to select lead extracts against the ERM•AcID interaction, there would have been in excess 
of 10,000 extracts for follow up study. Interestingly, a number of extracts resulted in 
enhanced binding of the ERM peptide to the AcID motif, suggesting that it may be possible 
to identify positive modulators of the interaction that enhance the affinity of the activator 
for AcID. The mechanism by which this occurs is unclear, but significant possibilities are 
that they stabilize the domain in a conformation that is preordered for interaction with the 
ERM TAD or stabilize the ERM•AcID complex and reduce the rate of dissociation. Such 
modulators would be useful as probes to further explore the role of ERM and the other 
PEA3 activators in malignant processes. 
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These initial hits were then filtered to remove false positives and extracts 
containing molecules with significant intrinsic fluorescence or the ability to quench the 
fluorescent tracer were removed from further consideration. The hits from the primary 
screen were then tested for inhibition of the interaction between the DNA binding domain 
of Gal4 and a fluorescently labeled DNA oligonucleotide in order to eliminate extracts that 
may interfere nonspecifically with the binding of transcriptional activators to DNA. 
Furthermore, this counter screen also likely eliminated extracts that non-specifically 
interfere with electrostatic interactions, as electrostatics play a central role in protein-DNA 
interactions, which was advantageous given the previously demonstrated importance of 
electrostatic contacts in activator•AcID interactions. This counter screen eliminated only 
a small number of extracts from further consideration, indicating that they may be 
selective for the AcID motif. 
The primary screen hits were then screened against the interaction between the 
TAD of the transcription factor MLL and the KIX domain of CBP/p300 in order to remove 
extracts containing natural products that non-specifically inhibit activator•coactivator 
interactions or mimic amphipathic TADs, resulting in extracts that are selective for the 
AcID motif and likely exert their activity through allosteric mechanisms of action. 
Additional selectivity experiments will be completed with the final natural products in order 
to further confirm their selectivity against the AcID motif. In particular, testing the inhibition 
against other ERM•coactivator interactions will demonstrate that the molecules are not 
functioning as mimics of the ERM TAD. 
As a final filter, overly promiscuous extracts, specifically those that were active in 
greater than ten screens of the NPE library, were also precluded from further analysis in 
an effort to identify selective inhibitors of the ERM•AcID interaction. Following these 
filtering steps, we were ultimately left with 332 extracts that were identified as inhibitors 
of the ERM•AcID FP assay. This large number of confirmed hits, which were selected 
using relatively stringent criteria, further underscores the hypothesis that AcID may be a 
significantly more targetable coactivator domain than is typical. 
In collaboration with the laboratory of Prof. David Sherman at the University of 
Michigan, thirty-one strains primarily belonging to the bacterial genus Actinomyces were 
regrown and freshly extracted material was prepared from each. These strains were 
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selected from the list of 332 hits on the basis of genetic diversity by selecting extracts 
from across the NPE library collected from different geographic locales, a range of 
inhibitory activities against the ERM•AcID interaction in order to identify inhibitors with 
distinct mechanisms of action, and the availability of pure spore stocks of the strain. The 
freshly prepared extracts were then tested for their ability to inhibit the ERM•AcID FP 
assay, with all but one extract demonstrating strong inhibition of the interaction, 
suggesting a low false positive hit rate for the extracts identified in the screen. 
Subsequently, the extracts were tested for the ability to inhibit the activity of an AcID-
dependent reporter assay in order to identify extracts with active cell-permeable natural 
products capable of inhibiting AcID-dependent interactions in a cellular environment. 
Strain 91085R demonstrated excellent inhibition of the ERM•AcID FP assay and the 
AcID-dependent reporter assay, resulting in the selection of the extracts from this strain 
for initial fractionation and structural elucidation of the active natural products. These 
natural products will then be further validated and employed as mechanistic probes to 
further study the role of the PEA3 subfamily in malignant process such as metastasis and 
tumorigenesis, as discussed in the Future Directions section of Chapter 5.  
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4.5 Materials and Methods 
Plasmids 
Plasmid pET21b-Med25(394-543)-His6, henceforth referred to as pAcID-His6, was a 
generous gift from Patrick Cramer.33 Plasmids encoding mutant AcID variants used in the 
mutational analysis experiments described in Figure 4.6 were described previously in 
Chapter 3. pGL3-RARE-luc was purchased from Addgene and was as previously 
described.56 pCMV-β-Gal and pBSSK (non-coding plasmid) were kind gifts from Jorge 
Iñiguez-Lluhí. 
 
Protein expression and purification 
AcID (Med25394-543) protein was expressed and purified together with Paul A. Bruno. 
Plasmid pAcID-His6 was transformed into heat-shock competent Rosetta pLysS cells 
(Novagen), streaked onto LB Agar plates containing ampicillin and chloramphenicol, and 
incubated at 37 °C overnight. The next evening, a 25 mL Terrific Broth (TB) starter culture 
with 0.1 mg/mL ampicillin and 0.034 mg/mL chloramphenicol was then inoculated with a 
colony selected from the LB Agar plate and incubated at 37 °C overnight. The next 
morning, 5 mL from the starter culture was added to 1L TB containing ampicillin and 
bacteria were grown at 37 °C to an OD600 of 0.8. Temperature was reduced to 18 °C and 
protein expression was induced upon addition of IPTG to a final concentration of 0.5 mM.  
Cells were incubated overnight at 18 °C. The 1 L cultures were then collected and 
centrifuged at 6000xg for 20 mins at 4 °C. Cell pellets were stored at -80 °C prior to 
purification. The harvested pellet was thawed on ice and resuspended in 20 mL of lysis 
buffer (50 mM phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 6.8). Cells were 
then lysed by sonication on ice and cellular lysates were cleared by centrifugation at 9500 
rpm for 20 min at 4 °C. The supernatant lysate was then added to Ni-NTA beads (Qiagen) 
and incubated for 1 hour at 4 °C. The resin was pelleted by centrifugation at 2500 rpm for 
2 min at 4 °C and washed with wash buffer (50 mM phosphate, 300 mM sodium chloride, 
30 mM imidazole, pH 6.8) a total of five times. Protein was then eluted with 2 mL of elution 
buffer (50 mM phosphate, 300 mM sodium chloride, 400 mM imidazole, pH 6.8) a total of 
three times. Eluent was then pooled and purified by cation exchange FPLC (Source 15S, 
GE Healthcare) using a gradient of Buffer B (50 mM phosphate, 100 mM NaCl, 1 mM 
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DTT, pH 6.8) in Buffer A (50 mM phosphate, 1 mM DTT). The FPLC purified protein was 
then dialyzed into storage buffer (10 mM phosphate, 50 mM NaCl, 10% v/v glycerol, 
0.001% v/v NP-40, pH 6.8) overnight, concentrated, aliquoted, and stored at -20 °C.  Final 
protein was greater than 90% pure as determined by coomassie stained polyacrylamide 
gel. Protein concentration was determined by UV-Vis spectroscopy using an extinction 
coefficient, ε = 22,460 M-1cm-1. 
 
Expression and purification of the AcID mutants used in Figure 4.6 was described 
previously in Chapter 3. 
 
Peptides 
All peptides used in the experiments presented within this chapter have been described 
previously in Chapter 2. 
 
Fluorescence polarization dose-response inhibition assays 
Inhibition assays were performed in triplicate with a final sample volume of 20 μL in a low 
volume, non-binding, 384-well black plate (Corning). A complex of the indicated 
fluorescent tracer and protein was prepared at a 2x concentration such that 50% of the 
tracer was bound following dilution onto the assay plate. Small molecule inhibitors were 
diluted in assay buffer (10 mM PBS, 100 mM NaCl, 10 % glycerol, 0.001% NP-40 pH 6.8) 
to the desired concentration and serially diluted two-fold on the assay plate to a final 
volume of 10 µL. 10 µL of the pre-formed fluorescent tracer-protein complex was then 
added to each well for a final volume of 20 µL. An additional well containing tracer only 
was prepared and used to determine optimal gain settings on the plate reader. Samples 
were incubated for thirty minutes at room temperature before fluorescence polarization 
was measured on a Pherastar plate reader with polarized excitation at 485 nm and 
emission intensity measured through a parallel and perpendicularly polarized 535 nm. 
Polarization values were converted to relative fraction bound and plotted opposite the log 
of inhibitor concentration using GraphPad Prism 5 and curves were fit with a non-linear 
regression using the built-in equation “log(inhibitor) vs response – variable slope” from 
which the IC50 value was calculated. 
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Fluorescence polarization direct binding assays 
Direct binding assays were performed in triplicate with a final sample volume of 20 μL in 
a low volume, non-binding, 384-well black plate (Corning). FITC-labeled peptides were 
diluted in assay buffer (10 mM PBS, 100 mM NaCl, 10 % glycerol, 0.001% NP-40 pH 6.8) 
to a centration of 40 nM. 10 µL of AcID protein was serially diluted two-fold on the 384-
well plate for the number of data points indicated for each experiment using assay buffer. 
10 µL of the diluted fluorescent peptide stock was then added to each well of diluted 
protein for a final tracer concentration of 20 nM. An additional well containing 10 µL buffer 
and 10 µL fluorescent peptide was prepared for use as a ‘tracer only control’ to determine 
optimal gain settings on the plate reader. Samples were then incubated for 30 minutes at 
room temperature before fluorescence polarization was measured on a Pherastar plate 
reader with polarized excitation at 485 nm and emission intensity measured through a 
parallel and perpendicularly polarized 535 nm. A binding isotherm that accounts for ligand 
depletion (assuming a 1:1 binding model of peptide to ACID) was fit to the observed 
polarization values as a function of ACID to obtain the apparent equilibrium dissociation, 
Kd:  
 𝑦 = 	𝑐 + 𝑏 − 𝑐 	×	 𝐾* + 	𝑎 + 𝑥 − (𝐾* + 𝑎 + 𝑥)/ − 4𝑎𝑥2𝑎  
 
Where “a” and “x” are the total concentrations of fluorescent peptide and AcID, 
respectively, “y” is the observed anisotropy at a given AcID concentration, “b” is the 
maximum observed anisotropy value, and “c” is the minimum observed anisotropy value. 
Each data point is an average of three independent experiments with the indicated error 
representing the standard deviation of the three replicates. All curves and calculations 
were generated using GraphPad Prism 5. 
 
Primary screen of NPE library against ERM•AcID 
The primary screen was completed together with Paul A. Bruno at the Center for Chemical 
Genomics (University of Michigan) in collaboration with Martha Larsen and Steve Vander 
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Roest. Assays were performed in a final volume of 20 µL in a low volume, non-binding, 
black 384- well plate (Corning) and read by plate reader (Pherastar) with polarized 
excitation at 485 nm and emission intensity measured through parallel and 
perpendicularly polarized 535 nm filters. Final concentration of AcID protein was 850 nM, 
final concentration of Flo-ERM(38-68) was 20 nM, and 200 nL of NPEs were assayed 
with a final DMSO concentration of 1% v/v.  10 µL of AcID protein at a concentration of 
1.7 µM was added to columns 1-22 of the assay plate by Multidrop dispenser (Thermo 
Fisher Scientific). Next, compounds were added to columns 3-22 of the assay plate and 
DMSO was added to columns 1-2 (negative control, AcID•ERM complex) and 23-24 
(positive control, VP16 tracer only) by pin tool. Finally, Flo-ERM(38-68) was added to all 
wells at a concentration of 40 nM. Plates were incubated for thirty minutes at room 
temperature and read by plate reader as described above with gain settings determined 
based on a well from columns 23-24 (tracer only). Data was published to and analyzed 
using MScreen (http://mscreen.lsi.umich.edu). 
 
Primary screen hit filtering 
Assays to validate extracts identified in the primary screen and initial hit filtering was 
completed with Paul A. Bruno at the Center for Chemical Genomics (University of 
Michigan). Hits selected for further study following the primary screen were assayed in 
triplicate using a slightly modified protocol from the primary screen. Assays were 
performed in a final volume of 20 µL in a low volume, non-binding, black 384- well plate 
(Corning) and read by plate reader (Pherastar) with polarized excitation at 485 nm and 
emission intensity measured through parallel and perpendicularly polarized 535 nm filters. 
Final concentration of AcID protein was 850 nM, final concentration of Flo-ERM(38-68) 
was 20 nM, and 200 nL of NPEs were assayed with a final DMSO concentration of 1% 
v/v. Rather than adding compounds to the plate by pin tool as described previously, 200 
nL of the desired extracts were pre-plated with the cherry-picker on the assay plates in 
columns 3-22, while 1-2 and 23-24 contained 200 nL of DMSO. 5 µL of buffer was added 
to all 24 columns and the plate was read to assess the intrinsic fluorescence of 
compounds within the extracts. Subsequently, 5 µL of Flo-ERM(38-68) at a concentration 
of 80 nM was added to all 24 columns. The plate was incubated for 30 minutes at room 
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temperature and the polarization of the plate was read to assess the ability of the extracts 
to quench the fluorescence of the tracer. Finally, 10 µL of AcID protein at a concentration 
of 1.7 µM was added to columns 1-22, while 10 µL of buffer was added to columns 23-
24. Plates were incubated an additional thirty minutes at room temperature and 
polarization was assessed as described previously. Data was published to and analyzed 
using MScreen. 
 
Gal4-DNA direct binding assay 
The Gal4-DNA direct binding assay was completed following the direct binding protocol 
described above and as previously reported.42 
 
Gal4(1-100)•DNA counter screen 
The Gal4 counter screen was completed with Paul A. Bruno at the Center for Chemical 
Genomics (University of Michigan). Assays were performed in a final volume of 20 µL in 
a low volume, non-binding, black 384- well plate (Corning) and read by plate reader 
(Pherastar) with polarized excitation at 485 nm and emission intensity measured through 
parallel and perpendicularly polarized 535 nm filters. Final concentration of Gal4(1-100) 
protein was 50 nM, final concentration of Flo-DNA(TCCGGAGGACTGTCCTCCGG) was 
10 nM, and 200 nL of NPEs were assayed with a final DMSO concentration of 1% v/v. 
Rather than adding compounds to the plate by pin tool as described previously, 200 nL 
of the desired extracts were pre-plated with the cherry-picker on the assay plates in 
columns 3-22, while 1-2 and 23-24 contained 200 nL of DMSO. 10 µL of 100 nM Gal4(1-
100) was added to columns 1-22 and 10 µL of buffer was added to columns 23-24. 
Subsequently, 10 µL of 20 nM Flo-DNA was added to all 24 columns and plates were 
incubated at room temperature for thirty minutes prior to measuring the polarization of the 
samples. Data was published to and analyzed using MScreen. 
 
KIX direct binding assays 
The MLL•KIX and pKID•KIX direct binding assays were completed following the direct 
binding protocol described above and as previously reported.46 
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MLL•KIX counter screen 
The MLL•KIX counter screen was completed with Paul A. Bruno at the Center for 
Chemical Genomics (University of Michigan). Assays were performed in a final volume of 
20 µL in a low volume, non-binding, black 384- well plate (Corning) and read by plate 
reader (Pherastar) with polarized excitation at 485 nm and emission intensity measured 
through parallel and perpendicularly polarized 535 nm filters. Final concentration of KIX 
protein was 10 µM, final concentration of Flo-MLL was 25 nM, and 200 nL of NPEs were 
assayed with a final DMSO concentration of 1% v/v. Rather than adding compounds to 
the plate by pin tool as described previously, 200 nL of the desired extracts were pre-
plated with the cherry-picker on the assay plates in columns 3-22, while 1-2 and 23-24 
contained 200 nL of DMSO. 10 µL of KIX protein at a concentration of 20 µM was added 
to columns 1-22, while 10 µL of buffer was added to columns 23-24. Subsequently, 10 µL 
of Flo-MLL at a concentration of 50 nM to all 24 columns and plates were incubated at 
room temperature for thirty minutes prior to measuring the polarization of the samples. 
Data was published to and analyzed using MScreen. 
 
Regrowth of strains identified in screen 
Strains were regrown by Matthew S. Beyersdorf (Mapp/Sherman Labs, University of 
Michigan). Strains were selected for regrowth following consultation with Pamela Schultz 
(University of Michigan) and completed following standard procedures. 
 
Retesting extracts from regrown strain 
Fresh extracts were prepared from the regrown strain following standard procedures by 
Matthew S. Beyersdorf. The freshly prepared extracts were then tested against the 
ERM•AcID FP assay following conditions analogous to the conditions used in the primary 
screen (20 µL total volume, 850 nM AcID, 20 nM ERM tracer) at concentrations of 0.3 
mg/mL.  
RARα luciferase reporter assay 
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The RARα luciferase reporter assay was performed as described in Chapter 3 by Paul 
A. Bruno. Natural products were assayed at a final concentration of 0.3 mg/mL, co-dosed 
with retinoic acid at a final concentration of 1 µM. 
 
HPLC fractionation of NPEs  
NPE fractionation was completed by Matthew S. Beyersdorf. The crude extract of strain 
91085R was fractionated by preparative HPLC on a C18 column using a gradient of 10% 
to 30% acetonitrile in water over fifteen minutes followed by a gradient of 30% to 45% 
acetonitrile in water over thirty minutes. Active material was then further sub-fractionated 
on a preparative C18 column using a gradient of 15% to 17.5% acetonitrile in water over 
twenty minutes followed by a gradient of 17.5% to 35% acetonitrile in water over ten 
minutes. Isolated fractions were then lyophilized to a fine powder, resuspended in DMSO 
at a concentration of 0.75 mg/mL, and assayed for inhibition of the ERM•AcID FP assay 
as described above.  
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CHAPTER 5 
Conclusions and Future Directions 
5.1 Conclusions 
The guiding hypothesis for the work described in this thesis was that we could 
identify selective small molecule inhibitors that perturbed the interactions of various 
transcriptional activators with the Activator Interaction Domain (AcID) of Med25. This 
hypothesis was made on the basis that AcID is comprised of a unique fold not previously 
identified in any known coactivator proteins and found in only one other protein of 
unknown function. Towards this goal, we first explored the molecular underpinnings that 
define the interaction of transcriptional activators with this unique coactivator domain in 
order to determine whether activators interact with AcID in a unique fashion from typical 
activator•coactivator interactions and to define features that may be effectively exploited 
in an inhibitor discovery strategy. We next completed a small high-throughput screen of 
known biologically active molecules and natural products and identified several molecules 
belonging to the depside and depsidone classes of natural products. Experiments 
validating these molecules as AcID-targeted inhibitors and preliminary elucidation of their 
mechanism of action were also completed. We finally described a screen of the full 
Natural Product Extracts Library held by the Center for Chemical Genomics at the 
University of Michigan against the interaction of a family of transcriptional activators linked 
to metastatic processes in cancer and the AcID motif in order to identify potent small 
molecule inhibitors that will be useful as mechanistic probes in exploring these processes. 
In order to better define the molecular underpinnings of activator interactions with 
Med25 AcID, we began with a serial truncation of the VP16 TAD that ultimately revealed 
that the majority of the binding affinity could be recapitulated solely by the purported α-
helices within the TAD, consistent with most other activator•coactivator interactions. This 
finding was interesting as the defining structural feature of the AcID motif is a β-barrel, 
which is highly uncommon for activator-targeted coactivator domains. The importance of 
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α-helical secondary structure in the TADs of activator binding partners was further 
supported by the ERM•AcID interaction, suggesting that this may be a common 
phenomenon in all AcID binding partners. 
We next completed a hotspot analysis using alanine scanning mutagenesis studies 
of the putative α-helices within the VP16 TAD in order to determine whether 
activator•AcID interactions require a few critical contacts, or broad interactions over large 
surfaces of the domain. The alanine scanning mutagenesis studies failed to identify 
specific hotspot residues, suggesting that VP16•AcID interactions rely upon a broad 
interaction surface wherein each residue contributes weakly to the affinity of the domain. 
Thus, small molecule inhibitors capable of inducing allosteric changes to the domain at 
surfaces required for activator binding were expected to offer the greatest opportunity for 
an effective inhibition strategy. 
The highly acidic nature of most activator binding partners for AcID and the highly 
basic character of the domain itself suggested that electrostatic contacts may be of 
particular importance in activator•AcID interactions. Determination of the binding affinity 
of a VP16 derived peptide in the presence of various concentrations of three different 
salts demonstrated that the affinity for AcID decreased with increasing salt concentration, 
supporting the hypothesis that electrostatic contacts are critical to activator•AcID 
interactions. This hypothesis was further supported by a mutation within the AcID motif 
that caused a charge inversion near a surface important for the binding of transcriptional 
activators that resulted in a significant decrease in affinity of the VP16 TAD for the domain. 
Interestingly, this mutation affected affinity of peptide ligands for both of the activator 
binding sites on the AcID motif, suggesting that this residue is not merely an electrostatic 
contact, but that the charge inversion may also result in structural changes to the 
secondary or tertiary structure of the domain. This observation thus supports the 
hypothesis that AcID motif is relatively plastic and capable of a variety of unique 
conformations. 
We next developed a fluorescence polarization based assay of the interaction 
between the VP16 TAD and AcID and optimized the assay for screening applications in 
a high-throughput format. This assay was then screened against a small library rich in 
known bioactive compounds, natural products, and FDA approved drugs, leading to the 
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identification of a number of potential lead molecules belonging to the depside and 
depsidone classes of small molecules. This observation was particularly significant as a 
previous screening project to identify inhibitors of an α-helix dependent 
activator•coactivator interaction completed in our laboratory also identified molecules 
belonging to these classes as effective inhibitors, suggesting that perhaps these core 
scaffolds may be privileged for the inhibition of α-helix dependent activator•coactivator 
interactions. The depsidones Norstictic Acid and Psoromic Acid were selected as lead 
molecules for further study based upon their activity in competitive inhibition assays and 
their structural similarities. 
These molecules were then confirmed as inhibitors of the VP16•AcID interaction 
by obtaining samples from commercial sources and testing their ability to inhibit the VP16 
interaction. Psoromic acid and norstictic acid were then tested for their ability to inhibit 
two other activator•coactivator interactions demonstrating that they were selective for 
AcID-dependent interactions. One of the interactions assayed was an alternative 
VP16•coactivator interaction, suggesting that they do not function merely as VP16 
mimetics and are in fact more selective for the AcID domain than one of its native binding 
partners. Subsequent studies, namely molecular dynamics simulations and inhibition 
studies in the presence of various salt concentrations, indicate that Norstictic and 
Psoromic Acid are localized to the AcID domain through electrostatic interactions 
between the acidic functionalities harbored by the molecules and positively charged 
surfaces of the domain.  
The presence of an aldehyde on all of the lead molecules identified in the primary 
screen led us to question whether they may be covalent inhibitors of AcID interactions. 
Subsequent mass spectrometric analyses of reduced covalent adducts between the AcID 
domain and small molecules indicated that they are in fact covalent and that this 
attachment occurs through the formation of a Schiff base between the aldehyde and 
nucleophilic lysine residues on the surface of the AcID domain. In order to identify 
potential sites of covalent labeling, we completed 1H,15N-HSQC chemical shift 
perturbation studies of the AcID domain in complex with norstictic acid. The strongest 
chemical shifts were induced in regions required for the binding of the VP16 TAD to the 
AcID domain, suggesting that Norstictic Acid directly perturbs surfaces required for 
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interaction with VP16. Furthermore, a subset of the chemical shifts occurred at residues 
at the interface of the two activator binding sites on the AcID motif, which suggests that 
norstictic acid may be capable of inducing allosteric changes in the domain that affects 
activator binding at both sites 
Subsequent mutational analysis studies in which lysine residues in close proximity 
to critical binding surfaces were mutated to arginine were undertaken in order to validate 
the role that they may play in the inhibitory activity of norstictic acid. These mutations did 
not alter the affinity of VP16 for the domain, but did significantly alter the inhibitory potency 
of norstictic acid and resulted in decreased labeling of the domain by the inhibitor, 
suggesting that these residues are involved in the covalent attachment of Norstictic Acid 
to the domain. Additionally, lysine to arginine mutations in the H1 or H2 binding sites 
individually was able to perturb the activity of norstictic acid against interactions at both 
sites, supporting the hypothesis that the two sites may be in allosteric communication. 
Taken together, these experiments suggest that norstictic acid may exert its inhibitory 
effects by interfering with critical electrostatic contacts between the domain and the TADs 
of activator binding partners by relieving the positive charge of specific lysine residues 
through the formation of an imine. The covalent attachment of norstictic acid to these 
lysine residues additionally adds steric bulk to regions important for activator binding, 
providing an additional mechanism by which norstictic acid inhibits the binding of 
activators to AcID. 
Finally, we tested the ability of norstictic acid and psoromic acid to perturb AcID-
dependent transcriptional processes within a cellular context. RT-qPCR analysis of the 
expression of a canonical target gene of an activator binding partner of AcID, ATF6α, 
revealed that expression of the gene was inhibited by treatment with norstictic acid and 
psoromic acid, likely through inhibition of the interaction between the activator and the 
AcID motif. Similarly, norstictic acid and psoromic acid are capable of inhibiting the 
transcriptional activity of RARα in a reporter assay, likely by inhibiting the recruitment of 
the histone acetyl transferase CBP through its interaction with the AcID domain. These 
results are consistent with the hypothesis that Norstictic Acid and Psoromic Acid are cell 
permeable small molecules that can perturb AcID-dependent transcriptional processes. 
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Following the observation that AcID-dependent interactions could be effectively 
targeted by small molecule inhibitors, we next sought to identify novel natural products 
capable of inhibiting the interaction between the transcriptional activation domains of the 
PEA3 subfamily of ETS transcription factors and the AcID domain of Med25. The 
discovery of such molecules was an attractive goal as these inhibitors will be useful 
molecular probes for the elucidation of the role of the PEA3 subfamily in cellular 
processes related to cancer progression, specifically metastasis and possibly 
tumorigenesis, and could potentially serve as lead molecules in the development of novel 
therapeutic strategies. Though norstictic acid and psoromic acid were identified as 
covalent inhibitors of AcID-dependent activator•coactivator interactions, we sought to 
identify novel inhibitors with the hypothesis that alternative non-covalent inhibitors of the 
AcID domain may allow for greater selectivity in a complex cellular environment and may 
be capable of inhibiting activator interactions with the domain through an alternative 
mechanism of action. 
Towards this goal, we first tested the ability of norstictic acid and psoromic acid to 
disrupt the interaction between the TAD of the PEA3 subfamily member ERM and AcID 
in order to demonstrate that the interaction was amenable to inhibition and found that 
both molecules were capable of perturbing the interaction. We then optimized an FP 
assay based on the ERM•AcID interaction for application in a high-throughput screen. 
Prior to screening the full NPE library, the optimized assay was tested against one sample 
plate of the library rich in natural products derived from lichens. This plate produced a 
number of hits, likely due to the presence of multiple extracts abundant in depsides and 
depsidones, indicating that the assay was well adapted to screening of the full library in 
a high-throughput format. 
Subsequently, a primary screen of the NPE library against the optimized assay 
resulted in 1,602 hits that were selected for further filtering steps. These initial hits were 
tested in triplicate to remove false positives and extracts containing molecules with 
significant intrinsic fluorescence or the ability to quench the fluorescent tracer were 
removed from further consideration. The hits from the primary screen were then tested 
for inhibition of alternative interactions, namely the interaction between the DBD of Gal4 
and DNA, as well as the interaction between the KIX domain of CBP/p300 and MLL in an 
 207 
effort to remove non-specific inhibitors from further analysis. As a final filter overly 
promiscuous extracts, specifically those that were active in greater than ten screens of 
the NPE library, were also precluded from further analysis in an effort to identify selective 
inhibitors of the ERM•AcID interaction. Following these filtering steps, we were ultimately 
left with 332 extracts that were validated inhibitors of the ERM•AcID FP assay, suggesting 
that AcID may be a significantly more targetable coactivator domain than is typical. 
In collaboration with the laboratory of Prof. David Sherman at the University of 
Michigan, thirty-one strains from the list of 332 validated hits were regrown and fresh 
extracts prepared on the basis of genetic diversity, a range of inhibitory activities against 
the ERM•AcID interaction, and the availability of pure spore stocks of the strain. The 
freshly prepared extracts were then tested for their ability to inhibit the ERM•AcID FP 
assay, with all but one extract demonstrating strong inhibition of the interaction, 
suggesting a low false positive hit rate for the extracts identified in the screen. 
Subsequently, the extracts were tested for the ability to inhibit the activity of an AcID-
dependent reporter assay in order to identify extracts with active cell-permeable natural 
products capable of inhibiting AcID-dependent interactions in a cellular environment. 
Strain 91085R demonstrated excellent inhibition of the ERM•AcID FP assay and the 
AcID-dependent reporter assay, resulting in the extracts from this strain being the first 
selected for fractionation and structural elucidation of the active natural products. 
The extract from strain 91085R has undergone multiple fractionation step by 
preparative HPLC, resulting in the isolation of three compounds within the extract that are 
capable of inhibiting the ERM•AcID interaction in vitro. This fractionated material is 
currently undergoing final purification steps by HPLC prior to elucidating their structures 
using various mass spectrometric, NMR, and crystallographic techniques. 
Through the experiments summarized above and described in this thesis, we have 
demonstrated that the Activator Interaction Domain of Med25 can be effectively targeted 
by small molecule inhibitors, despite the fact that activator binding partners bind to the 
domain over broad surfaces with moderate affinity. Furthermore, the evidence presented 
suggests that this inhibition can be achieved with selectivity, likely as a result of the unique 
protein fold that comprises the domain and the ability of the inhibitors to induce allosteric 
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changes to the structure of the domain due to the inherent conformation plasticity of the 
motif. 
5.2 Future Directions 
Using Natural Products as Molecular Probes for PEA3 Dependent Transcriptional 
Processes 
 Following the final deconvolution, purification, and structural elucidation of the 
active natural products within the extract of 91085R described in Chapter 4 we will use 
those molecules as molecular probes to gain a better understanding of PEA3 dependent 
transcriptional processes and their functional consequences. Initially, the affinity of these 
molecules and their binding mode will be assessed. Full inhibition curves will be 
generated against the ERM(38-68)•AcID FP assay in order to determine IC50 and Ki 
values, provided the molecules bind reversibly with a 1:1 stoichiometry, of the inhibitor for 
the AcID motif. Additionally, the Kd of the inhibitors for AcID will be assessed by isothermal 
titration calorimetry, provided that the affinity is between 100 nM and 10 µM. In the event 
that the affinity of the molecules for the domain is outside of that range, affinity will be 
alternatively assessed by transient kinetic analyses or with Protein Observed Fluorine 
NMR, as previously described. 1-3 In addition to determining the affinity of the molecules 
for AcID, their selectivity for the domain will also be assessed. In order to accomplish this, 
full inhibition curves will be generated against FP assays of the MLL•KIX (as validation of 
the results obtained during counter-screening), pKID•KIX, VP16•Med15, and HIF1-α•CH1 
interactions. 4-6 In the event that the isolated natural product does not exhibit at least five-
fold selectivity for AcID, an alternative extract will be fractionated and the active 
component identified.  
Subsequently, we will attempt to map the binding site of the inhibitors on the AcID 
domain using a combination of NMR techniques including 1H,15N-HSQC chemical shift 
perturbations, Protein Observed Fluorine (PrOF) NMR spectroscopy of an AcID mutant 
containing fluorinated amino acids in suspected binding sites, and 13C-CACO NMR 
spectroscopy. PrOF NMR leverages the incredible sensitivity of fluorine to changes in its 
chemical environment in order to identify subtle shifts in protein structure, allowing for a 
thorough accounting of shifts induced by binding of the molecule or allosteric changes in 
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the structure of the protein.1 13C-CACO NMR observes 13C directly, allowing for 
elucidation of structural changes in highly flexible protein structures that cannot be easily 
visualized using more conventional techniques such as HSQC.7 The information 
regarding putative natural product binding sites on AcID will then be used to generate 
AcID mutants that perturb the binding of the inhibitor, while leaving PEA3 activator 
interactions intact. These mutants will be particularly useful in studies designed to 
demonstrate target engagement within the complex environment of the cell. 
Following in vitro experiments designed to validate the activity of the natural 
products against the ERM•AcID interaction and elucidation of the mechanism of action 
by which this inhibition is achieved, we will next complete a series of experiments 
designed to demonstrate that the molecules engage the AcID domain within a complex 
cellular environment. Initially, a reporter assay using a fusion of the ERM TAD to the DBD 
of Gal4 to drive expression of a luciferase gene regulated by the Gal4 promoter will be 
developed and the ability of the natural products to inhibit the expression of this reporter 
gene will be assessed following transient transfection into a suitable host. In addition to 
the luciferase reporter plasmid, cells will also be transfected with a plasmid that 
constitutively expresses a β-galactosidase reporter gene. Thus, monitoring the activity of 
β-galactosidase in treated cells will allow for initial determination of the cytotoxicity of the 
identified natural products. In addition to a Gal4(DBD)-ERM(TAD) fusion, the ability of the 
molecule to inhibit analogous reporter assays using the TADs of transcriptional activators 
such as CREB or c-Jun, which are not dependent upon AcID for their activation, fused to 
the Gal4 DBD will be completed as an additional metric by which we can assess selectivity 
of the natural products against the AcID motif. Subsequently, the Gal4-ERM driven 
reporter assay will also be tested in cells that have been transfected with a plasmid 
expressing full length Med25 with the previously identified AcID mutations that abrogate 
inhibition by the natural products. In this case, loss of potency in the inhibition of the assay 
by the inhibitors would serve as further evidence of target engagement within the cell. 
Additionally, the ability of the small molecules to inhibit the co-immunoprecipitation (co-
IP) of the PEA3 family members (ER81/ETV1, PEA3/ETV4, and ERM/ETV5) and Med25 
will be assessed with variable doses as a further assessment of target engagement. 
Finally, if the natural products are synthetically accessible or contain non-critical reactive 
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handles, biotinylated variants will be synthesized in order to complete Med25 pull-down 
experiments. 
 Following successful demonstration of target engagement within the cell we will 
next assess the ability of the natural products to perturb the expression of PEA3-
dependent genes. A number of genes with distinct functional effects, including the matrix 
metalloproteinases MMP-1, MMP-2, MMP-3, and MMP-98,9, FAK (cell motility and 
migration) 9,10, CXCR4 (metastasis biomarker)11, and Cyclin D2 (proliferation and 
migration)12 have been identified as PEA3-dependent through a combination of shRNA 
knockdown studies and ‘squelching’ experiments in which overexpression of AcID 
reduces expression of the gene. Thus, the effects of the natural products on the 
expression of these genes over time will be assessed using RT-qPCR and western 
blotting at distinct time points. In support of this, a partially purified extract from the 
91085R strain has already been tested for its ability to inhibit the expression of MMP-2 
and MMP-9 at a concentration of 0.1 mg/mL and demonstrated to significantly attenuate 
the expression of these genes as shown in Figure 5.1 in a preliminary experiment. 
 
Figure 5.1- Inhibition of MMP-2 and MMP-9 Expression by a Partially Purified Extract of Strain 
91085R The expression of MMP-2 and MMP-9 in MDA-MB-231 cells treated with a partially purified 
extract of strain 91085R at a concentration of 0.1 mg/mL was assessed by RT-qPCR and compared 
to a control in which cells were treated with ethanol vehicle only. Experiments represent the mean of 
technical triplicates with error indicating the standard deviation of the fold expression. 
Subsequent to analysis by RT-qPCR, analysis of global gene expression by RNA-seq will 
be considered in order to identify the full subset of PEA3-dependent genes that are 
attenuated by treatment with the natural product inhibitors.13 
 Finally, we will use the natural products to probe the effects of inhibiting PEA3-
dependent transcriptional programs on cellular processes related to the tumorigenesis 
2.3 Modulation of core ETV/PEA3 genes by natural product enhancers and inhibitors Both shRNA knockdown 
experiments of the ETV/PEA3 activators and cla sic ‘squelching’ experiments using overexpressed Med25 
AcID have been shown to impact the ETV/PEA3-regulated genes PEA3 (13), MMP-1, MMP-2, MMP-3, MMP-9 
(9, 31), FAK (cell motility and migration)(2, 31), CXCR4 (metastasis marker) (74), and Cyclin D2 (proliferation 
and migration)(3). Preliminary experiments performed by us have shown that the most abundant active 
compound isolated from NPE strain 91085 (from Aim 1.2) i cap ble of mediating knockd wn of MMP-2 and 
MMP-9, two of these critical ETV/PEA3 genes (Figure 11). In this sub-Aim, we will assess the functional 
effects of the suite of inhibitors and enhancers identified in Aim 1 in two breast cancer cell lines, MCF7 and 
MDA-MB-231. Both mRNA products (qPCR) and 
protein (Western blot) will be examined over a range 
of time points (for qPCR: 2, 4, 8, 12 hours; for 
Western blot: 4,8, 12, 24 hours). The overall 
expectation is that the enhancers will lead to 
increased transcription and expression of these suite 
of genes, while the inhibitors will produce a dose-
depended decrease in both mRNA and protein 
levels. It is not necessarily expected, however, that 
these effects will be uniform across the molecules 
and genes. One comparison will be, for example, 
allosteric versus orthosteric inhibitor effects, and 
these experiments are expected to provide our first 
insight into the contexts in which the ETV/PEA3-
Med25 complex plays a major role in ETV/PEA3-
driven transcription. To further dissect these effects, 
we will carry out ChIP to examine changes in Med25 
and ETV/PEA3 occupancy at those genes.  
 
2.4 Dissecting the role of ETV/PEA3•Med25 complex on overall ETV/PEA3 function  A$ global$ RNA5Seq$
approach$will$ be$ utilized$ to$ comprehensively$ characterize$ the$ gene$ expression$ changes$ in$ breast$ carcinoma$
cells$treated$with$vehicle$(DMSO),$ETV/PEA3•Med25$enhancers$or$inhibitors.$$MCF7$and$MDA5MB5231$cells$
will$ be$ treated$with$ vehicle$ or$ ETV/PEA3•Med25$modulator$ (dose$ range$ of$ 0.1530$ qM,$ depending$ on$ EC50$
measurements$ from$Aim$1$and$preliminary$ transcriptional$effects$ identified$ in$Aim$2.3)$ for$4,$8$or$12$hours$
and$ RNA$ will$ be$ extracted.$ Transcriptome$ libraries$ will$ be$ prepared$ using$ the$ TrueSeq$ RNA$ Sample$
Preparation$ Kit$ (Illumina).$ The$ libraries$ will$ be$ paired5end$ sequenced$ at$ the$ University$ of$Michigan$ DNA$
Sequencing$ Microarray$ Core,$ who$ will$ also$ aid$ in$ the$ bioinformatic$ analysis.$ Expression$ values$ for$ each$
transcript$ will$ be$ represented$ as$ RPKM$ (Reads$ Per$ Kilobase$ per$ Million$ Mapped$ reads).$ $ The$ differential$
expressed$genes$will$be$ linear$models.$ $The$false$discovery$rate$ (FDR)$will$be$controlled$by$adjusting$the$p5
values$using$the$Benjamini–Hochberg$algorithm.$$We$will$use$FDR≤5%$and$fold$change>1.25$as$thresholds$for$
determining$ differentially$ expressed$ gene$ between$ control$ and$ experimental$ samples.$ $ A$ select$ number$ of$
differentially$ expressed$ mRNAs$ will$ be$ validated$ using$ qPCR.$ $ Next,$ Ingenuity$ Pathway$ Analysis$ (IPA)$
software,will$ be$ used$ to$ identify$ which$ signal$ transduction$ pathways$ and$ networks$ are$ modulated$ in$ the$
RNA5Seq$ dataset$ obtained$ above.$ We$ will$ compare$ treatment$ with$ vehicle$ vs.$ AcID$ inhibitor$ to$ reveal$
pathways/networks$ that$ are$ modulated$ by$ our$ Med255targeting$ molecules.$ In$ addition,$ AcID$ inhibitor$ vs.$
shRNA5mediated$ knockdown$ of$ ETV$ transcription$ factors$ will$ be$ compared$ to$ determine$ if$ similar$
pathways/networks$are$induced/ablated$following$chemical/shRNA$ETV$inhibition.$$This$tool$will$guide$us$to$
prioritize$ the$ pathways/networks$ for$ further$ investigation$ (Aim$ 3).$ $ After$ corroboration$ that$ the$ pathways$
postulated$by$the$bioinformatics$of$the$expression$analyses$are$indeed$activated$or$inhibited$by$probing$for$the$
presence$or$absence$of$the$pertinent$proteins$via$Western$blot,$over5expression$and$knockdown$studies$will$be$
performed$to$experimentally$validate$the$key$pathways$identified.$$
  
2.5#Pharmacokinetic# analysis# of# top#ETV/PEA3•Med25# inhibitors#Although$ in$ vivo$ studies$ are$ a$ relatively$
small$ component$ of$ our$ experimental$ plan$ (Aim$ 3.4),$ it$ will$ nonetheless$ be$ critical$ to$ have$ information$
regarding$the$stability$and$distribution$of$any$molecules$that$will$be$used$in$that$context$in$order$to$define$the$
best$dosing$strategy$and$identify$any$toxicity$concerns.$Towards$that$end,$the$top$three$inhibitors$that$emerge$
from$the$Aim$1$and$Aim$2$studies$will$be$analyzed$by$the$Pharmacokinetic$Core$at$the$College$of$Pharmacy$at$
the$University$of$Michigan.$Lead$by$Professor$Duxin$Sun$of$the$College$of$Pharmacy$and$established$in$2009,$
the$PK$Core$has$considerable$expertise$in$assisting$pre5clinical$studies.$In$our$case,$we$will$utilize$this$facility$
to$ assess$ the$microsomal$ stability$ of$ the$ top$ inhibitors$ (355$ natural$ products),$ as$ well$ as$ a$ murine$ in$ vivo$
pharmacokinetic$assessment$ in$order$ to$determine$optimal$dosing$ route$and$distribution$of$ the$molecule.$ If$
Figure! 11.$ The$ most$ abundant$ NPE$ strain$ 91085$ compound$
mediates$ the$ knockdown$ of$ Med255ETV$ dependent$ genes,$
MMP52$ and$ MMP59,$ in$ MDA5MB5231$ ce ls.$ Followi g$ a$ 65hr$
incubation$ with$ 75$ qM$ 91085$ compound,$ qPCR$ analysis$
demonstrated$ a$ statistically$ significant$ repression$ of$ both$
metastatic$genes$relative$to$vehicle5treated$cells.$!
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cascade, with a particular focus on breast cancer. The PEA3 subfamily has been shown 
to be critical for cellular proliferation, invasion, and migration in a number of breast cancer 
model systems. 14-20 Given these functional consequences associated with PEA3-
dependent transcription we will complete a number of phenotypic assays including 
assessing proliferative capacity using MTT, invasive potential using Matrigel invasion 
assays, cellular migration using wound healing assays, anchorage independent survival, 
and colony formation assays. These experiments will be completed using various 
concentrations of the natural products in order to define a dose response. Furthermore, 
these experiments will be completed using MB-231, SK-BR-3, and MCF-7 cell lines which 
overexpress, normally express, and underexpress the PEA3 subfamily, respectively. 18,21 
Analogous experiments will be additionally be completed in the non-tumorigenic HMEC 
and MCF-10A cell lines in order to assess off-target effects and cytotoxicity.  The effects 
of PEA3 inhibition on these phenotypic responses will further clarify the importance of 
PEA3 subfamily members in the tumorigenesis cascade and the conversion to a 
metastatic phenotype. 
Following the successful completion of these experiments, a potential avenue of 
research that we may investigate will be to test the effects of the natural product PEA3 
inhibitors in combination with inhibitors of other cellular pathways linked to PEA3 
transcription that are implicated in breast cancer, such as the Her2, Ras, or PI3K signaling 
axes.20,22 We have previously demonstrated that combination therapies incorporating 
transcriptional inhibitors can produce significant enhancement over the effects of either 
therapy in isolation, as in the case of the transcriptional activator ESX and 
Her2/EGFR.23,24 
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APPENDIX A 
Characterization of Synthesized Peptides 
 This appendix contains the analytical HPLC chromatograms of fluorescent tracers 
derived from transcriptional activators that have been used in the various fluorescence 
polarization based assays throughout the work described in this thesis. 
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Analytical HPLC Chromatogram of Flo-VP16(413-437) 
 
 
 
 
 
 
 
 
 
 217 
Analytical HPLC Chromatogram of Flo-VP16(438-464) 
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Analytical HPLC Chromatogram of Flo-VP16(465-490) 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) 
  
 220 
Analytical HPLC Chromatogram of Flo-VP16(467-488) 
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Analytical HPLC Chromatogram of Flo-ERM(38-68) 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) L439A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) D440A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) D441A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) F442A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) D443A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) L444A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) G450A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) D451A 
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Analytical HPLC Chromatogram of Flo-VP16(438-454) S452A 
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Analytical HPLC Chromatogram of Flo-VP16(467-488) Y488A 
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APPENDIX B 
List of Confirmed Extracts from NPE Library Screen of ERM•AcID Interaction 
 The full list of 332 extracts identified as validated hits of the ERM•AcID interaction 
following hit filtering and counter screens is presented below. The criteria used to select 
these hits is reviewed in Figure B.1. Those strains producing extracts with activity against 
the interaction that were selected for regrowth are highlighted in green in the table of hits. 
 
Figure B.1- Schematic Representation of Final Hit Selection The full battery of screens and 
counter screens utilized to identify natural product extracts containing small molecule inhibitors of the 
ERM•AcID interaction is represented schematically. 
  
NPE Library Primary Screen of ERM•AcID
33,400 Extracts Tested
Hit (NPE Library Part 1): ≥ 30% Inhibition
Hit (NPE Library Part 2): ≥ 60% Inhibition
OR
Hit (Full Library): ≥ 3 St. Dev. by Plate
EXCEPT
Full Library: Parallel Fluorescence ≥ 40,000 mAU
Hit Validation and Counter Screening
1,602 Extracts Tested
Intrinsic Fluorescence Filtering
Hit: ≤ 40,000 mAU in Parallel Channel
460 Validated Extracts
254 Extracts Eliminated
Fluorescence Quenching Filtering
Hit: ≤ 30% Inhibition by Quenching
460 Validated Extracts
0 Extracts Eliminated
Potency and Reproducibility Filtering
Hit: ≥ 50% Inhibition in Triplicate
714 Validated Extracts
888 Extracts Eliminated
Inhibition of MLL•KIX Interaction
Hit: ≥ 35% Inhibition in Duplicate
417 Validated Extracts
33 Extracts Eliminated
Inhibition of Gal4(DBD)•DNA Interaction
Hit: ≥ 50% Inhibition in Duplicate
450 Validated Extracts
10 Extracts Eliminated
Validated Extracts for Follow Up Study
332 Extracts
Selected for regrowth on basis of genetic diversity, 
range of inhibitory activity against ERM•AcID, and 
strain accessibility 
Strains Regrown and Compounds Extracted
31 Strains Regrown and Extracted
Promiscuity Filter
Hit: Active in ≤ 10 other screens
332 Validated Extracts
85 Extracts Eliminated
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Strain CCG	Identifier
%	ERM•AcID	
Inhibition
Parallel	
Fluorescence
%	
Fluorescence	
Quenching
%	
Gal4(DBD)•DN
A	Inhibition
%	MLL•KIX	
Inhibition Promiscuity	Filter
1 7719-N10I SID-9822 70.8 29645 -10.8 -65.2 7.9 9
2 82389-N2N SID-69812 73.6 35359 -3.8 -45 0.9 7
3 82389-N1Z SID-69741 52.5 34149 15.8 -69.7 4.3 5
4 65370-N4Z SID-69717 58 37181 -11.3 -79.5 7 6
5 74494-N1I SID-69497 98.8 37394 -20.2 -7.7 12.4 6
6 72479-N1I SID-69475 95.7 37398 -16.2 0.5 10.2 6
7 56390-N1N SID-69452 65.2 37029 -15.2 -20.9 9.3 4
8 73332N SID-69427 57.2 36476 -11.2 -30.7 5 3
9 78816I SID-69354 68.1 40306 -25.3 -84.8 5.8 4
10 72509-N1N SID-69284 73.3 35954 -11.7 -26.4 2.9 8
11 74424-N1N SID-69252 72.8 36858 -16 -4.4 7 7
12 74499-N1N SID-69195 59.5 36919 -11.2 -27.7 7.1 4
13 73260N SID-69113 80.9 38557 -17.9 -86 2.8 5
14 71961N SID-69043 70 38711 -14.3 -53.4 3.4 5
15 78799I SID-68915 58.4 39716 -17 -58.5 3.2 5
16 78921N SID-68879 67.9 39940 -21.4 -70.9 3.2 8
17 65435-N4N SID-68856 67.7 37994 -10.5 -21.4 3.1 8
18 55270-N4N SID-68851 73.7 39860 -18.4 -60.5 2.8 4
19 65395-N6I SID-68834 62.6 38301 -7.7 -80.4 -3.5 4
20 65409-1N SID-68805 95.6 29690 14.9 59.3 12.9 8
21 55270-N4I SID-68785 66.3 35206 22.9 -76.3 -0.7 4
22 67313-1I SID-68780 55.6 38657 -6.6 -82.6 -7.4 6
23 49385-2I SID-68717 74 38133 -13.8 -69.4 9.4 6
24 67360-N9N SID-68685 70.1 35517 -3.6 -18 11.4 4
25 65405-N9I SID-68681 64.5 38184 -12 10.4 14.9 7
26 49595-N4I SID-68651 62.6 38391 -21 -24.4 2.8 4
27 71839N SID-68620 65.9 39590 -22.5 1.9 11.5 9
28 78761I SID-68593 61.6 38808 -22.7 -78.2 -1.7 6
29 73293N SID-68571 65 34465 -3 -56.7 7.8 5
30 78928N SID-68570 71 34014 -3.3 -10.7 8 6
31 78935I SID-68568 71.5 34390 -7.7 -7.4 15.1 7
32 53116I SID-68527 65.7 37550 -20 -63.9 0.1 4
33 71885N SID-68498 55.8 35231 -9.7 -21.1 4.4 4
34 71777N SID-68492 58.6 37670 -14.7 19.9 12.6 8
35 73413I SID-68482 58.7 36678 -9.7 -70.3 -0.3 5
36 71533I SID-68473 59.8 37616 -17.5 -16.6 0.4 4
37 73397N SID-68466 57.7 34244 -2.9 -41.2 6.9 5
38 71885I SID-68465 80.5 35714 -6.7 -57.2 10.5 4
39 73239I SID-68460 57.3 38188 -14.9 -47.3 0.5 6
40 73370N SID-68455 77.7 35096 -1.8 -63.3 7.2 4
41 71953I SID-68435 62.9 32984 -6.9 -5.9 5.9 6
42 73273I SID-68420 64.1 38588 -18 -62.3 2.6 6
43 73276I SID-68419 73.7 39264 -23.7 -109.3 -0.5 5
44 53086N SID-68373 74 38543 -23.9 -96.3 0.5 7
45 53086I SID-68364 78 36184 -13 -58.4 1.6 6
46 71899I SID-68355 56.2 39465 -20.5 16.9 9.8 5
47 53088I SID-68336 82 34562 0.6 -34.8 -16.1 5
48 71757I SID-68315 56.9 39540 -26.8 -64.3 2 4
49 53072I SID-68311 59.4 40129 -28.6 -73.1 1.7 3
50 58140N SID-68308 62.8 38897 -24.2 -28.1 4.7 4
51 73393N SID-68300 64.3 37647 -17.4 -38.2 5.1 4
52 71835I SID-68294 53.5 36700 -15.1 -14 1.4 4
53 58146I SID-68255 72.6 32108 -0.8 -3 10.7 10
54 65455-N2I SID-68244 86.8 36981 -18.9 -15.1 8 9
55 65465-N1I SID-68220 61.4 40258 -28.6 -45.6 0.1 5
56 52249-1I SID-68214 95.1 34082 -4.6 14.1 18.3 10
57 64665-N3I SID-68213 85.6 37601 -17.6 -58.6 4.2 9
58 34395-1N SID-68209 51.8 33675 -1.3 -21.3 9.3 8
59 67325-N7I SID-68206 62.4 39962 -28.6 -26.7 2.1 6
60 34376-2I SID-68198 75.4 35631 -12.2 -49 7.1 10
61 49830-N4I SID-68174 58.9 39213 -24.1 -86.4 -3.7 4
62 49546-N4N SID-68163 61.5 36647 -4 -37.3 2.5 4
63 41429-N1I SID-68149 70.7 39078 -18.1 -42.7 8.5 4
64 41429-N1I SID-68148 82.3 39516 -28.6 -85.4 4.1 4
65 65440-N1I SID-68128 79.1 37997 -18.1 5.8 16.9 9
66 65440-N1N SID-68121 70 36498 -10.3 -34.5 6.5 3
67 64820-N5I SID-68101 62.8 39742 -17.4 -34.1 3.4 5
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67 64820-N5I SID-68101 62.8 39742 -17.4 -34.1 3.4 5
Strain CCG	Identifier
%	ERM•AcID	
Inhibition
Parallel	
Fluorescence
%	Fluorescence	
Quenching
%	Gal4(DBD)•DNA	
Inhibition
%	MLL•KIX	
Inhibition Promiscuity	Filter
68 49546-N4I SID-68085 52 39949 -14.7 -52.7 -4.3 8
69 71689N SID-68050 51.4 38786 -18 -3.3 5.4 4
70 58132N SID-67958 59.8 36237 -9.7 -17.2 0 5
71 58186I SID-67946 57.1 37825 -12.8 -99.7 -13.7 3
72 58092I SID-67943 54.8 39334 -16.2 -92.1 -13.5 4
73 71813I SID-67893 57.7 37950 -13.9 -70.3 -12.3 3
74 71579I SID-67887 57 38948 -10.3 -75.9 -11.1 3
75 71603I SID-67857 62 39216 -13.6 -84.6 -8.7 4
76 71865I SID-67795 56 38314 -9.4 -92.9 -11.7 7
77 71577I SID-67700 52.4 38773 -12 -80.6 -10 6
78 AM82677 SID-67401 65.1 34493 7.8 13.2 9.3 9
79 AM82597 SID-67356 62 36839 -8.5 9 2 4
80 AM82597 SID-67355 73 36443 -20.9 -66.8 7.6 5
81 AM82597 SID-67348 66.2 37678 -30.9 -117.7 8.8 6
82 AM77835 SID-35025 55.1 36011 -13 -150.7 0.7 6
83 AM77833 SID-35023 65.2 37123 -15.8 -140.4 -1.7 7
84 AM77794 SID-34984 54.2 38736 -27.5 -24.6 7.4 6
85 AM77733 SID-34923 72.5 37076 -4.8 -117.3 1.6 6
86 AM77732 SID-34922 68.5 36303 -1.4 -69.3 5.6 5
87 MS77698 SID-34888 63.7 34401 -11.1 -80.1 7.7 8
88 AM77658 SID-34848 82.6 37541 -22 16.8 13.5 10
89 AM77491 SID-34681 78.6 34422 -12.2 -5.7 19.8 6
90 AM77419 SID-34609 55.5 33375 -4.6 2 4.3 6
91 AM77414 SID-34604 83.3 34437 -2.5 -67 11.2 9
92 AM77412 SID-34602 65.9 35794 22.8 -78.8 7.5 9
93 AM77348 SID-34538 69.3 35310 -16.9 -17.6 14.4 7
94 MS75409 SID-34518 92.5 39420 -30.9 -30.5 15.8 8
95 MS75388 SID-34497 50.6 33638 10.9 -104.1 -0.4 7
96 MS75258 SID-34367 65.6 33327 -1.2 -14.6 10.3 8
97 MS75180 SID-34289 93.5 32737 3.6 -5.9 19.9 5
98 MS72144 SID-34022 60.3 38120 -16.2 -1.8 8.8 7
99 MS72040 SID-33918 59.3 38568 -19.3 -106.2 3.1 7
100 MS72036 SID-33914 52 38734 -22.6 7.2 11.3 6
101 MS72018 SID-33896 72.5 37295 -24.6 -41 -0.9 7
102 58222N SID-33845 77.3 35635 -6.9 -39.9 4.7 7
103 68179N SID-33795 54.8 33240 -2.9 -14.3 -10.4 4
104 58236I SID-33783 74.1 37049 -16.7 -69.1 2.1 9
105 58236I SID-33782 72.3 38062 -12.1 -74.1 8.3 6
106 58238N SID-33753 62.7 37595 -9.2 -59.1 0.5 7
107 68161I SID-33736 61.5 39012 -16.9 -74.8 -2.2 6
108 54925-N1I SID-33698 85.7 35780 -12.3 -88.4 4.8 9
109 54925-N1N SID-33685 81.7 38238 -14.9 -118.8 3.2 10
110 70189-C1I SID-33682 70.4 38462 -18 -86.8 1 5
111 41361-1I SID-33611 58.8 39205 -22.9 -78.2 -0.2 5
112 49800-N2N SID-33599 90.7 39067 -18 -37.5 13.2 9
113 49800-N2I SID-33594 69 38885 -17.4 -29.7 7.5 9
114 70189-C1N SID-33544 53.8 35037 -2.6 -23.1 5.1 6
115 70189-C1N SID-33543 65.8 35907 -8.1 -11.1 4.8 7
116 41445-N2I SID-33360 64.1 35115 19.5 -14.1 8.5 8
117 41445-N2I SID-33359 79.6 39192 -24.6 -50.2 4.8 8
118 41445-N2N SID-33326 74.8 37234 -18.4 -20.4 5.3 6
119 41445-N3N SID-33291 62.7 36068 -8.5 -12.9 4.9 5
120 52315-N6N SID-33285 65.6 36158 -8.1 -24.6 3.4 7
121 64825-N5AIA SID-33215 74.7 38527 -22.4 -29.1 9 9
122 52245-N2N SID-33188 101.7 35559 -18.2 11.9 20 5
123 52245-N2N SID-33187 65.5 38902 -20.8 -26.6 6.2 5
124 50247-1I SID-33181 63.7 39824 -19.8 -93.1 -3.4 4
125 52315-N6I SID-33179 66.2 34796 8 -10.2 4 10
126 52235-N2N SID-33146 53 35093 -9.9 -20.7 -1.6 8
127 44293-N1I SID-33138 86.1 37951 -23.3 -38 9.4 9
128 44293-N1N SID-33128 77.8 38368 -21.9 -90.4 -0.9 8
129 41454-AC3N SID-33066 67 34710 -8.6 -17.2 -6.7 4
130 5538-A2N SID-33058 75.9 35501 -12.5 -66 6 8
131 5538-A2N SID-33057 86.2 38027 -19 -54.9 7.1 7
132 54875-N1N SID-33042 59.7 38680 -22.7 -45.3 -1.3 8
133 65430-N16N SID-33027 69.1 38758 -20.6 3.7 6.5 8
134 34365-A1N SID-33026 60.6 34899 -8.4 -45.4 4.1 6
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134 34365-A1N SID-33026 60.6 34899 -8.4 -45.4 4.1 6
Strain CCG	Identifier
%	ERM•AcID	
Inhibition
Parallel	
Fluorescence
%	Fluorescence	
Quenching
%	Gal4(DBD)•DNA	
Inhibition
%	MLL•KIX	
Inhibition Promiscuity	Filter
135 65435-N4N SID-32992 65.7 36589 -16.2 -8.6 1.9 8
136 41450-N4N SID-32936 73.2 32329 -1.1 -23.8 -3.5 10
137 52260-N4AN SID-32929 76.5 32279 5.8 -29.7 -2 6
138 64825-N5N SID-32926 77.6 35565 -5.2 -34 1 10
139 54915-N1I SID-32858 71 37749 -8.5 -96.2 -7 9
140 41450-N4I SID-32808 84.9 39633 -13.9 7.5 6.6 8
141 64825-N3N SID-32737 56.9 38832 -13.6 -45.4 6.6 4
142 64825-N3I SID-32667 60.4 40523 -13.9 -63.5 4.2 7
143 41435-N1I SID-32595 69.2 39075 -13.9 -34.6 6.2 8
144 34389-1I SID-32497 68.2 39920 -13.9 -83.8 6.9 8
145 PAN101-7I SID-32305 74.1 38049 -20.4 -88.2 9.1 5
146 PAN91-1I SID-32295 61.3 37471 -8.7 -48.3 4.7 6
147 68157N SID-32195 55.1 36047 -3.1 -20.7 -1 3
148 68217I SID-32183 62.3 39238 -13.9 -51.4 -6.6 7
149 68175N SID-32061 61.9 38570 -13.9 -7.2 4.8 6
150 18112-N8N SID-31842 53.6 38368 -13.3 -50.6 -2.6 4
151 36180-2N SID-31830 57.4 37403 -10 -16.4 3.9 4
152 41374-AC5N SID-31827 61.7 38496 -13.9 -39.1 2.2 6
153 52328-4N SID-31753 85.3 35035 -4.1 25.3 10.8 10
154 32240-1I SID-31550 64.6 38317 -7.9 -14.1 6.6 6
155 34948-A3I SID-31544 68.2 35328 -8.2 -7.7 9.3 8
156 41422-AC3I SID-31541 65.1 38596 -12.5 -20.1 3.6 8
157 41445-N3I SID-31523 80.4 39056 -13.9 -28.7 13.3 8
158 32424-H2I SID-31484 53.1 38247 -13.9 -39.1 5.4 6
159 06-284-3I SID-31395 63.8 35946 -13.6 -44.5 4.1 5
160 06-284-3N SID-31377 52.3 35944 -10.5 12.1 2.4 5
161 06-282-1N SID-31351 56.6 32033 -6.3 -12.6 8.9 10
162 06-392-3I SID-31335 63.9 39812 -21.9 -47.3 0.3 4
163 06-226-H2I SID-31323 55.9 38013 -15.5 -71.9 -0.9 5
164 06-269-H2N SID-31303 62.8 35566 -13 -72.7 -0.6 4
165 52295-N2I SID-28739 67.5 36661 -13.7 -27.4 5.2 10
166 58069N SID-28433 59 38961 -10.9 -3.3 9.2 7
167 58241I SID-28408 54.7 39178 -13.9 10.7 6.7 8
168 58241N SID-28400 57.3 35823 -10.6 3.6 2.1 8
169 58235I SID-28392 67.2 36500 -4.1 28.1 7.6 9
170 58235I SID-28391 68.7 39028 -13.9 34.8 6.2 10
171 58195I SID-28073 84.5 38044 -4.1 -22.9 11.7 8
172 39040-1I SID-27645 64.4 39972 -15.1 -68.2 1.7 6
173 41392-AC5I SID-27633 57.8 37222 -5 -34 7.5 10
174 5746-A9I SID-27504 65.5 36663 -7.2 -53.5 4 7
175 MS60767 SID-27424 64.5 36975 -11.3 -19 8.1 7
176 MS60665 SID-27322 68.5 38728 -13.7 -104.1 6.8 10
177 MS60652 SID-27309 55.2 40536 -16.7 -66 6.3 9
178 MS60592 SID-27249 69.4 38904 -11.7 -64.9 13.2 9
179 36284-N18N SID-26726 56.1 37554 -8.3 -11.6 6.1 10
180 41426-A4I SID-26608 64.7 39542 -17.8 -51.3 11.3 8
181 18141-3N SID-26421 85.7 39419 -17.1 -10.4 13.1 9
182 32350-1I SID-24794 69.6 37778 -8.3 -55.8 5.6 9
183 34946-N13I SID-24274 57.9 39147 -16.8 -65.8 8.3 10
184 41392-MH5I SID-24167 52.9 36158 -6.5 -13.6 -8 5
185 MS38947 SID-20463 57.1 35924 -10.5 -52.7 7.1 10
186 MS38908 SID-20424 76.4 36876 -19.6 -139.4 -0.5 10
187 MS38768 SID-20284 53 34145 -2 -19.8 8.3 10
188 6425-L1I SID-18508 51.5 35979 -9.7 1.9 2.6 10
189 20731-H2I SID-18195 77 34656 -5.9 -4.5 2.2 10
190 AM86311 SID-143669 75.2 36327 -9.2 -126 8.6 5
191 AM86308 SID-143666 56.3 36334 -9.4 -64.6 5.4 3
192 AM88563 SID-143573 102.3 37526 4.8 39.3 23.4 6
193 AM88558 SID-143568 99.7 37519 5.6 -42 -8.5 3
194 AM96229 SID-143450 68 36764 4.8 -61.9 1.4 6
195 AM96213 SID-143434 53.9 37930 -4.4 -50.7 -2.3 3
196 AM96190 SID-143411 51.6 30442 -0.1 32.7 -0.1 3
197 MS96181 SID-143402 76.5 34958 -4 -17.5 10.3 5
198 FU96134 SID-143355 58.3 34196 13.9 -38.5 8.7 3
199 AM96065 SID-143286 54 32424 -8.1 6.1 9 2
200 FU95982 SID-143203 69.3 38172 -18.4 -37.9 3.3 4
201 FU95864 SID-143085 55.9 37467 -12.2 -37.3 8 3
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201 FU95864 SID-143085 55.9 37467 -12.2 -37.3 8 3
Strain CCG	Identifier
%	ERM•AcID	
Inhibition
Parallel	
Fluorescence
%	Fluorescence	
Quenching
%	Gal4(DBD)•DNA	
Inhibition
%	MLL•KIX	
Inhibition Promiscuity	Filter
202 78950C SID-143079 62.5 35298 6.5 -37.9 8.2 3
203 5644-N7C SID-143077 62.6 36207 -12.1 -53.3 5.7 3
204 9762-N2R SID-143067 59.7 36968 -9 -42.4 8.3 6
205 12587-2Z SID-143065 83.2 37498 3 -32.8 9.1 5
206 78874R SID-143056 65.5 36958 -6.5 -10.1 9.9 3
207 9848-1R SID-143048 81.9 37493 -10.3 -77.8 10.5 5
208 86815-N2Z SID-143008 102.5 38773 -8.9 -19.8 40.1 4
209 06131R SID-142998 56.3 35430 -6.1 -47.7 -7.9 2
210 91085R SID-142997 85.2 35887 -8.6 30.6 7.1 4
211 9814-N17R SID-142991 92.1 34878 11.3 -52.6 17.3 3
212 87774-1Z SID-142942 63 34446 20.4 -67.7 2.4 3
213 34318-1R SID-142926 71 34592 5.6 -116.5 1.8 5
214 65395-N2Z SID-142900 64.2 37401 -1.2 -105.8 2.6 5
215 74389-N6Z SID-142885 93 36458 25.7 -78.4 21.6 5
216 82284-N4Z SID-142882 89.6 37218 10.4 -111.1 12.5 3
217 82354-N1Z SID-142881 99.3 33466 36.9 -18 25.4 7
218 74393-3R SID-142875 94 38353 -1 -42.8 25.5 6
219 65392-5Z SID-142874 88.1 33963 71.1 -25.8 14.6 5
220 15538-H2Z SID-142872 57.7 34343 4.7 -119.3 3 3
221 24815-H2Z SID-142871 90.4 33750 32.7 -33 24.1 4
222 65371-3Z SID-142870 73.6 34733 25.7 -17.2 8 3
223 24889-H2Z SID-142869 59.3 37627 5.1 -126.4 -1.1 2
224 32294-H1Z SID-142868 82.1 35766 3.1 -103.6 13 5
225 34908-2Z SID-142867 83.2 35799 -3.7 -108.6 8.2 2
226 34318-1Z SID-142864 79.1 33932 2.7 -136 11.3 4
227 68950-2R SID-142854 69.2 36581 -2.5 -77.9 -2.9 5
228 18163-N13Z SID-142848 96.6 33242 3.9 -66.3 27.3 4
229 18035-H1Z SID-142847 59.8 33301 7.7 -80.7 4 3
230 87797-1N SID-142833 96.3 31359 10.1 58.4 11.1 7
231 86791-1I SID-142790 54.9 38588 -19.2 -40 -1 2
232 86870-N3N SID-142781 64.1 33906 -13 -46 -12.7 3
233 86840-1I SID-142768 56.7 33814 65.4 -54.4 3.9 4
234 86840-N1N SID-142763 78.5 34899 -5.2 -20.1 6.8 3
235 65392-5N SID-142733 55.2 34596 -7.6 -53.6 5.4 5
236 83115-N12N SID-142728 56.2 34526 -10.7 -40 9.8 4
237 74474-N2N SID-142649 77.9 37802 -16.8 -92.5 9.5 4
238 87767-1C SID-142602 77.2 34710 4.7 -58.5 10.1 3
239 86895-1Z SID-142590 79.5 35987 -13.1 -69.6 15.4 5
240 82294-N3R SID-142565 60 39764 -11.1 -40.2 0.8 6
241 84329-1Z SID-142557 54.8 35313 -9.8 -47.5 6.7 3
242 83011-1C SID-142553 56.2 35648 -9.5 -85.1 14.4 4
243 84131-2R SID-142545 56.6 39171 -6.1 -142.3 -3.6 5
244 54913-2I SID-142487 65.5 36171 -19.2 -20.7 14 8
245 74650-N2C SID-142438 72.6 37274 -17.8 -71.9 5.6 3
246 74389-1C SID-142430 52.4 39471 -23.8 -85.4 0.5 6
247 83615-N3C SID-142421 67.6 38904 -14.1 -43.9 5.3 5
248 64647-1R SID-142403 61.3 34704 -6.6 -81.2 9.3 5
249 64647-1Z SID-142401 71 34064 -3.6 -72.6 7.9 6
250 82402-N2R SID-142397 72.3 35467 -10.2 -63 6.9 4
251 69071-5R SID-142394 58.2 38148 -10.6 -105.3 1 5
252 86825-1R SID-142393 57.8 37873 -11.5 -94.3 1.6 4
253 72365-3BC SID-142392 79.5 37205 -15.1 -207.1 2.6 4
254 83138-2C SID-142384 69.7 35980 29 -85.7 5.9 3
255 74393-2C SID-142383 60.5 35480 -6.9 -62.6 5.5 5
256 82414-N10C SID-142382 58.5 34942 3.5 -36 7.8 4
257 54913-2Z SID-142372 89.4 37181 -9.7 -67.6 24.5 7
258 84243-1Z SID-142364 52.4 36120 -5.1 -48.5 3.3 5
259 82294-N3Z SID-142358 63 37871 -12.9 -57.3 -0.7 5
260 83105-N3I SID-142344 67.8 38433 -15.5 -56.9 0.9 2
261 69074-6I SID-142285 71.5 36024 -4.2 -65.7 4.3 4
262 78930Z SID-142279 63 37280 -14.4 -84.8 -4.2 4
263 71747Z SID-142274 81.2 38212 -16.8 -74 10.8 4
264 73371R SID-142257 61.3 34254 14.1 -135.7 -5.4 3
265 78670R SID-142256 55.4 33281 2.8 -38.7 -4.9 3
266 78699Z SID-142250 56.2 33550 -0.3 -64.8 -2.5 5
267 78699R SID-142237 62.8 34251 2.6 -93.3 -2.3 3
268 82362-1C SID-142174 57.8 34053 -0.5 -124.4 3.9 4
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268 82362-1C SID-142174 57.8 34053 -0.5 -124.4 3.9 4
Strain CCG	Identifier
%	ERM•AcID	
Inhibition
Parallel	
Fluorescence
%	Fluorescence	
Quenching
%	Gal4(DBD)•DNA	
Inhibition
%	MLL•KIX	
Inhibition Promiscuity	Filter
269 82339-N7Z SID-142171 52.4 35302 1.4 -15.2 5.1 4
270 65392-4C SID-142164 53 35946 13.9 -110.6 5.3 4
271 83115-N8Z SID-142128 71.4 36689 25.1 -179.1 7.1 3
272 83115-N8I SID-142114 77.8 38711 -4.7 -102.8 6.7 3
273 83017-2N SID-142098 94 38395 1.8 -60.1 26.5 3
274 41433-AC5N SID-142094 56.6 36110 -2.9 -27.5 4.5 2
275 84381-1I SID-142061 81.4 39925 -21 -67.2 4.9 4
276 78685N SID-142022 60.5 37913 -9.5 -56.7 5.5 5
277 78832I SID-141973 67.8 35497 -17.2 -44.2 7.7 3
278 71747I SID-141966 66.4 39419 -18.4 -129.1 0.4 5
279 34381-1R SID-141950 81.5 34965 -8.1 -73.4 5.1 6
280 83115-N8C SID-141939 62.5 35364 11.5 -97.9 1.3 5
281 82417-N10Z SID-141909 58.8 38694 -6.1 -65.2 0.7 4
282 82354-N2Z SID-141887 59.4 36311 -3.9 -119.7 -2.3 4
283 84250-3N SID-141875 68.8 39868 -21.6 -49.1 5.6 2
284 84215-1I SID-141865 100.5 35290 -4.5 -33.1 16.7 3
285 86810-N2N SID-141852 75.5 33365 1.8 -12.5 6.7 6
286 87690-N1N SID-141726 59.5 34599 -8.4 -33.7 -17.1 2
287 72365-3BI SID-141718 88 35136 -5.5 -58.3 9.9 5
288 82319-N8I SID-141677 70.7 35620 -6.7 -37.2 4.6 4
289 82319-N4I SID-141651 99.7 35423 -11.8 26.6 28.3 5
290 68923-4R SID-141639 94.4 35026 3.2 -27.6 11.5 4
291 68948-2C SID-141623 70.4 35067 -2.4 -47.7 8.2 4
292 54916-1C SID-141597 75 38438 -26.3 -101.4 7.9 4
293 67325-N7C SID-141528 87.9 36762 -10.8 -50 15.9 10
294 65387-4Z SID-141491 57.4 35908 -3.8 -58.7 1.4 5
295 84260-1C SID-141434 69.5 35393 -1.2 -30.9 6 3
296 69078-1BR SID-141381 54.8 36086 3.8 -75 6 3
297 84215-1Z SID-141266 77 38332 -14.1 -94.8 7.5 4
298 82319-N2I SID-141243 82.2 37700 -18.6 -43.1 6.9 4
299 74434-N2I SID-141235 60.6 36384 -8.1 -76.5 4.1 4
300 83115-N5N SID-141219 60.3 35582 -13.4 -43.7 6.2 2
301 82414-N2R SID-141113 76.2 36444 -14.6 -128.4 10.5 4
302 83665-1I SID-141073 65.8 35382 -13.9 -69.4 10.7 5
303 82344-N2AN SID-141041 56.6 34276 -5.5 -81.7 7.5 4
304 82422-N8I SID-140995 64.4 39088 -27.4 -98.5 2.7 2
305 83120-N3I SID-140985 91.9 39179 -26.1 -8 15.3 5
306 82399-N1I SID-140980 56.6 38292 -26 -101.6 5.7 3
307 86853-2I SID-140964 54.6 36399 -12.2 -54.6 3.7 4
308 49701-1I SID-140963 62.2 40415 -24.2 -104.5 0.5 3
309 87790-1N SID-140956 69.7 34124 -4.3 -38.7 1.7 4
310 7736-N9AI SID-140934 59.1 37010 -15.5 -44.1 4.8 5
311 82344-N7I SID-140926 69.7 37812 -14.7 -43.9 7 3
312 82299-N4I SID-140924 65.1 39637 -18.3 -33 -5.8 3
313 82344-N5I SID-140920 100.8 36759 -14.5 34.9 14.9 5
314 82344-N2AI SID-140919 85.9 37865 -24.6 -61.8 7.8 5
315 82344-N6I SID-140916 96 37214 -14.6 27.4 9.7 6
316 74604-N1I SID-140915 74 38202 -18.3 -45.9 6.1 3
317 82349-N4I SID-140914 73.6 37721 -13.3 -39.7 7.2 2
318 82299-N7I SID-140912 69.2 39813 -30.2 -64.7 7.2 6
319 82399-N3I SID-140908 91.8 39665 -25.3 11.7 16.2 6
320 82319-N1AI SID-140895 80.4 38345 -20.6 -20.9 8 4
321 82349-N1AI SID-140894 72.9 37550 -14.2 -39.5 0.5 3
322 83665-1N SID-140794 70.9 30390 9.9 -2.6 3 6
323 82284-N11I SID-140785 68 35749 -11.9 -58.1 -2.2 6
324 74474-N1R SID-140742 55.3 34234 12.3 -91.8 1.9 3
325 68926-2Z SID-140739 51.7 34394 10 -80.2 2.3 3
326 34951-A6R SID-140714 55 37486 -2.9 -54 6.4 3
327 68965-N5R SID-140703 78.2 38654 -10.9 -132.7 -0.4 4
328 78776N SID-140665 54.9 32604 -1.4 -36.4 -19.8 2
329 78796I SID-140657 52.8 38920 -13.7 -183 -4.7 5
330 73401N SID-140641 57 36386 -10.6 -46.6 5.1 2
331 58236N SID-140604 79.9 33193 -0.3 -7.9 9.3 5
332 32381-H1I SID-140525 52.9 36797 -10.5 -67.1 3.3 7
